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Abstract 
Introduction: Periodontal disease (PD) is the most common bone destructive 
chronic inflammatory disease in humans. Severe PD affects 8-15% of the population 
and impacts on the ability to chew and appearance, reduces quality of life, and is 
responsible for a substantial proportion of dental care costs. A dysbiotic oral biofilm 
is necessary but insufficient for development of PD. Rather, a dysregulated immune 
response to the disease-associated biofilm results in destruction of tooth supporting 
structures and eventual tooth loss. Despite the apparent involvement of the 
immune system in PD, clinical management focuses solely on the mechanical 
removal of the oral biofilm – with partial success and frequent recurrence. 
Therefore, a better understanding of the immune response in PD could highlight 
potential novel preventative and therapeutic strategies. T cells are present at sites 
of PD; however, there remains ambiguity regarding whether these T cells are 
protective or destructive in PD. The aim of these studies was to characterize CD4+ 
T cells in a P. gingivalis-induced murine model of PD.  
Results: P. gingivalis-infected mice displayed subtle changes in their CD4+ T cell 
compartment, predominantly in the draining lymph nodes (dLNs). Such changes 
included a suggested increase in T follicular helper cells, a trend towards a 
decrease in regulatory T cells and a trend towards increased production of IFN-γ. 
Elevated levels of IFN-γ were also noted in gingival CD8+ T cells and splenocytes, 
with similar trends in CD8+ T cells from dLNs. The transcriptome of CD4+ T cells 
isolated from gingivae and dLNs of P. gingivalis–infected suggested minimal changes 
in gene expression following infection; however, identified a profile of the mucosal 
oral CD4+ T cell compared with CD4+ T cells of the dLN. To investigate the response 
of CD4+ T cells specific for P. gingivalis, the bacteria were genetically manipulated 
to express ovalubumin (OVA) peptide 323-339. However, these OVA peptide 
expressing P. gingivalis failed to induce a response in OVA-specific T cells, both in 
vitro and in vivo.  
Conclusion: These data imply that CD4+ T cells do not substantially change upon P. 
gingivalis infection in a murine model. IFN-γ production, however, was elevated 
both locally and systemically. Together, the data presented in this thesis and data 
previously published warrant further investigations into the role of IFN-γ in PD and 
may point to IFN-γ as a biomarker or biological target for adjunctive PD therapy.  
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1 General Introduction 
1.1 Periodontal Disease 
1.1.1 Clinical Classification of Periodontal Disease 
 
Periodontal diseases include gingivitis and periodontitis (PD). Gingivitis is 
inflammation of the gingiva predominantly resulting from accumulation of dental 
plaque. As the removal of the dental plaque permits resolution of gingival 
inflammation, gingivitis is reversible. Conversely, PD is a chronic inflammatory 
disease that is characterized by the irreversible destruction of gingiva, periodontal 
ligament and alveolar bone, which ultimately results in tooth loss (Armitage, 2004). 
Whilst gingivitis precedes PD, all gingivitis cases do not progress to PD, with the 
manifestation of gingivitis offering only 30% of predictive value to PD (Listgarten et 
al., 1985).  
 
PD can be diagnosed based on clinical assessment of gingival inflammation and 
tissue destruction, which can be measured by assessing bleeding on probing (BOP) 
and loss of attachment (LOA) measurements, respectively. LOA is the distance 
between the cementoenamel junction (CEJ) and the gingival crevice (GC) and is 
measured by a periodontal probe. The periodontal pocket depth (PPD), which is the 
distance between the gingival margin (GM) and GC, is also increased in PD (figure 
1.1). Radiographs may be used to confirm the degree of alveolar bone loss 
(Armitage, 2004). PD can be generally categorized as chronic or aggressive (figure 
1.2). Chronic PD has a slow progression rate and is the most common type of PD, 
usually affecting those over the age of 35 (Armitage and Cullinan, 2010). By 
contrast, aggressive PD is less common, typically affects younger individuals and is 
differentiated by rapid loss of attachment and bone destruction (Albandar, 2014). 
The PD can be further described as mild, moderate or severe based on the amount 
of LOA (table 1.1). Finally, PD can be termed as localized if less than 30% of teeth 
are involved, or generalized if more than 30% of teeth are implicated (Armitage, 
2004). 
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Figure 1.1. Clinical assessment of periodontitis. 
Loss of attachment (LOA) determines the presence and severity of periodontitis. 
LOA is the distance from the cementoenamel junction (CEJ) to the gingival crevice 
(GC) and is measured using a periodontal probe. The periodontal pocket depth 
(PPD) is the distance between the gingival margin (GM) and the GC. Greater LOA 
and PPD are found in periodontitis compared to health. 
 
 
 
Table 1.1. Loss of attachment determines severity of PD. 	
Severity of PD Loss of attachment (mm) No. of affected sites 
Mild ≥ 3 ≥ 2 
Moderate ≥ 4 ≥ 2 
Severe ≥ 6 ≥ 2 
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Figure 1.2. Advanced and aggressive forms of periodontitis. 
Clinical photographs demonstrating advanced and aggressive forms of periodontitis 
in patients attending Glasgow Dental Hospital. The patients show gingival 
inflammation and recession, tooth loss, drifting teeth. All patients were unhappy 
with their appearance and all required extensive treatment, and require ongoing 
additional dental care throughout life. All patients maintained reasonable oral 
hygiene. Patient B suffered from Type 1 diabetes; patients A and C are healthy. All 
photos were reproduced with patient consent.  
 
 
1.1.2 Prevalence and treatment 
 
PD is the most common chronic inflammatory disease in humans. Its high worldwide 
prevalence qualifies PD as a global health concern. The global economic burden of 
dental diseases – contributed to significantly by PD – was $442 billion in 2010 and 
currently is likely to be greater (Listl et al., 2015). In the UK, approximately 45% of 
the total population will experience some form of PD; moreover, PD affects 60% of 
individuals over the age of 65 (White et al., 2012). PD is typically diagnosed and 
treated years after the initial onset, branding it a ‘silent’ disease. Severe PD, that 
affects 8-15% of the population, will compromise quality of life, affecting a 
A 
B 
C 
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patient’s appearance, speech, mastication and subsequently nutritional status 
(Chapple, 2014). The disease is not limited to the oral cavity; rather it is associated 
with systemic diseases including cardiovascular disease (CVD) (Dietrich et al., 
2013), rheumatoid arthritis (RA) (de Pablo et al., 2009) and type II diabetes 
(Chapple and Genco, 2013). The links between PD and systemic diseases are not 
fully described; however, each of these diseases is typified by chronic inflammation 
and results from a complex mix of genetic and environmental risk factors.  
 
The current treatment for PD is focused on the physical removal of dental plaque, 
in a non-specific manner. The therapy involves the non-surgical removal of 
supragingival and subgingival plaque by dentists or dental hygienists, through 
mechanical debridement, together with dental education and oral hygiene 
instructions (OHI) (Herrera et al., 2002, Needleman et al., 2005). PD progression 
can be halted by non-surgical plaque removal in patients exhibiting shallow to 
moderate PPDs; however, its success in patients with deep PPDs is variable (Tomasi 
et al., 2008, Nordland et al., 1987). Surgery can be indicated where non-surgical 
debridement has failed, with an aim of achieving shallower PPDs. As patients 
cannot remove plaque from deep periodontal pockets themselves, reducing the PPD 
allows maintenance of good oral hygiene and prevents disease progression (Wang 
and Greenwell, 2001).  
 
Antimicrobials and antibiotics have been used as adjuncts to mechanical 
debridement to promote elimination of pathogenic organisms in difficult-to-access 
sites (e.g. root furcations and deep pockets). The efficacies of various systemic 
antibiotics including amoxicillin, azithromycin, clindamycin, doxycycline, 
metronidazole, spiramycin and tetracycline for adjunctive therapy have been 
assessed in clinical trials (Jepsen and Jepsen, 2016). Together the studies implied 
that adjunctive antibiotic treatment tended to improve PD outcome – particularly 
in aggressive PD and patients with deep pockets – however, there was a high level 
of heterogeneity between studies (Herrera et al., 2002, Haffajee et al., 2003, Sanz 
et al., 2008, Keestra et al., 2015a, Keestra et al., 2015b). Therefore, it was 
suggested that due to systemic side effects, adverse side effects and prevalence of 
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bacterial resistance, dentists should assign therapy based on individual patients 
considering the balance of benefits and risks (Jepsen and Jepsen, 2016).  
 
Current PD treatment strategies frequently permit short-term improvements in PD 
state; however, the long-term stability is lacking (Mdala et al., 2013). 
Consequently, recurrence and progression of disease in patients with previous 
improvement is common – even in patients with strict compliance with OHI (Galindo 
et al., 2015). Therefore, it is fundamental to understand the host immune response 
that precedes and ensues in the progression of PD, to prevent disease and to 
identify novel targets for treatment 
 
1.1.3 Risk factors for PD 
 
The presence of a dental plaque biofilm is necessary for the initiation of PD, but is 
insufficient for the development of this disease. This was first described by Loe et 
al (1986), whereby Sri Lankan tea workers developed a range of severities of PD, 
despite exposure to the same environmental stimuli and presenting with similarly 
large dental plaque deposits (Löe et al., 1986). Thus, an individual’s susceptibility 
is not simply a reflection of their oral hygiene.  
 
Studies of twins have provided evidence that susceptibility to PD is around 50% 
attributed to genetic variation (Michalowicz et al., 2000, Torres de Heens et al., 
2010). Genome wide associations studies (GWAS) recognized PD risk to be 
associated with alterations in genetic factors involved in nervous system, cellular 
immunity, cytokine signaling and epithelial barrier function (Divaris et al., 2013, 
Offenbacher et al., 2016).  
 
The incidence of PD largely increases with age. Whilst juvenile PD does exist, the 
manifestation of disease typically occurs in adults with worsening of severity in 
increased patient age (Norderyd and Hugoson, 1998, Norderyd et al., 1999, Renvert 
et al., 2013). There is no definitive explanation for the association between age and 
PD, but this is believed to represent an accumulation of risk factor exposure over 
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time (Löe et al., 1986), and the concomitant impaired efficiency of tissue damage 
repair (Ashcroft et al., 2002). 
 
Gender has been implicated as a risk factor for PD, with some studies finding 
greater prevalence in men (Slade and Spencer, 1995, Albandar and Kingman, 1994). 
However, the correlation between sex and PD is not consistent between studies. 
Rather, the greater periodontal destruction observed in some studies has been 
linked with gender-related behaviour, for example reduced access to dental care 
and less stringent oral hygiene practice by men (AlJehani, 2014). 
 
A plethora of environmental and systemic factors deem an individual to be at an 
increased risk of developing of PD. These include, but are not limited to, smoking, 
diabetes, CVD, stress, obesity, osteoporosis and pregnancy (AlJehani, 2014).   
 
1.2 Microbiology of Periodontal Disease  
1.2.1 Composition of dental plaque biofilm 	
As aforementioned, the presence of a dental plaque biofilm is required for the 
initiation of PD. Therefore dental plaque is the primary etiological agent of PD and 
has been the focus of myriad studies investigating the disease.  
 
The evolution of new technologies has been a powerful tool for the study of the 
human microbiome. Conventional cultural methods prevented complete analysis of 
the bacterial diversity within the oral cavity, as many species are uncultivatable. 
This limitation was overcome by 16S ribosomal RNA (rRNA) profiling, particularly 
with the development of next generation sequencing (NGS) (Kilian et al., 2016). It 
has been estimated that over 700 species of bacteria reside within the oral cavity. 
Specifically, the periodontal pocket may harbour approximately 400 of these 
bacterial species and in general dental plaque is composed of around 100 different 
species (Paster et al., 2006).  
 
The development of an oral biofilm is initiated by the adherence of Streptococci 
and Actinomycetes species to salivary proteins covering the tooth surface, including 
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glycoproteins and mucins, through outer membrane proteins and pili (van Houte, 
1982). Subsequently, bacteria of the same or different genera adhere and aggregate 
to the early colonizers of the tooth surface, leading to eventual colonization of 
bacteria including Prevotella, Proprionibacteria and Veillonella. Whilst species 
within early colonizers would not typically aggregate with bacteria of the late 
colonizers, the adherence of intermediate colonisers, such as Fusobacterium 
nucleatum, acts as a link between members of the biofilm (Kolenbrander, 2000).  
 
The microbiome within the oral cavity is heterogeneous. Distinct microbial biofilms 
associate with different niches within the mouth, including teeth, supragingival 
surfaces, subgingival surfaces, tongue, soft and hard palate (Xu et al., 2015, 
Dewhirst et al., 2010). Likewise, different biofilms associate with health and 
disease. Socransky initially identified three ‘red complex’ bacterial species residing 
in subgingival plaque that most commonly associated with PD. The ‘red complex’ 
included Porphyromomas gingivalis (P. gingivalis), Tannerella forsythia (T. 
forsythia) and Treponema denticola (T. denticola) (Socransky et al., 1998). P. 
gingivalis was isolated from 25% of individuals displaying periodontal health but 79% 
of PD patients (Griffen et al., 1998). Not strictly complying with Koch’s postulates, 
P. gingivalis and the other ‘red complex’ bacteria were isolated from healthy 
individuals in low numbers, but were below the detectable limit post PD treatment 
and were found to increase upon PD regression (Costalonga and Herzberg, 2014). 
With the emergence of 16S rRNA NGS, 123 bacterial species were found in greater 
abundance in PD. These included previously described Spirochaetes and 
Bacterioidetes species, and Sinergistes. In healthy subgingival biofilms, 53 bacterial 
species – including Proteobacteriae – were found in greater numbers (Griffen et al., 
2012). The association of PD with a plethora of bacterial species implied that 
inflammation resulted from a polymicrobial infection.  
 
As specific bacteria could not be solely attributed to the development of PD, the 
dysbiosis hypothesis emerged. Hajishengalis et al (2011) illustrated that P. 
gingivalis present in small numbers within a biofilm mediated changes in the 
composition and abundance of commensal bacteria. The shift from a health-
associated biofilm to a dysbiotic PD-associated biofilm altered crosstalk with the 
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host, in a manner that was sufficient to induce inflammation and ultimately 
alveolar bone destruction (Hajishengallis et al., 2011b). Since P. gingivalis thrived 
at low frequencies, but had the capacity to modulate members of the biofilm, it 
was entitled a ‘keystone pathogen’ (Darveau et al., 2012). Interestingly, in an 
animal model lacking commensal bacteria, P. gingivalis was unable to induce bone 
loss, despite its maintained ability to colonize the mouth. The phrase, 
‘polymicrobial synergy and dysbiosis’ has been used to describe the changes in the 
oral biofilm that associate with disease (Hajishengallis et al., 2011).  
  
Animal models of PD have demonstrated that P. gingivalis does not directly destroy 
host alveolar bone, but rather alters the proportion and composition of commensal 
bacteria, disrupting homeostatic host-biofilm crosstalk, thereby leading to alveolar 
bone loss. Nonetheless, the presence of P. gingivalis in periodontal health indicated 
that the keystone pathogen does not consistently lead to disease. However, it is 
likely that genetic and environmental factors make an individual susceptible to PD. 
PD may now defined as a dysregulated immune response to a dysbiotic oral biofilm. 
 
1.2.2  Porphyromonas gingivalis 
 
Although clearly not in isolation causative of PD, P. gingivalis remains the most 
studied PD-associated bacteria and is commonly used in animal models. P. gingivalis 
is a non-motile, rod shaped, gram-negative anaerobe belonging to the phylum 
Bacteroidetes (Holt and Ebersole, 2005). Whilst the pathogenicity of different 
strains varies (table 1.2), P. gingivalis exerts a wide array of virulence factors that 
permit its establishment and survival within a host. 
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Table 1.2. Features of different strains of P. gingivalis isolated from humans. 	
Strain of P. gingivalis FimA type Capsular serotype Virulence 
W83 IV K1 High 
W50 IV K1 High 
HG184 II K2 High 
A7A1-28 (ATCC 53977) II K3 High 
ATCC 49417 II K4 High 
HG1690 II K5 High 
HG1691 Ib K6 High 
381 I No capsule Low 
ATCC 33277 I No capsule Low 
 
 
1.2.2.1  P. gingivalis virulence factors 
(i) Adherence 
 
In order for P. gingivalis to colonize the oral cavity, it must first adhere to the 
surface. The fimbriae, and precisely the major fimbrial component (FimA), are 
required for the adherence of the bacteria to the saliva-coated surfaces within the 
oral cavity (Malek et al., 1994). Inactivation of the fimA gene generated a P. 
gingivalis mutant incapable of fibrillin production and hence the mutant displayed 
incomplete fimbriae. Whilst this mutant was able to coaggreagte with 
Streptococcus gordonii G9B almost as efficiently as wildtype (WT) P. gingivalis 381, 
its capacity to bind to saliva-coated hydroxyapatite was significantly reduced along 
with an impaired ability to cause bone loss in a rat model of PD (Malek et al., 
1994). Additionally, the hemagglutinin domains of gingipains function in the 
adherence and colonization of P. gingivalis through direct adhesion to extracellular 
matrix (ECM) proteins and indirectly through the ability to process the fimbrillin 
subunit of fimbriae (Chen et al., 2001). The genes hagB and hagC encode two highly 
homologous hemagglutinins. P. gingivalis W83 mutants of either hagB or hagC 
showed less adherence to oral epithelial cells than WT bacteria. Surprisingly, a 
double mutant lacking expression of both genes displayed a reduction in capacity to 
adhere to cells than WT P. gingivalis, but increased adherence compared to single 
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mutants. This was explained by an increase in gingipain RgpA and Kgp gene 
expression (Connolly et al., 2017). 
 
(ii) Gingipains 
 
Gingipains are membrane bound cysteine proteases, which exert their functions 
upon secretion (Chen et al., 2001).  Gingipains are either arginine-specific (RgpA or 
RgpB) or lysine-specific (Kgp) proteases (Wilensky et al., 2013), and their activity is 
directly responsible for host tissue damage that promotes P. gingivalis colonization 
within the oral cavity. Major components of the periodontal connective tissue (type 
I and IV collagen) and ECM ptoteins, including laminin and fibrinogen, are subjected 
to gingipain-mediated tissue destruction (Holt et al., 1999). Furthermore, gingipains 
enhance survival of P. gingivalis in the gingival pocket through the capacity to 
attach to other bacteria and to host cells (Sheets et al., 2006), as well as providing 
a source of nutrition by cleavage of host proteins (Holt et al., 1999). As will be 
discussed below, gingipains are a key factor in host immune evasion strategies 
employed by P. gingivalis.  
 
(iii) Capsule Barrier 
 
Persistence of P. gingivalis within the host is aided by its capsule (Grenier and 
Mayrand, 1987). Primarily, the capsule acts as a barrier, preventing access of 
destructive host effectors to the bacterium (Singh et al., 2011). Furthermore, the 
increased hydrophobicity of the capsule is thought to reduce complement 
activation, thereby opsonization and subsequent phagocytosis are evaded 
(Schifferle et al., 1993a). Contributing to the inability to activate complement, the 
capsule can also conceal lipopolysaccharides (LPS) and other bacterial structures 
that are capable of inducing the host’s immune response (Schifferle et al., 1993b). 
Additionally, the hidden immune-inducing structures of P. gingivalis present 
implications for dendritic cell (DC) maturation. To mature, the immature DC must 
encounter antigen and subsequently upregulate CD11c, CD40, CD86 and major 
histocompatibility complex (MHC) class II expression on the surface of the cell. 
Using flow cytometry to determine the presence of these markers, it was 
demonstrated that a non-encapsulated mutant P. gingivalis strain triggered faster 
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DC maturation than that by the encapsulated W50 strain (Singh et al., 2011). 
Furthermore, presence of a capsule has been shown to modulate pro-inflammatory 
cytokine secretion by human fibrobasts in vitro (Brunner et al., 2010). The capsule 
therefore enhances P. gingivalis survival, promoting a prolonged infection and low-
grade chronic inflammation.  
 
1.2.2.2  P. gingivalis and immune system evasion 
(i) Gingipains and complement 
 
The activation of complement by the classical, alternative or mannose-binding 
lectin pathways forms part of the innate response (Song, 2012). C3 is an important 
complement component as its cleavage produces C3a and C3b. C3b opsonizes a 
pathogen to enhance phagocytosis, whilst C3a functions as an anaphylatoxin, 
thereby recruiting phagocytes. P. gingivalis is able to evade complement through 
heterodimeric high-molecular-mass RgpA (HRgpA), which cleaves C3 resulting in the 
production of C3b. This active fragment is then degraded, and hence becomes 
inactive (Popadiak et al., 2007). Thus, gingipains are again shown to be crucial for 
the survival of P. gingivalis.  
 
Toll-like receptors (TLRs) are structurally related, pattern recognition receptors 
expressed on the cell surface, which respond to microbial pathogens (Song, 2012). 
Cross talk between complement and TLRs is essential to coordinate an appropriate 
early innate immune response, and therefore provides a target for which invading 
pathogens can manipulate to enhance their survival (figure 1.3). Whilst P. 
gingivalis has been shown to generally inhibit the complement casacade, the 
bacterium has been shown to generate C5a through its C5 convertase-like enzyme. 
The production of C5a inhibited intracellular killing and enhanced the ability of the 
bacteria to survive within macrophages, an observation also noted in interferon 
gamma (IFN-γ) primed macrophages (Wang et al., 2010a). Further studies of these 
observations demonstrated that C5a together with P. gingivalis – in an intracellular 
Ca2+ dependent manner – synergistically increased intracellular cyclic adenosine 
monophosphate (cAMP) levels within macrophages, over three fold greater than 
that induced by P. gingivalis alone (Wang et al., 2010a). This has important 
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implications in the survival of P. gingivalis as cAMP can trigger immunosuppressive 
signaling (Parry and Mackman, 1997). The increase in cAMP levels was also 
dependent on TLR2, with confocal microscopy illustrating that in P. gingivalis–
infected macrophages, C5a receptor (C5aR), TLR2 and P. gingivalis all locate within 
close proximity of each other. P. gingivalis therefore induces subversive cross talk 
between complement and TLR2 in order to suppress cytokine signaling (Wang et al., 
2010a). Furthermore, TLR2 is fundamental for immune evasion by P. gingivalis as 
TLR2 deficient mice and TLR2 deficient macrophages are able to rapidly clear 
infection (Liang et al., 2011). 
 
	
Figure 1.3. The cross talk between toll-like receptors and complement. 
Pathogen-associated molecular patterns (PAMPS) can activate both Toll-like 
receptors (TLRs) and complement. The activation of complement, through the 
functions of G protein-coupled C5a and C3a receptors, regulates TLR signaling. 
Thus, complement activation regulates intracellular signaling molecules such as 
mitogen-activated protein kinase (MAPK) and therefore transcription factors such as 
nulear factor-kappa B (NF-κB), highlighting the importance of crosstalk between 
TLRs and complement. Decay-accelerating factor (DAF) is a negative regulator of 
complement hence its absence results in amplified complement activation and TLR 
signaling  (adapted from (Zhang et al., 2007)). 
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Additionally, binding of C5a to its receptor can also prevent the expression of 
Il12p35, Il12, Il23p40 and Il23p19 messenger RNA (mRNA), along with inhibiting IL-
12p70 and IL-23 protein expression through inhibition of TLR4 (Hawlisch et al., 
2005). This function is required to prevent T helper (Th) 1 and Th17 subset-
mediated tissue damage in health. The binding of C5a to C5aR also inhibits nitric 
oxide (NO) production in activated macrophages, a process exploited by various 
pathogens. Therefore, unregulated production of C5a by P. gingivalis can interfere 
with the initiation of T cell polarization and production of NO – ultimately 
restricting the induction of a protective immune response (Wang et al., 2010a).  
 
The ability of P. gingivalis to exert many of its pathogenic effects and alter the 
commensal abundance of an oral biofilm is complement dependent (Liang et al., 
2011, Hajishengallis et al., 2011b). In a P. gingivalis-induced PD model, the burden 
of P. gingivalis was reduced by 99% following inhibition of C5aR and concomitantly, 
a reduction in total oral anaerobic bacterial load was observed – to numbers present 
prior to P. gingivalis infection. The C5aR inhibition had no impact on the number of 
bacteria in the mouths of uninfected mice, demonstrating that blockade of C5aR 
does not directly effect commensal oral bacteria but rather the effect is mediated 
through P. gingivalis (Hajishengallis et al., 2011b).  
 
(ii) Antagonism of TLR4 
 
Upon recognition of the lipid A component of gram negative bacterial LPS by TLR4, 
a strong innate immune response is initiated through downstream signaling (figure 
1.4). TLR4 undergoes oligomerization following recognition of LPS, and through 
binding with Toll-interleukin-1 receptor (TIR), adaptor proteins are recruited. TLR4 
is able to recruit and signal through each of the five known TIR-containing adaptors 
– MyD88, TIRAP, TRIF, TRAM and SARM – a unique feature of this TLR. The signal 
transduction pathway of TLR4 can therefore be categorized into MyD88-dependent 
or MyD88-independent pathways, whereby the dependent pathway mediates pro-
inflammatory cytokine production and the independent pathway mediates the 
expression of Type I interferons (reviewed by(Lu et al., 2008). P. gingivalis, 
however, is able to evade and potently antagonise the TLR4 receptor, inhibiting the 
induction of this immune response. Endogenous lipid A 1- and 4’-phosphatases 
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function to alter P. gingivalis lipid A to its non-phosphorylated form, which is 
immunologically ‘silent’ and permits evasion of TLR4 activation. Still, in 
microenvironmental conditions where the concentration of hemin is high, lipid A 1- 
and 4’-phosphatase activities are inhibited, generating mono-phosphorylated tetra-
acylated lipid A that antagonizes TLR4, thereby actively suppressing immunity. 
Whilst the presence of lipid A TLR4 agonists were evident in P. gingivalis LPS 
isolates, strong TLR4 activation did not occur, suggesting that presence of immune 
evading or suppressing lipid A exerted dominance over the agonistic functions 
(Coats et al., 2009).  
 
	
Figure 1.4. Typical LPS/TLR4 signaling compared to P. gingivalis LPS antagonism 
of TLR4. 
LPS directly binds to LPS binding protein (LBP), which is the bridge between the 
association of CD14 and LPS. LPS is then transferred to the TLR4/MD2 receptor 
complex by CD14 and TLR4 undergoes oligomerization. Adaptor proteins are then 
recruited, resulting in either MyD88 dependent or independent signaling leading to 
the production of proinflammatory cytokines or type I interferons, respectively. In 
contrast, the lipid A component of P. gingivalis LPS is a potent antagonist of TLR4, 
hence the downstream signaling does not occur, preventing the production of 
inflammatory cytokines and interferons (Adapted from Lu et al., 2008). 
 
(iii) Surface molecule modulation 
 
Membrane-bound TLR co-receptor CD14 on macrophages is a receptor for LPS. 
CD14, in its soluble and biologically active form, interacts with cells that do not 
typically express the receptor itself, including epithelial and endothelial cells. This 
interaction enables endothelial or epithelial cells to become activated and induce 
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an inflammatory response that prevents bacterial colonization. Again, gingipains 
can interfere with this process by cleaving membrane-bound CD14 of macrophages. 
The cleavage of CD14 was concomitant with a reduction in TNF-α production and 
phagocytosis, in both human and murine macrophages (Duncan et al., 2004, 
Wilensky et al., 2015). 
 
T cells are crucial components of adaptive immunity (discussed later) and like other 
constituents of the immune response; T cells can be targeted by P. gingivalis. 
Gingipains have the capacity to manipulate T cells, through the binding of RgpA and 
Kgp gingipains to CD4 and CD2. In the gingipain bound state, CD4 and CD2 are 
cleaved, preventing anti-CD4 and anti-CD2 antibody labeling for flow cytometry. 
Further still, as CD4 is required for the binding of a T cell to its cognate antigen 
presented within MHC-II and CD2 is required for cell-cell interactions, RgpA and Kgp 
have the potential to reduce the ability of T cells to elicit an appropriate immune 
response (Yun et al., 2005).  
 
(iv) Interference with cytokines and chemokines 
 
A number of cytokines and chemokines are expressed in healthy periodontal tissues. 
IL-8 is expressed by epithelial cells at the interface with bacterial cells, thereby 
creating a gradient of expression directing neutrophil migration to the area of 
bacterial colonization whilst preventing damage to the periodontal tissues (Darveau 
et al., 1998). Neutrophils are important in initial protection against plaque bacteria 
– highlighted by the fact that patients with low neutrophil numbers or reduced 
neutrophil function often suffer from severe periodontitis (Madianos et al., 1997). 
Interestingly, it has been shown that neutrophil migration is not stimulated by P. 
gingivalis and in fact migration triggered by microbial stimuli is blocked by P. 
gingivalis. This phenomenon is linked with the ability of P. gingivalis to adhere to 
and invade epithelial cells, leading to reduction of IL-8 and intracellular adhesion 
molecule (ICAM)-1 expression (Madianos et al., 1997, Darveau et al., 1998). It was 
later found to be SerB, a haloacid dehydrogenase family phosphoserine phosphatase 
enzyme, located on the outer membrane of P. gingivalis that was responsible for 
the IL-8 inhibition, known as chemokine paralysis (Bainbridge et al., 2010). SerB is 
released from the membrane upon contact with gingival epithelial cells (Zhang et 
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al., 2005), however in both its membrane bound and released states, it can 
interfere with signaling pathways of the host cell which are responsible for 
cytoskeletal regulation. This causes rearrangements of actin microfilaments and 
tubulin microtubules, allowing invasion of the cell and inhibition of IL-8 secretion 
(Tribble and Lamont, 2010). SerB was imperative for the intracellular survival of P. 
gingivalis (Hasegawa et al., 2008) and for optimal bone loss in a rat model of PD 
(Bainbridge et al., 2010). 
 
Furthermore, P. gingivalis FimA mediated TLR2 signaling induced production of IL-
10 by naïve CD4+ T cells in a murine systemic infection model. This IL-10 
subsequently inhibited the production of IFN-γ by T cells, a response that is thought 
to help control early P. gingivalis infection (Gaddis et al., 2013).  
 
Not only is P. gingivalis able to inhibit cytokine production but it can also degrade 
cytokines that have been translated by human gingival epithelial cells (GEC). Whilst 
IL-8 was found to be downregulated by P. gingivalis, gene expression of Il6 and Il8 
by GECs stimulated with P. gingivalis was significantly increased by comparison to 
non-challenged GECs. Therefore, cytokine reduction by P. gingivalis is not 
consistently controlled at the transcriptional level. Kgp has the capacity to degrade 
IL-6, IL-8 and IL-1β, whilst RgpA and RgpB contribute only to the destruction of IL-8 
and IL-1β (Stathopoulou et al., 2009a). Arginine-specific gingipains have been 
shown to decrease the accumulation of IL-2 in Jurkat T cells co-cultured with P. 
gingivalis, despite the initial increase in Ca2+ concentration and reactive oxygen 
species (ROS) production. As IL-2 is fundamental for proliferation and 
communication of T cells, P. gingivalis may have the ability to downregulate and 
evade the adaptive immune response (Khalaf and Bengtsson, 2012).  
 
In addition to inhibition and degradation of cytokines, P. gingivalis can influence 
specific T cell cytokine production. Owing to differences in sugar composition and 
structure of the different capsular serotypes, which are determined by locus 
PG0106 – PG0120 variations, DC maturation may be influenced by specific strains of 
P. gingivalis. Thereby, the induction of a Th immune response is dictated by the 
capsular serotype in vitro. Th1 and Th17 immune responses were primed by DCs 
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previously exposed to K1 (W83) or K2 (HG184) serotypes (Vernal et al., 2014), which 
induce quantitatively stronger cytokine profiles (Vernal et al., 2009). A Th2 
response was primed upon weak co-stimulation during antigen presenting and hence 
weak DC maturation by K3 (A7A1-28), K4 (ATCC41497) and K5 (HG1690) (Vernal et 
al., 2014). Interestingly, it has been suggested that the K- strain (ATCC33277) (non-
encapsulated) may prime a regulatory T cell (Treg) immune response characterized 
by IL-10 and TGF-β1 (Vernal et al., 2014). 
 
A plethora of P. gingivalis virulence factors maintain its ability to colonize and 
survive in a host, with the pathogenicity predominantly aimed at suppressing the 
host’s immune responses, including T cells (table 1.3).  
 
Table 1.3. Virulence factors exerted by P. gingivalis that modulate T cell 
immunity. 
Modulation of T cell 
immunity P. gingivalis virulence Reference 
Inhibition of IL-2 production Arginine-specific gingipains 
(Khalaf and 
Bengtsson, 
2012) 
Inhibition of T cell IFN-γ 
production FimA 
(Gaddis et al., 
2013) 
Activation of specific Th 
cell subset Capsular serotype 
(Vernal et al., 
2014) 
Cleavage of CD2 and CD4 Lysine and arginine-specific gingipains 
(Yun et al., 
2005) 
Inhibition of Th1 and Th17 
activation through TLR4 
inhibition 
C5 convertase-like enzyme (Wang et al., 2010a) 
 
	  
 34	
1.3 T cells in PD 
1.3.1 T cells 
 
T cells are pivotal in the functioning of adaptive immunity. T cells are capable of 
direct killing of infected cells, and they have the ability to mediate the cellular 
microenviroment in which they reside (table 1.4). The importance of T cells is 
evident in X-linked SCID. Infants affected by this condition suffer from severe, 
persistent or recurrent infections and without reconstitution of the immune system, 
the infant will die, typically within the first year of life (Myers et al., 2002). 
Furthermore, deficiency of CD4+ T cells as a result of human immunodeficiency 
virus (HIV) leads to the devastating effects of acquired immunodeficiency syndrome 
(AIDS) that encompass opportunistic infections and cancer, ultimately resulting in 
death (Simon et al., 2006). 
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1.3.2 T cell development in the thymus 
 
Lymphocyte progenitors leave the bone marrow and enter the thymus via the 
bloodstream, where the cells lose the potential to become B cells or natural killer 
(NK) cells and instead develop into T cells (figure 1.5). The complex architecture of 
the thymus and its array of specialized cell types are vital for the generation of 
antigen-specific T cells. Genetic defects in humans (e.g. DiGeorge syndrome), or 
thymectomy in neonatal mice that result in the lack of a thymus cause a marked 
reduction in T cell numbers both in circulation and in peripheral tissues resulting in 
immunodeficiency and premature death (Miller, 1961, Miller, 1962, Davies, 2013).  
 
The committed T cell progenitors arrive in the thymus as double negative (DN) 
cells, thereby CD4 or CD8 molecules are absent. The progression of development of 
these DN cells is based on the expression of CD44 and CD25, whereby DN1 cells, 
which are CD44+ CD25-, sequentially develop to DN2 cells – CD44+ CD25+ – then DN3 
cells – CD44- CD25+ – and finally DN4, which do not express either CD44 or CD25 
(Godfrey et al., 1993).  
 
The T cell receptor (TCR) is known to be composed of α and β chains or γ and δ 
chains, and its presence is required for T cell development beyond DN3 (Malissen et 
al., 1995). The events that result in differentiation of DN cells to αβ or γδ 
expressing T cells remain somewhat elusive, but strength of TCR signaling is thought 
to play a role (Hayes et al. 2005). Pre-TCRα is expressed by T cell precursors that 
develop into T cells expressing αβ TCRs. This pre-TCRα pairs with a β chain (von 
Boehmer and Fehling, 1997). Unlike the pre-TCRα chain that is the product of a 
non-rearranging locus, the β chain is encoded by a locus that – through the 
expression of recombination-activating gene (RAG) 1 and RAG2 – undergoes somatic 
DNA arrangements. The β chain is composed of variable (V), diversity (D), joining 
(J) and constant (C) regions (Abbey and O'Neill, 2007). The αβ pre-TCR is associated 
with the CD3/ζ complex on the surface of the cell (van Oers et al., 1995) and 
providing the TCR has the capacity to successfully transmit signaling, the β chain is 
selected for, allowing maturation of the T cell to continue. Precursor T cells in 
which the pre-TCR complex prevents important adaptor and enzyme expression, are 
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unable to actively signal and hence maturation is halted (Negishi et al., 1995, van 
Oers et al., 1996).  
 
Following the selection of a β chain, the T cell divides approximately six times and 
subsequently recombination of the genes at the TCRα locus occurs, producing the 
mature α chain of the TCR. The pre-TCRα is lost during this phase and so the T cell 
expresses small numbers of the αβ TCR with the CD3/ζ complex on the cell surface 
(Hoffman et al., 1996, Dudley et al., 1994). The T cells at this stage begin to 
express CD8 and CD4 co-receptors, resulting in an abundance of CD8+ CD4+ (double 
positive (DP)) T cells expressing an αβ TCR.  
 
Selection of DP immature T cells expressing appropriate αβ TCRs ensues by death by 
neglect, negative selection, positive selection and lineage-specific development 
(von Boehmer et al., 1989, Robey and Fowlkes, 1994). In the outer cortex of the 
thymus, DP cells interact with cortical epithelial cells that express high levels of 
MHC-I and MHC-II. The vast majority of DP cells exert weak, inadequate interactions 
between TCRs and MHC ligands expressing self-peptide, resulting in death by 
neglect, as the DP cell does not receive critical survival signals. Conversely, DP cells 
that bind to self-peptide presented within MHC too strongly receive signals that 
trigger rapid apoptosis – a process known as negative selection that typically occurs 
in the thymic medulla. Negative selection is a fundamental stage of T cell 
development as T cells with a high avidity for self-peptide (self-reactive) could 
elicit autoimmune pathology upon release from the thymus (Starr et al., 2003). 
Cells that bind self peptide with less avidity than those that are deleted can 
differentiate into Tregs (Maloy and Powrie, 2001). DP cells that engage with MHC-
self-peptide with an appropriate intensity are positively selected for in the 
medulla. Positive selection occurs in fewer than 5% of DP cells, permitting survival 
of those with functional TCRs and supports downregulation of a co-receptor, giving 
rise to a population of single positive CD4+ or CD8+ T cell (Starr et al., 2003). T 
cells that recognize peptide presented within MHC-I or MHC-II become CD8+ or CD4+ 
lineage-specific T cells, respectively, and are permitted to exit the medulla for 
entry to peripheral lymphoid tissues. 
 
 38	
 
 
Figure 1.5. T cell development in the thymus. 
Lymphocyte progenitors exit the bone marrow and enter the thymus via blood. The 
lymphocyte progenitors then become committed T cells. Initially, the committed T 
cells are absent of CD4 or CD8 surface expression and are known as double negative 
(DN) cells. DN cells undergo four stages, illustrated by the expression of CD44 and 
CD25: DN1 (CD44+ CD25-); DN2 (CD44+ CD25+); DN3 (CD44- CD25+); and DN4 (CD44- 
CD25-). Through differentiation of DN cells from DN2 to DN4, cells express a pre-
TCR consisting of a non-rearranging pre-TCRα and a rearranging β chain. Upon β 
chain selection, the cells divide approximately six times and subsequently 
expression of pre-TCRα is replaced with a rearranged mature α chain. The cells 
expressing a mature αβ TCR begin to express CD4 and CD8 and are, at this stage, 
known as double positive (DP) cells. DP cells engage with cortical epithelial cells 
through binding of their TCR to self-peptides presented within major 
histocompatibility complexes (MHC). DP cells that bind self-peptide-MHC with weak 
avidity undergo apoptosis through a lack of TCR-mediated survival signaling, a 
process known as death by neglect. DP cells that bind self-peptide-MHC too strongly 
also undergo apoptosis, however, this active negative selection results in rapid 
apoptosis. DP cells that bind self-peptide-MHC appropriately are positively selected 
and mature into single positive CD8 or CD4 T cells, depending on TCR recognition of 
MHC-I or MHC-II, respectively. Diagram adapted from (Germain, 2002). 
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1.3.3 Antigen presentation and T cells in PD 
 
Dendritic cells (DCs) are antigen presenting cells (APCs) with the capacity to 
stimulate naïve T cell proliferation and activate a specific immune response, more 
potently than other APCs (Banchereau and Steinman, 1998, Banchereau et al., 
2000). The maturation state and anatomical location in which the DCs reside 
dictate the morphology that the DC will assume. As the oral mucosa is composed of 
numerous microenvironments, oral DC phenotypes will differ depending on the site 
inhabited by the DC (table 1.5) (Hovav, 2014).  
 
Whilst the oral cavity may be considered a site of tolerance induction (Novak et al., 
2008), upon pathogen insult, DCs effectively prime a T cell response (Iwasaki and 
Medzhitov, 2015).  
 
 
Table 1.5. DC subtypes that reside within the gingiva. 	
DC subtype Cell surface markers Location in gingiva 
Langerhans cell Langerin 
CD11c 
Ep-CAM 
MHC-II 
Epithelium 
Interstitial DC CD11c 
CD11b 
MHC-II 
Lamina propria 
CD103+ Interstitial DC CD11c 
CD11b 
CD103 
MHC-II 
Lamina propria 
Macrophage-like DC CD11b 
F4/80 
MHC-II 
Lamina propria 
Adapted from  (Wilensky et al. 2014).  
 
 
DCs patrol the peripheral tissues in an immature state, characterized by optimal 
phagocytosis function. Pathogen associated molecular patterns (PAMPs) of invading 
pathogens are recognized through TLRs, stimulating phagocytosis and processing of 
the pathogen by DCs. The DC then matures and expresses chemokine receptor 7 
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(CCR7) on its surface, enabling migration to the draining lymph node (dLN). During 
migration, the DCs upregulate expression of MHC-II and co-stimulatory molecules to 
permit efficient activation of CD4+ T cells in dLNs (Wilensky et al., 2014) (figure 
1.6). Clustering of mature DCs with CD4+ T cells has been observed in lamina 
propria of PD gingival tissues suggesting that in addition to activation of T cells 
within LNs, T cells might be primed at the local site of infection (Jotwani et al., 
2001). 
 
Langerhans cells (LCs) exist in low frequencies in health (Allam et al., 2008). An 
increase in abundance of gingival LCs followed accumulation of dental plaque and 
likewise, the numbers of LCs lessened with elimination of plaque (Dereka et al., 
2004). In a model of gingivitis, numbers of LCs increased until day 14, following 
which the numbers decreased, reaching baseline frequencies at day 21 (Moughal et 
al., 1992). However, Gemmel et al (2002) reported no differences in LC number 
between health, gingivitis and PD (Gemmell et al., 2002) and further still, the 
majority of studies found a decrease in the presence of LC cells in PD (Crawford et 
al., 1989, Cury et al., 2008, Séguier et al., 2000, Stelin et al., 2009). The latter 
studies imply that LCs migrate out of gingival tissues as inflammation amplifies. 
Differences between the studies may be explained by varying sampling techniques 
and stages of disease. As a decrease in intraepithelial LC presence is observed in 
the aging population and the incidence of PD increases, Wilensky et al have 
speculated that the decrease in LCs in PD observed in some studies is likely a true 
reflection LC behaviour in disease (Wilensky et al., 2014).  
 
Specific deletion of LCs was made possible through the use of langerin-DTR mice 
and was employed to evaluate LCs role in P. gingivalis-induced PD. A lack of LCs 
was concomitant with increased infiltration of T cells and B cells and exacerbated 
alveolar bone loss (Arizon et al., 2012). Furthermore, LCs were capable of 
stimulating Treg generation, which inhibited IFN-γ and subsequently resulted in a 
reduction in the expression of receptor activator of nuclear factor κB ligand 
(RANKL) on CD4+ T cells (Arizon et al., 2012). Furthermore, LCs are incapable of 
antigen presentation, which is instead primarily conducted – in the context of P. 
gingivalis antigens – by interstitial DCs (iDCs) to both CD4+ and CD8+ T cells, which 
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indicates that iDCs within the lamina propria can process and present oral 
pathogens causing activation of specific T cells. Rather, LCs inhibit the priming of 
specific T cells by iDCs (Arizon et al., 2012). DC subtypes within the oral cavity 
therefore play different roles in priming of T cells and regulating the inflammatory 
response characteristic of PD.  
 
	
Figure 1.6. Priming of T cells by dendritic cells. 
Dendritic cells (DC) patrol the peripheral tissues in an immature state. Pathogen 
associated molecular patterns of invading microbes are recognized through toll-like 
receptors (TLRs), stimulating phagocytosis and processing of the pathogen by DCs. 
The DC then matures and expresses chemokine receptor 7 (CCR7) on its surface, 
enabling migration to the draining lymph node (dLN). During migration, the DCs 
upregulate expression of MHC and co-stimulatory molecules to permit efficient 
activation of CD4+ T cells in lymph nodes (LN). Activated T cells exit the LN and 
migrate to the site of infection, where they exert effector functions and clear 
infection. Adapted from (Wilensky et al., 2014). 
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1.3.4 T cells in PD 
1.3.4.1  Cytotoxic CD8+ T cells 	
Cytotoxic T cells are CD8+ cells that recognize altered self-antigen presented in 
MHC-I from infected host cells (Zinkernagel, 1997). Activation of naïve CD8+ T cells 
is dependent upon: 1) specific antigen stimulation through the TCR; 2) co-
stimulation through binding of ligands to CD28, CD40 or ICOS; and 3) binding of 
cytokines (IFN-α and IL-12) to the receptor present on the cell surface (Curtsinger 
et al., 1999). Signals 1 and 2 alone will enable proliferation of the specific CD8+ T 
cells but only few will survive and these will become tolerant. Only in the presence 
of signal 3 will the activated T cells survive and develop effector function 
(Curtsinger et al., 2003). Clonal expansion of specific CD8+ T cells generates a vast 
pool of antigen-specific cytotoxic T cells that migrate to the site of infection. 
Pathogens are eliminated by host cell death through direct cell-cell contact or 
indirectly through the release of cytokines (Andersen et al., 2006). P. gingivalis is 
an interesting bacterium in that it invades and replicates within gingival epithelial 
cells  (GECs) (Belton et al., 1999), suggesting a niche for CD8+ T cells in PD. Studies 
have implied that CD8+ T cell number (Cifcibasi et al., 2015b) and phenotype (Petit 
et al., 2001) differ in patients with established PD. However, there are few studies 
indicating the role of these cells in disease.  
 
1.3.4.2  CD4+ T cells 	
Naïve CD4+ T cells, usually within secondary lymphoid organs, recognise their 
cognate antigen presented within MHC-II of an APC. Complete activation of specific 
naïve CD4+ T cells, like CD8+ T cells, is dependent on other signals. Binding of 
CD28, CD40 or ICOS to ligands present on APCs is necessary for the cell to receive 
co-stimulation signals. Whilst these two signals are sufficient for CD4+ T cell 
proliferation, IL-2 – as a third signal – doubles the proliferation rate of CD4+ T cells, 
hence three signals are necessary for optimal activation and proliferation 
(Curtsinger et al., 1999, Pape et al., 1997). The cytokine milieu in which antigen-
specific naïve CD4+ T cells become activated dictates the genetic programming and 
subsequently differentiation into specific Th subsets (figure 1.7). Th subsets 
include Th1, Th2, Th17, Th9, Th22, Treg and T follicular helper cells (Tfh).  
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Figure 1.7. CD4+ T helper subsets. 
Naïve CD4+ T cells become activated when presented with their cognate antigen 
non-covalently bound to MHC-II of an APC, with co-stimulation and appropriate 
cytokines. The cytokine milieu present (shown on the black arrows from naïve CD4+ 
T cells to specific subset) when naïve CD4+ T cells become activated dictate the Th 
subset into which the naïve cell will differentiate. Members of STAT family that are 
associated with specific subsets are shown above the cell and transcription factors 
are shown within the cell. The cytokines produced by each subtype are shown by 
the black arrows leaving the cells, and inhibitory cytokines are shown in red. *IFN-γ 
may not inhibit expansion of Th9 cells, but it inhibits the production of IL-9 by Th9 
cells. 
 
 
Deducing the CD4+ T cell contribution to PD has proven difficult. HIV-positive 
patients display reduced numbers of CD4+ T cells and are more commonly 
diagnosed with necrotizing periodontitis than their HIV-seronegative counterparts, 
which suggests a protective role of CD4+ T cells (Ryder et al., 2012). On the 
contrary, patients receiving immunosuppressive treatment, Cyclosporin A, often 
suffer gingival overgrowth but do not present with rapid progression of PD (Pejcic 
et al., 2014). This is despite a broad inhibition of T cells through blocking of 
calcineurin, which prevents nuclear factor of activated T cells (NFAT) activation 
(Ho et al., 1996). In a P. gingivalis-induced model of PD, C57BL/6J-Tcratm/Mom mice 
deficient in T cells showed reduced alveolar bone loss compared to normal C57BL/6 
mice (Baker et al., 2002). However, only depletion of CD4+ T cells, not CD8+ T cells 
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contributed to a reduction in alveolar bone loss (Baker et al., 1999a). A destructive 
role of CD4+ T cells in PD was thereby highlighted by the latter studies. 
 
Furthermore, efforts to decipher specific CD4+ Th cell responses in PD have proven 
contradictory. Th1 responses promote immunity to intracellular pathogens, whilst 
Th2 responses are protective against extracellular pathogens. It was initially 
assumed that the potential of human PD to progress was linked to the ratio of Th1 
to Th2 cells within gingival tissue. Th1 cytokines and chemokines were found more 
frequently in PD lesions than Th2 effectors, implying that Th1 cells posed a risk for 
development of PD (Seymour et al., 1993, Gamonal et al., 2001, Taubman and 
Kawai, 2001). Others demonstrated that unstimulated cells from patients with 
early-onset periodontitis (EOP, a form of aggressive periodontitis) (Manhart et al., 
1994) or advanced PD (Lappin et al., 2001) produced predominantly Th2 cytokines. 
However, co-existence of Th1 and Th2 cells in PD was also suggested, as gingival 
CD4+ T cells from PD patients produced cytokines characteristic of both Th1 and 
Th2 (Takeichi et al., 2000, Berglundh et al., 2002).  
 
Numerous studies have investigated the role of cytokines using animal models based 
on bacterial-induction of alveolar bone loss, using different members of the ‘red 
complex’. In a P. gingivalis-induced model of PD, a lack of IFN-γ conferred 
protection against alveolar bone loss (Baker et al., 1999a), whilst infection of IFN-γ 
knockout (KO) mice with A. actinomycetemcomitans resulted in reduced bone loss 
but also increased acute phase immune reaction, dissemination of the bacterial 
infection and eventual death (Garlet et al., 2008). It can therefore be postulated 
that IFN-γ contributes to bone loss in PD, yet in some contexts also provides 
protection against periodontal bacterial infections. The contribution of Th2 cells to 
bone destruction has also been debated. Th2 cells specific for A. 
actinomycetemcomitans were transferred to athymic rats orally infected with A. 
actinomycetemcomitans and the rats subsequently displayed reduced bone 
destruction compared to their athymic counterparts that received no T cells. It was 
therefore suggested that Th2 cells ameliorated the clinical symptoms of PD 
(Eastcott et al., 1994). Opposing this finding, STAT-6 deficient mice infected with 
T. forsythia did not develop bone loss to the extent of WT mice. As STAT-6 plays a 
 45	
role in Th2 polarisation through its involvement in downstream TLR2 signaling, this 
study implied that the TLR2-Th2 inflammatory response was a driver of alveolar 
bone loss (Myneni et al., 2011). Likewise, IL-33 – a Th2 cytokine - has recently been 
shown to exacerbate bone destruction following P. gingivalis infection (Malcolm et 
al., 2015a). Whilst there is a plethora of evidence indicating the presence of Th1 
and Th2 cells and mediators in the oral mucosa in human and murine PD, no 
definite conclusion has been drawn regarding the role of these cells in PD.  
 
With the emergence of Th17 cells, cytokines and chemokines emanating from the 
new Th subset were studied in PD, and IL-17A and IL-21 were identified in human 
periodontal lesions. The Th1/Th2 paradigm could not effectively describe the 
immune-mediated pathogenesis of PD (Gaffen and Hajishengallis, 2008). Th17 cells 
promote immunity to extracellular bacteria and fungi, particularly at mucosal sites; 
hence it seems plausible that they play a role in PD. Gingival tissue of PD patients 
have elevated gene expression of Th17 inducing cytokines (il1β, il6 and il21) 
compared to control tissue (Cardoso et al., 2009, Dutzan et al., 2012a, Gaffen and 
Hajishengallis, 2008). Whilst lower levels of TGF-β were found in disease (Dutzan et 
al., 2012a), it has been suggested that Th17 differentiation can occur in its absence 
(Ghoreschi et al., 2010). Further, IL-23p19-producing macrophages have been 
identified in severely inflamed PD lesion sites and have the potential to amplify the 
Th17 response through IL-23 secretion (Allam et al., 2011). IL-17, a cytokine 
indicative of an active Th17 response, has been identified at increased levels in PD 
patients compared to both gingivitis patients (Honda et al., 2008, Moutsopoulos et 
al., 2012) and healthy controls (Beklen et al., 2007, Cardoso et al., 2009, Allam et 
al., 2011, Adibrad et al., 2012, Awang et al., 2014), and T cells were shown to be 
the predominant source (Cardoso et al., 2009). The local cytokine milieu necessary 
for Th17 cell differentiation is likely promoted by the oral microbiota. Cell culture 
supernatants from human APCs stimulated by P. gingivalis induced a Th17 response 
– explained by the minimal release of IL-12p35, and the greater resistance of IL-1β 
to proteolytic degradation by gingipains compared with IL-12 (Moutsopoulos et al., 
2012). In addition to increased IL-17 in gingival crevicular fluid (GCF) from PD 
patients, IL-35 protein and ebi3 and il12a mRNA (components of IL-35) were also 
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found to be elevated. As IL-35 is a suppressor of Th17, it may be found in PD to 
compensate for the increased numbers of Th17 cells (Mitani et al., 2015).  
 
Whilst human studies found a clear association between Th17 cells and PD, the 
findings from mouse studies were ambiguous. Mice deficient in IL-17RA displayed 
increased alveolar bone loss when orally infected with P. gingivalis. In this model, 
IL-17-dependent neutrophil recruitment to the inflamed gingival tissue – imperative 
for defense against bacteria – was diminished, resulting in a total reduction of 
neutrophils to the site of infection and exacerbated bone loss (Yu et al., 2007). 
However, Del-1 deficient mice portrayed a role for IL-17 in the destruction of 
alveolar bone. Del-1 inhibits lymphocyte function-associated antigen (LFA)-
dependent neutrophil adhesion but is itself blocked by IL-17. Conflicting the 
observations made by Yu et al (2007), increased production of IL-17 and 
recruitment of neutrophils was found to cause spontaneous PD in this study (Eskan 
et al., 2012). Although Th17 cells are present in experimental PD, unlike human 
studies, a role in protection or destruction cannot be appointed. 
 
Perhaps, in part, explaining the conflicting evidence of Th cells identified in PD is 
Th cell plasticity. Th plasticity occurs when a differentiated Th cell expresses 
mediators associated with a different Th subtype. Whilst there is limited data 
supporting the occurrence of Th plasticity in PD, this phenomenon has been 
observed in other chronic inflammatory conditions. Th17 cells that display IL-12Rβ2 
have the capacity to co-express T-bet upon IL-12 stimulation, thereby enabling 
conversion to non-classical Th1 cells (Nistala et al., 2010). This has been observed 
in juvenile autoimmune arthritis, whereby the majority of Th17 cells in synovial 
fluid express both RORC2 and T-bet transcription factors (Nistala et al., 2010). In 
patients with fistulating Crohn’s disease, Th1, Th7 and Th1/Th17 intermediate cells 
were found infiltrating the fistula in greater numbers than in peripheral blood and 
it was therefore postulated that Th1/Th17 intermediate cells were a feature of 
inflammatory sites (Maggi et al., 2013). Furthermore, by comparison to healthy 
controls, an increase in IL-17 producing ‘Th2’ cells was observed in patients with 
atopic asthma. These Th2/Th17 cells expressed classical Th2 cytokines together 
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with IL-17 and IL-22, and transcription factors of both Th2 and Th17 subsets (Wang 
et al., 2010b).  
 
1.3.4.3  Memory T cells 
 
Specific T cells undergo clonal proliferation upon recognition of their cognate 
antigen and migrate to the site of infection, where CD4+ T cell cytokine production 
amplifies the immune response to the pathogen, or CD8+ T cells mediate direct 
killing of infected-host cells. Most of the specific effector T cells die as the immune 
response comes to an end; however, a few of these will become memory cells 
(MacLeod et al., 2010). Memory cells present the host with the advantage of a fast 
and effective immune response in the event of re-infection. By comparison to naïve 
T cells, memory T cells can respond to lower doses of antigen and decreased levels 
of co-stimulation (London et al., 2000, Kaech et al., 2002). Memory T cells 
therefore respond to the pathogen at earlier stages of infection, before extensive 
damage has been caused. Unlike naïve CD8+ T cells, memory CD8+ T cells 
constitutively express cytotoxic mediators, including perforin and granzyme B, 
permitting an immediate response upon re-infection (Bachmann et al., 1999). As 
memory CD4+ T cells undergo fewer proliferation cycles than naïve cells, it has 
been suggested that the protective role of memory CD4+ T cells are exerted 
through cytokine production and their influence on other immune cells, rather than 
direct killing (MacLeod et al., 2008). Based on expression of CCR7 and CD62L - and 
hence their anatomical location - memory T cells can be divided into two subsets – 
central memory (TCM, CD44+ CD62L+ CCR7+) and effector memory (TEM, CD44+ 
CD62Llo CCR7lo) T cells (Unsoeld and Pircher, 2005). This enables TCM cells to enter 
lymphatics from blood. Molecules on the surface of TEM cells enable their migration 
to the appropriate tissue type; for example, α4β7 expression facilitates migration to 
the gut. More recently, a subset of memory T cells has been shown to reside within 
tissues – tissue-resident memory T cells (TRMs). TRMs are found within epithelial 
barrier tissues at the border between the host and the environment, with 
specificity to antigens previously encountered at that site. Thus, TRMs in the gut 
will have a specificity distinct from that of TRMs found within the lungs (Schlapbach 
et al., 2014). There is evolving knowledge that TRMs contribute to inflammatory 
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diseases (Park and Kupper, 2015). Psoriatic lesions can be cleared by appropriate 
treatments; however, upon disuse of the treatment the lesion will often return in 
the same position and to the same extent as prior to therapy. Analysis of resolved 
psoriatic skin lesions from patients identified T cells and cytokines that contribute 
to pathogenesis of the disease, suggesting that TRMs remain within lesion sites 
(Suárez-Fariñas et al., 2011). Furthermore, due to areas of disease being separated 
by areas of healthy mucosa within the gut in Crohn’s disease, it has been postulated 
that TRMs mediate inflammation in this context (Kleinschek et al., 2009, Park and 
Kupper, 2015).  
 
In human PD, CD4+ T cells were found to be the major source of increased IL-17 
expression and upon further characterization of the cells, it was highlighted that 
TRMs (effector TRM: CD45RO+ CCR7- CD69+; central TRM: CD45RO+ CCR7+ CD69+) 
comprised the greatest proportion of CD4+ IL17+ cells (Dutzan et al., 2016). With 
regards to memory cells, early studies demonstrated that in both healthy and PD 
gingival samples, CD45RO+ memory cells predominate and few CD45RA+ naïve cells 
comprise the tissue. The memory cells were presumed to be specific for commensal 
bacteria present in oral plaque biofilms. Interestingly, it appeared that greater 
numbers of naïve cells were found in disease (Gemmell et al., 1992). Human studies 
have therefore illustrated that memory T cells are evident in gingival tissue 
irrespective of PD, yet the role of these cells in both health and disease remains an 
enigma. Memory T cell status of mice with experimental PD, however, remains 
completely unknown.  
 
1.3.4.4  T cells and osteoimmunology 
 
Binding of RANKL to RANK expressed on the surface of pre-osteoclasts induces 
differentiation to mature osteoclasts. RANKL-induced osteoclastogenesis is 
responsible for the alveolar bone destruction in PD and RANKL expression has been 
identified on T cells (Kawai et al., 2006, Vernal et al., 2006, Han et al., 2009). 
Therefore, it is plausible that T cells are directly involved in bone resorption of PD 
(Taubman and Kawai, 2001, Belibasakis and Bostanci, 2012).  
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1.3.4.5  Tregs in PD 
 
Tregs function to suppress immune responses, which is important for many reasons. 
By generating and maintaining self-tolerance, Tregs prevent autoimmunity – a 
factor highlighted by immunodysregulation polyendocrinopathy enteropathy X-
linked syndrome (IPEX). Owing to mutations in FOXP3, IPEX sufferers are deficient 
in Tregs and subsequently experience a range of autoimmune diseases, including 
type I diabetes and thyroiditis (Charbonnier et al., 2015). Arguably, most relevant 
to the study of the chronic inflammation associated with PD is that Tregs regulate 
the immune response mounted by Th cells (Oldenhove et al., 2003). As such, these 
cells have been the focus of many PD studies. Tregs have been identified in both 
gingivitis and PD patients, but an increase in both Tregs and their associated anti-
inflammatory cytokines has been noted in PD (Nakajima et al., 2005, Cardoso et al., 
2008b). Depletion of Tregs using anti-glucocorticoid-induced tumour necrosis factor 
receptor (GITR) in an A. actinomycetemcomitans-induced experimental PD model 
exacerbated alveolar bone loss, implying that Tregs regulate inflammation in the 
oral cavity in this environment (Garlet et al., 2010b). Nonetheless, the ability of 
Tregs to efficiently modulate inflammation has been under speculation. T cell 
proliferation can be inhibited by cell-cell contact through CTLA-4. However, whilst 
Tregs from active PD lesions showed increased expression of FOXP3, CTLA-4 
expression was unchanged compared with gingival biopsies from stable lesions 
(Dutzan et al., 2009). This suggests that Tregs do not exhibit regulation through 
cell-cell contact but does not completely disregard these cells as mediators of 
inflammation in the context of PD. Despite the evidence that Tregs are present in 
periodontal tissues in PD, the role of Tregs in the initiation of disease is largely 
unknown. 
 
1.3.4.6  Interaction between T cells and B cells in PD 
 
B cells are constituents of adaptive immunity that respond to specific antigens. 
Unlike T cells that only recognize antigen presented within MHC by an APC, B cells 
can directly bind free antigen. Upon activation of B cells by specific antigen, the 
cells proliferate and differentiate to antibody-producing plasma cells or memory B 
cells (Warrington et al., 2011).  
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Within healthy gingival tissue, few leukocytes reside, with B cells and plasma cells 
comprising approximately 5% (Gemmell et al., 2002). However, the inflammatory 
infiltrate of PD lesions is comprised of around 70% B cells and plasma cells 
(Berglundh and Donati, 2005). As such, an increase in abundance of B cells and 
plasma cells has been linked with PD progression, severity and activity (Amunulla et 
al., 2008, Lappin et al., 1999, Thorbert-Mros et al., 2015). It is believed that B cells 
contribute to the pathogenesis of PD, possibly through their expression of RANKL 
(Kawai et al., 2006, Han et al., 2006). 
 
IgG, IgA and IgM antibodies have been found within inflamed PD lesion sites – which 
is indicative of class-switching (Graswinckel et al., 2004, Okada et al., 1983, Ogawa 
et al., 1989). This evidence of B cell class switching and presence of plasma cells 
suggests a role for T cells. Upon specific-antigen recognition by T cells and B cells 
within the T cell zone and primary follicle, respectively, of a lymph node, the cells 
become activated and migrate to the interfollicular region. At this site, T cells and 
B cells interact, resulting in full activation of B cells and committed T cells 
differentiate into Tfh cells by upregulation of B cell lymphoma 6 (Bcl-6), CXC-
chemokine receptor 5 (CXCR5), programmed cell death protein 1 (PD-1) and GL7. 
Tfh cells have the capacity to migrate into follicular region, where the activated B 
cells meet them (De Silva and Klein, 2015). Germinal centre (GC) B cells migrate 
through two distinct regions of the follicle: the light zone and dark zone. Within the 
light zone, GC B cells bind specific antigen and subsequently present antigen within 
MHC to Tfh cells. Tfh cells provide survival signals to the GC B cells, which then 
locate to dark zones to proliferate and undergo somatic hypermutation to generate 
B cell receptors with a range of affinities for specific antigens. Mutated GC B cells 
re-encounter Tfh cells in the light zone and only GC B cells with high affinities for 
antigen receive survival signals enabling further proliferation (Crotty, 2014). The 
differentiation of high affinity GC B cells into plasma cells has been shown to 
involve IL-21 signaling by Tfh cells that is induced by PD-1 signaling (Good-Jacobson 
et al., 2010, Hamel et al., 2010). Despite the role of Tfh cells in maturation of B 
cells and the accumulating evidence of B cells in PD pathogenesis, there is limited 
knowledge of the role of Tfh cells in PD.  
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On the other hand, B cells can also provide T cell help. B cells within severe PD 
lesions have been shown to express high levels of co-stimulatory molecules CD86 
and CD83 (molecules found on mature DCs), which suggests that they play a role as 
APCs in PD, thereby activating T cells (Mahanonda et al., 2002).  
Similar to T cell subsets, B cells can exert pro-inflammatory and anti-inflammatory 
functions. Regulatory B cells (Bregs) produce IL-10, IL-35 and TFG-β that 
subsequently inhibit differentiation of Th1, Th17 and cytotoxic T cells, and inhibit 
TNF-α and IL-12 production by monocytes and DCs respectively. Furthermore, Bregs 
are capable of stimulating Treg differentiation (Rosser and Mauri, 2015). In a mouse 
model of inflammatory bowel disease (IBD), activation of IL-10 producing Bregs 
through exogenous IL-33 and protected mice from inflammatory disease (Sattler et 
al., 2014).  The value of Bregs in inflammatory disease was further highlighted in 
RA. RA patients displayed decreased frequencies of Bregs in peripheral blood than 
their healthy counterparts, and this negatively correlated with DAS28 scores (a 
measurement of disease activity) (Cui et al., 2015). In a collagen-induced arthritis 
model (experimental RA), adoptive transfer of IL-10 expressing B cells reduced both 
the incidence and severity of disease through inhibition of Th1 cell differentiation 
(Mauri et al., 2003). Likewise, there is evidence that Bregs can ameliorate 
inflammation in PD. Induction of local IL-10 producing Bregs in gingival tissues of 
mice through administration of low dose CD40L and cytidine-phosphate-guanosine 
oligodeoxynucleotide (CpG) reduced bone loss in a ligature model of PD. In the 
presence of increased IL-10 producing Bregs, alveolar bone loss was reduced with 
concomitant reductions in inflammatory cytokines and osteoclast numbers on the 
bone surface (Yu et al., 2016). Therefore, Bregs could serve as targets for novel 
therapeutics in PD. 
1.4 Models of PD 
1.4.1 Human in vivo models of PD 
A human model of gingivitis was established by Löe et al (1965) to investigate the 
role of plaque in gingivitis induction. In this study, dental students ceased teeth 
brushing for 21 days, which illustrated that accumulation of plaque correlated with 
increased gingival inflammation and that removal of the plaque by restoration of 
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oral hygiene resulted in elimination of inflammation (Löe et al., 1965). This simple 
model was subsequently used as a platform for myriad investigations including 
those of inflammatory markers, induction and resolution transcriptome profiles of 
gingival lesions, differing inflammation in smokers versus non-smokers and the 
capacity of antimicrobials to lessen clinical parameters of gingival inflammation 
(Eberhard et al., 2013, Jönsson et al., 2011, Heasman et al., 1993, Dommisch et 
al., 2015, Offenbacher et al., 2009, Branco et al., 2015).  
Experimental gingivitis has also been exploited to determine the composition of 
plaque in the transition from health to gingivitis by 454-pyrosequencing (Kistler et 
al., 2013). Further, the bacterial composition of plaque derived from smokers and 
non-smokers has been assessed using the experimental gingivitis model (Peruzzo et 
al., 2016). Such studies were conducted with the ultimate aim of identifying risk 
biomarkers for development of PD. 
A limitation of experimental gingivitis is that it does not represent PD. The 
inflammation that occurs in the presence of the accumulating plaque is an acute 
response that does not cause destruction of local periodontal structures. However, 
PD is a chronic inflammatory condition that occurs over a period of months to 
years, rather than days to weeks, and causes irreversible damage to periodontal 
structures and bone.  
Another means of researching the immune response and composition of the dental 
plaque biofilm in human disease is through extraction of gingival tissue lesions from 
patients with clinically diagnosed PD. Removal of inflamed tissue at periodontal 
surgery offers the potential for study of otherwise discarded tissue (figure 1.8). 
Whilst this provides a tool to understand the immune mechanisms in established PD, 
it does not enable the study of the immune response during the initiation and 
progression towards PD; in particular the dysregulated immune response that 
ultimately mediates bone destruction. Furthermore, it is difficult to precisely 
control, as patients will present at different stages of disease progression with 
varying severity of PD. Whilst the severity of disease can be accurately quantified 
clinically, there are no reliable clinical indicators of disease duration. Thus, studies 
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using experimental gingivitis and established PD in humans are complex, difficult to 
control, and confounded by patient heterogeneity.   
	
Figure 1.8. Surgical periodontal treatment. 
Clinical photograph to show surgical periodontal treatment to permit better access 
for removal of inflamed tissue beneath the gingivae and to allow debridement of 
the root surfaces. Photograph also shows alveolar bone loss.  
 
 
1.4.2 Animal in vivo models of PD 
Animal models of PD offer numerous advantages over human studies including the 
potential to investigate mechanisms of evolving disease and disease intervention in 
controlled environments, by techniques not applicable to humans in the first 
instance because of ethical considerations. Due to the multifactorial nature and 
complexity of PD, in vitro models are insufficient in mirroring the 
immunopathogenesis of PD. In vivo models of PD encompass spontaneous and 
experimentally induced disease, in a number of different animals.  
As there is a plethora of animal models of PD described in the literature, an 
appropriate model must be chosen based on both the scientific objectives and the 
specific experimental techniques i.e. consideration of feature of disease under 
investigation, experiment reproducibility, complexity, cost, ethical considerations 
an the time required for optimisation of the technique (Struillou et al., 2010).  
Non-human primates are the most relevant animal models of PD due to their 
similarities in anatomy, immunology and microbiology to humans. Non-human 
primates are susceptible to naturally occurring PD and display comparable clinical 
symptoms to human disease. Disease can also be exacerbated through tying sutures 
round the teeth at gum level. Despite arguably baring the closest resemblance to 
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human PD of all the animal models, there are huge ethical implications, 
maintenance and appropriate housing are expensive, and non-human primates are 
susceptible to infectious diseases. For investigation of PD these animals are 
therefore rarely used (Oz and Puleo, 2011). 
Dogs offer another platform for studying naturally occurring PD (Pavlica et al., 
2004, Oliveira et al., 2016), and are susceptible to experimentally-induced disease 
by placement of sutures around teeth (Carcuac et al., 2013). Microbiologically, 
there is overlap between humans and dogs, with the subgingival plaques from dogs 
being composed of similar bacteria found in humans at the genus level, but not 
species level (Dahlén et al., 2012). Furthermore, as is evident in humans, severity 
of PD increases with age. However, not all breeds share equal disease 
susceptibility, likely due to differing genetics. The pattern of pathogenesis is 
dissimilar to that seen in humans; rather than affecting only the gingival tissue 
adjacent to the periodontal pocket, the entire width of the marginal gingiva is 
implicated in canine PD (Oz and Puleo, 2011). Moreover, maintenance of the dogs is 
costly and carries ethical considerations.  
Rodents – mice and rats – are the most common animal type used for the 
investigation of PD in vivo. A particular benefit of rodents, and more so in mice, is 
the wide availability of experiment reagents for investigating the immune response, 
and the ability to generate genetically manipulated strains, which can assist the 
study of cause and effect relationships in disease settings. Rodents are relatively 
easy to handle, have high reproducibility rates and are fairly inexpensive and simple 
to maintain, offering further advantage. Disadvantages of rodents are that they 
tend to be naturally resistant to PD, and differ anatomically and microbiologically 
to humans. It has also been shown that female mice are more susceptible to 
alveolar bone loss than male mice, a contrast to that observed in humans (Duan et 
al., 2016). Even still, rodents are valuable tools for studying the complex 
pathogenesis of PD and a range of models are described in the literature. 
The calvarial (scalp) model was first introduced in 1989 to investigate the role of 
cytokines in osteoclastogenesis (Boyce et al., 1989) and was subsequently adapted 
to determine the impact of oral pathogens on osteoclastogenesis. Specifically, this 
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model employed injections of P. gingivalis into the connective tissue overlying the 
skull to trigger inflammation and bone resorption (Graves et al., 2001). Whilst this 
model provides an insight into bacteria-induced immunity, it fails to assess the 
interactions between P. gingivalis, epithelial cells and mucosal tissue and ensuing 
downstream effects on osteoclastogenesis. Moreover, there is no evidence of the 
impact of P. gingivalis in the oral cavity in this model; the anatomical site affected 
in PD. 
Originally developed to investigate synovial membrane function (Edwards et al., 
1981), the air pouch model was adapted to study the host response to oral 
pathogens. Sterile air is injected subcutaneously into the dorsum of the mouse to 
create an air pouch, into which P. gingivalis is introduced.  Infiltrating leukocytes 
and mediators are then determined by aspiration of the air pouch fluid, to assess 
the P. gingivalis induced inflammatory response (Pouliot et al., 2000). However, 
the chronic response to oral pathogens cannot be evaluated due to the short 
duration of the air pouch. This limitation was overcome through development of the 
chamber model. A coiled, stainless steel wire is inserted subcutaneously by surgical 
means into the dorsum of the mouse. To enable healing and epithelialisation, the 
mice are rested for 10 days, followed by injection of bacteria into the chamber 
(Genco et al., 1991). Both acute and chronic inflammatory responses can be 
determined through exudation of chamber fluid or the chamber can be removed for 
histological studies. As for the calvarial model, the chamber model does not provide 
a platform for studying the immune response to periodontal bacteria in the oral 
cavity; hence does not truly represent PD.   
A successful model of PD in mice, initially described by Baker et al (1994), is 
achieved by orally introducing pathogenic, human PD-associated bacteria that are 
absent from murine microflora (Baker et al., 1994b). Prior to repeated oral 
inoculations, commensal microflora are depleted through administration of 
antibitoics to aid the colonisation of the foreign bacteria. Originally, and still 
currently, P. gingivalis is used to induce PD and its associated clinical symptoms; 
however, other ‘red complex’ bacteria including A. actinomycetemcomitans and T. 
forsythia can replace the role of P. gingivalis (Baker et al., 1994b, Garlet et al., 
2008, Sharma et al., 2005). A major advantage of rodent models of PD is that the 
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immune response can be investigated at any stage pre or post infection, to 
understand the changes in immunity that occur along with the development of a 
dysbiotic biofilm and the mechanisms by which these causes alveolar bone 
resorption. However, caveats include the requirement of un-physiologically high 
numbers of bacteria and repeated inoculations to induce the clinical features of PD. 
Furthermore, the administered antibiotics are not specific for oral microbiota, 
hence gut microflora will also be affected, perhaps altering systemic immune 
responses. 
An alternative method for investigating PD in rodents is the ligature model. 
Ligatures – typically cotton or silk – are placed around posterior teeth to promote 
the accumulation of bacteria and trigger an inflammatory response. The ligature 
may also be soaked with P. gingivalis. A benefit of using this model is that removal 
of the ligature enables assessment of resolving inflammation (Abe and 
Hajishengallis, 2013). Unlike the bacteria-induced PD model described above that 
typically takes four to six weeks to cause bone loss, the rodent ligature model 
requires only a matter of days for similar destruction to become evident (Bezerra et 
al., 2000, Li and Amar, 2007). A comparative study recently demonstrated that the 
ligature model is a more effective method than oral infections for investigating PD-
associated inflammation at later stages of infection (45 and 60 days) (de Molon et 
al., 2016). Drawbacks of ligature-induced PD are that high technical skills are 
necessary to place the suture around teeth in such small animals, and this requires 
magnification with a surgical microscope. The ligature is prone to displacement; 
hence a larger number of animals are needed to appropriately power the 
experiments to compensate for this possibility.  
No single animal model fully represents human PD, however, the models permit 
investigation of the inflammatory response to periodontal pathogens and the 
immune-mediated mechanisms of alveolar bone loss. Animal models therefore act 
as a bridge between hypotheses and human PD. Although each animal model of PD 
presents with advantages and disadvantages (table 1.6), mice have been described 
as the most convenient, adaptable and least expensive models (Graves et al., 2008) 
and subsequently have been the animal choice of all studies described in this thesis.   
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Table 1.6. Advantages and disadvantages of animal models of PD. 	
Animal Advantages Disadvantages Models References 
Non-human 
primates 
Comparable 
anatomy to 
humans 
Comparable 
oral 
microbiology 
to humans 
Naturally 
occurring PD 
Expensive to 
house and 
maintain 
Ethical 
implications 
Susceptible to 
infectious 
diseases 
 
Naturally-
occurring PD 
Ligature 
(Graves et 
al., 2008) 
(Oz and 
Puleo, 2011) 
(Struillou et 
al., 2010) 
Dogs Naturally occurring PD 
Expensive to 
house and 
maintain 
Ethical 
implications 
Different 
pattern of PD 
pathogenesis 
Naturally-
occurring PD 
Ligature 
Rodents 
Relatively 
inexpensive to 
maintain 
Easy handling 
Genetically 
modified 
strains 
available 
Rodent-
specific 
reagents 
available 
High 
reproducibility 
rate of models 
Different 
anatomy to 
humans 
Different oral 
microbiology 
to humans 
Resistant to 
PD 
 
Air pouch 
Chamber 
Calvarial 
Oral 
infections 
Ligature 
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1.5 Summary and Aims 
In summary, PD is the most common chronic inflammatory disease in humans and is 
therefore a global health concern. A dysbiotic oral biofilm – found to be mediated 
in some instances by P. gingivalis – forms on the tooth surface altering host:biofilm 
interactions and ultimately results in a dysregulated immune response. The biofilm 
is necessary for PD to ensue but disease progression and destruction of periodontal 
structures are mediated by the immune response. Despite this, current PD 
treatment strategies remain focused on elimination of the dental plaque. With a 
greater understanding of the immunological basis of PD, novel and more efficient 
treatments can be designed.  
The study of the inflammatory infiltrate of PD lesions in humans has suggested that 
T cells and their inflammatory effectors are predominant in disease. Furthermore, 
studies using CD4+ T cell KO mice imply a role for these cells in mediating alveolar 
bone destruction. The role of precise CD4+ T cell subsets in PD remains ambiguous, 
likely due to patients presenting with different severities and stages of disease and 
the use of different animal models.   
It is hypothesized that CD4+ T cells in the oral cavity have a unique phenotype and 
that that will alter with functional consequence in response to oral P. gingivalis-
infection and inflammation.  
The overall aim of this thesis was to determine the phenotype and function of CD4+ 
T cells in a murine model of P. gingivalis-induced PD at early stages of disease.  
The specific aims were: 
1. To optimise a protocol for CD4+ T cell isolation from murine gingival tissue 
(Chapter 3). 
2. To determine T cell subsets in the oral mucosa and whether these change 
with experimental PD, at different stages of disease progression (Chapter 
4). 
3. To identify a time-point at which the greatest difference between T cells in 
‘health’ and PD could be observed in a murine model of PD (Chapter 4). 
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4. To determine the transcriptome of CD4+ T cells from the gingivae and dLNs 
of mice infected with P. gingivalis – at the time-point identified in aim 3 
(Chapter 5). 
5. To investigate systems to track the antigen specific CD4+ T cell response in 
the oral cavity, using an OVA-expressing transgenic strain of P. gingivalis 
(Chapter 6).  
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2 Materials and Methods 
2.1  Materials 
 
The materials and reagents used for the studies in this thesis are described in table 
2.1. 
 
Table 2.1. Suppliers of materials and reagents. 
Material/Reagent Supplier Supplier location 
Sterile de-ionised water 
from Milli-Q® Direct 8 
Water Purification 
System 
Merck Millipore Hertfordshire, UK 
Flow cytometry 
antibodies  
eBioscience 
BD Biosciences 
Biolegend 
Hatfield, UK 
Oxford, UK 
London, UK 
Pipette tips Starlab Milton Keynes, UK 
Minisart syringe filters Sartorious Stedim 
Biotech 
Göttingen, Germany 
Needles Henke Sass Wolf Tuttlingen, Deutschland 
Syringes BD Biosciences Oxford, UK 
Cell strainers eBioscience 
Greiner Bio-One 
Hatfield, UK 
Gloucestershire, UK 
Reaction tubes Greiner Bio-One Gloucestershire, UK 
Western blot reagents 
and equipment 
BIO-RAD* California, USA 
Multiplex Immunoassay 
reagents and equipment 
BIO-RAD* California, USA 
Other plastic lab 
equipment 
Sigma-Aldrich* Dorset, UK 
Chemicals Sigma-Aldrich* Dorset, UK 
Culture media and 
supplements for mouse 
cells and microbiology  
Thermo Fisher* Paisley, UK 
*Unless stated otherwise 
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2.2 Porphyromonas gingivalis  
2.2.1 P. gingivalis W83 growth 
 
Porphyromonas gingivalis W83 (ATCC BAA-308™, Middlesex, UK) originating from a 
human oral infection (isolated by Werner, H. in Germany in the 1950s (Loos et al., 
1993) were maintained frozen in 10% glycerol at −80°C for long-term storage.  
Frozen bacteria were streaked onto Schaedler anaerobic agar supplemented with 
10% heat-inactivated fetal calf serum (HI-FCS), 5% defibrinated horse blood (E&O 
laboratories, Bonnybridge, Scotland) and 1 µg/ml menadione, using sterile P200 
pipette tips. The streaked agar plate was incubated in an anaerobic cabinet (Don 
Whitely, Yorkshire, UK) with 5% CO2, 10% H2 and 85% N2 at 37°C for 72-96 hours. 
Two to three colonies were then inoculated into 35 ml of de-oxygenated Schaedler 
anaerobe broth supplemented with 1 µg/ml menadione and incubated anaerobically 
for a further 48 hours.  
 
2.2.2 OVA-expressing P. gingivalis W83 (RgpbOVA-A) growth 
 
P. gingivalis W83 was genetically modified to introduce OVA peptide 
(ISQAVHAAHAEINEAGR) into the RgpB gene LNE/SIA site (table 2.2) and the 
transgenic strain was resistant to tetracycline (kind gift of Jan Potempa, 
Jagiellonian University). The bacteria were maintained frozen in 10% glycerol at 
−80°C for long-term storage. Frozen bacteria were streaked onto Schaedler 
anaerobic agar supplemented with 10% HI-FCS, 5% defibrinated horse blood, 1 
µg/ml menadione and 1 µg/ml tetracycline, using sterile P200 pipette tips. The 
streaked agar plate was incubated in an anaerobic cabinet with 5% CO2, 10% H2 and 
85% N2 at 37°C for 72-96 hours. Two to three colonies were then inoculated into 35 
ml of de-oxygenated Schaedler anaerobe broth supplemented with 1 µg/ml 
menadione and 1 µg/ml tetracycline and incubated anaerobically for a further 48 
hours. 
 
 
  
 62	
Table 2.2. Amino acid sequence of RgpbOVA-A. 	
RgpbOVA-A amino acid sequence 
 
MKKNFSRIVSIVAFSSLLGGMAFAQPAERGRNPQVRLLSAEQSMSKVQFRMDNLQFTGVQTSKGVA
QVPTFTEGVNISEKGTPILPILSRSLAVSETRAMKVEVVSSKFIEKKDVLIAPSKGVISRAENPDQIPYV
YGQSYNEDKFFPGEIATLSDPFILRDVRGQVVNFAPLQYNPVTKTLRIYTEIVVAVSETAEAGQNTIS
LVKNSTFTGFEDIYKSVFMNYEATRYTPVEEKENGRMIVIVPKKYEEDIEDFVDWKNQRGLRTEVKV
AEDIASPVTANAIQQFVKQEYEKEGNDLTYVLLVGHDKDIPAKITPGIKSDQVYGQIVGNDHYNEVF
IGRFSCESKEDLKTQIDRTIHYERNITTEDKWLGQALCIASAEGGPSADNGESDIQHWNIIANLLTQY
GYTKIIKCYDPGVTPKNIIDAFNGGISLANYTGHGSETAWGTSHFGTTHVKQLTNSNQLPFIFDVAC
VNGDFLYNVPCFAEALMRAQKDGKPTGTVAIIASTINQSWASPMRGQDEMNEILCEKHPNNIKRTF
GGVTMNGMFAMVEKYKKDGEKMLDTWTVFGDPSLLVRTLVPTKMQVTAPANISASAQTEEVACD
YNGAIATLSDDGDMVGTAIVKDGKAIIKLNEISQAVHAAHAEINEAGRSIADETNLTLTVVGYNKVT
VIKDVKVEGTSIADVANDKPYTVAVSGKTITVESPAAGLTIFDMNGRRVATAKNRMVFEAQNGVYA
VRIATEGKTYTEKVIVK 
 
OVA peptide is highlighted in yellow. 
 
2.2.3 Preparation of P. gingivalis for final application 
 
After the 48 hour incubation, the broths were centrifuged at 4000 x g for 20 
minutes at room temperature. Most of the supernatant was discarded and the 
bacterial pellet was resuspended in the remaining broth, which was then 
transferred into 1.5 ml reaction tubes. The tubes were centrifuged at 14000 rpm 
(maximum speed) for 5 minutes and the supernatant was removed and discarded. 
The bacterial pellets were pooled and washed twice by resuspending in 1 ml 
phosphate buffered saline (PBS) per tube, centrifuging at 14000 rpm for 5 minutes 
and discarding the supernatant.   
The bacteria were then prepared according to the final application: 
 
(i) Oral Infections 	
After the addition of PBS for the second wash, around 20 µl was removed to 
determine the number of CFU of P. gingivalis. The bacteria were diluted 1/200 in 
PBS and the optical density (OD) measured at 600 nm using a GeneQuant 
spectrophotometer. Using a previously generated standard curve (kindly provided 
by Dr Emma Millhouse, University of Glasgow Dental School) the number of CFU 
could be determined and the bacteria were resuspended in 2% CMC in PBS to give a 
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final concentration of approximately 1 x 109 CFU per 75 µl (volume given to each 
mouse). 
 
(ii) Assessment of anti-P gingivalis antibodies by ELISA 
 
After the second wash with PBS, the supernatant was removed. The pellet was 
resuspended and 50 µl aliquots were transferred into 0.5 ml reaction tubes. The 
tubes were then sealed shut with parafilm M® (Bemis, Oshkosh, USA) and placed 
into a 50 ml centrifuge tube containing hot water. The centrifuge tube was then 
placed in a water bath at 60oC for 30 minutes to heat-kill the bacteria. The aliquots 
were stored at -80oC until required.  
 
2.2.4 Recovery of live P. gingivalis after infection 
 
In order to quantify the viability of the remaining P. gingivalis in the inoculum from 
the oral infections, the Miles and Misra method was used (Miles et al., 1938). The 
inoculum was serially diluted ten-fold to 10-10 with sterile PBS and 10 µl drop-plated 
in triplicate on blood agar. The agar plate was incubated in an anaerobic cabinet 
with 5% CO2, 10% H2 and 85% N2 at 37°C for 48-72 hours (figure 2.1). The colonies 
were then counted and CFU/ml calculated: mean number of colonies in dilution x 
100 x dilution factor. The average recovery was 3 x 108 CFU per 75 µl of bacterial 
inoculate. 
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Figure 2.1. Quantification of viable P. gingivalis following oral infections. 
Viable P. gingivalis were quantified following oral infections using the Miles and 
Misra method. The inoculum was serially diluted ten-fold to 10-10 with sterile PBS 
and 10 µl drop-plated in triplicate on blood agar. The agar plate was incubated in 
an anaerobic cabinet for 48-72 hours. (A) Representation of plating 10 µl of four 
lowest dilutions of P. gingivalis, represented as dark grey circles. (B) Growth of 
recovered, viable P. gingivalis on blood agar. Colonies were counted and CFU/ml 
calculated: mean number of colonies in dilution x 100 x dilution factor. 
 
 
2.3 Mice 
 
6-8 week female BALB/c mice were purchased from Harlan or Charles River 
Laboratories for all in vivo periodontal disease models and studies of gingival tissue. 
Ubiquitously expressing CRE mice (bred at the University of Glasgow Joint Research 
Facility) were also used for studies on gingival tissue (these mice were surplus to 
breeding colony requirements and phenotypically normal). A maximum of 10 mice 
were housed in standard cages and were maintained on a 12 hour light-dark cycle 
with ad libitum access to food and water. All mice were maintained and 
experiments carried out in accordance with local and UK home office regulations 
(Licences 60/4041 and 70/8166). 
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2.4 Murine models 
2.4.1 Murine model of PD 
 
Female BALB/c mice were pretreated with antibiotics (0.08% sulfamethoxazole and 
0.016% trimethoprim) in drinking water for 10 days to deplete oral microflora and 
create a niche for P. gingivalis colonisation, followed by a 2-day antibiotic-free rest 
period. Mice were divided into separate cages and half were orally infected by 
gavage with 109 CFU P. gingivalis in 2% CMC, in a volume of 75 µl, administered 
using P200 pipette and tips (previously described by (Baker et al., 1994a). Sham-
infected control groups were inoculated orally with an equal volume of 2% CMC 
only.  Mice were infected 3 or 4 times within 7 days. One or two days before the 14 
and 28 day post-infection end points, approximately 100 µl of blood was collected 
from each mouse by tail bleeding to determine the presence of anti-P. gingivalis 
IgG antibodies as an indication of infection status. At 7, 14 and 28 days post-
infection, blood was collected by cardiac puncture under anesthetic, followed by 
euthanizing of the mice by dislocation of the neck. The timeline of the PD model is 
described in figure 2.2. Plaque was collected from the oral cavity of the mouse 
using eSwabs™ (Copan, USA) and these were placed in 1 ml liquid Amies transport 
medium. Gingivae, teeth, draining lymph nodes (cervical lymph nodes; dLN) and 
spleens were collected.  
 
 
	
 
Figure 2.2. Timeline of murine experimental PD model. 
BALB/c mice were treated with antibiotics for 10 days to deplete oral commensal 
bacteria. After a 2-day antibiotic-free rest period, mice were orally infected 3-4 
times within one week with approximately 1 x 109 CFU of P. gingivalis W83 in CMC 
or sham-infected mice received CMC only. End points occurred 7, 14 and 28 days 
Antibotics Infections 
-12 -2 0 2 4 6 7 14 28 
Tail bleeds 
End points 
Day: 
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post first infection, with tail bleeds being taken 1-2 days prior to end points to 
assess infection status of the mice. 
 
2.4.2 Assessing OVA-specific T cell stimulation by RgpbOVA-A in vivo 
 
Five DO11.10 4GET mice (with transgenic T cells specific for OVA) were sacrificed 
and their LNs and spleens were collected into a bijou containing 4 ml RPMI 1640 
medium supplemented with 10% HI-FCS, 2 mM L-glutamine, 100 U/ml penicillin and 
100 µg/ml streptomycin (complete media). A single cell suspension was obtained 
and counted, as described in 2.5.2. To determine the percentage of viable, 
transgenic cells (CD4+ KJ1.26+) within the suspension, 5 x 105 cells were stained 
with viability dye, anti-CD4, anti-KJ1.26 and controls were stained with the isotype 
of anti-KJ1.26, rat IgG2a. The protocol described in 2.7.1 was followed and the 
cells were analysed using a MACSQuant® flow cytometer (Miltenyi Biotech) (figure 
2.3). The total number of transgenic T cells in the sample was calculated using the 
total cells counts and proportion of CD4+ KJ1.26+ cells identified by flow 
cytometry. The cell were resuspended in a volume that gave 3 x 106 CD4+ KJ1.26+ 
in 100 µl of incomplete media (RPMI 1640 supplemented with 2 mM L-glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin). Recipient BALB/c mice were 
placed into a heat box preheated to 37oC for 5 minutes. One hundred µl of cells 
were injected into the tail vein of each animal.  
 
Twenty-four hours after the transfer of transgenic cells, each mouse was injected 
subcutaneously in the scruff with 100 µl Complete Freud’s Adjuvant (CFA) only or 
CFA in combination with the following antigens:  1 x 108 CFU P. gingivalis W83; 1 x 
108 CFU OVA-expressing P. gingivalis; or 1 x 108 CFU P. gingivalis W83 and 100 µg 
OVA protein (table 2.3). CFA was prepared by repeated aspiration until it formed 
an emulsion. Both strains of P. gingivalis were heat-killed for scruff and footpad 
injections as described in 2.3.3.  
 
Ten days after the scruff injections, mice received a second encounter with the 
antigen given previously with CFA. Fifty µl containing one or a combination of: 1 x 
108 CFU P. gingivalis W83; 1 x 108 CFU OVA-expressing P. gingivalis; 100 µg OVA 
protein or PBS was injected into the footpad (table 2.3). 
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Figure 2.3. Example of flow cytometry plots used to identify CD4+ KJ1.26+ 
cells. 
A single cell suspension of spleen and LNs was obtained and stained with viability 
dye, anti- CD4 and either (A) anti-KJ1.26 or (B) the isotype control, rat IgG2a. The 
samples were analysed by a MACSQuant® flow cytometer and FlowJo software. 
Lymphocytes were gated on based on their forward scatter (FSC) and side scatter 
(SSC). Viable lymphocytes were gated on based on the exclusion of viability dye. 
From this gate, CD4+ T cells could be gated on and subsequently the expression of 
CD4+ KJ1.26+ T cells could be identified.  
 
Three days post-footpad injections, blood was collected by cardiac puncture under 
anesthetic, followed by euthanizing of the mice by dislocation of the neck. 
Popliteal LNs were collected into complete media. The timeline is described in 
figure 2.4. 
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Figure 2.4. Timeline of in vivo testing of OVA-expressing P. gingivalis. 
LN cells and splenocytes from DO11.10 mice were isolated and the percentage of 
KJ1.26+ CD4+ cells assessed by flow cytometry. Three million KJ.126+ CD4+ were 
transferred to recipient BALB/c mice by tail vein injection. Twenty-four hours post 
transgenic cell transfer, the mice were subcutaneously injected in the scruff with 
100 µl Complete Freuds Adjuvant (CFA) or CFA in combination with 1 x 108 CFU P. 
gingivalis W83, 1 x 108 CFU OVA-expressing P. gingivalis or 1 x 108 CFU P. gingivalis 
W83 and 100 µg OVA protein. Ten days post scruff injection, the mice received a 
second encounter with the antigen previously given with CFA by footpad injections 
(50 µl). The mice that received CFA alone received 50 µl PBS footpad injection. 
Three days later, the mice were culled. 
 
 
 
Table 2.3. Groups for assessing OVA-specific T cell stimulation by RgpbOVA-A in 
vivo. 	
Group 
(n=3) 
Transfer 
DO11 
Scruff injection Footpad injections 
1 ✔ P. gingivalis W83 + CFA P. gingivalis W83 
2 ✔ RgpbOVA-A + CFA RgpbOVA-A 
3 ✔ P. gingivalis W83 + OVA protein + 
CFA 
P. gingivalis W83 + OVA 
protein 
4 ✔ CFA only PBS 
  
0 1 11 14 
Transfer 3 x 106 
KJ1.26+ cells 
Scuff injection of 
antigen in CFA 
Footpad injection 
of antigen 
End point 
Day: 
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2.5 Tissue harvest and cell isolation 
2.5.1 Gingival tissue harvest  
 
Whole palates were collected from euthanized mice by cutting both sides of the 
oral cavity, including cheeks and the ramus of the mandible with scissors. Soft and 
hard tissues were then cut 1 mm behind the third molars with a scalpel blade, 
followed by cutting the tissue that connects the maxilla to the cheek. The maxilla 
was then detached from the skull. The gingival and palatal tissues were then 
carefully removed from the maxilla using tweezers. For the majority of 
experiments, the entire palate was used but for trial experiments only gingival 
strips were taken (figure 2.5). The tissue was collected into PBS supplemented with 
2% HI-FCS (PBS + 2% FCS).  
 
2.5.2 Cell isolation  
 
(i) Lymph nodes and spleen  	
LNs and spleens were collected into a 6-well plate containing complete media. LNs 
and spleens were then transferred to a 40 µm cell strainer and mashed using the 
plunger from a 2.5 ml syringe into complete media to generate a single cell 
suspension. LN cells were then counted. Splenocytes were washed using complete 
media and centrifuged at 400 x g for 5 minutes. Splenocytes were resuspended in 5 
ml RBC lysis buffer (eBioscience) and incubated for 5 minutes at room temperature. 
Cells were washed (as described above) then resuspended in complete media for 
counting. 
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Figure 2.5. Dissection of murine palate and/or gingiva. 
(A) The hard (H) and soft palates (S) were cut using a scalpel blade along the lines 
shown in purple. The gingival tissue was then cut away from the masseter muscle 
(M), shown in green, using scissors. The palate and teeth were removed from the 
mouse’s head and the palate was carefully peeled away from the teeth. (B) The 
palatal tissue was used for the majority of experiments or (C) gingival strips were 
taken by cutting along the dashed lines as indicated. Abbreviations: M, masseter 
muscle; H, hard palate; S, soft palate; T, tongue. 
 
 
(ii) Gingivae  
 
Various methods of gingival digestion were performed to optimize a protocol: 
 
MACS dissociation 
 
The palate was collected as described in 2.5.1 and placed into a bijou containing 1 
ml of cold PBS. Two hundred µl (500 µg) of dispase-high liberase (Roche, 
Indianapolis, USA), or collagenase D or no enzyme was added to the bijoux and the 
tissue was cut up into smaller fragments using scissors. The bijoux were then 
incubated at 37oC for 30-40 minutes with intermittent pipetting. The enzymatic 
reaction was inhibited through the addition of 3 ml complete media and the tissue 
suspension was transferred to a gentleMACS™ C tube (Miltenyi Biotech).  A 
gentleMACS™ dissociator (Miltenyi Biotech) was used to homogenize the tissue 
further by running 2 cycles of one of the following programs: Protocol B; M_spleen; 
M_liver; or Program A. The cell suspension was strained over a 40 µm cell strainer 
M M
T 
S 
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using the plunger from a 2.5 ml syringe and the cells were washed in complete 
media by centrifugation at 380 x g and 4oC for 5 minutes. The cells were 
resuspended in 5 ml complete media for counting. 
 
Enzymatic and Mechanical Dissociation (Collagenase/DNAse based dissociation) 
 
The palate was collected as described in 2.5.1 and digested with a modified 
protocol (Mizraji et al., 2013). Palatal tissue from a single mouse was minced using 
a no. 15 scalpel blade (Swann-Morton®, Sheffield, UK) in a 35 mm tissue culture 
dish containing 1 ml PBS + 2% FCS, 2mg/ml collagenase II (Lorne Laboratories, 
Berkshire, UK) and 1mg/ml DNase Type I. The minced gingival tissue and cells were 
transferred to a 15 ml centrifuge tube and the tissue culture dish was washed with 
1 ml PBS + 2% FCS to collect remaining cells. The tubes were transferred to a 
shaking incubator (Innova™ 4400, New Brunswick™) for 30 minutes at 37oC and 200 
rpm, with 0.5M EDTA added 10 minutes prior to the end of the incubation to stop 
the enzymatic reactions. The samples were removed from the incubator and topped 
up to 12ml with PBS + 2% FCS, then centrifuged at 400 x g for 8 minutes at 4oC. The 
supernatant was discarded and the pellet was resuspended in 2 ml of PBS + 2% FCS, 
then the cells were passed through a 70 µm strainer into a new 50 ml centrifuge 
tube to remove the remaining tissue. Strained cells were then centrifuged at 380 x 
g for 5 minutes and the supernatant was discarded. To allow for more accurate cell 
counting, the pellet was resuspended in 300 µl PBS + 2% FCS.  
 
2.5.3 Cell counts 
 
Ten µl of cells were mixed with 10 µl of 0.04% trypan blue and were counted using a 
haemocytometer (Naubeur improved, Marienfeld-Superior, Germany) and BH-2 light 
microscope (Olympus, UK). Dead cells were excluded by trypan blue staining of the 
cells (figure 2.6). The total cell count was calculated by: count x dilution factor x 
104 x volume. 
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Figure 2.6. Cell counting using a haemocytometer. 
Ten µl of cells mixed with an equal volume of trypan blue were pipetted onto a 
haemocytometer. The cells in all 25 boxes were counted for gingival tissue and LNs. 
For spleens only the 5 numbered boxes were counted. The zoomed in image of box 
2 illustrates live (non-shaded) and dead cells (shaded) that have been stained with 
trypan blue and are therefore excluded from the cell count. Image generously 
donated by Ana Adrados-Planell. 
 
 
2.6 T cell purification  
2.6.1 Magnetic-activated cell sorting (MACS) 
 
(i) Ficoll density gradient separation and positive selection with CD3ε 
Microbeads 	
A single cell suspension of dLNs and gingivae were prepared as described in 2.5 and 
were centrifuged at 400 x g for 5 minutes and the cell pellet was resuspended in 3 
ml of room temperature PBS. The cells were then carefully layered over 3 ml of 
room temperature Histopaque® 1083 in a 15 ml centrifuge tube. The sample was 
centrifuged at 400 x g and room temperature for 30 minutes, with the brake off 
(figure 2.7). The mononuclear cell layer was carefully removed using a Pasteur 
pipette and transferred to a fresh 15 ml centrifuge tube. After 10 ml of incomplete 
media was added to the cells and the tube was inverted gently, several times, the 
tube was centrifuged at 250 x g for 10 minutes. The supernatant was removed and 
the pellet was resuspended in 0.5 ml of incomplete media, vortexed briefly and 
then an additional 4.5 ml of incomplete media was added, and mixed by inversion, 
1 2
34
5
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to wash away the remaining Histopaque®. The tube was centrifuged at 250 x g for 
10 minutes and supernatant discarded. The wash step was repeated.  
One hundred µl of MACS buffer (composed of PBS, 0.5% bovine serum albumin (BSA) 
and 2mM EDTA) was added to the cells, followed by the addition of 10 µl anti-
mouse CD3ε-Biotin antibodies. This was incubated at 4oC for 10 minutes, followed 
by a wash with 1-2 ml of MACS buffer and centrifugation at 300 x g for 10 minutes. 
The supernatant was carefully pipetted off and the cell pellet was resuspended in 
80 µl of MACS buffer, followed by 20 µl of Anti-Biotin MicroBeads. This was 
incubated at 4oC for 15 minutes then the cells were washed, as described above. An 
LD column (Miltenyi Biotech) was rinsed with 2 ml MACS buffer and placed in the 
magnetic field of a MACS™ separator (Miltenyi Biotech). The cells were resuspended 
in 500 µl MACS buffer and loaded onto the column. The unlabeled cells passed 
through, then the column was rinsed 3 times by adding 500 µl of MACS buffer. The 
column was removed from the magnetic separator and placed into a 15 ml 
centrifuge tube. One ml of MACS buffer was added to the column and the CD3+ T 
cells bound to the magnetic beads were immediately flushed out using the plunger 
supplied with the column. CD3+ T cells were then separated and ready for use in 
downstream applications. 
 
 
	
Figure 2.7. Cell layers following Histopaque® 1083 density gradient separation. 
To enable mononuclear cell separation, a single cell suspension of murine LN and 
gingival tissue was layered upon Histopaque® 1083. After centrifugation, distinct 
layers could be seen including PBS, mononuclear cells, Histopaque® 1083 and red 
blood cells (RBCs). The shaded mononuclear cell layer was aspirated for further 
analysis. 
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(ii) Dead Cell Removal and positive selection with CD90.2 MicroBeads 
 
A single cell suspension of dLNs and gingivae were prepared as described in 2.5 and 
a maximum of 1 x 107 cells in complete media were centrifuged at 300 x g for 10 
minutes. The supernatant was carefully and completely removed using a pipette 
and resuspended in 50 µl of MACS buffer. Five µl of Basic Microbeads (diluted 1 in 
10 with MACS buffer) was added to the cells, mixed well and incubated at 4oC for 
15 minutes. The Microbeads then bound to dead cells within the sample. The cells 
were washed with 1 ml of MACS buffer, followed by a centrifugation at 300 x g for 
10 minutes. The supernatant was carefully removed with a pipette and the cells 
were resuspended in 500 µl of MACS buffer. An MS column (Miltenyi Biotech) was 
placed in the magnetic field of a MiniMACS™ separator (Miltenyi Biotech) and was 
prepared for separation by rinsing with 500 µl of MACS buffer. The cell suspension 
was added to the column, allowing unlabeled cells to pass through, and then the 
column was rinsed three times by adding 500 µl of MACS buffer. The unlabeled cells 
were collected.  
 
The cells were washed, as above, at 300 x g for 10 minutes and the supernatant 
discarded. The pellet was resuspended in 90 µl of MACS buffer, followed by the 
addition of 10 µl CD90.2 MicroBeads (pan T cell marker). The cells were incubated 
at 4oC for 15 minutes then washed with 1-2 ml of MACS buffer. The pellet was 
resuspended in 500 µl of MACS buffer. An MS column was placed in the magnetic 
field of a MiniMACS™ separator and was prepared for separation by rinsing with 500 
µl of MACS buffer. The cell suspension was added to the column, allowing unlabeled 
cells to pass through, and then the column was rinsed three times by adding 500 µl 
of MACS buffer. The column was then removed from the separator and placed into a 
15 ml centrifuge tube. One ml of MACS buffer was added to the column and the 
CD90.2+ cells bound to the magnetic beads were immediately flushed out using the 
plunger supplied with the column. T cells were then separated and ready for use in 
downstream applications. 
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(iii) CD4 positive selection with MicroBeads 
 
A single cell suspension of dLNs and gingivae were prepared as described in 2.5 and 
a maximum of 1 x 107 cells in complete media were centrifuged at 300 x g for 10 
minutes. The supernatant was carefully and completely removed using a pipette 
and resuspended in 90 µl of MACS buffer. Ten µl of CD4 (L3T4) MicroBeads (Miltenyi 
Biotech) were added and mixed well, then incubated at 4oC for 15 minutes. Anti-
CD4 APC efluor 780 was added at a dilution of 1/400 to the sample and incubated at 
4oC for 5 minutes protected from light, as recommended by manufacturer’s guide 
for flow cytometry analysis. Cells were washed with 1-2 ml of MACS buffer and 
centrifuged at 300 x g for 10 minutes. The supernatant was removed using a pipette 
and the pellet was resuspended in 500 µl of MACS buffer. An MS column was placed 
in the magnetic field of a MiniMACS™ separator and was prepared for separation by 
rinsing with 500 µl of MACS buffer. The cell suspension was added to the column, 
allowing unlabeled cells to pass through, and then the column was rinsed three 
times by adding 500 µl of MACS buffer. The column was then removed from the 
separator and placed into a 15 ml centrifuge tube. One ml of MACS buffer was 
added to the column and the CD4+ T cells bound to the magnetic beads were 
immediately flushed out using the plunger supplied with the column.  CD4+ T cells 
were then separated and ready for use in downstream applications. 
 
2.6.2 Fluorescence-activated cell sorting (FACS) 
 
A single cell suspension of dLNs and gingivae were prepared and stained 
extracellularly for flow cytometry as described in 2.5 and 2.7.1, respectively. The 
cells were stained with anti-CD45, anti-CD4, anti-CD8 antibodies and viability dye 
as described in table 2.4. The cells were passed through nitex prior to sorting using 
the BD FACSAria™ I or BD FACSAria™ III, depending on availability of the sorter. A 70 
µm nozzle was used for sorting T cells and the set up was kindly conducted by Diane 
Vaughan (Flow Cytometry Facility Manager, University of Glasgow). Single, viable, 
CD45+ CD4+ and single, viable, CD45+ CD8+ T cells were sorted separately into 1.5 
ml reaction tubes containing PBS or lysis buffer, depending on downstream analysis.  
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Table 2.4. Antibodies used for T cell sorting by FACS. 	
Antibody Clone Staining 
type 
Final 
Dilution  
Dilution 
Buffer 
Supplier 
CD45 FITC 30-F11 EC 1/200 FACS buffer eBioscience 
CD4 eFluor 780 RM4-5 EC 1/400 FACS buffer eBioscience 
CD8a PE 53-6.7 EC 1/200 FACS buffer eBioscience 
VD eFluor 450  - EC 1/1000 PBS eBioscience 
Abbreviations: EC, extracellular; VD, viability dye. 
 
2.7 Flow cytometry 
2.7.1 Extracellular staining protocol 
 
A single cell suspension of various tissue types was prepared as described in 2.5. 
Cells were centrifuged at 400 x g for 5 minutes and resuspended in FcR blocking 
buffer (5% mouse serum in 2.4G2 hybridoma supernatant (containing monoclonal 
antibodies which block FcRs)) to give a concentration of approximately 1 x 106 
cells/100 µl and this was incubated at 4oC for 15 minutes. Extracellular antibodies 
were prepared in FACS buffer (composed of 0.01% NaN3 and 2% HI-FCS in PBS) as 
shown in table 2.5, and 100 µl of the antibody preparation was incubated with 100 
µl of cells in FcR blocking buffer for 20 minutes at 4oC, protected from light. The 
cells were washed with 200 µl of PBS then centrifuged at 400 x g for 5 minutes at 
4oC. This step was repeated once more. 
 
Viability dye was prepared as described in table 2.5. One hundred µl was added to 
1 x 106 cells and incubated at 4oC for 20 minutes, again protected from light. The 
cells were washed with 200 µl of PBS then centrifuged at 400 x g for 5 minutes at 
4oC. This step was repeated once more.  Samples only having extracellular antibody 
staining were resuspended in 200 µl FACS buffer and passed through nitex nylon 
mesh prior to flow cytometry. Cells requiring intracellular staining were incubated 
with fix/perm buffer as described in 2.7.2. 
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2.7.2 Intracellular staining 
 
(i) Transcription factor staining 	
Intracellular staining for transcription factors was conducted using a Transcription 
Factor Buffer Set (BD Biosciences) following the manufacturer’s guidelines. Briefly, 
cells were incubated with 100 µl of fix/perm at 4oC for 20 minutes in the dark. Cells 
were washed with 100 µl of perm/wash by centrifugation at 400 x g and 4oC for 5 
minutes, the supernatant was discarded and the cells were washed again in 200 µl 
of perm/wash at the same centrifugation. The intracellular antibodies were 
prepared as described in table 2.5 and 100 µl of the antibody preparation was 
added to 1 x 106 cells and incubated at 4oC for 50 minutes. The cells were washed 
with 100 µl of perm/wash by centrifugation at 400 x g and 4oC for 5 minutes, the 
supernatant was discarded and the cells were washed again in 200 µl of perm/wash 
at the same centrifugation. The cells were then resuspended in 200 µl of FACS 
buffer and passed through nitex nylon mesh prior to flow cytometry. 
 
(ii) Cytokine staining 
 
Intracellular staining for cytokines was conducted using a BD Cytofix/Cytoperm™ 
Plus Fixation and Permeabilisation kit (BD Biosciences) following the manufacturer’s 
guidelines. Briefly, cells were incubated with 100 µl of BD Cytofix/Cytoperm™ at 
4oC for 20 minutes in the dark. Cells were washed with 100 µl of BD Perm/Wash™ 
buffer by centrifugation at 400 x g and 4oC for 5 minutes, the supernatant was 
discarded and the cells were washed again in 200 µl of BD Perm/Wash™ buffer at 
the same centrifugation. The intracellular antibodies were prepared as described in 
table 2.5, and 100 µl of the antibody preparation was added to 1 x 106 cells and 
incubated at 4oC for 30 minutes. Cells were washed with 100 µl of BD Perm/Wash™ 
buffer by centrifugation at 400 x g and 4oC for 5 minutes, the supernatant was 
discarded and the cells were washed again in 200 µl of BD Perm/Wash™ buffer at 
the same centrifugation. The cells were then resuspended in 200 µl of FACS buffer 
and passed through nitex nylon mesh prior to flow cytometry. 
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2.7.3 Flow cytometry analysis 
 
Cells were passed through nitex nylon mesh prior to flow cytometry using a 
MACSQuant® flow cytometer and were subsequently analysed using FlowJo® 
software (Tree Star Inc.). 
 
 
Table 2.5. Antibodies used for flow cytometry staining. 	
Antibody Clone Staining 
type 
Final 
Dilution  
Dilution 
Buffer 
Supplier 
CD45 PerCP 30-F11 EC 1/200 FACS buffer BD  
CD4 eFluor 780 RM4-5 EC 1/400 FACS buffer eBioscience 
CD8a e450 53-6.7 EC 1/400 FACS buffer eBioscience 
CD8a PE-Cy7 53-6.7 EC 1/200 FACS buffer eBioscience 
CD44 APC IM7 EC 1/400 FACS buffer eBioscience 
CD62L FITC Mel-4 EC 1/200 FACS buffer BD  
CD69 PE H1.2F3 EC 1/200 FACS buffer BD  
CD25 FITC 7D4 EC 1/200 FACS buffer eBioscience 
VD eFluor 450 N/A EC 1/1000 PBS eBioscience 
VD eFluor 506 N/A EC 1/1000 PBS eBioscience 
ICOS AF 88 C398.4A EC 1/200 FACS buffer BioLegend 
PD-1 PE Cy7 J43 EC 1/400 FACS buffer eBioscience 
CXCR5 APC 2G8 EC 1/50 FACS buffer BD  
B220 eFluor 450 RA3-6B2 EC 1/400 FACS buffer eBioscience 
F4/80 eFluor 450 BM8 EC 1/400 FACS buffer eBioscience 
Ki67 PE-Cy7 SolA15 IC (1) 1/500 Perm/wash eBioscience 
Foxp3 APC FJK-16s IC (1) 1/200 Perm/wash eBioscience 
IFNγ PE-Cy7 B27 IC (2) 1/200 Perm/Wash BioLegend 
IL-4 biotin BVD6-24G2 IC (2) 1/200 Perm/Wash BD  
IL-17A PE TC11-18H10 IC (2) 1/200 Perm/Wash BD 
SA PerCP N/A IC (2) 1/200 Perm/Wash BD 
Bcl6 PE K112-91 IC (2) 1/50 Perm/wash BD  
(1) – Transcription factor staining; (2) – cytokine staining 
Abbreviations: AF, alexa fluor; EC, extracellular; IC, intracellular; N/A, not 
applicable; SA, streptavidin; TF, transcription factor; VD, viability dye. 
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2.8 Immunohistochemistry 
2.8.1 Whole-mount staining for fluorescent microscopy 
 
Palates were collected as described in 2.5.1 and fixed using 1% paraformaldehyde 
(PFA) in PBS overnight at 4oC. The tissue was then washed 3 times using whole-
mount buffer (1% BSA, 0.3% Triton™ X-100, 0.2% NaN3). For each wash, tissue was 
incubated at 4oC for 1 hour then the buffer was removed. The tissue was 
transferred to a 48-well plate and incubated overnight at 4oC with 300 µl of 
appropriate combinations of fluorescently labeled antibodies in whole-mount buffer 
(table 2.6). The tissues were then transferred to bijoux and washed by adding 4 ml 
cold PBS followed by an incubation at 4oC for 30 minutes. PBS was discarded and 
the wash step repeated another 2 times (3 washes total). The tissue was further 
washed by adding 4 ml whole-mount buffer to the bijoux and incubating at 4oC for 
one hour. Whole-mount buffer was discarded and the wash step repeated twice 
more (3 washes total). The samples were transferred into PBS for mounting. The 
tissue was blotted dry then placed onto a Superfrost™ Plus Microscope Slide 
(Thermo Fisher) with the inside of the palate facing up. ProLong® Gold Antifade 
Mountant (Thermo Fisher) was added to the tissue and a coverslip was placed on 
top carefully to avoid creating air bubbles. The coverslip was sealed using clear nail 
varnish. The samples were then incubated at room temperature for 24 hours to 
allow ProLong® Gold to cure. With thanks to Owain Millington at University of 
Strathclyde, the palates were imaged by confocal microscopy and analysed using 
Volocity™ software (Improvision, Perkin Elmer).  
 
Table 2.6. Antibodies used for whole-mount staining and confocal microscopy. 	
Antibody Clone Final Dilution Dilution Buffer Supplier 
CD4 AF 647 RM4-5 1/100 Whole-mount buffer BD  
B220 PE RA3-6B2 1/100 Whole-mount buffer eBioscience 
Abbreviations: AF, alexa-fluor. 
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2.8.2 Haematoxylin and eosin staining 
 
Palates were collected as described in 2.5.1 and were kindly processed by Jim 
Reilly and Shauna Kerr (Histology department, III, University of Glasgow). Palates 
were fixed in 10% formalin then embedded in paraffin. A Leica-LM microtome (Leica 
Microsystems, Germany) was used to cut 5 µm sections and these were placed onto 
Superfrost™ Ultra Plus Microscope Slides (Gerhard Menzel, Germany). Sections 
containing gingival tissue were heated at 60oC for 35 minutes to soften the wax. In 
order to remove the paraffin and rehydrate the sections, the sections were 
immersed in xylene for 3 minutes. This step was repeated, as were all subsequent 
steps until water washing. The sections were immersed in 100% ethanol, then 90% 
ethanol and finally 70% ethanol, each for 3 minutes. The sections were immersed in 
running water for 3 minutes. 
 
The sections were then stained by immersion in Harris haematoxylin for 2 minutes 
followed by washing in running water for 3 minutes. To reduce the background 
staining, the sections were dipped twice into 1% HCl in 70% ethanol, rinsed in 
running water then immersed in Scotts tap water substitute for 30 seconds. The 
sections were again rinsed in running water before counter staining with 1% eosin in 
tap water for 2 minutes.  The excess stain was washed off by running water. The 
sections were dehydrated in 70% ethanol for 30 seconds, followed by 1 minute in 
90% ethanol. The sections were then immersed in 100% ethanol for 3 minutes, 
transferred to fresh 100% ethanol for another 3 minutes before being immersed in 
xylene in for 3 minutes, followed by a final immersion in fresh xylene for another 3 
minutes. The sections were mounted with DPX. 
 
2.9 Measurement of bone loss 
 
The maxilla was separated from the skull and gingiva removed as described in 
2.5.1. The remaining tissue on the maxilla was removed by enzymatic digestion 
with 100 U/ml DNase I, 4 mg/ml collagenase IV and 2 mg/ml hyaluronidase (from 
bovine testes) in PBS.  Five hundred µl of the enzyme digestion mix was added to 
the maxillae of one mouse in a well of a 24-well plate. Plates were transferred to a 
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shaking incubator for 30 minutes at 37oC and 100 rpm. The enzymatic reaction was 
stopped by adding complete media and the teeth were washed using tap water 
after this step and all subsequent steps.  The teeth were incubated at 4oC overnight 
with 3% H2O2, fixed with 4% PFA at 4oC overnight, then were stained with 0.5% 
methylene blue in dH2O for 30 minutes at room temperature. The teeth were given 
a final wash with tap water and were left to air-dry. Images were captured using an 
Olympus SZX7 stereo zoom microscope fitted with SC100 digital colour camera. 
Measurements of the distance between the cemento–enamel junction and the 
alveolar bone crest were made using cellSens software (Olympus) to assess alveolar 
bone loss. Both the left and right maxillae were measured by taking 12 
measurements from the 3 molars on the palatal side of the bone, resulting in a total 
of 24 measurements per mouse (figure 2.8). The mean of the 24 measurements was 
the final alveolar bone level for the mouse. All measurements were conducted with 
the examiner blinded to the experimental group of each maxilla. 
 
 
	
Figure 2.8. Measurement of alveolar bone loss in mice. 
Maxillae from mice were excised, defleshed and stained for imaging. Images of the 
maxillae were captured using Olympus SZX7 stereo zoom microscope fitted with 
SC100 digital colour camera. (A) The assessment of alveolar bone loss was 
determined by applying 12 vertical measurements (white dashed lines) between the 
cemento-enamel junction (CEJ) (yellow line) and the alveolar bone crest (ABC) (red 
line) on the palatal side of the maxillae, using the cellSens software (Olympus). (B) 
The vertical measurements represent the alveolar bone loss.  
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2.10 Detection of antibodies by ELISA  
2.10.1 Processing of murine blood 
 
Murine blood was collected by tail bleeds (approximately 100 µl) prior to 
experiment end-points or at end-points by cardiac puncture (approximately 700 µl) 
under terminal anesthesia. Blood was transferred into 1.5 ml reaction tubes and 
allowed to clot by incubating at room temperature for a minimum of 2 hours. The 
reaction tubes were centrifuged at 12000 rpm in an Eppendorf™ microcentrifuge for 
12 minutes and the supernatants (serum) transferred to fresh reaction tubes. Serum 
samples were then aliquoted and stored at -20 oC.  
 
2.10.2 Anti-P. gingivalis ELISA 
 
P. gingivalis W83 was grown as described in 2.2.1. Aliquots of frozen heat-killed P. 
gingivalis were thawed at room temperature then resuspended at an OD of 0.02 at 
600 nm (4 x 107 CFU/ml) in 0.5 M carbonate-bicarbonate buffer. Immulon 1B ELISA 
plates (Fisher Scientific) were coated with 100 µl/well P. gingivalis in carbonate-
bicarbonate buffer and incubated overnight at 4oC. The plates were washed with 
0.05% Tween-20 in PBS (PBS-T) 3 times after this step and all subsequent steps until 
the addition of TMB stop solution. The plates were blocked with 200 µl/well 
blocking buffer (10% HI-FCS in PBS) at 37oC for 1 hour.  Serial dilutions of serum 
ranging from 1/50 to 1/400 were made using dilution buffer (0.2% HI-FCS in PBS-T) 
and 50 µl of each diluted sample was added to duplicate wells. Previously tested 
positive and negative serum samples were included in each plate, as well as a no-
sample blank control. The plates were incubated for 2 hours at 37oC or overnight at 
4oC. Fifty µl/well of the detection goat anti-mouse antibody conjugated to 
horseradish peroxidase (HRP) (table 2.7) was then added and incubated for 1 hour 
at 37oC before the reaction was visualized by the addition of 100 µl/well of TMB 
stop solution. The reaction was stopped using 50 µl/well of 10% HCl and the plate 
was read by a microplate absorbance reader at 450 nm with a reference wavelength 
of 630 nm. 	  
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2.10.3 Anti-OVA ELISA 	
One hundred µl of 20 µg/ml OVA protein in 0.5 M Carbonate-Bicarbonate buffer was 
added to a 96 well plate and incubated overnight at 4oC. The plates were washed 
with PBS-T 3 times after this step and all subsequent steps until the addition of TMB 
stop solution. The plates were blocked with 200 µl/well blocking buffer at 37oC for 
1 hour.  Serial dilutions of serum ranging from 1/100 to 1/6400 were made using 
dilution buffer and 50 µl of each diluted sample was added to duplicate wells. 
Previously tested positive and negative serum samples were included in each plate, 
as well as a no-sample blank control. The plates were incubated for 2 hours at 37oC 
or overnight at 4oC. Fifty µl/well of the detection goat anti-mouse (table 2.7) 
antibody was then added and incubated for 1 hour at 37oC before the reaction was 
visualized by the addition of 100 µl/well of TMB stop solution. The reaction was 
stopped using 50 µl/well of 10% HCl and the plate was read by a microplate 
absorbance reader at 450 nm with a reference wavelength of 630 nm. 
 
 
Table 2.7. Detection antibodies used in anti-P. gingivalis and anti-OVA ELISAs. 	
Detection antibody Dilution Supplier 
Anti-mouse IgG (HRP) 1/10000 Southern Biotech 
Anti-mouse IgG1 (HRP) 1/10000 Southern Biotech 
Anti-mouse IgG2a (HRP) 1/10000 Southern Biotech 
Antibody concentrations were previously optimized by Ana Adrados Plannell. 
 
2.10.4 Calculation of ELISA units (EU) 
 
A mean blank-corrected value was obtained for each dilution of each serum sample 
by subtracting the mean OD of blank wells from the mean sample ODs. The y-
intercept of the slope of the blank-corrected ODs from all serial dilutions was 
determined and this value was multiplied by 1000 to give ELISA units (EU), as 
previously described (Gmür et al., 1986). 
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2.11 Quantification of cytokines by ELISA and multiplex assay 
2.11.1 Anti-IFN-γ ELISA 
 
The concentration of IFN-γ from cell culture supernatants (described in 2.14.1) was 
measured using IFN-γ ELISA Ready-SET-Go! Kit (eBioscience) following the 
manufacturer’s guide. One hundred µl of diluted capture antibody in 1X Coating 
buffer was added to each well of a 96-well plate and incubated overnight at 4oC. 
The plates were washed with PBS-T 3 times after this step and all subsequent steps 
until the addition of Avidin-HRP. The plates were blocked with 200 µl/well 1X ELISA 
diluent and incubated for 1 hour at room temperature. Standards were serially 
diluted two-fold and ranged from 15 pg/ml to 2000 pg/ml. Samples were diluted 
1/2 with 1X ELISA diluent. One hundred µl/well of standards and samples were 
added and incubated for 2 hours at room temperature. Detection antibody was 
diluted in 1X ELISA diluent and incubated for 1 hour at room temperature. One 
hundred µl/well avidin-HRP was diluted in ELISA diluent and incubated for 30 
minutes at room temperature. The plates were washed at least 5 times, followed 
by visualization by the addition of 100 µl/well TMB stop solution (KPL, Maryland, 
USA). The reaction was stopped using 50 µl/well of 10% HCl and the plate was read 
by a microplate absorbance reader (Sunrise™, Tecan) at 450 nm with a reference 
wavelength of 570 nm. 
 
A mean blank-corrected value was obtained for each standard and sample by 
subtracting the mean OD of blank wells from the standard or sample ODs. The 
blank-corrected OD of each serially diluted standard was used to generate a 
standard curve, from which concentrations of IFN-γ in each cell culture supernatant 
were calculated.  
 
2.11.2 Bio-Plex® Multiplex Immunoassay  
 
The Bio-Plex® Multiplex Immunoassay was used to identify IL-6, IL-10, IL-13, IL-17A 
and IFN-γ from cell culture supernatants (described in 2.14.1) and the protocol 
from the manufacturer’s guide was followed. Standards provided in the kit were 
prepared by reconstitution with 500 µl of complete media. Standards were then 
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vortexed and incubated on ice for 30 minutes, and then serially diluted four-fold to 
have 8 standards containing known concentrations of the cytokines, the ranges of 
which are described in table 2.8. Cell culture supernatants were centrifuged at 
1000 x g for 15 minutes at 4oC to remove cellular debris. The beads for each 
cytokine in this assay are distinctly coloured by use of different ratios of two 
fluorescent dyes (red and infrared). The beads are then conjugated to anti-cytokine 
antibodies. The cytokine beads diluted to a 1X concentration in assay buffer were 
vortexed and 50 µl added to each well of the flat-bottom 96-well plate provided. 
The plate was then washed twice with 100 µl Bio-Plex® wash buffer using the Bio-
Plex handheld magnetic washer, as were all subsequent wash steps. Fifty µl of 
vortexed diluted standards, blanks (complete media) and neat samples were 
transferred to wells of the 96-well plate. The plate was covered with sealing tape 
and aluminum foil to protect from light and was incubated on a shaker at 850 +/- 50 
rpm for 30 minutes at room temperature. The plate was then washed 3 times with 
100 µl wash buffer and 25 µl of 1X biotinylated detection antibodies added to each 
well. The plate was sealed and incubated on a shaker at 850 +/- 50 rpm overnight 
at 4 oC. After 3 washes with 100 µl wash buffer, 50 µl of 1X streptavidin-PE was 
added to each well and the plate sealed and incubated on a shaker at 850 +/- 50 
rpm for 10 minutes at room temperature. The plate was then washed 3 times with 
100 µl wash buffer and beads resuspended in 125 µl assay buffer. Prior to plate 
reading, the plate was shaken at 850 +/- 50 rpm for 30 seconds. The plate was read 
on a BIO-RAD Bio-Plex 100 at a low RP1 (PMT) setting. A mean blank-corrected 
value was obtained for each standard and sample by subtracting the mean 
fluorescence of blank wells from the standard and sample fluorescences. The blank-
corrected fluorescence of each serially diluted standard was used to generate a 
standard curve for each cytokine, from which concentrations of cytokines in each 
cell culture supernatant were calculated.  
 
Table 2.8. The concentration range of multiplex cytokine standards. 
Cytokine Highest standard 
concentration (pg/ml) 
Lowest standard 
concentration (pg/ml) 
IL-6 20,832 1.27 
IL-10 19,679 1.20 
IL-13 19,968 1.22 
IL-17A 44,706 2.73 
IFN-γ 13,205 0.81 
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2.12 Molecular Biology 
2.12.1 RNA extraction 
 
(i) Qiagen RNeasy® Micro kit 	
RNA extraction was performed using the Qiagen RNeasy® Micro kit (Qiagen, The 
Netherlands) following the manufacturer’s guidelines. In brief, cells in a 1.5 ml 
reaction tube were centrifuged at 3000 x g for 5 minutes and the supernatant was 
discarded. To lyse the cells, the pellet was loosened and resuspended in 350 µl 
Buffer RLT. The sample and buffer were mixed by vortexing and the cells were 
homogenized by passing lysate 10 times through a 20-gauge needle attached to a 1 
ml plastic syringe. Three hundred and fifty µl of 70% ethanol was added to the 
lysate and was mixed by pipetting. The sample was transferred to an RNeasy 
MinElute spin column placed in a 2 ml collection tube and was centrifuged at 8000 x 
g for 15 seconds. The flow-through was discarded and 350 µl Buffer RW1 was added 
to the spin column, and then it was centrifuged at 8000 x g for 15 seconds. To 
remove genomic DNA (gDNA), 80 µl of DNase I incubation mix (70 µl Buffer RDD and 
10 µl DNase I stock solution) was added directly to the column membrane and was 
incubated at room temperature for 15 minutes. Three hundred and fifty µl of Buffer 
RW1 was added to the column and it was centrifuged at 8000 x g for 15 seconds and 
the collection tube and flow through were discarded. Five hundred µl Buffer RPE 
was added to the column, then placed in a new 2 ml collection tube, and was 
centrifuged at 8000 x g for 15 seconds. The flow through was discarded and 500 µl 
of 80% ethanol was added to the column. The column was centrifuged at 8000 x g 
for 2 minutes to wash the membrane then the collection tube and flow through 
were discarded. The column was placed onto a new 2 ml collection tube and with 
the lid opened to dry the column membrane it was centrifuged at full speed for 5 
minutes. The collection tube and flow through were discarded and the column was 
placed on a new 1.5 ml collection tube. Fourteen µl of RNase-free water was added 
to the column membrane and the column was centrifuged at full speed for 1 minute 
to elute the RNA. RNA samples were stored at -80oC until required. 
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(ii) RNAqueous-Micro® total RNA Isolation kit 
 
RNA extraction was performed using RNAqueous-Micro® total RNA Isolation kit 
(Thermo Fisher) following the manufacturer’s guidelines. In brief, cells in a 1.5 ml 
PCR tube were centrifuged at 3000 x g for 5 minutes and the supernatant was 
discarded. One hundred µl of Lysis Solution was added to the cells and vortexed 
vigorously. Fifty µl of 100% ethanol was added to the sample, followed by a brief 
vortex. The lysate/ethanol mixture was loaded onto a Micro Filter Cartridge 
Assembly and centrifuged at full speed for 10 seconds to allow the RNA to bind to 
the filter. One hundred and eighty µl of Wash Solution 1 was added to the Micro 
Filter Cartridge Assembly then centrifuged at 16000 x g for 10 seconds. One 
hundred and eighty µl of Wash Solution 2/3 was added to the Micro Filter Cartridge 
Assembly then centrifuged at 16000 x g for 10 seconds. This step was repeated and 
the flow-through was discarded. To dry the filter, the filter cartridge was 
centrifuged at full speed for 1 minute and the filter cartridge was placed in a new 
1.5 ml collection tube. Five µl of prehreated (75oC) Elution Solution was added 
directly to the membrane of the filter cartridge and incubated at room temperature 
for 1 minute. The filter cartridge was centrifuged at full speed for 30 seconds to 
elute the RNA. A second 5 µl of Elution Solution was added to the membrane and all 
subsequent steps were repeated. To remove gDNA, 1 µl of 10X DNase I Buffer and 1 
µl of DNase I was added to the sample and mixed, then incubated at 37oC for 20 
minutes. Two µl of DNase Inactivation Reagent was added to the sample and was 
incubated at room temperature for 2 minutes, vortexing once during the 
incubation. The tube was centrifuged at full speed for 1.5 minutes to pellet the 
DNase Inactivation Reagent and the supernatant (containing RNA) was transferred 
to a fresh RNase free 0.5 ml PCR tube. RNA samples were stored at -80oC until 
required. 
 
(iii) Arcturus® PicoPure™ RNA Isolation kit  
 
RNA extraction was performed following the manufacturer’s guidelines. In brief, for 
trial experiments, cells in a 1.5 ml PCR tube were pelleted by centrifugation at 
3000 x g for 5 minutes and the supernatant was discarded. The cell pellet was 
resuspended in 100 µl of Extraction Buffer and mixed by pipetting. For T cell sorting 
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for RNA-sequencing, cells were sorted into 1.5 ml PCR tubes containing 100 µl of 
Extraction Buffer. The cell/Extraction Buffer mix was incubated at 42oC for 30 
minutes followed by a centrifugation at 3000 x g for 2 minutes. The supernatant 
containing the RNA was transferred to a fresh 1.5 ml PCR and an equal volume of 
70% ethanol was added and was mixed by pipetting. The cell extract/ethanol 
mixture was added to a column pre-conditioned with Conditioning Buffer. RNA was 
bound to the column by centrifugation at 100 x g for 2 minutes, followed by a 
centrifugation at 16000 x g for 30 seconds to remove the flow through. One hundred 
µl Wash Buffer 1 was added to the column and was centrifuged at 8000 x g for 1 
minute. Genomic DNA was then removed from the column by mixing 5 µl of DNase I 
Stock Solution (Qiagen) to 35 µl Buffer RDD (Qiagen) (not supplied with RNA 
extraction kit) and adding the total 40 µl directly to the purification column. The 
DNase mix was incubated on the column at room temperature for 15 minutes. Forty 
µl of Wash Buffer 1 was added to the column containing the DNase mix and the 
column was centrifuged at 8000 x g for 15 seconds. One hundred µl of Wash Buffer 2 
was added to column and centrifuged at 8000 x g for 1 minute. This step was 
repeated with the centrifugation being increased to 16000 x g for 2 minutes. The 
column was transferred to a new 0.5 ml PCR tube and 11 µl of Elution Buffer was 
pipetted directly onto the membrane of the column. The column was incubated for 
1 minute at room temperature then centrifuged at 1000 x g for 1 minute to ensure 
the Elution Buffer was distributed across the membrane, followed by a 
centrifugation at 16000 x g for 1 minute to elute the RNA. RNA samples were stored 
at -80oC until required. 
 
(iv) Cells-to-CT™ kit 
 
For RNA-sequencing verification experiments, CD4+ T cells were.sorted from cell 
isolates of 5 pooled gingivae or dLNs. Owing to the low numbers of CD4+ T cells 
sorted from gingivae (approximately 1 x 104), the Cells-to-CT™ Kit (Thermo Fisher) 
was used and protocol from the manufacturer’s guide followed. Cells-to-CT™ 
enables reverse transcription of lysates from 10 to 1 x 105 cells, without the typical 
initial RNA purification step that can result in loss of RNA from small samples. 
Sorted cells were transferred to a 96-well plate and resuspended in 50 µl of cold 
PBS, then washed by centrifugation at 400 x g for 3 minutes. DNase I was diluted in 
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Lysis Solution at 1/100 to remove gDNA. Fifty µl of Lysis Solution was added to each 
sample and mixed by pipetting up and down 5 times. After the lysis reaction was 
incubated for 5 minutes, 5 µl Stop Solution was added and mixed by pipetting 5 
times, followed by a 2 minute incubation. Ten 10 µl of lysate was added to 40 µl of 
master mix containing 25 µl 2X RT Buffer, 2.5 µl 20X RT Enzyme Mix and 12.5 µl of 
nuclease-free water in a 0.2 ml PCR tube on ice. The PCR tubes were briefly 
centrifuged to ensure that all contents were collected at the bottom, and then 
were loaded into an Applied Biosystems Veriti thermal cycler (Thermo Fisher) and 
the program described in table 2.9 was run. The quantitative RT-PCR was 
conducted as described in 2.11.4. 
 
 
Table 2.9. Thermal cycling program for reverse transcription using Cells-to-CT™  
kit. 	
Stage No. of cycles Temperature 
(oC) 
Time 
(minutes:seconds) 
1 1 37 60:00 
2 1 95 05:00 
3 1 4 Infinity 
 
2.12.2 Assessment of RNA quality and concentration 
 
(i) Nanodrop 	
The concentration and quality of isolated RNA was evaluated by measuring the 
absorbance of 1.5 µl sample at 230 nm, 260 nm, 280 nm and 340 nm with a 
Nanodrop1000 spectrophotometer (Thermo Fisher). The absorbance at 230 
corresponds with organic compounds including phenol and also peptide bonds in 
proteins. The absorbance at 260 nm corresponds with the peak absorption of 
nucleic acid, and at 280 nm with proteins and phenol. The absorbance at 340 nm 
establishes a baseline close to zero for the spectrum normalization. The Beer-
Lambert Law was used to determine the concentration of RNA in each sample: RNA 
concentration (ng/µl) = (Abs260 – Abs340) x 40. 
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The ratio of absorbance at 260/280 indicates the purity of the RNA sample, with a 
desirable ratio being approximately 2.0. As a second measure of purity, the ratio of 
absorbance at 260/230 should range between approximately 2.0 and 2.2. 
  
(ii) Bioanalyzer 
 
As a more sensitive means of RNA concentration and quality determination, the 
Agilent RNA 6000 Pico Kit was used along with the Agilent 2100 Bioanalyzer 
instrument (Agilent, Cheshire, UK). The detection range of RNA concentrations was 
between 200 and 5000 pg/µl. Each RNA chip contained an interconnected set of 
microchannels that were used for separation of nucleic acid fragments based on 
size during electrophoresis. The protocol as described in manufacturer’s guide was 
followed. First, the chip priming station was set up by replacing the old syringe 
with the new one provided in the kit and the base plate was adjusted to position C. 
The ladder was briefly centrifuged and transferred to a PCR tube, and then heat 
denatured for 2 minutes at 70oC on a heat block and immediately cooled on ice. 
After the addition of 90 µl RNase-free water, the prepared ladders were aliquoted 
and stored at -70oC. All reagents were equilibrated to room temperature before 
subsequent steps were conducted. Five hundred and fifty µl of RNA gel matrix was 
transferred to a spin column and centrifuged at 1500 x g for 10 minutes at room 
temperature, and then 65 µl aliquots stored in 0.2 ml PCR tubes at 4oC for a 
maximum of 4 weeks. The gel-dye mix was then prepared by vortexing the RNA dye 
concentrate for 10 seconds and briefly centrifuging to bring all contents to the 
bottom of the tube. To a 65 µl aliquot of gel, 1 µl of dye was added, gel-dye mix 
was then vortexed and centrifuged at 13000 x g for 10 minutes at room 
temperature. The prepared gel-dye mix was used within 1 day. To prepare the RNA 
chip for assessment by the Bioanalyzer, 9 µl of gel-dye mix was loaded into the 
appropriate marked well of the chip positioned in the chip priming station. The 
plunger of the syringe was adjusted to 1 ml position and the chip priming station 
was closed. The plunger was pressed down until held by the clip and after 30 
seconds the clip was released. After 5 seconds, the plunger was pulled back up to 
the 1 ml position. The chip priming station was then opened and 9 µl of gel-dye mix 
added to remaining marked wells. Nine µl and 5 µl of RNA conditioning solution and 
RNA marker, respectively, were added to appropriate wells. One µl of heat-
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denatured ladder was added to the appropriate well, followed by the addition of 1 
µl of each sample (maximum 11 per chip) to appropriate sample wells of the chip. 
Samples were previously heat denatured at 70oC on a heat block for 2 minutes and 
cooled on ice. The chip was then vortexed at 2400 rpm for 1 minute on the IKA 
vortexer and immediately run on the bioanalyzer. Thanks go to Dr Donna Nile 
(Beatson Institute, Glasgow) for providing advice and access to equipment.  
 
2.12.3 Reverse Transcription 
 
Reverse transcription of RNA to cDNA was carried out using the Applied Biosystems 
High Capacity cDNA Reverse Transcription Kit (Thermo Fisher). Into 0.2 ml PCR 
tubes, 5 µl of RNA template was added (as the amount of extracted RNA from 
different RNA extraction kits was being compared), along with 5 µl of nuclease-free 
H2O and 10 µl of master mix from the reverse transcription kit. This master mix 
contained manufacturer optimised concentrations of MgCl2, along with 
deoxynucleotide triphosphates (dNTPs), random primers and MultiScribe™ reverse 
transcriptase enzyme (RT). A negative RT control was also included, whereby RT 
was excluded and instead replaced with an equal volume of nuclease-free H2O to 
determine the presence of contaminating gDNA. The PCR tubes were briefly 
centrifuged to ensure that all contents were collected at the bottom then were 
loaded into a thermal cycler and the program described in table 2.10 was run. 
 
 
Table 2.10. Thermal cycling program for reverse transcription using High 
Capacity cDNA Reverse Transcription Kit. 	
Stage No. of Cycles Temperature 
(oC) 
Time 
(minutes:seconds) 
1 1 25 10:00 
2 1 37 120:00 
3 1 85 05:00 
4  1 4 Infinity 
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2.12.4 Quantitative RT-PCR 
 
Quantitative RT-PCR (qRT-PCR) was carried out using Taqman® reagents (Thermo 
Fisher) and reactions were prepared in MicroAmp® 96-well reaction plates (Thermo 
Fisher). Each reaction consisted of between 1-100 ng of cDNA in a volume of 0.5-9 
µl, 1 µl Taqman® Primer Probe Assay Mix, 10 µl Taqman® Fast Universal PCR Master 
Mix and a volume of nuclease-free H2O to make the reaction volume 20 µl. The 96-
well plate was then sealed shut and briefly centrifuged to bring all components to 
the bottom of the wells. The plate was placed in an Applied Biosystems 7500 Fast 
Real-Time PCR System (Thermo Fisher), and a thermal cycling program was 
conducted as described in table 2.11. The threshold cycle (CT) for each well was 
calculated using the Real-Time PCR System software and expression relative to 
housekeeping gene calculated in excel. 
 
 
Table 2.11. Thermal cycling program for qRT-PCR amplification of cDNA using 
7500 Fast Real-Time PCR system. 	
Stage No. of Cycles Temperature 
(oC) 
Time 
(minutes:seconds) 
1 1 95 0:20 
2 40 95 0:03 
60 0:30 
 
2.12.5 RT2 Profiler PCR Array 
 
Cells were isolated from single gingiva and dLNs of a single mouse as described in 
2.5.2. RNA was extracted using the Arcturus® PicoPure™ RNA Isolation kit. A 
cytokine and chemokine RT2 profiler PCR Array (Qiagen) was used to assess RNA 
isolated from gingivae and dLNs of mice sham and P. gingivalis-infected. The 
protocol was followed as described in the manufacturer’s guide. Each sample was 
diluted to 400 ng of RNA in 8 µl using RNase-free H2O (recommended by 
manufacturer), to which 2 µl of Buffer GE was added for gDNA elimination. The 
RNA-gDNA elimination mixture was mixed gently by pipetting up and down, then 
centrifuged briefly. The RNA-gDNA elimination mixture was incubated at 42oC for 5 
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minutes, then immediately placed on ice for at least 1 minute. The reverse-
transcription mix was prepared as described in table 2.12 and 10 µl added to 10 µl 
RNA-gDNA elimination mixture. The mixture was then mixed gently by pipetting and 
incubated at 42oC for 15 minutes. To stop the reaction, mixtures were immediately 
incubated at 95oC for 5 minutes. Ninety-one µl of RNase-free H2O was added to 
each sample and mixed. The PCR component mix was prepared as described in 
table 2.13 for each sample. Ten µl of PCR component mix was added into the 
appropriate wells of the 384 well array plate that already contained forward and 
reverse primers of the genes of interest. The plate was sealed with an optical 
adhesive film and centrifuged at 1000 x g for 1 minute at room temperature to 
bring contents to the bottom of the plate and remove bubbles. The plate was 
placed in an Applied Biosystems 7900HT Fast Real-Time PCR System (Thermo 
Fisher), and a thermal cycling program was conducted as described in table 2.14. 
The CT for each well was calculated using the Real-Time PCR System software and 
expression relative to housekeeping gene calculated in excel. 
 
Table 2.12. Reverse-transcription mix per reaction. 	
Reverse-transcription component Volume (µl) Total Volume (µl) 
5X Buffer BC3 4 10 
Control P2 1 
RE3 Reverse transcriptase mix 2 
RNase-free H2O 3 
 
 
Table 2.13. PCR component mix for each sample (for use in 384 well plate - 4 x 
96 well format). 	
PCR component Volume (µl) Total Volume (µl) 
2X RT2 SYBR Green Mastermix 650 1300 
cDNA synthesis reaction 102 
RNase free H2O 548 
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Table 2.14. Thermal cycling program for qRT-PCR amplification of cDNA using 
7900HT Fast Real-Time PCR system. 	
Stage No. of Cycles Temperature 
(oC) 
Time 
(minutes:seconds) 
1 1 95 10:00 
2 40 95 00:15 
60 01:00 
 
2.12.6 Pre-amplification of RNA 
 
Clonetech SMART-Seq® v4 Ultra® Low Input RNA kit for sequencing (Takara Bio, 
Saint-Germain-en-Laye, France) was used to pre-amplify the RNA isolated from 
CD4+ T cells for RNA-sequencing. The amplification was performed following the 
manufacturer’s guidelines. The components of all buffers required for pre-
amplification are described in table 2.15. In brief, 1–9.5 µl RNA (table 2.16) was 
added to a 0.5 ml RNase free PCR tube. The volume was then increased to 9.5 µl 
with the addition of nuclease-free H2O and 1 µl of 10X Reaction Buffer was added. 
Whilst the samples were on ice, 2 µl of 3’ SMART-Seq CDS Primer II A (12 µM) was 
added. The samples were incubated for 3 minutes in a thermal cycler at 72oC, 
followed by an incubation on ice for 2 minutes. The thermal cycler was pre-heated 
to 42oC and 7.5 µl master mix was added to the samples. The samples and master 
mix were mixed by gentle pipetting then were briefly centrifuged to ensure the 
contents were collected at the bottom of the PCR tubes. The samples were placed 
in a thermal cycler and the program described in table 2.17 was run for first strand 
cDNA synthesis. For cDNA amplification by long distance PCR, 30 µl of PCR 
mastermix was added to 20 µl of first-strand cDNA product and mixed well. Again 
the samples were centrifuged to ensure the contents were collected at the bottom 
of the PCR tubes. The samples were placed in a thermal cycler and the program 
described in table 2.18 was run. The samples were shipped on dry ice to Source 
BioScience for all downstream steps of the SMART-Seq® v4 Ultra® Low Input RNA 
kit: purification of amplified cDNA using the Agencourt AMPure XP kit; validation 
using the Agilent 2100 BioAnalyzer and Illumina library preparation using Nextera 
DNA library preparation kits.   
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Table 2.15. Components of buffers required for pre-amplification. 	
Buffer Components Volume 
(µl) 
Total 
volume (µl)* 
10X Reaction 
Buffer 
10X lysis buffer 19 20 
RNase Inhibitor 1 
First Strand 
cDNA Synthesis 
Master Mix 
5X Ultra Low First-Strand Buffer 4 5.5 
SMART-Seq v4 Oligonucleotide 
(48 µM) 
1 
RNase Inhibitor (40 U/µl) 0.5 
PCR Master Mix 2X SeqAmp PCR Buffer 25 30 
PCR Primer II A (12 µM) 1 
SeqAmp DNA Polymerase 1 
Nuclease-Free H2O 3 
*Volume per reaction. 
 
Table 2.16. Concentration of RNA used for pre-amplification. 	
Experimental 
Repeat 
Sample RNA for pre-
amplification (ng) 
Volume of 
RNA (µl)* 
Volume of 
H2O 
1 CMC LN 10 5 4.5 
PG LN 10 5 4.5 
CMC G 10 6.9 2.6 
PG G  5.814 9.5 0 
2 CMC LN 10 5 4.5 
PG LN 10 5 4.5 
CMC G 7.825 9.5 0 
PG G  10 9.5 0 
3 CMC LN 10 5 4.5 
PG LN 10 5 4.5 
CMC G 8.313 9.5 0 
PG G  6.873 9.5 0 
*RNA from LN samples were previously diluted in H2O.  
Abbreviations: CMC, carboxymethylcellulose; PG, P. gingivalis-infected; LN, lymph 
node; G, gingivae. 
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Table 2.17. Thermal cycling program for first strand cDNA synthesis. 	
Stage No. of Cycles Temperature 
(°C) 
Time 
(minutes:seconds) 
1 1 42 90:00 
2 1 70 10:00 
3 1 4 Infinity 
 
 
Table 2.18. Thermal cycling program for cDNA amplification. 	
Stage No. of Cycles Temperature 
(°C) 
Time 
(minutes:seconds) 
1 1 95  1:00 
2 10 98 0:10 
65 0:30 
68 3:00 
3 1 72 10:00 
4 1 4 Infinity 
 
2.12.7 RNA-sequencing 
 
RNA-sequencing workflow is shown in figure 2.9. RNA-sequencing was conducted by 
Source BioScience on the Illumina NextSeq 500 v2 platform using one High-Output 
flow cell (12 indexes per flow cell) at 75bp paired-end. RNA-sequencing analysis 
was conducted by a bioinformatician at Source BioScience and included five steps: 
adaptor and quality trimming of data using Skewer (version 0.1.12); spliced 
mapping of trimmed reads based on a Mus Musculus reference genome (UCSC 
(mm10)) using HISAT (version 0.1.6); gene-wise read counting based on reference 
genome using DESeq2; calculation of differential gene expression between groups 
using DESeq2; and gene-set enrichment analysis using fold changes obtained from 
sample comparisons in previous step.  
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Figure 2.9. Work flow of RNA-sequencing. 
The steps required for RNA-sequencing, from oral infections of mice to end point 
data analysis. The location in which each step was conducted is described on the 
left. Abbreviations: dLN, draining lymph node; ds, double-stranded; LD PCR, long 
distance polymerase chain reaction; P. gingivalis, Porphyromonas gingivalis. 
 
  
Oral infections with P. gingivalis 
Gingivae and dLN harvest  
Cell isolation 
CD4+ T cell sort 
RNA extraction 
RNA validation by Bioanalyzer 
SMARTer First-strand cDNA synthesis 
Full-length ds cDNA amplification by LD-PCR 
Amplified cDNA purification and validation 
Illumina Library preparation 
RNA-sequencing 
Data analysis 
In
-h
ou
se
 
So
ur
ce
 B
io
Sc
ie
nc
e 
 98	
2.12.8 Bacterial DNA extraction from oral swabs and PCR 
 
Oral swabs were taken from mice at the end point of the murine models of PD, as 
described in 2.4.1. The swabs were placed into the container with 1 ml of liquid 
amies transport medium and vortexed to ensure the release of bacteria from the 
swab. The transport medium and any bacteria were then transferred to 1.5 ml PCR 
tubes and stored long term at -80oC. Bacterial DNA was isolated using the 
MasterPure™ Gram Positive DNA Purification Kit (Epicentre, Wisconsin, USA), 
following the manufacturer’s guidelines with a few modifications. In brief, the 
bacteria were pelleted by centrifugation at full speed for 10 minutes in a microfuge 
and the supernatant was discarded. One hundred and fifty µl of TE buffer was 
added and the bacterial pellet was resuspended by vortexing. One µl of Ready-Lyse 
Lysosyme was added, followed by an incubation at 37oC for 2 hours. One µl of 
Proteinase K (50 µg/µl) was mixed with 150 µl of Gram positive Lysis Solution and 
added to the sample, and this was incubated at 70oC for 15 minutes, vortexing the 
sample every 5 minutes. After cooling the samples to 37oC, they were placed on ice 
for 5 minutes. One hundred and seventy five µl of MPC Protein Precipitation 
Reagent was added to the sample and was mixed vigorously for 10 seconds. The 
samples were centrifuged at full speed for 10 minutes at 4oC and the supernatants 
were transferred to fresh 1.5 ml PCR tubes, avoiding pick up of pelleted debris. One 
µl of RNase A (5 µg/µl) was added to the samples and incubated at 37oC for 30 
minutes. Next, 500 µl of isopropanol was added and this was mixed with the sample 
by inverting approximately 40 times. The DNA was pelleted by centrifugation at full 
speed for 10 minutes and the supernatant was discarded, followed by rinsing of the 
pellet with 200 µl of 70% ethanol. DNA from each sample was resuspended in 35 µl 
TE buffer. 
 
One µl of extracted DNA was added to a PCR mixture composed of 10 µl SYBR® 
Select Master Mix (Thermo Fisher), 7 µl nuclease-free H2O, 1 µl forward primers and 
1 µl reverse primers (giving a final concentration of 10 µM) (table 2.19). The 
primers were supplied by Integrated DNA technologies (Leuven, Belgium). The 
reaction mixture was prepared in a MicroAmp® 96-well plate, sealed shut and 
briefly centrifuged to bring all components to the bottom of the wells. The plate 
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was placed in an Applied Biosystems 7500 Fast Real-Time PCR System, and a 
thermal cycling program was conducted as described in table 2.20. 
 
Table 2.19. DNA primers used for identification of bacteria found in the oral 
cavity of P. gingivalis-infected mice. 	
Primer Sequence (5’-3’) Reference 
P. gingivalis 
rpoB 
Forward: GGA AGA GAA GAC CGT AGC ACA AGG A 
 
Reverse: GAG TAG GCG AAA CGT CCA TCA GGT C 
 
(Park et al., 
2011) 
Universal 
16S 
Forward: ACT CCT ACG GGA GGC AGC AGT  
Reverse: TAT TAC CGC GGC TGC TGG C  
(Matsuda et 
al., 2011) 
Abbreviations: rpoB, RNA polymerase β-subunit gene. 
 
 
Table 2.20. Thermal cycling program for PCR amplification of DNA from bacteria 
found in the oral cavity of P. gingivalis-infected mice. 	
Step No. of cycles Temperature 
(oC) 
Time 
(minutes:seconds) 
1 1 50 2:00 
2 1 95 2:00 
3 40 95 0:15 
60 1:00 
 
 
2.13 Assessment of RgpbOVA-A OVA expression by western blot 
2.13.1 Isolation of bacterial protein 
 
P. gingivalis W83 and OVA-expressing P. gingivalis were cultured as described in 
2.2, for 24 hours. In 1.5 ml reaction tubes, 1.5 ml of the cultures were centrifuged 
at full speed for 10 minutes. The supernatant was discarded and the pellets from 2 
reaction tubes were pooled (i.e. a pellet from 3 ml of culture) then frozen at -80oC 
overnight, or until required. Upon thawing, the bacterial pellets were resuspended 
in 250 µl bacterial lysis buffer (composed of 50 mM Tris, 10% glycerol, 0.1% Triton 
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X-100, 100 µl/ml lysozyme, 1 miniTab protease inhibitor, 3 units DNase and 2 mM 
MgCl2 in dH2O) and were then incubated at 15 minutes on a heat-block at 30oC.  
After transferring the samples to ice for another 15 minute incubation, the samples 
were sonicated 3 times, each for 20 seconds with a 10 second rest using a Soniprep 
150 (MSE, London, UK). The samples were centrifuged at full speed and 4oC for 20 
minutes and the supernatants were collected and transferred to fresh 1.5 ml 
reaction tubes. 
 
To ensure that the same amount of protein was used for western blotting, a 
Bradford Assay was conducted to determine the concentration of protein in the 
lysed bacterial samples, relative to a control. Protein Assay Dye Reagent 
Concentrate was diluted 1/5 with dH2O and was filtered using a sterile filter. Five 
dilutions of BSA were made in dH2O, to give a standard curve ranging from 0.5 
mg/ml to 0.05 mg/ml. Ten µl of standards and samples were added to separate 
wells of a 96 well plate in triplicate, followed by the addition of 200 µl of diluted 
dye reagent. The samples and dye were mixed by repeated aspiration and 
dispersion using a pipette and the plate was incubated at room temperature for at 
least 5 minutes, but no longer than 1 hour. The plate was read by a microplate 
absorbance reader at 595 nm. The OD of each serially diluted standard was used to 
generate a standard curve for BSA, from which concentrations of bacterial protein 
in each cell culture supernatant were calculated. The mean concentration from 
‘blank’ wells (which were not incubated with protein samples but otherwise treated 
the same as the other wells) was subtracted from the concentration of all other 
wells to give the final concentration. 
 
2.13.2 Western blot 
 
Samples were diluted in dH2O to give a final concentration of 20 µg in 32 µl and 
positive control samples OVA peptide (0.5 µg and 0.1 µg) or OVA protein (10 µg, 5 
µg and 1 µg) were diluted in dH2O to give a final volume of 32 µl. Eight µl of 5X 
sodium dodecyl sulfate (SDS) loading buffer was added to each sample to give a 
total loading volume of 40 µl. SDS loading buffer was composed of 5% β-
mercaptoethanol, 0.02% bromophenol blue, 30% glycerol, 10% SDS and 250mM Tris-
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Cl (pH 6.8). Two 18% Ready Gel® Tris-HCl gels were placed into the modules of a 
Mini-PROTEAN® electrophoresis Tetra system and 1X TGS buffer was added to the 
cell up to the fill line of the tank. The samples and 10 µl of neat Precision Plus 
Protein Dual Xtra Standards were loaded into the wells of the gel and 
electrophoresis was conducted by setting the voltage to 120V for around 1 hour (or 
until the bands of the standards had separated appropriately). 
 
The proteins from the gel were then transferred to nitrocellulose membranes using 
the Mini Trans-Blot® Electrophoretic Transfer Cell following the manufacturer’s 
instructions. In brief, the gel sandwich was prepared by placing the cassette grey 
side down, then one fibre pad pre-wetted in 1X TG buffer was placed on. Pre-
wetted filter paper was then placed on top, following the addition of the gel and 
another piece of pre-wetted filter paper. To ensure the removal of bubbles, a 50 ml 
centrifuge tube was carefully rolled over the sandwich and the other fibre pad was 
placed on top of the filter and the cassette was closed. The cassette was placed in 
the module and together with a frozen blue cooling unit, was placed in the tank of 
the Tetra system. The voltage was set to 100 V and was run for 1 hour.  
 
The nitrocellulose membrane was blocked in 5% milk in PBS-T for 1 hour then 
blocking buffer was removed and the primary antibody added and incubated at 4oC 
on a shaker overnight. The membrane was washed with PBS-T on a shaker at room 
temperature for 10 minutes. Fresh PBS-T was added and the process was repeated 3 
times. The secondary antibody was added and incubated on a shaker at room 
temperature for 1 hour. Antibodies used in western blots are described in table 
2.21 and were diluted in PBS-T. The membrane was washed with PBS-T as 
previously described. The membrane was placed onto cling film and bands of the 
ladder marked with a chemiluminescent pen. Equal parts of WesternBright™ Sirius™ 
luminol/enhancer solution (Advansta, California, USA) and WesternBright™ peroxide 
chemiluminescent detection reagent (Advansta) were mixed and poured over the 
membrane and the reaction was developed for 2 minutes. The membrane was 
placed in a development machine (LI-COR®, Cambridge, UK) to visualize the 
western blot images. 
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Table 2.21. Antibodies used for western blots. 	
Primary 
antibody 
Dilution Secondary 
antibody  
Dilution Supplier 
Anti-GroEL 1/1000 Goat anti-rabbit 
IgG (HRP) 
1/50000 Both - Abcam 
(Cambridge, UK) 
Anti-OVA 
323-339 
1/1000 Goat anti-rabbit 
IgG (HRP) 
1/50000 Primary – Innovagen 
(Lund, Sweden) 
 
Secondary – Abcam 
(Cambridge, UK) 
 
 
2.14 In vitro cell culture assays 
2.14.1 Restimulation of splenocytes with P. gingivalis 
 
A single cell suspension of splenocytes was obtained as described in 2.5.2 and 2 x 
105 cells in 200 µl of complete media were added into each well of a round bottom 
96-well plate. P. gingivalis W83 was cultured and heat-killed as described in 2.2.3 
and 50 CFU/cell were added to the wells. The cells were stimulated separately with 
0.5 µg/ml anti-CD28 antibody in wells pre-coated overnight at 4°C with 1 µg/ml 
anti-CD3 antibody in PBS as a positive control or complete media only as a negative 
control. After 72 hours of incubation at 37°C with 5% CO2, the plate was centrifuged 
at 400 x g for 3 minutes and the supernatants transferred to a fresh 96-well plate. 
The cells were stained with anti-CD45, anti-CD4, anti-CD8, anti-Ki67 and viability 
dye to assess the proliferation of T cells by flow cytometry (described in 2.7). 
 
2.14.2 Stimulation of OVA-specific T cells with RgpbOVA-A 
 
A single cell suspension of splenocytes and cervical LN cells from DO11.10 4GET 
mice were obtained as described in 2.5.2. As a source of APCs, 2 x 105 splenocytes 
in 100 µl complete media were added to the wells of a round bottom 96-well plate 
and incubated at 37oC with 5% CO2 for 2 hours. The non-adherent cells in the 
supernatant were removed, leaving the adherent, APCs in the wells. One hundred µl 
OVA protein (1 mg/ml), 1 x 107 CFU P. gingivalis W83, 1 x 107 CFU P. gingivalis W83 
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with OVA protein (1 mg/ml), 1 x 107 CFU RgpbOVA-A, anti-CD3 antibody or media 
were added to the wells and incubated with APCs at 37oC with 5% CO2 for 20 
minutes. P. gingivalis W83 and RgpbOVA-A used in this assay were cultured and 
heat-killed as described in 2.2.3. To the wells, 2 x 105 LN cells in 100 µl complete 
media were added and the plate was incubated at 37°C with 5% CO2 for 72 hours. 
After the incubation, the plate was centrifuged at 400 x g for 3 minutes and 
supernatants were discarded. The cells were stained with anti-CD4, anti-KJ1.26, 
anti-CD69, anti-Ki67 antibodies and viability dye to assess the activation state and 
proliferation of the transgenic T cells by flow cytometry (described in 2.7).  
 
2.14.3 Stimulation of gingival and LN cells for assessment of cytokine 
production by flow cytometry 
 
A single cell suspension of gingival tissue and LNs were obtained from sham and P. 
gingivalis-infected mice as described in 2.5.2. To a round bottom 96 well plate, 5 x 
105 cells were added in 200 µl complete media, followed by the addition of 2 µl of a 
stimulation mix or BD GolgiStop™ alone. The mix was composed of 10 ng/ml PMA, 
500 ng/ml ionomycin and BD GolgiStop™ (4 µl in every 6 ml of complete media (BD 
Biosciences)). BD GolgiStop™ was added to inhibit protein transport, causing an 
intracellular accumulation of cytokines. The 96 well plate was incubated at 37oC 
with 5% CO2 for 4 hours. After the incubation, the plate was centrifuged at 400 x g 
for 3 minutes and the supernatant was discarded. The cells were stained with 
viability dye, anti-CD45, anti-CD4, anti-CD8, anti-IFNγ, anti-IL-17A and anti-IL-4 
antibodies and were analysed by flow cytometry (described in 2.7).  
 
2.15 Statistics 
 
All statistical analysis was performed using GraphPad Prism®
 
software version 6 
(GraphPad Software, California, USA). For RNA-sequencing and qRT-PCR, where 
gene expression was shown as fold change or relative expression, data were log 
transformed to conduct statistical analysis. All other statistical analysis was 
conducted on raw data. To test if the means of two samples differed when the data 
was normally distributed, two-tailed unpaired T tests were employed. To test if the 
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means of two samples differed when the data was non-normally distributed, Mann-
Whitney tests were employed. To test if the means of two samples from a larger 
data set differed, multiple unpaired T tests followed by Holm-Sidak multiple 
comparison correction was employed. To compare the means of samples from the 
same mouse, two-tailed paired T tests were employed. To test if the means of more 
than two samples differed, a one-way ANOVA was employed. Differential gene 
expression from RNA-sequencing was determined using Wald-test (P value) followed 
by Benjamini-Hochberg correction (adjusted P value, Padj). A P value < 0.05 was 
considered significant for T tests, Mann-Whitney tests and one-way ANOVA. A Padj 
value < 0.1 was considered significant for Wald-test and Benjamini-Hochberg 
correction. 
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3 Optimizing a protocol for digesting gingival tissue 	
3.1 Introduction 
 
The immune response can localize to tissue specific sites, and the response is 
influenced by the architecture and milieu of cells and their products present within 
that given site. The phenotype and function of immune cells residing within specific 
anatomical locations will, therefore, be unique (Kroemer et al., 1993). The 
hallmark of PD is alveolar bone destruction. Gingival tissue is located in close 
proximity to alveolar bone, therefore is a propitious site to study the immune 
response that mediates bone remodeling in inflammation. Whilst the murine model 
offers an advantage to deciphering the immunological basis of PD over human 
studies (discussed in chapter 1.4), the small size of the mouse’s gingiva 
complicates isolation of the residing cells.   
 
To isolate cells of murine LNs, the LNs are removed and mashed over a cell 
strainer. Gingival tissue is extremely tough by comparison, as it is composed of a 
dense network of predominantly collagen fibres (Laurell et al., 1987). Gingivae are 
thereby resistant to processing by manual techniques appropriate for LNs. 
Enzymatic digestions are commonly used for isolating cells from gut tissue 
(Goodyear et al., 2014) and typically utilize collagenase and dispase I, combined 
with DNase and EDTA to enhance tissue disruption and reduce clumping of cells. 
However, the integrity of the cell surface may be impeded, affecting expression of 
surface markers and function (Ford et al., 1996). Despite this caveat, cells cannot 
be reliably obtained from certain tissue types using mechanical disruption alone 
(Autengruber et al., 2012).  
 
Investigating the cellular composition of gingivae is fundamental to understanding 
the immune response in PD; therefore the aims of this chapter were to: 
• Optimize a method for gingival tissue digestion. 
• Optimize a T cell purification method for downstream analysis of this specific 
cell type.  
  
 106	
3.2 Results 
 
This project sought to determine the role of CD4+ T cells in PD, including 
investigating CD4+ T cells at the local site of infection. As such, initial experiments 
focused on optimizing a protocol for efficiently obtaining a viable, single cell 
suspension of cells isolated from the gingivae of mice. The original gingival 
digestion protocol (method A) had been used for previous studies, but only 
highlighted the need for an improved protocol as cell numbers greatly varied 
between experiments and cell viability was poor. With the aim of achieving 
improved reproducibility and viability, six protocols were constructed, as described 
in table 3.1, using a combination of enzymes with four tissue disruption methods. 
These protocols were based on studies previously carried out within the group 
(Malcolm et al., 2015b), protocols that were previously published (Mizraji et al., 
2013, Goodyear et al., 2014), and others were discussed with MACS manufacturer.  
 
 
Table 3.1. Methods of gingival digestion. 	
Method Enzymatic digestion Tissue Disruption 
A Liberase DH GentleMACS™ dissociator Program A 
B No enzyme GentleMACS™ dissociator Program M_liver 
C Collagenase D GentleMACS™ dissociator Program M_liver 
D Collagenase D GentleMACS™ dissociator Program M_spleen 
E Collagenase D GentleMACS™ dissociator Program A 
F Collagenase II + DNase I Manual disruption with scalpel blade 
Abbreviations: DH, dispase high. 
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Gingival tissue was excised from four (methods A-E) or five (method F) female 
BALB/c mice and cells isolated according to one of the six protocols. The cells were 
then stained with anti-CD4, anti-CD8 and viability dye for flow cytometry analysis. 
The plots in figure 3.1 clearly illustrate that methods B-E failed to achieve a 
suspension of predominantly viable cells and instead depict small, poorly defined 
populations of viable CD4+ and CD8+ T cells. Whilst both methods A and F generate 
largely viable cell populations, method F yielded a greater population of CD4+ and 
an identifiable CD8+ population. This, however, is not simply a reflection of using 
an additional mouse in the group of pooled gingivae. Figure 3.2 and table 3.2 both 
demonstrate cell numbers per individual mouse and show that numbers of 
lymphocytes, viable lymphocytes, viable CD4+ and viable CD8+ cells are all greatest 
when using method F. Method F was therefore deemed the preferred protocol for 
cell isolations from gingival tissue.  
 
In some experiments, gingival strips were obtained (figure 2.5C). However, very 
few cells were isolated from gingival strips, compared with gingival and palatal 
tissue described above. On average, 76 viable CD4+ T cells and 8 viable CD8+ T cells 
were obtained per gingival strip (data not shown). Pooling the gingival strips from 
five mice would still give T cell numbers insufficient for analysis. As the main aim 
was to investigate oral mucosal T cells, and therefore encompass the oral mucosal 
tissue, and given the very low cell numbers obtained from gingival strips, in 
subsequent experiments, gingival tissue investigations in this thesis included palatal 
tissue.  
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Figure 3.1. Flow cytometry of cells obtained following different gingival digest 
protocols. 
Single cell suspensions were obtained from gingival tissue of BALB/c mice by 
combinations of different enzymatic digestion followed by different tissue 
disruption methods, as summarized in table 3.1. The resulting cell suspensions from 
each protocol were stained with cell viability dye, anti-CD4 and anti-CD8 antibodies 
then analysed by flow cytometry. (A) Liberase DH with gentleMACS™ dissociator 
Program B; (B) No enzyme with Program M_liver; (C) Collagenase D with Program 
M_liver; (D) Collagenase D with Program M_spleen; (E) Collagenase D with Program 
A; (F) Collagenase II and DNase I with manual disruption with scalpel blade. 	
 		
	
Figure 3.2. Numbers of cells obtained following different gingival digest 
protocols, per mouse. 
Single cell suspensions were obtained from gingival tissue of BALB/c mice by 
combinations of different enzymatic digestion followed by different tissue 
disruption methods, as summarized in table 3.1. The resulting cell suspension from 
each protocol was stained with cell viability dye and anti-CD4 and anti-CD8 
antibodies then analysed by flow cytometry. Cells were pooled from 4 or 5 mice for 
processing and analysis but normalized numbers per mouse are plotted. (A) Liberase 
DH with gentleMACS™ dissociator program Program B; (B) No enzyme with programs 
Program M_liver; (C) Collagenase D with Program M_liver; (D) Collagenase D with 
Program M_spleen; (E) Collagenase D with Program A; (F) Collagenase II and DNase I 
with manual disruption with scalpel blade. Each bar represents the cell numbers 
per mouse. (A) Number of lymphocytes; (B) Number of live lymphocytes; (C) 
Number of live CD4 cells; (D) Number of live CD8 cells. 
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Table 3.2. Proportions and total number of CD4 and CD8 T cells obtained 
following different gingival digest protocols. 	
Method 
Lymphocytes 
 
Viable 
Lymphocytes 
 
Viable CD4 Viable CD8 
No. No. % No. % No. % 
A 4067 3384 83.2 244 7.2 117 3.5 
B 4024 1706 42.4 53 3.1 95 5.6 
C 1782 1243 69.8 98 7.9 133 10.7 
D 1805 1160 64.3 113 9.7 145 12.5 
E 1230 738 60.0 60 8.1 61 8.3 
F 8486 7049 83.1 1208 17.1 244 3.5 
A, Liberase DH with Program B; B, No enzyme with Program M_liver; C, Collagenase 
D with Program M_liver; D, Collagenase D with Program M_spleen; E, Collagenase D 
with Program A; F, Collagenase II and DNase I with manual disruption. No. = cell 
number per mouse; % is of total number of lymphocytes.  
 
 
As enzymatic digestion can affect the extracellular expression of some markers, the 
next experiment assessed whether the use of collagenase II and DNase I affected 
the expression of the memory marker CD62L that is particularly prone to cleavage 
from the cell surface. To address this, cells were isolated from inguinal LNs by 
mechanical tissue disruption (no enzymes) or by method F enzymatic digestion, and 
were stained with viability dye, anti-CD45, anti-CD4, anti-CD62L and anti-CD44 for 
analysis by flow cytometry. The expression of CD62L by memory CD4+ T cells 
(CD45+ CD4+ CD62L+/- and CD44+/-) was evaluated (figure 3.3) and highlighted 
that the entire cell populations had slightly altered forward/side scatter following 
isolation by enzymatic digestion. Applying identical gates to cells from both 
disruption types suggested that expression of CD62L differed when cells were 
isolated in the presence of enzymes (CD62L+ cell numbers: mean 17147 +/- 108.5 
no enzymes vs. mean 15984 +/- 59 enzymes, P < 0.05) (table 3.3). However, when 
the gating strategy was slightly modified, to better fit the cell populations from 
enzymatically-digested tissues, the expression of CD62L was similar to that of cells 
isolated by non-enzymatic disruption (CD62L+ cell numbers: mean 17147 +/- 108.5 
no enzymes vs. mean 17431 +/- 575 enzymes, NS). Therefore, the use of DNase I 
and collagenase II did not appear to affect antibody binding to these lymphocyte 
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cell surface molecules, which were used for phenotyping cells in subsequent 
experiments.  
 
	
Figure 3.3. Effect of enzymatic digest on cleavage of CD62L from cell surface. 
Single cell suspensions were obtained from inguinal LNs by (A) mechanical tissue 
disruption (no enzymes) or (B and C) enzymatic digestion (Method F). The resulting 
cell suspensions were stained with cell viability dye, anti-CD45, anti-CD4, anti-CD44 
and anti-CD62L for analysis of memory CD4+ T cells by flow cytometry. (A and B) 
Cell gates were applied based on mechanical tissue disruption. (C) Gate in B was 
moved to better fit the populations’ slightly altered FSC/SSC. Populations of naïve 
and effector memory T cells (TEM) are highlighted by black gates.  
 
 
Table 3.3. Effect of enzymatic digest on cell surface CD62L expression. 	
Cell 
isolation 
type* 
Mouse 
No. 
No. of 
CD62L+ 
cells 
(same 
cell gate) 
No. of 
CD62L- 
cells 
(same 
cell gate) 
Ratio of 
CD62L+ 
To 
CD62L- 
No. of 
CD62L+ 
cells 
(gate 
adjusted) 
No. of 
CD62L- 
cells 
(gate 
adjusted) 
Ratio of 
CD62L+ 
To 
CD62L- 
No enzymes 1 17255 1984 8.7 - - - 
No enzymes 2 17038 2034 8.4 - - - 
Enzymes 1 15925 2876 5.5 16586 1950 8.5 
Enzymes 2 16043 4506 3.6 18006 2546 7.1 
*No enzymes, non-enzymatic mechanical tissue disruption; Enzymes, enzymatic 
digestion (Method F).  
 
 
To analyse T cells in PD by RNA-sequencing, the T cells would have to be purified 
from the total gingival tissue cell population. Therefore, the next experiments were 
conducted in order to optimize T cell purification. Two methods were trialed; using 
either magnetic-labeled antibody cell selection or flow cytometry based sorting 
(fluorescence-activated cell sorting, FACS).  
CD
44
 
CD62L 
CD
44
 
CD62L 
No Enzymes Enzymes A B 
CD
44
 
CD62L 
Enzymes – adjusted gate C 
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To improve the efficiency of binding of magnetic-labeled antibody beads to cells 
and therefore of cells to the column, the T cell population within the gingival cell 
suspension was enriched by eliminating other populations; either by using ficoll 
gradient separation, or by using MACS® Basic MicroBeads to remove dead cells. The 
T cells were purified from the enriched fraction using positive selection with either 
anti-CD3ε magnetic-labeled antibody beads, or anti CD90.2-labeled beads; the 
latter are reported to cause no T cell stimulation.  In all cases, the purity was 
assessed by flow cytometry (table 3.4). These methods of T cell purification had 
limited success. Using ficoll and anti-CD3ε-labeled beads (figure 3.4), the purified 
population was comprised of around 22% viable CD3+ cells and 21% of viable CD3- 
cells. Using Basic Microbeads and CD90.2-labeled beads resulted in poor viability, 
with only 8% of cells being viable and positive for CD3 and CD4 (figure 3.5). 
 
Table 3.4. Antibody panel used to assess purity of separated T cells. 
Protocol Antibody Panel 
Ficoll + anti-CD3ε beads Viability dye, anti-CD3, anti-CD4 
Basic Microbeads + anti-CD90.2 beads Viability dye, anti-CD3, anti-CD4 
Basic Microbeads + anti-CD4 beads Viability dye, anti-CD45, anti-CD4 
FACS Viability dye, anti-CD45, anti-CD4 
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Figure 3.4. T cell purification using ficoll and magnetic-labeled antibody beads. 
Single cell suspensions were obtained from gingival tissue of BALB/c mice, by 
liberase DH enzymatic digestion followed by Program B gentleMACS™ dissociation. 
Mononuclear cells were separated by Histopaque® 1083 density gradient separation 
then T cells purified using MACS® CD3ε MicroBeads. Cells were stained with cell 
viability dye, anti-CD3 and anti-CD4 antibodies then were analysed by flow 
cytometry. The dashed arrows indicate gating strategy. 
 
	
Figure 3.5. T cell purification using magnetic-labeled antibody beads. 
Single cell suspensions were obtained from gingival tissue of BALB/c mice, by 
liberase DH enzymatic digestion followed by Program B gentleMACS™ dissociation. 
Dead cells were removed using MACS® Basic MicroBeads then T cells were purified 
by MACS® CD90.2 MicroBeads. Cells were stained with cell viability dye, anti-CD3 
and anti-CD4 antibodies then were analysed by flow cytometry. The dashed arrows 
indicate gating strategy. 
 
 
In addition to the poor viability and purity, there was potential for anti-CD3ε beads 
to activate T cells and interfere with downstream analysis, and anti-CD90.2 could 
purify innate lymphoid cells (ILCs) (Hams et al., 2014). Therefore, the next 
experiments purified the CD4+ T cell population using anti-CD4-labeled beads in 
combination with Basic Microbeads. In these experiments, anti-CD45 was used for 
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flow cytometry to help identify CD4+ T cells and confirm purity as CD45 allows 
discrimination of leukocytes from non-hematopoietic cells. This was necessary since 
CD3 was removed from the panel to avoid stimulating the cells (table 3.4). The 
cells purified using anti-CD4 beads were stained with viability dye, anti-CD45 and 
anti-CD4 antibodies (figure 3.6B). Flow cytometry indicated that of the total 
population purified, only 11.1% were viable cells but 93.9% of the viable cells were 
CD4+.  
 
Using the antibodies in table 3.4, viable CD45+ CD4+ T cells were sorted by FACS 
(figure 3.6A), which yielded 100% pure, viable CD4+ T cells. Thus, the cells 
obtained by FACS were of greater viability and purity. Moreover, using magnetic-
labeled antibody beads requires the purified populations to be assessed for purity. 
By comparison, the total FACS sorted CD4+ T cell population can be used for 
downstream analysis (table 3.5). FACS sorting was therefore the preferred method 
for obtaining viable, CD4+ T cells for RNA-sequencing.  
	
 
Figure 3.6. CD4+ T cell purification using fluorescence-activated cell sorting and 
magnetic-labeled antibody beads. 
Single cell suspensions were obtained from gingival tissue of BALB/c mice, by 
collagenase II and DNase I enzymatic digestion followed by manual disruption with a 
scalpel blade (table 3.1, protocol F). (A) The unsorted cell suspension was stained 
with cell viability dye, anti-CD45 and anti-CD4 antibodies. (B) The cell suspension 
was CD4 purified using MACS® Basic MicroBeads followed by CD4 MicroBeads. The 
purified cells were stained for flow cytometry (as in A) to assess purity. The dashed 
arrows indicate gating strategy. 
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Table 3.5. Purity of T cells following different separation methods. 	
Purification 
method 
No. of cells 
post 
purification 
Can all 
purified cells 
be used for 
downstream  
analysis? 
Percentage 
of pure, 
viable T cells 
Estimation of 
T cell no. for 
downstream 
analysis*** 
Histopaque® 
1083 and 
MACS® CD3 
MicroBeads* 
2.0 x 104 
No; purity 
must be 
assessed 
21.9 3.3 x 103 
MACS® Basic 
MicroBeads 
and CD90.2 
MicroBeads** 
1.1 x 105 
No; purity 
must be 
assessed 
8.3 6.8 x 103 
MACS® Basic 
MicroBeads 
and CD4 
MicroBeads 
1.4 x 104 
No; purity 
must be 
assessed 
10.5 7.9 x 102 
Flow-
cytometry 
based CD4 
cell sorting 
1.2 x 104 Yes 100.0 1.2 x 104 
*CD3 beads may activate T cells thus interfering with downstream analysis 
** CD90.2 beads may not be specific for T cells; could purify ILCs 
***Estimation based on percentage of pure T cells and ¼ of purified sample being 
assessed by flow cytometry. 
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3.3 Discussion 
 
As the overall aim of this thesis was to determine the role of CD4+ T cells in PD, it 
was crucial to explore the immune response in the gingiva. Specific anatomical 
locations are home to distinct immune cells. For example, there is discrete 
distribution of Ig class by plasma cells in the gut compared to LNs and bone marrow 
(Crabbe et al., 1965). Likewise, the oral mucosa is populated by different immune 
components (Horav 2014). It was therefore imperative to define a protocol that 
enabled isolation of viable and functionally active cells from the gingiva.  
 
Due to the tough nature of gingival tissue, manual dissociation in the absence of 
enzymes failed to disrupt the tissue enough to allow the release of cells – in 
contrast to LNs and spleens which are readily disrupted by manual dissociation. 
These data indicate that specific enzymes in combination with tissue disruption 
methods were crucial variables in optimizing gingival T cell isolation. Rather 
unexpectedly, enzymes proved non-essential when using GentleMACS™ dissociation 
to obtain viable lymphocytes, however, a lack of enzymes resulted in the poorest 
retrieval of CD4+ T cells. It was demonstrated that using a combination of DNase I 
and collagenase II effectively isolated viable CD4+ and CD8+ T cells. This was 
similar to previous studies that substantiated a combination of liberase, DNase and 
collagenase was optimal for the isolation of cells from the small intestine from 
various strains of mice (Goodyear et al., 2014). The mouse lung is another tough 
tissue type to digest, and likewise has been dissociated with DNase, however 
GentleMACS™ was necessary to aid in the isolation of cells (Jungblut et al., 2009). 
Ideally, every combination of enzyme and mechanical disruption would have been 
assessed. However, this would have used an unacceptable number of animals. 
Despite this, protocol F that required manual dissociation with a scalpel blade 
proved to produce viable lymphocytes, and in particular T cells, in a reproducible 
manner.  
 
A concern when using enzymatic digests is alteration of true cell phenotype through 
cleavage of cell-surface markers (Autengruber et al., 2012). Although not always 
possible, the isolation of tissue resident cells can be achieved without the use of 
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enzymes. One such technique is the 3D explant method in which tissue samples are 
placed over a titanium matrix and cultured in media (Henderson et al., 2014). In 
this model, cells migrate out of the sample into media leaving behind the tissue 
structure. Whilst this system avoids the use of enzymes, a disadvantage is the bias 
of obtaining only cells with migratory capacity. Moreover, the relatively small 
number of CD4+ T cells available in the gingival tissue would potentially limit the 
usefulness of this passive migration method. Optimized method F illustrated that 
enzymes were crucial for optimal isolation of CD4+ T cells from gingival tissue; 
however, it was demonstrated that these enzymes did not affect the expression of 
memory marker CD62L, which is prone to enzymatic cleavage. Therefore, it seemed 
unlikely that the phenotype of gingival cells would be affected by either 
collagenase II or DNase I in the context of tissue digest.  
 
The combination protocol F enabled the phenotype and potential function of T cells 
from the oral mucosa to be determined using flow cytometry. However, to evaluate 
CD4+ T cells in an unbiased manner, further aims of this project were to conduct 
transcriptomic studies. For this technique, T cells must be purified from the total 
gingival cell isolate. Magnetic-labeled antibody beads have allowed successful 
separation of a plethora of cells including DCs (Arora and Porcelli, 2016), 
neutrophils (Hasenberg et al., 2011), mast cells (Jamur et al., 2001) and B cells 
(Cato et al., 2011). Purification of the total T cell population using anti-CD3 
magnetic-labeled antibody beads was not an appropriate method as there was 
potential for the T cells to become activated – the reason for the use of CD90.2 
beads. Whilst CD90.2 beads do not activate T cells, a caveat is the potential 
isolation of ILCs. Moreover, the particular focus of these studies was to address the 
contribution of CD4+ T cells in PD, hence anti-CD4 magnetic-labeled antibody beads 
and FACS sorting of CD4+ T cells were compared. Despite the high purity rate of 
cells separated by beads, only a small percentage of the total population were 
viable cells and further, a fraction of the CD4+ T cells were required for cell type 
confirmation by flow cytometry. By contrast, cell sorting by FACS allowed 
simultaneous cell purification and analysis of the purified population. The FACS 
sorted CD4+ T cells could have been re-assessed by flow cytometry to determine 
the absolute specificity of the sorter and viability of the cells post-sort; however, it 
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was optimal to keep numbers as high as possible for downstream analysis. Whilst 
the target population described could be identified through the use of only three 
antibodies (viability dye, anti-CD45 and anti-CD4), FACS offers numerous 
advantages over other conventional sorting methods. For example, cells can be 
sorted based on expression of numerous proteins, internal protein expression and 
density of expression (Basu et al., 2010). A caveat of FACS is the expense of the 
sorter and the slow rate at which target populations are purified. A fairly recently 
developed method for cell sorting that surpasses the limitations of FACS is 
buoyancy-activated cell sorting (BACS). This technique employs antibody-
conjugated microbubbles that bind targeted cells, which then float to the surface 
of the liquid based sample and are harvested. BACS is inexpensive and the absence 
of magnetic beads means that magnetic-induced damage to cells will not occur. 
Instead, the stress and tension of the rising of the cell to the surface is incapable of 
impacting cell integrity (Liou et al., 2015). As with MACS, a proportion of the BACS-
sorted cells would have to be assessed for purity, therefore the number of cells for 
downstream analysis would be limiting. Another novel method of sorting for 
downstream analysis is PCR-activated cell sorting (PACS), which exploits 
multiplexed TaqMan assays to evaluate individual cells in microfluidic droplets for 
transcripts, non-coding RNAs or genomic DNA then appropriate cells are sorted 
(Pellegrino et al., 2016). Similar to FACS, a pre-selection of known phenotype is 
required for sorting, as is it a high throughput and highly specific sorting technique. 
Therefore, PACS would not have provided any benefits over the chosen method of 
FACS for the sorting of CD4+ T cells. Rather, the transcriptome may not truly 
reflect the protein expression of a cell (Vogel and Marcotte, 2012).   
 
In conclusion, gingival tissue is composed of a dense network of collagen fibres 
making it resistant to digestion methods appropriate for LNs and spleens. However, 
a method for obtaining viable lymphocytes from the oral mucosa has been 
optimized with the use of an enzymatic digest combined with mechanical 
disruption. For downstream analysis of CD4+ T cells specifically, FACS sorting was 
found to purify the greatest yield with the greatest purity. This will enable efficient 
analysis of CD4+ T cells by transcriptomic methods.  
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Key findings from chapter 3: 
• A combination of DNase I and collagenase II with manual dissociation enables 
efficient isolation of gingival cells. 
• The enzymatic digestion does not affect cell surface expression of CD62L. 
• FACS sorting enables efficient purification of CD4+ T cells from total gingival 
cell isolate. 
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4 Phenotype of CD4+ T cells in PD 
4.1 Introduction 
 
Characterization of immune cells in a disease setting aids understanding of the 
immunological basis of the disease and the development of potential new 
treatments. For example, evidence that aberrant T cells play a predominant role in 
the activation of the inflammatory cells infiltrating the synovial membrane of RA 
led to development of treatments targeting T cells (Cope, 2008). Abatacept is a 
blockade of co-stimulation and modulates the interaction of CD80/CD86 with CD28 
to inhibit T cell activation and consequently reduces inflammation (Westhovens and 
Verschueren, 2010). Evidence of T cell responses in PD has been reported in human 
and murine studies. Unquestionably, these studies have illustrated that T cells are 
present in PD, yet their function remains disputed.  
 
Flow cytometry is a powerful method for single-cell analysis of components of the 
immune system. Various parameters of single cells can be evaluated, which 
facilitates the characterization of individual cells from small or large samples of 
tissue. To determine the immune response associated with PD in human studies, 
IHC, ELISA and PCR were most commonly employed (Gamonal et al., 2001, Lappin 
et al., 2001, Berglundh et al., 2002, Takeichi et al., 2000, Cardoso et al., 2009, 
Dutzan et al., 2012b, Honda et al., 2008, Beklen et al., 2007, Adibrad et al., 2012). 
Flow cytometry was used in a small number of studies investigating T cell subsets. 
More commonly, cell lines were stimulated with periodontal pathogens and then 
assessed by flow cytometry (Moutsopoulos et al., 2012).  
 
The immune response associated with PD in murine models has been studied by 
flow cytometry. The majority of these studies have evaluated responses in spleen 
and draining lymph nodes, and only a very few have evaluated the cells infiltrating 
the gingival tissues. Inflammation at the local infection site was investigated at 
multiple time points – 14 days or more post infection - in an A. 
actinomycetemcomitans-induced PD mouse model (Garlet et al., 2010a).  
 
 121	
Developments in flow cytometers and fluorochromes allow a greater number of 
markers of phenotype and function to be measured in a single experiment. A 
disadvantage, however, is that cells must be crudely disrupted from their location 
within tissue, preventing analysis of cell-cell interactions and expression 
characteristics. For example, it is known that antigens of varying shapes and sizes 
are presented by APCs to T cells. However, the use of multi-photon imaging 
confirmed that contact duration between DCs and T cells was increased in 
presentation of large antigens, whilst velocity was reduced (Benson et al., 2015). 
Thereby, the imaging of cells in their natural anatomical location can provide 
further insights into the behaviour and function of cells in a disease milieu. Light 
and fluorescent microscopy have identified subsets of T cells in gingival biopsies of 
PD patients, but there is a lack of similar investigations in mouse models of the 
disease.  
 
In this chapter, detailed analysis of T cell phenotype at both the local and draining 
site of infection in a P. gingivalis-induced PD model will be investigated. In an 
attempt to understand the changes in the immune response that ultimately result in 
alveolar bone loss – rather than immunology of established disease - the specific T 
cell phenotypes will be investigated at 7, 14 and 28 days post infection using flow 
cytometry and IHC.   
 
The aims of this chapter were to: 
• Phenotype CD4+ and CD8+ T cells at early stages of experimental PD by flow 
cytometry. 
• Determine the systemic immune response at early stages of experimental PD 
by flow cytometry, and ex vivo cell culture.  
• Determine the localization of T cells in the oral mucosa at early stages of 
experimental PD. 
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4.2 Results 
 
To investigate whether signs of PD could be established in mice at 28 days post 
infection, alveolar bone loss was assessed in mice orally infected with CMC (sham) 
or P. gingivalis (figure 4.1). There was a trend towards increased bone loss in P. 
gingivalis-infected mice (mean 0.345 +/- 0.0023 mm sham vs. 0.366 +/- 0.0110 mm 
P. gingivalis, NS). Serum anti-P. gingivalis IgG titres were measured and highlighted 
that whilst there was a significant increase in infected mice (56.70 +/- 17.27 EU 
sham vs. 351.3 +/- 96.45 EU P. gingivalis, P < 0.05), two animals from this group 
displayed antibody titres mimicking that of sham-infected mice. As a result of this 
finding, bone loss in each mouse was viewed in relation to antibody titre, 
demonstrating that the absence of antibody associated with absence of bone loss 
(figure 4.1E).  The infected two mice with low antibody titres were excluded from 
the data set and alveolar bone loss reanalyzed. P. gingivalis-infected mice then 
showed significantly greater bone loss than their infected counterparts (mean 0.345 
+/- 0.0023 sham vs. 0.382 +/- 0.0078 P. gingivalis, P < 0.05), indicating that P. 
gingivalis infection induced PD at 28 days post infection; however, only in the 
presence of specific bacterial IgG antibodies.   
 
In the above experiments, serum antibodies were assessed after mice were 
sacrificed. For analysis of gingival cells, gingival tissue from 5 mice were pooled, 
therefore, cells from mice not displaying PD could potentially skew the 
investigation of T cells in the disease model. Data from figure 4.1 suggests that 
serum anti-P. gingivalis IgG titres reflect alveolar bone loss and hence 
establishment of PD. For this reason, mice from all subsequent PD models were tail 
bled prior to the cull day to examine serum antibodies and only those mice with 
antibodies greater at least one standard deviation greater than the average of the 
control were sacrificed. This would increase the likelihood of phenotyping cells 
from mice only with PD. 
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Figure 4.1. Alveolar bone loss and anti-P. gingivalis IgG titres at 28 days post P. 
gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with carrier 
vehicle, CMC, only. At 28 days post infection, alveolar bone loss and anti-P. gingivalis 
IgG titres were measured. (A) Alveolar bone loss data are shown as mean per mouse 
(symbols) with mean +/- SEM for each group (lines), n = 5 mice/group. Red symbols 
indicate two infected mice with low bone loss that were removed in reanalysis. (B) 
Anti-P. gingivalis IgG titres in serum were measured by ELISA. Data are ELISA Units (EU) 
shown as individual mice (symbols) with mean +/- SEM for each group (lines), n = 5 
mice/group. Red symbols indicate two infected mice with low IgG titres that were 
removed in reanalysis. (C) Alveolar bone loss is represented as described for A with the 
exception that two mice with low anti-P. gingivalis IgG titres are excluded from the 
graph. (D) Anti-P. gingivalis IgG titres are represented as described in B with the 
exception that two mice with low anti-P. gingivalis IgG titres are excluded from the 
graph. (E) Alveolar bone loss in relation to P. gingivalis IgG antibody titre. Antibody 
titre and bone loss from each of the ten sham or P. gingivalis-infected mice with line of 
best fit (R2 = 0.56). Statistical significance was determined by Mann-Whitney test, as 
indicated on the graph (*P < 0.05). 
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To gauge a clearer understanding of the contribution of the immune response to the 
initiation, progression and ultimately establishment of PD, sham or P. gingivalis-
infected mice were culled prior at 7, 14 and 28 days post infection. Initially, IgG 
isotypes were investigated to determine whether Th1 or Th2 responses 
predominated in this model (figure 4.2). Greater serum anti-P. gingivalis IgG titres 
were apparent in the majority of infected mice at 14 and 28 days post infection 
compared to sham-infected mice (Day 7: mean 46.54 +/- 11.75 sham vs. mean 
249.77 +/- 155.82 P. gingivalis, NS. Day 14: mean 22.62 +/- 7.89 sham vs. mean 
786.25 +/- 189.60 P. gingivalis, P < 0.0001. Day 28: mean 97.51 +/- 24.63 sham vs. 
mean 675.54 +/- 174.39 P. gingivalis, P < 0.001). No significant differences in serum 
IgG1 between control and infected mice at any of the time-points investigated were 
observed. IgG2a was significantly increased in P. gingivalis-infection at 14 days post 
infection (mean 1.27 +/- 1.27 sham vs. mean 91.44 +/- 43.46 P. gingivalis, P < 
0.05). Thus an association of Ig2a isotype with PD was noted; therefore, serum IgG 
titres to P. gingivalis suggested the presence of a Th1 response.  
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Figure 4.2. Anti-P. gingivalis antibody titres at 7, 14 and 28 days post P. 
gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. Anti-P. gingivalis (A) IgG, (B) IgG1 and (C) IgG2a titres in 
serum were measured by ELISA at  7, 14 and 28 days post infection. Data are ELISA 
Units (EU) shown as individual mice (symbols) with mean +/- SEM for each group 
(lines). Data are combined from 2 independent experiments, n = 5 mice/group at 
each time-point. Statistical significance was determined by Mann-Whitney tests 
comparing sham and P. gingivalis-infection at each time point (*P < 0.05, **P < 0.01, 
***P < 0.001 and ****P < 0.0001).  
  
 
Alveolar bone loss was determined at 7, 14 and 28 days post infection (figure 4.3). 
In these experiments, there was no evidence of significant alveolar bone loss at any 
time point, despite high P. gingivalis-specific IgG titres in serum at both 14 and 28 
days. Compared with bone levels at 7 days, naturally occurring bone loss could be 
seen at 14 and 28 days post sham-infection (figure 4.3D).  
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With the exception of the initial model described in figure 4.1, alveolar bone loss 
did not occur in any PD model, hence it was necessary to ascertain successful 
colonization of P. gingivalis. The oral cavity of each mouse was swabbed and the 
presence of P. gingivalis gpoB was determined by qRT-PCR. Irrespective of stage of 
infection (mid-infections, 7, 14 or 28 days post infection), P. gingivalis gpoB was 
undetectable by this method (data not shown), preventing the confirmation of oral 
colonization. The P. gingivalis primers were able to detect DNA from cultured P. 
gingivalis, the positive control sample. Universal 16S primers were able to detect 
the presence of bacteria on the swabs. As only small numbers of P. gingivalis are 
required to modulate oral commensal bacteria and elicit the immune response 
associated with PD, the mass of the bacteria present may have been below the 
lower detection limit of 1000 P. gingivalis per mouse - rather than being completely 
absent (Dr Jessica Oliver-Bell, Ph.D. thesis). Previous studies have found P. 
gingivalis to comprise less than 0.01% of the total bacterial cell counts from oral 
swabs, the difference of which being 4 – 5 log10 units (Hajishengallis et al., 2011a). 		
  
 127	
	
Figure 4.3. Alveolar bone loss at 7, 14 and 28 days post P. gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At (A) 7, (B) 14 and (C) 28 days post infection alveolar 
bone loss was measured. Data are shown as mean per mouse (symbols) with mean 
+/- SEM for each group (lines), from 2 independent experiments at 7 days post 
infection and 4 independent experiments at 14 and 28 days post infection, n = 3 - 5 
mice/group. (D) Mean alveolar bone loss over time. Data are shown as mean per 
group (symbols) +/- SEM (lines) at 7, 14 and 28 days post infection. (A–C) Statistical 
insignificance was determined by unpaired T test. (D) Statistical significance was 
determined by Tukey’s comparison 2way ANOVA comparing mean bone loss at each 
time-point (sham vs. sham and P. gingivalis vs. P. gingivalis) (*P < 0.05, **P < 0.01).  
 
As antigen from the oral cavity is thought to drain to superficial cervical LNs 
(Yamazaki et al., Walk et al., 2015, Mkonyi et al., 2012), four of these LNs were 
excised from the mice. Antigen presentation in LNs can initiate an adaptive immune 
response, signified by T and B cell proliferation; therefore cell counts were 
performed on single cell suspensions of the dLNs, as well as the gingivae (figure 
4.4). At 7 days post infection, a greater number of cells were present in the dLNs 
from P. gingivalis-infected mice compared to the sham-infected controls (mean 
9.696 x 106 +/- 9.035 x 105 sham vs. mean 1.651 x 107 +/- 2.823 x 106 P. gingivalis, P 
< 0.05). The cell counts at later time-points did not differ. Gingival cell counts 
appeared similar irrespective of infection status, at all time-points. This was also 
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true for the proportions of CD4+ and CD8+ T cells of the total viable cell suspension 
in both gingivae and dLNs, as defined by flow cytometry analysis. The gating 
strategy to identify CD4+ and CD8+ T cells has been illustrated in the first five plots 
of figure 4.5. 
 
	
 
Figure 4.4. Counts of cells and percentages of T cells isolated from gingivae and 
draining lymph nodes at 7, 14 and 28 days post P. gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 7, 14 and 28 days post infection cells were isolated 
from gingivae and draining lymph nodes. (A) Number of cells isolated from indicated 
tissues at each time-point, counted using a haemocytometer. Percentages of (B) 
CD4+ and (C) CD8+ T cells from their parent single, viable cell populations at each 
time-point, analysed by flow cytometry. For total cell counts, single gingivae and 
draining lymph nodes were counted. For CD4+ and CD8+ T cell analysis, cells from 5 
gingivae of each group were pooled, as were draining lymph node cells. Data are 
shown as mean + SEM. Data are combined from 5 independent experiments at 7 
days post infection and 4 independent experiments at 14 and 28 days post 
infection, n = 5 mice/group at each time-point. Statistical significance was 
determined by unpaired T test for each tissue at each time-point (*P < 0.05). 
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Whilst the percentage of T cells infiltrating the gingivae and dLNs did not change in 
infection, other T cell characteristics were investigated to definitively conclude 
whether P. gingivalis-infection influenced changes in T cells. As the P. gingivalis-
induced PD model is a chronic infection, memory T cells were analysed by flow 
cytometry (figure 4.5). Memory cells were identified based on their lymph node 
homing receptors and ligands, CCR7 and CD62L. Attempts were made to identify 
CCR7 by flow cytometry. However, positive staining could not be achieved on 
gingival cells (data not shown). This was likely due to the enzymatic digest that 
potentially cleaved some markers from the cell’s surface. The majority of CD4+ T 
cells were naïve (CD44- CD62L+) at each time-point in both the gingivae and dLNs, 
with a small percentage of CD4+ T cells being TEM (CD44+ CD62L-) and even less 
being TCM cells (CD44+ CD62L+) (figure 4.6A, C). The proportions of memory cells 
were similar irrespective of infection. At each time-point, regardless of infection, 
there was a predominance of naïve CD8+ T cells in both gingivae and dLNs, with no 
significant changes in percentage of this cell type between control and infected 
mice (figure 4.6B, D). Similar to CD4+ memory T cells, only a small percentage of 
the total CD8+ T cell population were TEM and TCM cells. However, these cells 
were found in a lower abundance than those of the CD4+ T cell population. Again, 
there were no significant changes in the disease state.  
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Figure 4.5. Example of gating strategy used to identify memory T cells by flow 
cytometry. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 7, 14 and 28 days post infection cells were isolated 
from gingivae and draining lymph nodes and memory T cells analysed by flow 
cytometry. Dead cells and debris were excluded, based on forward scatter (FSC) 
and side scatter (SSC), followed by doublet discrimination. Viable, CD45+ cells were 
then gated upon to assess CD4+ and CD8+ T cells. Memory cells were identified 
using CD44 and CD62L in both CD4+ and CD8+ T cell populations, as indicated in the 
stained samples. Naïve cells were identified as CD44- CD62L+, T effector memory 
(TEM) as CD44+ CD62L- and T central memory cells (TCM) as CD44+ CD62L+. The 
fluorescence minus one (FMO) control samples were stained with all of the markers 
in the gating strategy, excluding CD44 or CD62L, as indicated in the figure. The 
example plot is from sham-infected LN cells at 7 days post infection. 
 131	
	
Figure 4.6. Memory T cells from gingivae and draining lymph nodes at 7,14 and 
28 days post P. gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 7, 14 and 28 days post infection cells were isolated 
from gingivae and draining lymph nodes and memory T cells analysed by flow 
cytometry. Naïve cells were identified as CD44- CD62L+, T effector memory (TEM) 
as CD44+ CD62L- and T central memory cells (TCM) as CD44+ CD62L+. Percentage of 
CD4+ (A and C) and CD8+ (B and D) memory T cells of the total CD4+ or CD8+ T cell 
population at each time-point in (A and B) gingivae and (C and D) draining lymph 
nodes (dLN). Cells from 5 gingivae of each group were pooled, as were lymph node 
cells. Data are shown as mean + SEM and are from 1 experiment at 14 days and 
combined from 2 independent experiments at 7 and 28 days, n = 5 mice/group at 
each time-point. Statistical insignificance was determined by unpaired T tests.  
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The hallmark of PD is alveolar bone destruction that occurs from, arguably, reduced 
regulation of the immune response. As the role of Tregs is to maintain an 
appropriate immune response, the number and proportion of these cells within the 
gingivae and dLN were investigated by flow cytometry (figure 4.7). However, no 
differences were found in Treg numbers or percentages of the total CD4+ 
population in infection compared with controls at 7 and 14 days post infection, in 
either gingivae or dLNs (figure 4.8). Whilst not significant, there was a trend 
towards a decrease in Tregs within the gingivae in P. gingivalis-infection at 28 days 
post infection, both in percentage (mean 8.82 +/- 1.68 sham vs. mean 7.11 +/- 1.47 
P. gingivalis, NS) and number (mean 1191.5 +/- 141.5 sham vs. mean 642 +/- 189.0 
P. gingivalis, NS). This was comparable to dLNs in infection, whereby a decrease in 
Tregs could be seen – again in both percentage (mean 12.6 +/- 1.0 sham vs. mean 
12.1 +/- 0.4 P. gingivalis, NS) and number (mean 1.56 x 104 +/- 695 sham vs. mean 
1.30 x 104 +/- 498 P. gingivalis, NS) – but this did not reach statistical significance.  
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Figure 4.7. Example of gating strategy used to identify regulatory T cells by flow 
cytometry. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 7, 14 and 28 days post infection cells were isolated 
from gingivae and draining lymph nodes and regulatory T cells (Tregs) analysed by 
flow cytometry. Dead cells and debris were excluded, based on forward scatter 
(FSC) and side scatter (SSC), followed by doublet discrimination. Viable, CD45+ cells 
were then gated upon to assess CD4+ and CD8+ T cells. Tregs can be identified in 
the CD4+ T cell population based on expression of both CD25 and Foxp3. The 
fluorescence minus one (FMO) control sample was stained with all of the markers in 
the gating strategy, excluding Foxp3 and CD25.  The example plot is from sham-
infected LN cells at 7 days post infection. 
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Figure 4.8. Regulatory T cells from gingivae and draining lymph nodes at 7, 14 
and 28 days post P. gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 7, 14 and 28 days post infection cells were isolated 
from gingivae and draining lymph nodes and regulatory T cells (Tregs) analysed by 
flow cytometry. Tregs were identified as CD4+ CD25+ FOXP3+ cells. (A) Percentage 
of Tregs of the total CD4+ T cell population in indicated tissues at each time-point. 
(B) Number of Tregs in indicated tissues at each time-point. Cells from 5 gingivae of 
each group were pooled, as were lymph node cells. Data are shown as mean + SEM 
and are combined from 2 independent experiments, n = 5 mice/group. Statistical 
insignificance was determined by unpaired T tests.  
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6 was significantly increased by comparison to cells from control dLNs (mean 0.127 
+/- 0.012 sham vs. mean 0.336 +/- 0.019 P. gingivalis, P < 0.0001). This was also 
true of the numbers of CD4+ Bcl6+ cells (mean 171.4 +/- 10.95 sham vs. mean 459.8 
+/- 35.48 P. gingivalis, P < 0.0001) (figure 4.10). The population of CD4+ Bcl6+ 
cells was too small to accurately quantify the proportions of cells expressing ICOS 
and PD-1. Nonetheless, there were a greater proportion of CD4+ cells with 
expression of both ICOS and PD-1 (mean 0.456 +/- 0.046 sham vs. mean 1.862 +/- 
0.188 P. gingivalis, P < 0.0001). The increase in CD4+ ICOS+ PD-1+ cell numbers in 
infection was also statistically significant (mean 637.2 +/- 100.9 sham vs. mean 
3465 +/- 712.7 P. gingivalis, P < 0.01). No cells were stained with anti-CXCR5 
antibody. Limitations of time and resource prevented further investigation and 
optimization of this staining. Without this marker, the presence of Tfh cells cannot 
be definitively concluded, however, with the presence of Bcl-6, ICOS and PD-1, it is 
likely that the dLNs of mice infected with P. gingivalis did contain Tfh cells. 
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Figure 4.9. Example of gating strategy to identify T follicular helper cells by flow 
cytometry. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 14 days post infection cells were isolated from 
draining lymph nodes and T follicular helper cells analysed by flow cytometry. Dead 
cells and debris were excluded, based on forward scatter (FSC) and side scatter 
(SSC), followed by doublet discrimination. Viable, CD45+ Bcl6+ cells were then 
gated to assess CD4+ T cells with T follicular helper cell transcription factor 
expression. A dump gate included CD8, B220 and F4/80 to ensure no inclusion of the 
cells commonly known to express T follicular helper markers. The fluorescence 
minus one (FMO) control samples were stained with all of the markers in the gating 
strategy, excluding Bcl6 or ICOS along with a PD-1 isotype control antibody, as 
indicated in the figure. The example plots are from sham and P. gingivalis-infected 
LN cells. 
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Figure 4.10. T follicular helper cells in draining lymph nodes at 14 days post P. 
gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 14 days post infection cells were isolated from 
draining lymph nodes and T follicular helper cells analysed by flow cytometry. (A) 
Percentage of Bcl6+ CD4+ T cells of the total CD4+ T cell population. (B) Number of 
Bcl6+ CD4+ T cells. (C) Percentage of ICOS+ PD-1+ CD4+ T cells of the total CD4 
population. (D) Number of ICOS+ PD-1+ CD4+ T cells. Data are shown as mean + SEM 
from 1 experiment, n = 5 mice/group, LN from each mouse analysed individually. 
Statistical significance was determined by unpaired T tests, as indicated on the 
graph (**P < 0.01, ***P < 0.001 and ****P < 0.0001). 
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trends between control and infection could be seen, repetition of the experiment 
and use of additional mice could not be justified. At 14 days post infection, 
although no changes in IL-4 and IL-17A production by the infected group were 
found, there was a trend towards an increased percentage of IFN-γ producing cells 
of the CD4+ population in dLNs (mean 0.664 +/- 0.119 sham vs. 0.968 +/- 0.243 P. 
gingivalis, NS). A similar pattern of cytokine expression could be observed at 28 
days post infection, whereby IFN-γ production was increased in P. gingivalis 
infection in dLNs, particularly when comparing control and infection by fold change 
of media control (mean 7.569 +/- 1.985 sham vs. 28.394 +/- 6.843 P. gingivalis, NS). 
As observed at previous time points, at day 28 there were no differences in IL-4 and 
IL-17A.  
The cytokine production by T cells in the gingivae did not resemble the seemingly 
increased Th1 response from dLNs, but instead highlighted no differences between 
control and infected mice at any of the time-points (figure 4.13).  
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Figure 4.11. Example of gating strategy used to identify cytokine producing T 
cells. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 7, 14 and 28 days post infection cells were isolated 
from draining lymph nodes. The isolated cells were stimulated with PMA/ionomycin 
or controls received only media and also incubated with BD GolgiStop™ for 4 hours 
then analysed by flow cytometry. Dead cells and debris were excluded, based on 
forward scatter (FSC) and side scatter (SSC), followed by doublet discrimination. 
Viable, CD45+ cells were then gated to identify CD4+ and CD8+ T cells. Cytokine 
producing CD4+ and CD8+ T cells were then identified. The fluorescence minus one 
(FMO) control samples were stained with all of the markers in the gating strategy, 
excluding IFN-γ, IL-17A or IL-4, as indicated in the figure. The example plots are 
from sham-infected lymph node cells stimulated with PMA/ionomycin from a 7 days 
post infection model. 
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Figure 4.12. T helper cell cytokine production in draining lymph nodes at 7, 14 
and 28 days post P. gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 7, 14 and 28 days post infection cells were isolated 
from draining lymph nodes. The isolated cells were stimulated with PMA/ionomycin 
or controls received only media and all were incubated with BD GolgiStop™ for 4 
hours then analysed by flow cytometry. (A) Percentage of PMA/ionomycin-
stimulated CD4+ T cells producing indicated cytokines of the total CD4+ T cell 
population, at each time-point. (B) Number of PMA/ionomycin-stimulated CD4+ T 
cells producing indicated cytokines at each time-point. (C) Fold change of number 
of stimulated cytokine-producing CD4+ T cells compared to number of cytokine-
producing CD4+ T cells from media controls. Cells from 5 lymph nodes were pooled 
from each group. Data are shown as mean + SEM from 1 experiment at 7 days and 
combined from 2 independent experiments at 14 and 28 days, n = 5 mice/group at 
each time-point. Statistical insignificance was determined by unpaired T test. 
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Figure 4.13. T helper cell cytokine production in gingivae at 7, 14 and 28 days 
post P. gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 7, 14 and 28 days post infection cells were isolated 
from gingivae. The isolated cells were stimulated with PMA/ionomycin or controls 
received only media. Cells  were incubated with BD GolgiStop™ for 4 hours then 
analysed by flow cytometry. (A) Percentage of PMA/ionomycin-stimulated CD4+ T 
cells producing indicated cytokines of the total CD4+ T cell population, at each 
time-point. (B) Number of PMA/ionomycin-stimulated CD4+ T cells producing 
indicated cytokines at each time-point. (C) Fold change of number of stimulated 
cytokine-producing CD4+ T cells compared to number of cytokine-producing CD4+ T 
cells from media controls. Cells from 5 gingivae were pooled from each group. Data 
are shown as mean + SEM from 1 experiment at 7 days and combined from 2 
independent experiments at 14 and 28 days, n = 5 mice/group at each time point. 
Statistical insignificance was determined by multiple unpaired T tests.  
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As P. gingivalis has the ability to infect cells intracellularly, CD8+ T cell IFN-γ 
production was next assessed by flow cytometry. Infected and sham control animals 
showed similar proportions of IFN-γ producing CD8+ T cells at 7 or 28 days post 
infection in the gingivae. At 14 days, the percentage of CD8+ T cells producing IFN-
γ was greater in the gingivae of P. gingivalis infected mice (mean 9.32 +/- 0.96 
sham vs. mean 20.85 +/- 1.70 P. gingivalis, P < 0.05) (figure 4.14). At both 7 and 
14 days post infection, there were no effects of P. gingivalis-infection on the 
percentage or number of IFN-γ-producing CD8+ T cells from dLNs. At 28 days post 
infection, there was an increase in IFN-γ production by CD8+ T cells, although this 
did not reach statistical significance (mean 222.26 +/- 189.35 sham vs. 892.40 +/- 
767.21 P. gingivalis, NS). The variation between experiments was high; thereby the 
increase in IFN-γ by CD8+ T cells at this time-point was not significant. However, 
consistent in both experiments was that cytokine production is approximately 4 
times (3.804 from experiment 1 and 4.032 from experiment 2) greater in dLNs of 
mice infected with P. gingivalis than sham-infected control, using data from fold 
change of media control.  
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Figure 4.14. IFN-γ producing CD8+ T cells in gingivae and draining lymph nodes 
at 7, 14 and 28 days post P. gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 7, 14 and 28 days post infection cells were isolated 
from gingivae and draining lymph nodes. The isolated cells were stimulated with 
PMA/ionomycin or controls received only media and were incubated with BD 
GolgiStop™ for 4 hours then analysed by flow cytometry. (A) Percentage of 
PMA/ionomycin-stimulated CD8+ T cells producing IFN-γ of the total CD8+ T cell 
population, at each time-point. (B) Number of PMA/ionomycin-stimulated CD8+ T 
cells producing IFN-γ at each time-point. (C) Fold change of number of stimulated 
IFN-γ-producing CD8+ T cells compared to number of IFN-γ-producing CD8+ T cells 
from media controls. Cells from 5 gingivae were pooled from each group, as were 
lymph node cells. Data are shown as mean + SEM from 1 experiment at 7 days and 
combined from 2 independent experiments at 14 and 28 days, n = 5 mice/group. 
Statistical significance was determined by unpaired T tests, as indicated on the 
graph (*P < 0.05).  
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To assess the systemic response in the PD model, splenocytes from sham and P. 
gingivalis-infected mice were restimulated with P. gingivalis, incubated for 72 
hours and the proliferation (anti-Ki67) state of CD4+ and CD8+ T cells was 
determined by flow cytometry. The results indicated that P. gingivalis induced a 
similar extent of splenocyte proliferation from sham and P. gingivalis-infected 
mice. The proliferation stimulated by P. gingivalis was lower than that induced by 
anti-CD3 and anti-CD28 (data not shown). The supernatants from the assays were 
collected and the level of IFN-γ measured by ELISA. IFN-γ was selected due to 
indications from flow cytometry experiments that there were trends towards 
increased production of this cytokine by CD4+ and CD8+ T cells at 28 days post 
infection. The ELISA demonstrated that IFN-γ was increased by splenocytes from P. 
gingivalis-infected mice upon restimulation with P. gingivalis at 28 days post 
infection (mean 1132.10 +/- 193.53 pg/ml sham vs. mean 2028.90 +/- 315.67 pg/ml 
P. gingivalis, P < 0.05) (figure 4.15).  
 
 
Figure 4.15. IFN-γ production by splenocytes incubated with P. gingivalis. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. At 28 days post infection, cells were isolated from 
spleens and stimulated with heat-killed P. gingivalis (PG), media (negative control) 
and anti-CD3 and anti-CD28 (aCD3) (positive control) for 72 hours. The supernatants 
were analysed for IFN-γ by ELISA. Data are shown as mean + SEM from 1 
experiment, n = 5 mice/group. Statistical significance was determined by unpaired 
T tests, as indicated on the graph (*P < 0.05). 
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The concentrations of IL-6, IL-10, IL-13, IL-17A and IFN-γ in supernatants were then 
determined by multiplex to further evaluate systemic Th responses (figure 4.16). 
The production of all cytokines investigated was upregulated somewhat – although 
not significantly – by splenocytes from P. gingivalis-infected mice at 7, 14 and 28 
days post infection. At 14 days post infection, there was a significant increase in 
IFN-γ, IL-13 and IL-10 production by splenocytes from P. gingivalis infected mice 
(IFN-γ: mean 500.59 +/- 180.63 pg/ml sham vs. 2627.48 +/- 589.944 pg/ml P. 
gingivalis, P < 0.05. IL-13: mean 1410.98 +/- 540.13 pg/ml sham vs. mean 4555.44 
+/- 942.35 pg/ml P. gingivalis, P < 0.05. IL-10: mean 83.83 +/- 22.53 pg/ml sham 
vs. mean 339.50 +/- 88.26 pg/ml P. gingivalis, P < 0.05). At 28 days post infection, 
IL-6 was significantly increased from splenocytes of P. gingivalis-infected mice 
(mean 169.36 +/- 15.76 pg/ml sham vs. mean 296.95 +/- 41.00 pg/ml P. gingivalis, 
P < 0.05). As a number of cytokines were elevated by re-stimulation of splenocytes 
from P. gingivalis-infected mice, there was a suggestion of a systemic inflammatory 
response. There was no obvious cytokine profile of a particular Th response in P. 
gingivalis infection from splenocytes.  
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Figure 4.16. Cytokine production by P. gingivalis stimulated splenocytes  
Mice were orally infected with P. gingivalis or were sham-infected (sham) with carrier 
vehicle, CMC, only. At 7, 14 and 28 days post infection, cells were isolated from 
spleens and stimulated with heat-killed P. gingivalis for 72 hours. The supernatant was 
analyzed for cytokines using multiplex technology. Concentrations of IL-6, IL-10, IL-13, 
IL-17A and IFN-γ at (A) 7 days, (B) 14 days and (C) 28 days post infection. Data are 
shown as mean + SEM from 1 experiment at 7 days post infection, and combined from 3 
and 4 independent experiments at 14 and 28 days post infection, respectively, n = 5 
mice/group. Statistical significance was determined by multiple T tests and Holm-Sidak 
multiple comparison correction, as indicated on the graph (*P < 0.05). 
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Thus far, phenotyping of T cells has involved the disruption of cells from their 
anatomical position within tissue. For this reason, the next experiments looked to 
address the location and distribution of T cells within tissue. Initially, gingival tissue 
was fixed and embedded in paraffin wax, then sectioned. H&E staining of the 
sections (figure 4.17) revealed that an even section could not be obtained, the 
‘ruffled’ architecture of the palatal ruggae caused large gaps in the section and 
that the tissue was prone to tearing. As a result, gingivae were stained 
‘wholemount’ with fluorescent antibodies to CD4 and B220 and were imaged using a 
confocal microscope (figure 4.18).  
 
	
 
Figure 4.17. H&E staining of sectioned gingiva. 
Gingiva was extracted from the mouth of a mouse, formalin fixed and paraffin 
embedded. Five µm sections were cut using a microtome and stained by H&E. 
Olympus SZX7 stereo zoom microscope fitted with SC100 digital color camera was 
used to capture the image. Scale bar represents 2 mm.  
 
The images in figure 4.20A enabled visualization of CD4+ T cells and B220+ B cells 
within lymphoid aggregates, in which CD4+ T cells clustered around a clearly 
defined B cell population. Very few CD4+ T cells or B cells were visible out with 
these aggregates. The single stain controls illustrated that the staining of the cells 
was not simply the result of autofluorescence (figure 4.20B-C). To determine the 
orientation of the lymphoid structures a	suture was placed in the bottom right hand 
side of the palate. With the suture in place, the location of these aggregates was 
found to be within the hard palate, at the uppermost region closest to the central 
incisors.  
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Figure 4.18. Fluorescent microscopy of intact gingiva. 
Gingivae were extracted from the mouths of mice and paraformaldehyde fixed. 
Samples were stained with fluorescent anti-B220 (blue) and anti-CD4 (red) 
antibodies then visualized using a confocal microscope. (A) Gingiva stained with 
anti-B220 and anti-CD4. Scale bar represents 150 µm (B) Gingiva single stain control 
stained with anti-B220 only. Scale bar represents 50 µm (C) Gingiva single stain 
control stained with anti-CD4. Scale bar represents 50 µm. 
 
Next, mice were sham- or P. gingivalis-infected and the lymphoid aggregates within 
the oral mucosa were imaged at various stages post infection to assess whether P. 
gingivalis influenced a notable change in these structures.  At 14, 35 and 49 days 
post infection, irrespective of infection status, clearly defined populations of CD4+ 
T cells and B cells were seen (figure 4.19). As implied by the memory T cell data by 
which the gingivae was predominated by naïve T cells (figure 4.6A), lymphoid 
aggregates were present in this tissue irrespective of P. gingivalis-infection. 
Although the majority of CD4+ T cells resided around a clustering of B cells in both 
A B 
C 
CD4+ 
B220+ 
 149	
control and infected mice, a number of CD4+ T cells migrated into the B cell area. 
These data suggest that CD4+ T cells may be providing B cell help in both oral 
infection states.  
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Figure 4.19. Fluorescent microscopy of intact gingivae at 14, 35 and 49 days 
post P. gingivalis infection. 
Mice were orally infected with P. gingivalis (B, D, F) or were sham-infected (sham) 
with carrier vehicle, CMC (A, C, E), only. At 14 (A and B), 35 (C and D) and 49 (E 
and F) days post infection gingivae were extracted from the mouths of mice and 
paraformaldehyde fixed. Samples were stained wholemount with fluorescent anti-
B220 (blue) and anti-CD4 (red) antibodies then visualized using a confocal 
microscope. (A-D) Scale bar represents 150 µm. (E-F) Scale bar represents 100 µm. 
Representative of n = 3. 
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To investigate the expression of a broader range of cytokines and chemokines than 
could be practically achieved by intracellular staining and flow cytometry, gene 
expression was next assessed by qRT-PCR using a Qiagen cytokine and chemokine 
array. As the greatest trends in CD4+ T cell cytokine production and numbers of 
Tregs were noted at 28 days post infection, along with an interest in the stage at 
which alveolar bone loss develops, this time point was investigated. Mice were 
sham or P. gingivalis-infected as previous PD models. Groups contained three mice. 
For the array, the entire gingival cell isolate from a single mouse was sufficient for 
analysis, hence three mice per group enabled generation of three independent data 
points. Cells from three sham-infected and three P. gingivalis-infected mice 
expressed each of the housekeeping genes in the array. Likewise, positive PCR 
controls and reverse transcription controls were positive for each sample. There 
was indication of gDNA contamination in both the gingivae and dLN samples from 
one of the three experiments. This experimental replicate was therefore excluded 
from further analysis. Of the 5 housekeeping genes in the assay, Actb expression 
(actin β) was the most conserved amongst the samples, hence was chosen to 
determine relative expression of test genes.  
 
From the 84 test genes in the array, 21 genes were differentially expressed 
between the groups compared (control vs infection and gingivae vs. dLN) and are 
shown in figure 4.20. Six genes were significantly differentially expressed in 
gingivae from sham compared to P. gingivalis-infected mice (figure 4.20A). Il-1α is 
released from stressed or dead cells and acts as an alarmin. The expression of ila 
was – not surprisingly – increased in P. gingivalis infection (mean 7.38 x 10-3 +/- 
8.79 x 10-4 sham vs. mean 1.55 x 10-2 +/- 1.67 x 10-3 P. gingivalis, P < 0.05). IL-7 is 
important for lymphocyte development in the bone marrow and thymus. It also 
interacts with TCRs on mature CD4+ and CD8+ cells to promote survival (Kondrack 
et al., 2003, Kaech et al., 2003). Expression of Il7 gene was reduced in P. gingivalis-
infection (mean 1.85 x 10-3 +/- 7.00 x 10-5 sham vs. mean 6.78 x 10-4 +/- 5.96 x 10-5 
P. gingivalis, P < 0.01). Cardiotrophin-1 is involved in the protection of cardiac 
myocytes from injury due to ischemia or reperfusion, and also prevents apoptosis. 
Ctf1 expression was upregulated in P. gingivalis infection (mean 1.00 x 10-3 +/- 5 x 
10-5 sham vs. mean 3.00 x 10-3 +/- 4 x 10-4 P. gingivalis, P < 0.05). The product of 
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Gpi1 expression is glucose phosphate isomerase 1. Glucose phosphate isomerase 1 
exerts a range of effects, including an involvement in the interconversion of 
glucose-6-phosphate to fructose-6-phosphate. Perhaps most interesting with regard 
to the PD model, glucose phosphate isomerase 1 stimulates immunoglobulin 
secretion (https://www.ncbi.nlm.nih.gov/gene – accessed on 04/04/17). Glucose 
phosphate isomerase 1 was increased in P. gingivalis infection (mean 6.20 x 10-2 +/- 
5.21 x 10-3 sham vs. mean 1.31 x 10-1 +/- 5.00 x 10-4 P. gingivalis, P < 0.05), possibly 
reflecting the increase in anti-P. gingivalis IgG. Bmp4 expression was also 
upregulated in gingivae of P. gingivalis-infected mice (mean 3.00 x 10-3 +/- 5.00 x 
10-5 sham vs. mean 4.00 x 10-3 +/- 4.00 x 10-4 P. gingivalis, P < 0.05). Embryos of 
the bone morphogenetic protein (BMP) 4 KO mice develop bilateral cleft lip; 
therefore BMP4 has been described as a regulator of lip fusion during midfacial 
morphogenesis. The final gene differentially expressed (down-regulated) in the 
gingivae of P. gingivalis-infected mice was Tnfsf13b. TNF (ligand) superfamily 
member 13B (otherwise known as B-cell activating factor) plays a role in 
proliferation and differentiation of B cells (Mackay and Browning, 2002). 
  
Within the dLNs, only Bmp7 expression was down-regulated upon P. gingivalis 
infection (mean 2.00 x 10-4 +/- 4.28 x 10-6 sham vs. mean 1.00 x 10-4 +/- 1.08 x 10-6 
P. gingivalis, P < 0.01) (figure 4.20B). BMP7 plays a role in eye, brain, palate and 
ear development (Wyatt et al., 2010). The greatest variation in gene expression was 
noted between gingivae and dLN (figure 4.20C-D). Genes differentially expressed 
between the two different tissues and their functions are described in table 4.1 
and table 4.2. 
 
As the RT2 profiler was employed as an exploratory platform to identify chemokine 
and cytokine genes that were differentially expressed in the PD model, the 
statistical analysis was devoid of post hoc corrections for multiple T tests. A caveat 
of this approach was that false positives could be incorporated into the analysis. 
However, the application of post hoc correction may have included false negatives. 
Therefore, it was concluded that as an exploratory experiment to pinpoint potential 
gene candidates it was more beneficial to eliminate false negative statistical tests.   
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Figure 4.20. Differential gene expression within gingivae and draining lymph 
nodes from sham and P. gingivalis-infected mice. 
Mice were orally infected with P. gingivalis or were sham-infected with carrier 
vehicle, CMC, only. At 28 days post infection, cells were isolated from gingivae and 
dLN. RNA was extracted, reverse-transcribed to cDNA and the expression of 
cytokine and chemokine genes determined by qRT-PCR using Qiagen RT2 profiler 
PCR array. Graphs show gene expression relative to Actb and the 21 genes that 
were differentially expressed between groups are presented. (A) Gingival gene 
expression, comparing sham and P. gingivalis-infection. (B) dLN gene expression, 
comparing sham and P. gingivalis-infection. (C) Gene expression from sham-
infected mice, comparing gingivae and dLN. (D) Gene expression from P. gingivalis-
infected mice, comparing gingivae and dLN. Data are shown as mean + SEM 
combined from one independent experiment, n = 2 mice/group. Statistical analysis 
was conducted on log transformed data (raw data shown on graph). (A and B) 
Statistical significance was determined using multiple unpaired T tests. (C and D) 
Statistical significance was determined using paired T tests as gingivae and dLN 
were harvested from the same mouse. Statistical significance is indicated on the 
graph (*P < 0.05 and **P < 0.01). ND, not detected.  
 
  
 155	
Table 4.1. Expression of cytokine and chemokine genes in gingivae and draining 
lymph nodes of sham and P. gingivalis-infected mice. 	
 P. gingivalis vs Sham dLN vs gingivae 
Gene Gingivae dLN Sham P. gingivalis 
Bmp4 é* N/A N/A N/A 
Bmp6 NS NS NS ê* 
Bmp7 NS ê** NS ê* 
Ccl3 NS NS NS ê* 
Ccl4 NS NS NS ê* 
Ctf1 é* N/A N/A N/A 
Csf1 NS NS ê* ê* 
Cxcl1 NS NS ê* NS 
Cxcl10 NS NS ê* ê* 
Cxcl12 NS NS ê** ê* 
Cxcl13 NS NS ê* ê* 
Cxcl16 NS NS ê* NS 
Gpi1 é* NS NS NS 
Il15 NS NS ê* NS 
Il1a é* NS ê* ê* 
Il1b NS NS ê* ê** 
Il1rn NS NS NS ê* 
Il7 ê** NS ê** ê* 
Mif NS NS NS ê* 
Pf4 NS NS ê* ê* 
Tnfsf13b ê* NS NS NS 
Statistical significance is represented as *P < 0.05 and **P <0.01(determined by 
unpaired T tests for P. gingivalis vs. sham and paired T tests for gingivae vs. dLN). 
Abbreviations: dLN, draining (cervical) lymph nodes; N/A, not applicable (due to no 
detection of gene expression in at least one sample); NS, not significant; é, 
upregulated; ê, downregulated. 
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Table 4.2. Functions of cytokine and chemokine genes expressed in gingivae and 
draining lymph nodes of sham and P. gingivalis-infected mice. 	
Gene Gene product Function 
Bmp4 BMP 4 Regulator of limb and lip development (Wang et al., 2014) 
Bmp6 BMP 6 Regulator of hepcidin expression and iron metabolism (Andriopoulos et al., 2009) 
Bmp7 BMP 7 Role in eye, brain, palate and ear development (Wyatt et al., 2010) 
Ccl3 CCL3 CD8+ T cell and B cell chemoattractant (O'Grady et al., 1999) 
Ccl4 CCL4 Naïve CD4+ T cell chemoattractant (O'Grady et al., 1999) 
Ctf1 Cardiotrophin-1 
Protects cardiac myocytes from ischemic and reperfusion 
injury (Bristow and Long, 2002) 
Csf1 CSF-1 Differentiation of haematopoietic cells to macrophages (Rettenmier et al., 1988) 
Cxcl1 CXCL1 Neutrophil chemoattractant (Moser et al., 1990) 
Cxcl10 CXCl10 Monocyte, T cell and NK cell chemoattractant (Liu et al., 2011, Carlsen et al., 2002) 
Cxcl12 CXCL12 Role in monocyte extravasation and recruitment (Sánchez-Martín et al., 2011) 
Cxcl13 CXCL13 B cell chemoattractant and plays role in development of lymphoid structure organization (Carlsen et al., 2002) 
Cxcl16 CXCL16 Chemoattractant for activated CD8+ T cells and NKT cells expressing CXCR6 (Tohyama et al., 2007) 
Gpi1 GPI-1 
Functions as glycolytic enzyme, promotes skeletal motor 
neurons and sensory neurons and stimulates Ig secretion 
(NCBI Gene) 
Il15 IL-15 Plays a role in NK cell development and proliferation of T cells and NK cells (Di Sabatino et al., 2011) 
Il1a IL-1α Acts as an alarmin and is pro-inflammatory (Di Paolo and Shayakhmetov, 2016) 
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Il1b IL-1β Pro-inflammatory (Di Paolo and Shayakhmetov, 2016) 
Il1rn IL-1R antagonist 
Inhibitor of pro-inflammatory IL1- α and IL-1β (Perrier et 
al., 2006) 
Il7 IL-7 Role in T cell and B cell development (Kittipatarin and Khaled, 2007) 
Mif MIF Role in activation and proliferation of T cells and regulates lymphocyte trafficking (Calandra and Roger, 2003) 
Pf4 PF4 Role in wound repair and inflammation (Lord et al., 2017) 
Tnfsf13b 
TNF (ligand) 
superfamily, 
member 13B 
Role in proliferation and differentiation of B cells (Mackay 
and Browning, 2002) 
(https://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&dopt=Graphics&list_uids=14751 - 
accessed on 04/04/17). Abbreviations: BMP, bone morphogenetic protein; CCL, 
chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C motif) ligand; CSF, Colony 
stimulating factor; GPI, glucose phosphate isomerase; IL, interleukin; MIF, 
macrophage migration inhibitory factor; PF, platelet factor; TNF, tumour necrosis 
factor. 
 
Principle component analysis was conducted on the samples analyzed by RT2 
profiler, which highlighted that gingival gene expression clustered irrespective of 
infection and clustered separately from dLN. dLN gene expression also clustered 
irrespective of infection (figure 4.21) 
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Figure 4.21. Principle component analysis (PCA) plot of gene expression from 
gingivae and draining lymph nodes of sham and P. gingivalis-infected mice. 
Mice were orally infected with P. gingivalis or were sham-infected with carrier 
vehicle, CMC, only. At 28 days post infection, cells were isolated from gingivae and 
dLN. RNA was extracted, reverse-transcribed to cDNA and the expression of 
cytokine and chemokine genes determined by qRT-PCR using Qiagen RT2 profiler 
PCR array. Gene expression relative to Actb was calculated (2-ΔCT) and log 
transformed. The log transformed data was input into PAST software to generate 
the PCA plot.  
 
 
A number of genes associated with T cell development, activation and migration 
were differentially expressed in gingivae compared to dLNs, which suggested that 
chemokines and cytokines play a role in the movement and homing of T cells to the 
oral mucosa. However, the chemokine and cytokine gene expression from this 
experiment do not solely regulate T cells, therefore their presence may have 
influenced changes in other cell types. The use of the array highlighted that gene 
expression differs in cells from gingivae of sham vs. P. gingivalis-infected mice. 
However, gene expression was determined from a mixed cell population from each 
tissue, and there were no immediately obvious signatures of any particular cell 
type; therefore gene expression attributed to CD4+ T cells remained elusive. 
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4.3 Discussion 
 
These data document for the first time the chemokine signature of gingival tissue 
relative to draining lymph node. To the best of the author’s knowledge, this is also 
the first description of Tfh cells in the oral cavity, despite previous evidence of an 
increased presence of B cells and antibodies in PD. Furthermore, a novel protocol 
for visualizing cells within the intact murine oral mucosa has been established and 
has illustrated that CD4+ T cells and B cells form aggregates in this tissue 
irrespective of infection.  
 
Initial studies proved that alveolar bone loss occurred only in the presence of anti-
P. gingivalis serum titres at 28 days post infection, similar to previous findings at 42 
days post infection (Oliver-Bell et al., 2015). However, the elevated antibody titres 
of latter experiments were not reflected by significant alveolar bone loss. A 
potential explanation is that the detection method used was not reliable. A highly 
accurate and reproducible methodology used to assess rodent alveolar bone loss is 
micro-computed tomography (micro-CT). Using micro-CT, mandibles and maxillae 
are imaged at the micron level enabling precise analysis of bone architecture (Park 
et al., 2007). Therefore, this technique has frequently been employed for 
identification of bone resorption in experimental PD (Zhang et al., 2014, Kim et al., 
2015, Huang et al., 2016, Xu et al., 2014). What the studies described in this 
chapter have perhaps highlighted is the requirement for an efficient method for 
identification of bone loss in mice infected with PD prior to culling, particularly for 
analysis of the local immune response in which the gingivae of 5 mice were pooled. 
IVIS Luminex XR has been utilized for several years to assess hind limb bone density 
following spinal cord injury (McManus and Grill, 2011), a method that enables 
longitudinal measurements in a living mouse. A similar technique could be valuable 
for bone loss measurements in experimental PD; however, to date there is no 
literature describing bone density assessment in the oral cavity, likely due to the 
size and anatomy of the murine mouth. A limitation in the studies described in this 
chapter was the lack of alveolar bone loss, preventing the validation of 
experimental PD in mice. Whilst previous studies described the presence of bone 
destruction as early as 26 days post infection (Baker et al., 1999b), the majority of 
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murine models of PD are examined at least 42 days post infection (Yu et al., 2007, 
Baker et al., 1999a, Malcolm et al., 2015b, Oliver-Bell et al., 2015, Malcolm et al., 
2016, Myneni et al., 2011), so perhaps at the early stages of P. gingivalis-infection 
bone loss had not yet occurred. It is also noteworthy that oral commensal bacteria 
have a significant impact upon the induction of bone loss, so much so that co-caging 
of GF mice with SPF mice enables complete transmission of commensals to GF and 
promotes alveolar bone loss (Hajishengallis et al., 2011c). The commensal bacteria 
present within the oral cavity of BALB/c mice have been shown to differ when 
purchased from different suppliers, a phenomenon that persists for at least one 
week after recaging in-house (Rodrigue and Lavoie, 1996). It is important to note 
that initial studies in this chapter were conducted from BALB/c mice that 
originated from Harlan, whilst latter studies were conducted on mice supplied by 
Charles River and all mice began antibiotic treatment within one day of arrival. 
Altogether, these studies suggested that the oral commensal bacteria present 
within the oral cavity of each mouse greatly influenced the ability of P. gingivalis to 
induce bone destruction. Whilst mice in our studies were pre-treated with 
antibiotics, oral microflora was not completely depleted and therefore may have 
influenced the colonization of P. gingivalis and development of alveolar bone loss. 
The identification of P. gingivalis-specific antibodies did suggest a successful 
infection, but the technologies readily available were unable to confirm oral 
colonization. Other investigators have determined P. gingivalis colonization by 
harvesting and lysing palatal and gingival tissues to remove gDNA then bacterial 
numbers quantified by qRT-PCR (McIntosh and Hajishengallis, 2012). As an aim of 
this chapter was to address the immune response at the local site of infection, this 
method could not be employed. However, to enhance detection of P. gingivalis 
obtained by oral swabs, more sensitive primers – such as P. gingivalis ISPg1 gene 
primers – could be used (McIntosh and Hajishengallis, 2012).  
A major caveat with regard to the study of the local site of infection is the small 
size of the murine gingivae. Despite optimization of cell isolation, the entire palate 
and gingivae were excised from each mouse as too few cells                                                                               
were obtained from the narrow strips of gingival tissue only (data not shown). It is 
likely that the inflammation associated with PD would be located proximal to 
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alveolar bone – in gingival tissue – and consequently the immune components at the 
infection site are potentially being diluted out. Interpretation of gingival cells only 
is plausible but would require an increase in the number of mice used per group. 
Further, the disease can be localised to specific sites in humans (Armitage, 2004), 
and tissue around these teeth are often studied as a means of investigating the 
immune response in PD. Given the small size of the oral cavity of the mouse, it is 
impossible to assign disease sites by clinical techniques used for human examination 
that are readily available, therefore any immune responses specific to P. gingivalis 
infection could be masked by collection of the whole gingival tissues. For this 
reason, gingival tissue data should be interpreted with a degree of caution. 
In early studies of PD in mice, Baker demonstrated that whilst the differences were 
not as profound as in B cell ablated mice, the depletion of CD4+ T cells contributed 
to a reduction in alveolar bone loss (Baker et al., 1999a). Yet, the differences in 
percentages of CD4+ and CD8+ T cells in sham vs. infected mice were non-existent 
irrespective of infection stage. Likewise, P. gingivalis-infection had no impact on 
the balance of memory and naïve T cells in both local and draining sites of 
infection. Human gingival tissue was found to harbour memory T cells regardless of 
disease (Gemmell et al., 1992). However, the current paradigm of TEM and TCM is 
under scrutiny following the identification of TRM cells. In RA, another immune-
mediated bone destructive disease, TRMs constitute a large proportion of both CD4+ 
and CD8+ T cells in synovium, which are though to contribute to chronic 
inflammation at sites of disease (Henderson et al., 2014). As the transcriptional 
status of TRMs is distinct to that of TEMs or TCMs (Mackay et al., 2013), it would be 
interesting to assess the presence and function of TRMs at early stages of P. 
gingivalis-infection, particularly as the role of memory T cells in PD remains 
elusive.  
At 28 days post infection there was a trend towards a decrease in both the number 
and percentage of Tregs in gingival tissue in PD, however as mentioned previously 
there are limitations with the platforms employed. As pooling of five gingivae may 
dilute out the immune response, it could be speculated that the tendency towards 
fewer Tregs in infection would be significant at the true sites of disease. A similar 
trend was noted in dLNs. Treg data from other studies have in fact shown the 
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opposite. Both an increase in Treg numbers and cytokines have been observed in 
lesion sites from PD patients (Nakajima et al., 2005, Cardoso et al., 2008a), 
however, as mentioned previously, these patients had chronic PD, in which clinical 
parameters of disease were established. In an A. actinomycetemcomitans model of 
mouse PD, depletion of Tregs exacerbated alveolar bone loss, which suggested that 
the presence of Tregs was preventing further progression of disease (Garlet et al., 
2010a). Like in a murine model of LMCV clone 13 infection, in which the expansion 
of splenic Tregs dipped in very early stages, followed by a sharp increase in 
numbers (Punkosdy et al., 2011), perhaps the decrease in Tregs at 28 days post P. 
gingivalis-infection would have preceded a proliferation of Tregs that mimics 
human chronic PD. To test this hypothesis, the duration of the murine model of PD 
could be extended to determine the composition of Tregs in a more chronic phase 
of infection.  
 
As previously discussed, anti-P. gingivalis antibodies were an important factor in 
defining successful infection in the PD model, yet they also signified a role for Tfh 
cells. Thus far, there is no literature discussing either the role or presence of this 
cell type in PD. Whilst the flow cytometry data of dLN cells was not entirely 
conclusive as to the presence of Tfh cells due to a lack of CXCR5 expression, the 
upregulated expression of Bcl-6, ICOS and PD-1 on CD4+ T cells was suggestive of 
Tfh cells. For the first time, it has been implied that P. gingivalis infection induces 
Tfh cell expansion within cervical LNs, likely providing GC B cell help to support the 
generation of high-affinity antibodies. However, despite the presence of P. 
gingivalis-specific antibodies in experimental PD, they do not protect mice from 
disease-associated bone loss (Baker et al., 1999b). 
 
Since the discovery of Th cells, attempts have been made to assign Th subsets to 
the protection or progression of disease. Initial studies evaluated the role of Th1 
and Th2 cells in PD (Seymour et al., 1993, Eastcott et al., 1994, Manhart et al., 
1994, Baker et al., 1999a, Gamonal et al., 2001, Lappin et al., 2001, Berglundh et 
al., 2002). As the existence of other Th subsets was revealed, the nature of the T 
cell-mediated immune response in PD grew more complex. In more recent studies, 
a correlation between Th17 cells and their cytokines have been associated with the 
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pathogenesis of human PD (Cardoso et al., 2009, Dutzan et al., 2012b, Allam et al., 
2011, Honda et al., 2008, Moutsopoulos et al., 2012, Beklen et al., 2007, Adibrad et 
al., 2012, Awang et al., 2014). From the two repeats of the experiment, an 
association of gingival Th cell subtype with disease progression could not be 
commented upon. Nonetheless, our flow cytometry results assessing Th cells in 
dLNs of P. gingivalis-infected mice showed clearer trends of cytokine production 
but did not corroborate the link between Th17 and disease. The mice were used as 
a platform to explore the early immune response that ultimately causes disease, 
yet as discussed previously, Th17 responses were noted in patients with established 
PD. Furthermore, a definitive role of Th17 cells has not been concluded in other 
mouse models of PD (Yu et al., 2007, Eskan et al., 2012).  
 
Whilst a pattern of CD4+ T cell cytokine production in gingivae was not notable in 
our studies, CD8+ T cells elevated IFN-γ production in gingival tissue at 14 days post 
infection. Furthermore, although not significant, at 28 days post-infection an 
increase in IFN-γ production by CD4+ T cells was observed (implying a Th1 response) 
in dLNs. Similarly, CD8+ T cells produced insignificantly increased concentrations of 
IFN-γ in dLNs from P. gingivalis-infected mice. The lack of significance was likely 
due to repetition of the experiment only twice, therefore a further repeat would be 
necessary to argue the definite presence of Th1 cells and IFN-γ production at early 
stages of PD. In addition to cytokine production, a Th cell can be identified based 
on the expression of transcription factors. The presence of Th1 and Th2 cells in 
human PD gingival tissue biopsies were evaluated by transcription factors T-bet and 
GATA-3, respectively, through qRT-PCR (Rajesh et al., 2015). Transcription factors 
could have been assessed in our studies by qRT-PCR or intracellular flow cytometry 
staining (similar to identification of Foxp3 expression by Tregs). 
 
Systemically, IFN-γ was upregulated in spleen supernatants in P. gingivalis-infection 
at 14 and 28 days post infection by luminex and ELISA, respectively.  Together with 
suggested CD4+ and CD8+ T cell IFN-γ production in both gingivae and dLNs, it is 
implicated that P. gingivalis may induce local and systemic Th1 responses. In 
support of these findings, Baker et al. (1999) demonstrated that genetic deletion of 
IFN-γ ameliorated alveolar bone loss in mice infected with P. gingivalis (Baker et 
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al., 1999a). This was perhaps a little surprising considering that in other studies 
IFN-γ directly inhibited osteoclastogenesis (Fox and Chambers, 2000). However, the 
stimulation of T cells by IFN-γ induced secretion of osteoclastogenic cytokines 
RANKL and TNF-α, outweighing its inhibitory effects on osteoclasts, and thereby 
promoted bone loss (Gao et al., 2007).  
 
Although flow cytometry is unequalled as a technology for single-cell analysis, a 
limitation is its dependence on fluorochromes. The use of greater numbers of 
fluorescently labeled antibodies can increase autofluorescence and spectral 
overlap, hence impeding efficiency. Furthermore, a maximum of eight 
fluorochromes could be analysed by the MACSQuant used in these studies, thereby 
cells were either split into different panels or were harvested from mice of 
repeated experiments to assess different T cell types. Due to the limited number of 
cells isolated from the gingivae, experiments were typically repeated, resulting in 
increased consumption of time and resources. Mass spectrometry, otherwise known 
as CyTOF (Cytometry by Time-Of-Flight), is an emerging technology that permits 
phenotyping of cells through detection of 40 markers from small sample sizes 
(starting from as few as 10,000 cells). In CyTOF, fluorochromes are replaced with 
rare heavy metal ion-labeled antibodies that prevent autofluorescence and there is 
very little overlap between channels. CyTOF works in a similar manner to mass 
spectrometry in that cells are accelerated through an electrical field and the time 
taken by ions to reach the detector is measured – lighter ions will reach the 
detector more quickly than heavier ions (Yao et al., 2014). CyTOF could have 
enhanced the flow cytometry analysis described in this chapter; however 
acquisition is slower and reagents are more expensive. 
 
A different approach to identifying a role for T cells in PD was microscopy. This 
enabled the visualization of cells in their anatomical position within intact tissue – 
as the cells would have been in the murine mouth. Whilst obtaining sections of 
gingival tissue was unsuccessful in this model, sections of human gingival tissue are 
commonly assessed to determine specific cells and cytokines within disease 
(Gamonal et al., 2001, Lappin et al., 2001, Berglundh et al., 2002, Cardoso et al., 
2009, Dutzan et al., 2016). Human tissue is larger and can be easily placed in the 
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correct position for embedding, and sections with recognizable architecture cut. 
The small and thin tissue obtained from mice was difficult to position appropriately 
for embedding and consequently the sections cut by the microtome were uneven 
and caused the tissue to tear. Conversely, staining the tissue wholemount enabled 
clear imaging of cells within the hard palate. Due to the position of the lymphoid 
aggregates at the front of the hard palate, it was likely that these cells comprised 
the nasal-associated lymphoid tissue (NALT) (Wu et al., 1997). As the NALT was in 
close proximity to the gingival tissue, it seemed plausible that this immunological 
tissue played a role in the induction of the immune response in PD. This has not 
been widely described in the literature, however, it has been found that nasal 
immunization of BALB/c mice with a fusion protein composed of the 25kDa 
antigenic region of P. gingivalis haemagglutinin A and the maltose binding protein 
of Escherichia coli (25k-hagA-MBP) conferred protection against P. gingivalis-
induced alveolar bone loss. Bone loss was prevented from one week to one-year 
post-immunisation (Du et al., 2011), suggesting a role for NALT in oral immunity. 
 
It was therefore hypothesized that a greater number of CD4+ T cells would migrate 
into B cell regions in NALT to provide B cell help upon bacterial insult in the oral 
cavity. However, there appeared to be no obvious differences in the structure and 
B cell and CD4+ T cell composition of the aggregates. Upon intranasal immunization 
with flagellin-modified circumsporozite protein, typical organization of the T cells 
and B cells is very apparently lost and lymphocyte arrangement is notably different 
by eye (Nacer et al., 2014). It therefore seems unlikely that P. gingivalis infection 
caused any differences in NALT lymphocyte structure. Computational analysis of the 
precise numbers of CD4+ T cells within B cell regions may have proven otherwise. 
There were various issues regarding this technique. Ideally, numbers of CD4+ T cells 
would have been counted using Volocity software but T cells resided close to each 
other, preventing discrimination of individual cell borders. A more appropriate 
measurement was the area of red (CD4+ T cells) within areas of blue (B cells); 
however, a major caveat of wholemount staining was that the depth of tissue at 
which images were taken was difficult to control. Furthermore, the location of T 
cells and B cells within the NALT of rats has been shown to differ (Kuper et al., 
1990), which is a possibility within the mouse. Therefore, it would not be possible 
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to differentiate between true differences in migratory CD4+ T cells between 
infection states and whether the images had been captured at different sites within 
the gingivae. Nevertheless, these data suggest that CD4+ T cells provided B cell 
help under both steady state and infection conditions. Microbiota that reside within 
the oral cavity induce an immune response despite usually being harmless to the 
host. It is thought that the induction of innate (e.g. mucins) and adaptive immunity 
(e.g. secretory IgA) maintains homeostasis between commensal bacteria and the 
host (Marcotte and Lavoie, 1998), which potentially explains the reason for which T 
cells appear to communicate with B cells in the palate of control mice. The use of 
germ-free (GF) mice has illustrated that commensal flora contribute to the 
structure and function of paranasal sinuses, including NALT. NALT was evident in GF 
mice, but was a smaller size compared to that of SPF mice (Jain et al., 2016).    
 
As flow cytometry had revealed an upregulation of IFN-γ by CD8+ T cells in the 
gingivae of mice, it would have been interesting to visualize the production of the 
cytokine within the oral mucosa by confocal microscopy. For this experiment, mice 
could be orally infected with sham or P. gingivalis and sacrificed at different days 
post infection. As positive controls, mice could be given OVA emulsified in CFA in 
the scruff as this has been reported to stimulate IFN-γ production (Ke et al., 1995). 
The intact palatal tissue from P. gingivalis-infected mice and dLNs from OVA-CFA 
mice could be stained wholemount with anti-IFN-γ, anti-CD4 and anti-CD8 
antibodies, as previously described and visualized by fluorescent confocal 
microscopy.  
 
Whilst the data generated from this study have revealed a subtle role of T cells in 
PD, perhaps repeating the experiments would have identified statistically 
significant differences in the cells in infection. It is also important to note that the 
entire T cell population was analyzed in this chapter; therefore the function of the 
P. gingivalis-specific T cells in experimental PD remains unknown. The antigen-
specific T cells would likely be involved in at least the early stages of infection 
after their activation and expansion. The antigen-specific T cells at the infection 
site would then orchestrate the ensuing immune response. Thus, assessing P. 
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gingivalis-specific cells could provide a different insight into CD4+ T cell response in 
experimental PD (Chapter 6). 
 
In conclusion, oral P. gingivalis-infection in BALB/c mice induced a slight increase 
in IFN-γ production by CD8+ T cells from gingivae, CD4+ and CD8+ T cells from dLNs 
and systemically by splenocytes. Therefore, it seemed likely that infection by these 
‘red complex’ bacteria induced some Th1 differentiation, however, the 
contribution of Th1 skewed immunity towards development of PD cannot be 
commented upon due to the lack of alveolar bone loss in these animal models. 
Furthermore, NALT has been imaged in the context of PD for the first time. This 
technique highlighted that CD4+ T cells within the lymphoid structure migrate to B 
cell areas, seemingly to provide B cell help, irrespective of oral P. gingivalis 
infection.  
 
Key findings from chapter 4: 
• There was a trend towards a decrease in number and percentage of Tregs in 
gingivae and dLNs at 28 days post P. gingivalis-infection. 
• The identification of CD4+ T cells expressing Bcl-6, ICOS and PD-1 suggested 
that oral P. gingivalis infection induced Tfh cell expansion in dLNs. 
• There was a trend towards an increase in IFN-γ production by CD4+ and CD8+ 
T cells in dLNs and a significant increase in gingival CD8+ T cell IFN-γ 
production from infected mice, along with a systemic elevation of IFN-γ in 
response to P. gingivalis stimulation. 
• CD4+ T cells predominantly clustered around B cells in NALT, with some CD4+ 
T cells migrating to B cell regions – irrespective of infection.  		
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5 Transcriptome of CD4+ T cells in PD  
5.1 Introduction 
 
The murine model of PD described in chapter 4 illustrated subtle changes in T cell 
phenotypes upon oral infection with P. gingivalis. A caveat of this approach was the 
biased manner in which T cell phenotypes were assessed, possibly masking changes 
in T cells in PD. Global detection of genes, transcripts, proteins and metabolites 
through ‘omics’ technologies is conducted in an untargeted manner and eliminates 
the bias of assessing only preselected targets.  
 
‘Omics’ have the potential to define physiological processes and disease pathologies 
through simultaneous quantification of numerous molecules. Genomics is the study 
of the entire genome – total DNA – of a cell or organism. Whilst this technique can 
identify disease-associated sequence polymorphisms, it does not reveal 
functionality of DNA. Active gene expression and regulation is evaluated through 
RNA transcripts by transcriptomics. This enables recognition of cell-specific or 
disease-specific gene expression, but may not be a true representation of down-
stream protein translation (Wang et al., 2009). Proteomics assesses the proteome of 
a cell, to determine protein pathways and functions in a given environment. 
However, limitations include poor sensitivity of low abundance proteins and analysis 
of protein complexes (Chandramouli and Qian, 2009). Metabolomics can be defined 
as the assessment of the metabolic profile of a cell. It is considered the truest 
reflection of the cell phenotype, as metabolites – final product of gene expression 
and environmental stimulus – can be amplified in response to small changes in 
transcriptomics and proteomics. However, unlike the other ‘omics’ technologies in 
which a single instrument is capable of conducting analysis, metabolomics requires 
a variety of instrumentation (Wishart, 2016).  
 
Although disease characteristics cannot be fully explored by transcriptomics in an 
equal manner to metabolomics, small sample quantities can be readily evaluated by 
transcriptomics. The cell’s transcriptome can be analysed by qRT-PCR, microarrays 
and RNA-sequencing. As mentioned above, bias-driven experimentation is not 
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optimal, eliminating qRT-PCR and microarray assays. RNA-sequencing, however, 
enables universal quantification of a cell’s transcripts.  
 
Human PD has been assessed at the transcriptome level, with a particular focus on 
peripheral blood monocytes (Liu et al., 2016) or the total cell composition of the 
gingivae (Davanian et al., 2012, Lundmark et al., 2015) using RNA-sequencing. 
Further, this technique has been used to characterise the microbial dysbiosis that 
associates with disease (Szafrański et al., 2015). 
 
Whilst RNA-seq has provided a greater insight into gene expression and regulation in 
human PD in some studies, there is a complete lack of equivalent analysis in the 
mouse model, and minimal analysis of discrete cell populations. For this reason, the 
transcriptomes CD4+ T cells in the oral mucosa and dLNs were analysed by RNA-
sequencing to better define the disease phenotype of PD.  
 
The aims of this chapter were to: 
• Optimize an RNA extraction method. 
• Determine a PD gingival CD4+ T cell transcriptome profile. 
• Determine a PD dLN CD4+ T cell transcriptome profile. 
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5.2 Results 
 
The aim of this chapter was to assess the transcriptome of CD4+ T cells from the 
local and draining sites of P. gingivalis-infection. Limited cell numbers could be 
obtained from the gingivae, of which even fewer were CD4+ T cells (1.2 x 104 cells 
from five mice; chapter 3). Therefore, initial experiments were conducted to 
determine the optimal method for RNA extraction from low cell numbers. Three 
RNA extraction kits were selected based on the manufacturer specification for use 
with small cell numbers; Qiagen RNeasy® Micro Kit (≤ 5 x 105 cells), Ambion™ 
RNAqueous® - Micro Total RNA Isolation Kit (≤ 5 x 105 cells) and Arcturus® 
PicoPure® RNA Isolation Kit (< 10 cells, maximum cell number not specified). Cells 
from cervical LNs not required in other experiments were isolated and resuspended 
at 106, 5 x 105, 5 x 104, 5 x 103 and 5 x 102 cells for RNA extraction using the 
RNeasy® Micro Kit. For the other kits, cervical LN cells were resuspended at 106, 
105, 104, 103 and 102 cells. The concentration of RNA was assessed by 
spectrophotemtry, using a nanodrop (table 5.1). Only small amounts of RNA were 
obtained from the RNeasy® Micro Kit, regardless of cell number, and RNA 
concentration did not increase in a linear manner with increasing cell number. Both 
RNAqueous® and PicoPure® kits extracted concentrations of RNA that better 
reflected the cell count; however, the concentrations remained relatively low. The 
ratio of absorbance at 260/280 indicates the purity of the RNA sample, with a 
desirable ratio being approximately 2.0. With a few exceptions, the majority of the 
samples fell below or above the acceptable range. A low 260/280 ratio may be 
indicative of contamination with phenol or a reagent used in the extraction 
method, or may result from concentrations of RNA lower than 10 ng/µl. As a second 
measure of purity, the ratio of absorbance at 260/230 should range between 
approximately 2.0 and 2.2. All samples failed to reach purity, substantially, by this 
ratio, ranging between 0.02 and 0.88, which can often signify phenol or guanidine 
contamination.  
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Table 5.1. Assessment of RNA by nanodrop. 	
RNA 
extraction 
kit 
Cell number Concentration (ng/µl)* 
Ratio of 
absorbance 
at 260/280 
Ratio of 
absorbance 
at 260/230 
Qiagen 
RNeasy® 
Micro Kit 
106 10.3 1.83 0.20 
5 x 105 11.4 1.33 0.20 
5 x 104 3.0 1.77 0.06 
5 x 103 7.4 1.44 0.64 
5 x 102 11.5 1.86 0.77 
Ambion™ 
RNAqueous®-
Micro Total 
RNA Isolation 
Kit** 
106 62.3 1.83 0.77 
105 12.7 1.91 0.26 
104 2.1 1.83 0.1 
103 1.4 1.3 0.05 
102 1.4 2.25 0.02 
Arcturus® 
PicoPure® 
RNA Isolation 
Kit** 
106 74.1 1.99 0.88 
105 13.0 1.53 0.23 
104 4.8 1.32 0.13 
103 4.8 1.55 0.16 
102 7.4 1.37 0.28 
* RNA was eluted into the same volume of buffer hence concentration of RNA from 
each extraction method can be compared.  
**Representative of 2 independent experiments. 
 
 
To further investigate the quality and quantity of these small amounts of RNA, a 
bioanalyser pico chip was used to ensure maximum sensitivity. A bioanalyser is a 
capillary electrophoresis machine that analyses DNA, RNA and protein. Whilst a 
nanodrop assesses concentration and the presence of contamination in a sample, it 
will not determine the presence of contaminating DNA and whether the RNA 
samples are intact or fragmented. The RNA integrity number (RIN) generated by the 
bioanalyser is far more comprehensive and gives details of sample integrity based 
on electropherograms. The number of CD4+ T cells to be sorted from gingival tissue 
by flow cytometry was expected to be within the range of 5 x 105 and 103, due to 
the results of trial sorts (chapter 3) and so in the interests of conserving resources, 
RNA from 106 and 102 cells were not analysed by this method. The 
electropherograms generated using the bioanalyzer (figure 5.1) show marker peaks 
(control to indicate a successful run) and where applicable 18S and 28S ribosomal 
peaks. Small peaks at 18S and 28S were found only from RNA extracted from 5 x 105 
cells using the RNeasy® kits. There were 18S and 28S peaks from RNA extracted 
from 1 x 105 cells RNA using the RNAqueous extraction kit. There was no detectable 
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RNA obtained following extraction of RNA from cell numbers below 1 x 105 from 
both the RNeasy® kit and the RNAqueous kit. Due to a labeling error using 
Picopure® kit, the only sample known was that from 103 cells. The other samples 
were estimated based on their ribosomal peaks. However, it can clearly be 
concluded that this kit could isolate quantifiable RNA from even 103 cells, with 18S 
and 28S peaks having far greater height than the RNA from corresponding cell 
counts using the other kits.  
 
	
Figure 5.1. Assessment of RNA extracted using three different kits. 
RNA was extracted from mouse lymphocytes and the quality of the RNA extraction 
by each kit was assessed using a Bioanalyzer. (A-C) Electropherograms of RNA 
extracted using the Qiagen RNeasy® from (A) 5 x 105, (B) 5 x 104 and (C) 5 x 103 
cells. (D-F) RNA extracted by Ambion™ RNAqueous®-Micro Total RNA Isolation Kit 
from (D) 105, (E) 104 and (F) 103 cells. (G-I) Electropherogram of RNA extracted by 
Arcturus® PicoPure® RNA Isolation Kit* from (G) 105, (H) 104 and (I) 103 cells. 
‘Marker’ is a positive control indicative of a successful run and is shown on the 
electropherograms along with ribosomal 18S and 28S in A, D, G-I. 
*103 cells is the only sample that is known due to a labeling error, 104 and 105 have 
been estimated based on their peaks. 
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The bioanalyzer also determined RIN – a measurement of quality whereby a range of 
between 8 and 10 is usually accepted for NGS – as well as RNA concentration (table 
5.2). The RIN from each of the RNA samples isolated by RNeasy® kit was lower than 
required for RNA-sequencing. A high RIN of 8.5 was assigned to RNA obtained from 
105 cells by RNAqueous® kit, but the quality of the samples of lower cell counts was 
so poor that RINs could not be determined. As suggested by the electropherograms, 
the RNA from Picopure® kit was generally of greater quality, with 103 cells having a 
RIN of 4.8, 104 having a RIN of 7.6 and 105 with a RIN of 7.8. Although not optimal, 
RNA from 105 and 104 cells were of borderline quality and 103 quite low, however, 
the lower cell count samples were of greater quality from Picopure® kit than the 
others. 
 
Table 5.2. Assessment of RNA extraction kits by Bioanalyzer. 
RNA extraction 
kit Cell number RIN 
Concentration 
(pg/µl) 
Qiagen RNeasy® 
Micro Kit 
5 x 105 5 105.0 
5 x 104 1 22.1 
5 x 103 1 21.8 
Ambion™ 
RNAqueous®-
Micro Total RNA 
Isolation Kit 
105 8.5 298.0 
104 N/A 19.3 
103 N/A 6.1 
Arcturus® 
PicoPure® RNA 
Isolation Kit 
105 * 7.8 2820.5 
104 * 7.6 86.3 
103 4.8 13.0 
* Due to a labeling error, 103 cells is the only sample that is known, 104 and 105 have 
been estimated based on their peaks on the electropherograms (figure 5.1). 
 
 
The results from bioanalyzer analysis seemed more informative than those of the 
nanodrop and so RNA samples were reverse-transcribed to cDNA and qRT-PCR 
conducted to determine whether 18S expression could be identified with such low 
quantities of starting RNA. Figure 5.2 shows that 18S expression was found in all 
samples from each kit and indicated that the greater the starting cell count, the 
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lower the CT value. The change in CT value best represented the changes in 
starting cell numbers using cDNA from RNA from the Picopure® kit.  
 
Whilst expression of the 18S housekeeping gene could be identified in all samples, 
the bioanalyzer results indicated that Picopure® kit extracted the best quality of 
RNA from lower cell counts. This kit was then trialed for extraction of RNA from 
CD4+ T cells sorted from the gingivae and dLNs of five mice. Analysis of RNA by the 
bioanalyzer highlighted that high quality RNA could be extracted from gingival and 
dLN CD4+ T cells (RIN of 9 and 9.4, respectively) (table 5.3), hence was selected 
for use for the RNA-sequencing experiment. The concentrations of RNA from 
gingival cells were low, suggesting that greater numbers of mice may be required. 
 
	
Figure 5.2. Amplification plots of PCR for 18S of cDNA generated from RNA 
extracted using different RNA extraction kits. 
RNA was extracted from cervical lymph node cells using (A) Qiagen RNeasy® Micro 
Kit, (B) Ambion™ RNAqueous®-Micro Total RNA Isolation Kit or (C) Arcturus® 
Picopure® RNA Isolation Kit. RNA was extracted from the cell numbers indicated on 
the plots and reverse transcribed to cDNA and expression of 18S determined by qRT-
PCR.  
106 105 104 103 102 
106 105 104 103 102 106 5x105 5x104 5x103 5x102 
A B 
C 
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Table 5.3. Concentrations of RNA extracted using Picopure® kit following FACS 
sort of gingival and draining lymph node CD4+ T cells. 	
Tissue No. of mice 
Cell no. 
pre-sort 
CD4+ T 
cell no. 
post-sort 
Total RNA 
(ng) RIN 
Gingivae 5 7.0 x 105* 7.4 x 103 3 9 
dLN 5 1.5 x 106** 3.7 x 105 170 9.4 
*Cells from 5 gingivae were pooled and all cells were used for sort. 
**Cells from 5 dLNs were pooled (approximately 5 x 107 cells) but only 1.5 x 106 
were used for sort.  
 
The initial analysis of gene expression in whole gingivae or dLN was carried out 
using a selection of genes and cell surface molecules speculated to contribute to PD 
progression. The data presented in chapter 4 suggest subtle alterations in T cell 
phenotype in P. gingivalis-infection, and that perhaps the changes were not fully 
exposed with the methodology used. Subsequently, the transcriptome of CD4+ T 
cells from experimental PD models were analyzed by NGS. Due to the cost of the 
RNA-sequencing experiment, it was not feasible to assess CD4+ T cells at all time-
points. The data from chapter 4 implied that IFN-γ production by both CD4+ and 
CD8+ T cells within the dLNs of infected mice increased at 28 days post infection, 
along with a trend towards a decrease in Tregs. Furthermore, it was of interest to 
determine T cell responses occurring at the time of alveolar bone loss development. 
Therefore, RNA-sequencing of gingival and dLN CD4+ T cells was conducted at 28 
days post infection. 
 
As discussed in chapter 4, serum anti-P. gingivalis IgG titres reflected alveolar bone 
loss in initial studies. Although in some models serum antibody was observed with 
minimal bone loss, previous models and some replicates of these studies 
demonstrated that an absence of serum antibody was likely to represent failed 
infection and absence of bone loss. Therefore, antibody titres were assessed using 
serum obtained by tail bleed, prior to cull. RNA-sequencing experiments excluded 
mice that did not produce IgG to P. gingivalis. Groups of 20 mice were used for 
each experiment, with 10 orally infected with CMC/sham and 10 mice infected with 
P. gingivalis. The rationale behind the increased group size was that around 7000 
CD4+ T cells could be sorted from the gingivae pooled from 5 mice, from which 
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around 3 ng of RNA could be extracted (table 5.3). The recommended minimum 
concentration of cDNA required was 10 ng at a concentration of 1 ng/µl. Of mice 
infected with P. gingivalis, a maximum of 20% of the infected animals had very low 
or undetectable IgG titres. As an appropriate control, the same numbers of sham-
infected mice were also excluded. Therefore, an experiment with 10 mice per 
group would allow the exclusion of P. gingivalis-antibody negative mice, whilst 
increasing the number of CD4+ T cells to be sorted.  
 
The serum antibody titres of the mice used for RNA-sequencing experiments are 
described in figure 5.3. The infected mice had significantly greater serum antibody 
titers than their sham-infected counterparts (mean 148.7 +/- 30.3 EU sham vs. 
mean 1569.0 +/- 101.6 EU P. gingivalis, P < 0.0001). Despite this, the mice 
developed alveolar bone loss mirroring that of the sham-infected mice (mean 0.229 
+/- 0.005 mm sham vs. mean 0.231 +/- 0.006 mm P. gingivalis, NS). To investigate 
whether the duration of the infection was insufficient to cause bone destruction, 
five supplementary mice were orally infected with the same cultures of P. 
gingivalis, concurrently with a group of animals from which cells were used for 
RNA-sequencing and similarly, five extra mice were sham-infected. The mice 
infected for 49 days displayed increased anti-P. gingivalis IgG titres (mean 157.8 +/- 
39.36 EU sham vs. mean 1675.0 +/- 47.27 EU P. gingivalis, P < 0.0001) (figure 
5.3C). Further more, alveolar bone loss was apparent in four of the five mice at 49 
days post infection compared to control mice (mean 0.270 +/- 0.004 mm sham vs. 
mean 0.290 +/- 0.007 mm P. gingivalis, P < 0.05) (figure 5.3D). The data therefore 
suggested that in this system, at 28 days post-infection, the local and potentially 
systemic changes that lead to development of PD were occurring and the RNA-
sequencing data would pinpoint the correlating changes in CD4+ T cell gene 
expression – perhaps corroborating the suggested association of CD4+ T cell IFN-γ 
production and PD (chapter 4). 
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Figure 5.3. Anti-P. gingivalis IgG titres and alveolar bone loss at 28 and 49 days 
post P. gingivalis infection. 
Mice were orally infected with P. gingivalis or were sham-infected (sham) with 
carrier vehicle, CMC, only. (A and B) 28 days post infection; (C and D) 49 days post 
infection. (A and C) Anti-P. gingivalis IgG titres in serum were measured by ELISA. 
Data are ELISA Units (EU) shown as individual mice (symbols) with mean +/- SEM for 
each group (lines). (B and D) Alveolar bone loss. Data are shown as mean per mouse 
(symbols) with mean +/- SEM for each group (lines). (A and B) Data are combined 
from 3 independent experiments, n = 4-5 mice/group. (C and D) Data are combined 
from 1 experiment, n = 4-5 mice/group. Statistical significance was determined by 
unpaired T test, as indicated on the graph (*P < 0.05, ****P < 0.0001). 
 
 
A total of three independent experiments were set up for RNA-sequencing, each 
consisting of sham infected mice (n = 10) and P. gingivalis-infected mice (n = 10). In 
the tables below, the independent experiments are designated ‘3’, ‘4’, and ‘5’ as 
experiments ‘1’ and ‘2’ were unusable due to RNA degradation. Cells from gingivae 
of each group were pooled and sorted by flow cytometry. Two to three million cells 
from a pooled population of dLN cells were similarly sorted. Surplus lymphocytes 
were used for compensation controls. Details of the mice, CD4+ T cells sorted and 
RNA extracted are described in table 5.4. From the gingivae, the number of CD4+ T 
cells sorted ranged from 1.2 x 104 to 3.5 x 104 and the extracted RNA samples had 
RINs of at least 8.6. From the dLNs, between 3.0 x 105 and 1 x 106 CD4+ T cells were 
sorted, giving extracted RNA with RINs of at least 9.0 (sham dLN from batch 3 was 
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not analysed by the bioanalyzer due to an error in the loading of the chip). All 
samples were of sufficient quality for RNA-sequencing. However, with low starting 
concentrations of RNA, the sequencing platform used from Source BioScience 
advised a pre-amplification step.  
 
 
Table 5.4. RNA of CD4+ T cells sorted from gingivae and draining lymph nodes of 
sham and P. gingivalis-infected mice. 	
Sample 
No. of 
mice 
CD4+ T 
cell 
count 
post sort 
RIN 
Conc. of 
RNA 
(ng/µl) 
Total RNA 
(ng) 
Name  Repeat* 
Sham 
gingivae 3 8 3.2 x 10
4 9.3 1.46 14.6 
P. gingivalis 
gingivae 3 8 3.5 x 10
4 9.4 0.58 5.8 
Sham  
dLN** 3 8 1.0 x 10
6 - - - 
P. gingivalis 
dLN 3 8 1.0 x 10
6 9.4 47.8 478 
Sham 
gingivae 4 8 1.9 x 10
4 8.8 0.78 7.8 
P. gingivalis 
gingivae 4 8 2.3 x 10
4 8.6 1.01 10.1 
Sham  
dLN 4 8 5.0 x 10
5 9.0 72.4 724 
P. gingivalis 
dLN 4 8 4.9 x 10
5 9.4 33.1 331 
Sham 
gingivae 5 9 2.2 x 10
4 9.2 0.83 8.3 
P. gingivalis 
gingivae 5 9 1.2 x 10
4 9.1 0.69 6.9 
Sham  
dLN 5 9 3.0 x 10
5 10 20.5 205 
P. gingivalis 
dLN 5 9 3.7 x 10
5 9.6 29.2 292 
*RNA-sequencing was performed on 3 independent experiments. Experiment repeats 
were assigned numbers 3, 4 or 5. Experiments 1 and 2 were not used due to RNA 
degradation. 
**No Bioanalyzer readout for Sham dLN due to error loading sample into chip 
Abbreviations: No., number; RIN, RNA integrity number; conc., concentration; dLN, 
draining (cervical) lymph node.  
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The SMART-Seq® v4 Ultra® Low Input RNA Kit was used to generate full-length 
cDNA from low concentrations of RNA (10 pg – 10 ng). SMART (Switching Mechanism 
at 5’ End of RNA Template) technology generates full length cDNAs by exploiting 
the switching activity of reverse transcriptases. Defined PCR adapters are added to 
both ends of first strand cDNA. These adaptors are meant to ensure that final cDNA 
libraries contain the 5’ end of mRNA and this should help accurate representation 
of the initial mRNA transcripts. A maximum of 10 ng could be used for first-strand 
cDNA was synthesis, therefore RNA from dLNs were diluted but the whole sample of 
gingivae RNA was used. cDNA was amplified by ‘long distance PCR’; a technique 
that enables amplification of DNA lengths (>30 kb) that conventional PCR methods 
are unable to amplify. Amplified cDNA was then sent to Source BioScience for 
purification and validation using Agilent’s 2100 Bioanalyzer and high sensitivity DNA 
kit. All samples passed quality control testing and concentrations of each sample 
ranged between 0.41 and 2.64 ng/µl. The samples were diluted to 1 ng total cDNA 
for preparation of Nextera XT libraries and all libraries were validated using the 
Bioanalyzer.  NGS was then conducted using the NextSeq 500 platform. This 
platform is advantageous in that it provides highly accurate results in rapid 
turnaround times (48 hours). Differential gene expression and gene set enrichment 
analysis were conducted by Source BioScience using DESeq2.  
 
The heatmap in figure 5.4 depicts the expression of the 50 most highly expressed 
genes. The clustering analysis shows 2 primary branches, one of which groups 
gingival samples and the other groups the dLNs. Thirty-nine of the 50 genes appear 
to be expressed fairly similarly by the all samples irrespective of tissue origin and 
infection status. However, the remaining genes are differentially expressed 
between gingivae and dLNs – particularly Ppp1r15a, Vps37b, Tnfaip3, Junb, Hspa5, 
Ier2 and Pnrc1. The expression of these genes does not differ in infection compared 
to control. There is some variation in expression between different experimental 
replicates, which is especially evident in expression of Gm26917, Ppp1r15a, 
Tnfaip3, Junb by dLN replicates. Along with the clustering analysis, these data 
suggest that P. gingivalis infection does not cause great changes in gene expression 
of CD4+ T cells.  
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These findings are consolidated by the MA-plot (figure 5.5A), which is a visual 
representation of genomic data with log ratio plotted against mean expression for a 
set of genes. In this plot comparing gene expression from CD4+ T cells of sham and 
P. gingivalis-infected gingivae, it was clearly demonstrated that only 3 genes are 
upregulated in disease at 28 days post infection. The difference between control 
and P. gingivalis-infection in dLNs is even smaller; with the down-regulation of a 
single gene being the only difference in CD4+ T cell gene expression corresponding 
with infection (figure 5.5B). As the data from the heatmap implied, the majority of 
differential gene expression occurs between gingivae and dLN (figure 5.5C-F). 
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Figure 5.4. Heatmap of the 50 most highly expressed genes in CD4+ T cells 
isolated from the gingivae and draining lymph nodes of sham and P. gingivalis-
infected mice. 
 Mice were orally infected with P. gingivalis or were sham-infected with carrier 
vehicle, CMC, only. At 28 days post infection, cells were isolated from gingivae and 
draining lymph nodes and CD4+ T cells were sorted. RNA was extracted, pre-
amplified, then reverse transcribed for next-generation sequencing using NextSeq 
platform. DESeq2 was used to determine differential gene expression and generate 
heatmaps. The data were transformed by variance stabilizing transformation prior 
to clustering. The length and grouping of the branches correspond to similarity of 
the samples. The branching and height of the tree reflects the distance. Size factor 
indicates how much sequencing differs between samples; 0.9 indicates a sample in 
which 90% of the mean total reads mapped are different. PG - P. gingivalis 
infection, CMC - sham infection, G - gingivae, LN - draining lymph node and the 
following number represents the independent experiment batch number. 
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Figure 5.5. MA-plots of gene expression from CD4+ T cells isolated from sham 
versus P. gingivalis-infected gingivae and draining lymph nodes. 
Samples were prepared as in figure 5.4. DESeq2 was used to determine differential 
gene expression and generate MA-plots. MA-plots showing log2 fold change of gene 
expression against their mean expression comparing CD4+ T cell expression from (A) 
gingivae of sham and P. gingivalis-infected mice, (B) draining lymph nodes of sham and 
P. gingivalis-infected mice, (C) sham-infected draining lymph nodes and sham-infected 
gingivae, (D) P. gingivalis-infected draining lymph nodes and P. gingivalis-infected 
gingivae, (E) sham-infected gingivae and P. gingivalis-infected draining lymph nodes 
and (F) sham-infected draining lymph node and P. gingivalis-infected gingivae.  
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As the MA-plot and heatmap suggested, the clustering of samples occurred between 
gingivae irrespective of infection and dLNs irrespective of infection, and this is 
similarly represented in the PCA plot (figure 5.6). A similar pattern of clustering of 
gene expression from total cell isolate of gingivae and dLNs was noted using the RT2 
profiler in chapter 4 (figure 4.16). 
 
 
 
	
Figure 5.6. Principle component analysis (PCA) of CD4+ T cells from sham and P. 
gingivalis-infected mice. 
Samples were prepared as in figure 5.4. DESeq2 was used generate PCA plot. 
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The three genes statistically significantly upregulated by CD4+ T cells from gingivae 
of infected mice were Btg3, Gm20634 and Gm20633 (figure 5.7A). The functions of 
each of these genes are described in table 5.5. In the dLNs in P. gingivalis 
infection, CD4+ T cells were found to down-regulate the expression of Gm5451 
compared with its expression in sham-infection (figure 5.7B). The details of 
Gm5451 are described in table 5.5.   
 
The four genes described above were significantly differentially expressed in 
infection when analysed to obtain a Padj value – a corrected P value that eliminates 
random events falsely appearing as significant in high throughput experimentation. 
P values are generally insufficient for identifying statistical significance in such high 
throughput experiments. However, given the surprisingly small number of 
differentially expressed genes identified, to further interrogate the data, the genes 
with the lowest P values (but a Padj value of > 0.1) are shown in figure 5.7C-D. 
Using this method, within the gingivae, two genes were found to be upregulated - 
Hmgb1-ps1 and Bc147527 – and three genes were found to be down-regulated – 
Prdm2, Gm13169 and Tcf20. Gm14173 and Gm10231 were upregulated by CD4+ T 
cells in dLNs of P. gingivalis-infected mice, whilst there was a down-regulation of 
Trav6-d6.  
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Figure 5.7. Differential CD4+ T cell gene expression in gingivae and draining 
lymph nodes from sham and P. gingivalis-infected mice. 
Samples were prepared as in figure 5.4. DESeq2 was used to determine differential 
gene expression. (A) Genes significantly differentially expressed in the gingivae of 
P. gingivalis-infected mice, determined by Padj value. (B) Single gene significantly 
differentially expressed in the draining lymph nodes of P. gingivalis-infected mice, 
determined by Padj value. (C) Genes differentially expressed in gingivae of P. 
gingivalis-infected mice, determined by P value. (D) Genes differentially expressed 
in draining lymph nodes of P. gingivalis-infected mice, determined by P value. Data 
shown are mean log2 fold change of P. gingivalis-infection compared to sham-
infection, from 3 independent experiments, n=1/group. Statistical significance was 
determined using Wald-test (P value) followed by Benjamini-Hochberg correction 
(adjusted P value, Padj) (*Padj < 0.1, **Padj < 0.05, ***Padj < 0.01 and §P < 0.001). 
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Table 5.5. Details of genes with differential expression in P. gingivalis infection. 
Gene symbol Gene name 
Chromosome 
location 
Function Reference 
Btg3 
B cell 
translocation 
gene 3 
16 
Anti-
proliferation 
(Du et al., 
2015) 
Gm20634 
Predicted 
gene 20634 
3 
Unclassified 
non-coding gene 
Mouse Genome 
Informatics 
Gm20633 
Predicted 
gene 20633 
3 
Anti-sense 
IncRNA gene 
Mouse Genome 
Informatics 
Gm5451 
Predicted 
gene 5451 
13 Pseudogene 
Mouse Genome 
Informatics 
Prdm2 
PR domain 
containing 2, 
with ZNF 
finger 
4 
Protein coding 
gene 
Mouse Genome 
Informatics 
Hmgb1-ps1 
High mobility 
group box 1, 
pseudogene 1 
11 Pseudogene 
Mouse Genome 
Informatics 
Gm13169 
Predicted 
gene 13169 
4 Pseudogene 
Mouse Genome 
Informatics 
Bc147527 
cDNA 
sequence 
Bc147527 
13 
Protein coding 
gene 
Mouse Genome 
Informatics 
Tcf20 
Transcription 
factor 20 
15 
Protein coding 
gene 
Mouse Genome 
Informatics 
Gm14173 
Predicted 
gene 14173 
2 Pseudogene 
Mouse Genome 
Informatics 
Trav6d-6 
T cell receptor 
alpha variable 
6D-6 
14 
Gene that 
rearranges at 
the DNA level 
and encodes 
variable region 
of TCRs 
Ensembl 
Gm10231 
Predicted 
gene 10231 
17 Pseudogene 
Mouse Genome 
Informatics 
http://www.informatics.jax.org/marker/MGI:5313081 (accessed on 03/02/17) 
http://www.informatics.jax.org/marker/MGI:5313080 (accessed on 03/02/17) 
http://www.informatics.jax.org/marker/MGI:3643790 (accessed on 03/02/17) 
http://www.informatics.jax.org/marker/MGI:107628 (accessed on 03/02/17) 
http://www.informatics.jax.org/marker/MGI:3768536 (accessed on 03/02/17) 
http://www.informatics.jax.org/marker/MGI:3651793 (accessed on 03/02/17) 
http://www.informatics.jax.org/marker/MGI:4840510 (accessed on 03/02/17) 
http://www.informatics.jax.org/marker/MGI:108399 (accessed on 03/02/17) 
http://www.informatics.jax.org/marker/MGI:3650930 (accessed on 03/02/17) 
http://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000094176;r=14:528
21922-52822359;t=ENSMUST00000197754 (accessed on 03/02/17) 
http://www.informatics.jax.org/marker/MGI:3704468 (accessed on 03/02/17) 
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Since analysis of dLN T helper cytokine production by flow cytometry (chapter 4) 
suggested that P. gingivalis-infection induced IFN-γ but not IL-17A or IL-4 
production, the expression of these genes, as found by RNA-sequencing, was 
assessed (figure 5.10). Similar to the findings by flow cytometry of gingivae, there 
were no differences in the expression of Ifnγ, Il17A or Il4 by CD4+ T cells from sham 
or P. gingivalis-infected mice. Likewise, the results of cytokine production in dLNs 
by flow cytometry were mirrored in the RNA-sequencing experiment, whereby Ifnγ 
expression was increased in P. gingivalis-infection. This finding was not significant 
by corrected P value, Padj, but had a P value < 0.05.  
 
 
 
Figure 5.8. Differential gene expression of CD4+ T helper cytokines in gingivae 
and draining lymph nodes from sham and P. gingivalis-infected mice. 
Samples were prepared as in figure 5.4. DESeq2 was used to determine differential 
gene expression. Log2 fold change of Ifny, Il17a and Il4 gene expression in (A) 
gingivae and (B) draining lymph nodes. Data is shown as mean log2 fold change of P. 
gingivalis-infection compared to sham-infection, from 3 independent experiments, 
n=1/group. Statistical insignificance was determined using Wald-test (P value) 
followed by Benjamini-Hochberg correction (adjusted P value, Padj). * represents P 
< 0.05 as indicated on the graph. 
 
 
As a trend towards a decrease in the proportion of Tregs in P. gingivalis-infection 
was also observed by flow cytometry at 28 days post infection, Treg markers were 
evaluated from the RNA-sequencing data-set. There was, however, no difference in 
expression of Cd25, Foxp3, Il10, Ctla4, TgfB1 or TgfB2 between CD4+ T cells from 
control and infected mice, in both gingivae and dLNs (figure 5.9). To further 
compare the flow cytometry data to that of RNA-sequencing, Tfh gene expression 
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was assessed. However, no differential expression of Bcl6, Cxcr5, Icos, Pd1 or Il21 
was found in CD4+ T cells from dLNs of sham or P. gingivalis-infected mice (data 
not shown).  
 
	
Figure 5.9. Differential gene expression of regulatory T cell associated genes in 
gingivae and draining lymph nodes from sham and P. gingivalis-infected mice. 
Samples were prepared as in figure 5.4. DESeq2 was used to determine differential 
gene expression. Log2 fold change of Cd25, Foxp3, Il10, Ctla4, Tgfb1 and Tgfb2 
gene expression in (A) gingivae and (B) draining lymph nodes. Data is shown as 
mean log2 fold change of P. gingivalis-infection compared to sham-infection, from 3 
independent experiments, n=1/group. Statistical insignificance was determined 
using Wald-test (P value) followed by Benjamini-Hochberg correction (adjusted P 
value, Padj). 
 
 
As shown by the MA-plots, the greatest differences were of gene expression of CD4+ 
T cells from different sites. Specifically, 4277 genes were expressed differently 
between gingivae and dLNs from sham-infected mice. Between gingivae and dLNs 
from P. gingivalis-infected mice, 4576 genes were differentially expressed. Of the 
top 20 differentially expressed genes upregulated in sham gingivae compared to 
sham dLNs and of the top 20 differentially expressed genes upregulated in infected 
gingivae compared to infected dLN, 15 genes were commonly upregulated within 
the gingivae, irrespective of infection status (table 5.6). Of the top 20 
differentially expressed genes down-regulated in sham gingivae compared to sham 
dLNs and of the top 20 differentially expressed genes down-regulated in infected 
gingivae compared to infected dLN, 9 genes were commonly down-regulated (table 
5.6). These genes may give an indication as to why particular CD4+ T cells reside 
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within the gingivae. Maff was the gene with the greatest decrease in expression by 
CD4+ T cells from dLNs. This gene encodes a transcription factor that is thought to 
play a role in blood coagulation and skeletal muscle development amongst others 
(http://www.uniprot.org/uniprot/O54791- accessed 03/02/17). Of the genes 
increased in the dLNs compared to the gingivae, Clec2d had the highest fold 
change. Clec2d encodes C-type lectin domain family 2, member d 
(https://www.ncbi.nlm.nih.gov/gene/93694 - accessed 03/02/17), which is a 
negative regulator of osteoclast differentiation and plays a role in protection 
against NK cell mediated cytotoxicity. As the gingivae is proximal to alveolar bone 
and teeth, it is not surprising that a gene involved in negatively regulating 
osteoclast differentiation is found downregulated in the gingival CD4+ T cells. Thus 
implying that these CD4+ T cells are more likely to promote osteoclast 
differentiation. Interestingly, Cx3cl1 expression was increased in gingival CD4+ T 
cells compared to dLN CD4+ T cells. CX3CL1 has been shown to promote immune 
cell migration, particularly T cells, B cells, NK cells and monocytes (Ferretti et al., 
2014). CX3CL1 is typically expressed by neurons, gut, vascular and airway 
epithelium but not usually T cells (Johnson and Jackson, 2013). Perhaps some of the 
CD4+ T cells isolated from gingivae were intraepithelial lymphocytes and shared the 
immune trafficking behaviour that epithelial cells can exert.  
 
Of the genes statistically significantly expressed differently by CD4+ T cells of 
gingivae and dLN, a number of these genes were previously identified through the 
RT2 profiler (table 4.1) This included a down-regulation of Cxcl10 by cells of dLN 
compared to gingivae in both sham and P. gingivalis infection, a down-regulation of 
Cxcl16 in dLN compared to gingivae in sham-infection and a decrease in Ccl4 
expression in dLN compared to gingivae in P. gingivalis-infection.    
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Table 5.6. Genes differentially expressed in CD4+ T cells from gingivae 
compared to draining lymph nodes. 	
Transcript 
Log2 fold change 
(dLN v. gingivae)* Padj value 
Sham P. gingivalis Sham P. gingivalis 
Maff -4.39 -5.38 5.57 x 10-70 3.64 x 10-97 
Fosl2 -4.70 -4.79 5.25 x 10-92 1.07 x 10-96 
Vegfa -4.34 -4.65 1.86 x 10-59 3.67 x 10-66 
Chad -4.22 -4.40 1.51 x 10-35 2.18 x 10-37 
Rnd1 -4.25 -4.39 1.62 x 10-53 1.26 x 10-57 
Cdkn1a -3.88 -4.07 2.24 x 10-25 5.67 x 10-28 
4930438A08Rik -3.55 -4.06 1.67 x 10-21 2.28 x 10-28 
Errfi1 -3.78 -4.06 6.89 x 10-67 2.33 x 10-77 
Crem -3.81 -4.05 3.22 x 10-75 4.98 x 10-85 
Tgif1 -3.64 -4.04 1.49 x 10-64 6.66 x 10-79 
Ccno -3.49 -3.99 1.78 x 10-28 4.41 x 10-36 
Dusp8 -4.15 -3.91 4.60 x 10-32 2.68 x 10-29 
Nr4a1 -3.54 -3.75 6.86 x 10-27 2.68 x 10-30 
Cx3cl1  -3.80 -3.73 1.66 x 10-24 1.14 x 10-23 
Pmaip1 -3.72 -3.68 1.40 x 10-74 3.79 x 10-72 
Clec2d 2.45 2.69 7.41 x 10-23 1.13 x 10-26 
RP24-417N13.5 1.69 2.19 1.18 x 10-05 1.01 x 10-08 
2010008C14Rik 1.85 2.06 2.90 x 10-08 7.07 x 10-10 
Ifit1 2.13 2.06 6.53 x 10-17 8.50 x 10-16 
Gm12250 1.68 1.92 1.90 x 10-12 2.22 x 10-16 
Lpar5 1.63 1.90 1.19 x 10-08 1.03 x 10-11 
Al467606 1.52 1.84 1.65 x 10-25 2.40 x 10-37 
Ifit1bl1 1.64 1.66 2.61 x 10-10 1.40 x 10-10 
Gm37766 1.81 1.63 4.39 x 10-05 2.69 x 10-04 
*Gene expression comparisons are shown as an up/downregulation in the draining 
lymph node compared to the gingivae in either sham-infection vs. sham-infection or 
P. gingivalis-infection v. P. gingivalis infection. 
Abbreviations: dLN, draining (cervical) lymph nodes 
 
Gene set enrichment analysis was conducted to determine whether defined sets of 
genes (i.e. genes that are together involved in a pathway) were significantly 
different in CD4+ T cells from gingivae or dLNs. The computational gene set 
enrichment analysis highlighted pathways that were differentially regulated, and 
those with a false discovery rate (FDR) < 1 were defined as being statistically 
significant. Twenty-two pathways were down-regulated in CD4+ T cells from the 
dLN compared to gingivae from sham-infected mice. The five pathways with the 
lowest FDR were cytokine-cytokine receptor interaction, osteoclast differentiation, 
MAPK signaling, TNF signaling and apoptosis pathways. As aforementioned the 
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gingiva is within close location of bone, therefore it is not unexpected that 
osteoclast differentiation pathways were upregulated in CD4+ T cells of gingival 
tissue. Of the pathways upregulated in CD4+ T cells from dLN compared to gingivae 
from sham-infected mice, three were statistically significant. The pathways 
included ribosome, oxidative phosphorylation and proteasome pathways. Comparing 
CD4+ T cell pathways from gingivae and dLN of P. gingivalis-infected mice, 16 
pathways were downregulated in the dLN. The five pathways with the lowest FDR 
were the same as those from sham-infected mice. Of the pathways upregulated in 
CD4+ T cells from dLNs of P. gingivalis-infected mice compared to that of sham-
infected mice, only two pathways were statistically significant; ribosome and 
oxidative phosphorylation pathways. Therefore, the changes in pathway gene 
expression in gingivae and dLN occur irrespective of P. gingivalis infection. 
 
To verify the RNA-sequencing results by qRT-PCR, another two PD models were set 
up as previously described, with the exception that five mice per group were used. 
Each of the infected mice displayed serum anti-P. gingivalis IgG but once more did 
not exhibit alveolar bone loss (data not shown) at 28 days post infection. Curiously, 
the only RNA-sequencing-flagged gene of known function that was upregulated by 
CD4+ T cells in P. gingivalis infection in the gingivae was Btg3. This begged the 
question of whether B cells were sorted along with CD4+ T cells. CD4+ T cells were 
sorted based on positive selection for expression of CD45 and CD4. However, studies 
have shown that Epstein-Barr virus-immortilised B cells (Hoennscheidt et al., 2009) 
and Hodgkin’s lymphoma B cells (Tzankov et al., 2005), can too express CD4. To 
address whether B cells contaminated the sorted CD4+ T cell population, an extra 
antibody was added to the sorting antibody panel to identify B cells – B220. In 
sham-infected mice, CD4+ B cells (CD45+ CD4+ B220+) were sorted from both 
gingivae and dLN at a ratio of approximately 1 B cell:1000 CD4+ T cells (CD45+ CD4+ 
B220-). In P. gingivalis-infection, the ratio was a little tighter, with on average 1 B 
cell:588 CD4+ T cells (table 5.7). In both groups the number of interfering B cells 
was small and therefore unlikely to contribute to the RNA-sequencing results. To 
confirm this, RNA from sorted CD4+ T cells and CD4+ B cells was extracted, reverse-
transcribed to cDNA and 18S expression was analysed by qRT-PCR. Expression of 18S 
could be found in CD4+ T cells but not of the CD4+ B cells from any of the samples 
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(data not shown). It can be concluded that CD4+ B cells are very unlikely to have 
contributed to the results of the RNA-sequencing experiment. 
 
 
Table 5.7. Interference of B220+ cells in the CD4+ cell gate. 	
Sample 
No. of sorted 
CD4+ B220- 
T cells 
No. of sorted 
CD4+ B220+ 
cells 
Ratio CD4+ 
B220- T 
cells:CD4+ 
B220+ cells 
Expression 
of target 
genes by 
CD4+ B220+ 
cells? 
Sham 
gingivae 9931 10 993:1 No 
P. gingivalis 
gingivae 10144 15 676:1 No 
Sham 
dLN 100244 106 946:1 No 
P. gingivalis 
dLN 100229 200 500:1 No 
 
 
To determine whether the differential gene expression of CD4+ T cells in P. 
gingivalis-infection - identified by RNA-sequencing – was reproducible, qRT-PCR was 
conducted. Of the 4 genes with significantly different expression in CD4+ T cells 
from gingivae or dLNs from P. gingivalis-infected mice, only the primers for Btg3 
were readily available and optimized in the available time. As the changes in 
expression of Prdm2, Bc147527 and Tcf20 were of borderline significance, their 
expression was also evaluated by qRT-PCR. The qRT-PCR suggested that increased 
expression of Btg3 was observed in CD4+ T cells from only gingivae of infected mice 
(mean relative expression 6 x 10-5 +/- 4 x 10-6 sham vs mean relative expression 1 x 
10-4 +/- 1 x 10-5 P. gingivalis, P < 0.05) (figure 5.10). However, using 18S primers 
that are known to amplify both cDNA and gDNA, contamination was detected in 
these samples. The Btg3 primers also amplify both cDNA and gDNA therefore 
changes in expression of Btg3 could not be definitely defined.  
 
Expression of Prdm2 could not be detected in CD4+ T cells from sham gingivae but 
could be detected in infected gingival CD4 T cells. The expression of Bc147527 was 
not detected in CD4+ T cells from gingivae of either control or infected animals. 
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CD4+ T cells from the gingivae of infected mice appeared to express Tcf20 more 
than cells of control mice. However, expression of this gene was only detected in 
sham-infected gingivae from one experiment so the data were not significantly 
different. The findings of qRT-PCR do not entirely reflect the pattern of expression 
determined by RNA-sequencing. However, the expression of Btg3, Prdm2, Bc147527 
and Tcf20 by CD4+ T cells of dLNs was not found to be different in either infection 
state – both by RNA-sequencing and qRT-PCR.  
 
	
 
Figure 5.10. Verification of up- and down-regulation of genes in the gingivae 
from P. gingivalis-infected mice by quantitative real-time PCR. 
Mice were orally infected with P. gingivalis or were sham-infected with carrier 
vehicle, CMC, only. At 28 days post infection, cells were isolated from gingivae and 
draining lymph nodes and CD4+ T cells were sorted. RNA was extracted and reverse 
transcribed to cDNA to determine expression of (A) Btg3, (B) Prdm2, (C) Bc147527 
and (D) Tcf20 relative to 18S by quantitative PCR. Not determined (N.D.) represents 
no expression of the appropriate gene. Data are shown as mean + SEM, combined 
from 2 independent experiments, n = 5/group from which cells were pooled. 
Statistical analysis was conducted on log transformed data (raw data shown on 
graph). Statistical significance was determined by unpaired T tests, as indicated on 
the graphs (*P < 0.05).  
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5.3 Discussion 
 
The data presented in chapter 4 demonstrated that subtle changes in T cell 
phenotype occurred in response to oral P. gingivalis infection at 28 days post 
infection. These studies were based on analysis of a small selection of cell surface 
markers and cell products that were thought to contribute to PD. Therefore, 
alterations in T cell phenotype may not have been completely exposed. RNA-
sequencing was therefore employed as a platform to fully explore the phenotype 
and function of CD4+ T cells at the transcriptome level, in a non-biased manner. 
However, commensurate with the data in chapter 4, very few differences in gene 
expression were found between sham and P. gingivalis infection in CD4+ T cells. 
 
For these studies, RNA-sequencing was selected over microarray technology as the 
former permits identification of novel transcripts, gene fusions and insertions and 
deletions, as opposed to the requirement of transcript-specific probes. The Next-
seq platform was used to conduct RNA-sequencing as it is highly accurate and data 
can be generated in 48 hours. As the amount of RNA in gingival samples was 
limiting, perhaps a better sequencing platform would be Helicos due to simple 
sample preparation. A true and direct reflection of gene expression is likely 
achieved using the Helicos system, as reverse transcription, PCR amplification and 
cDNA are not required. Whilst Helicos may be advantageous for low RNA 
concentrations, a major limitation with this platform is the high rate of error (~5%), 
predominantly insertions and deletions, making matching of sequencing reads to a 
reference genome difficult. Illumina (NextSeq, HiSeq and MiSeq) and SOLiD 
sequencing platforms, however, have low error rates (<1%) (Chu and Corey, 2012). 
SOLiD sequencing takes 6-7 days to generate high quality data, of which there is 
less output than illumina platforms. Of the illumina platforms, HiSeq generates 
higher quality data than that generated by MiSeq or NextSeq but has longer 
turnaround times (11-14 days) (Gupta and Gupta, 2014). Furthermore, large-scale 
projects are better suited to NextSeq or HiSeq, and despite long turnaround times, 
HiSeq is more cost efficient (Glenn, 2011). The Hi-Seq platform may have provided 
better quality data, and may have highlighted other differences in CD4+ T gene 
expression in PD, however, the faster turnaround time, accurate data generation 
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and cost efficiency of the NextSeq platform was advantageous for the study 
described in this chapter.  
 
Of the total transcriptome analyzed by RNA-sequencing, only three genes were 
significantly differentially expressed by CD4+ T cells in gingivae from P. gingivalis-
infected mice. These genes did not encode proteins that were analysed in chapter 
4, confirming that the bias-driven manner in which previous experiments were 
executed may mask the PD phenotype of CD4+ T cells. The number of genes up or 
down-regulated upon P. gingivalis infection was surprisingly low, considering that 
an initial human PD RNA-sequencing study of gingival tissue determined that 453 
genes were differentially expressed in disease (Davanian et al., 2012). However, it 
is important to note that the complete cell composition of gingival tissue was 
analyzed in the human study, rather than a single cell population. Nonetheless, of 
the known genes found to be significantly (Btg3) or close to being significantly 
(Prdm2, Hmgb1-ps1, Bc147527, Tcf20) differentially expressed in murine gingivae 
by CD4+ T cells, none were differentially expressed in human PD RNA-sequencing 
studies (Davanian et al., 2012, Lundmark et al., 2015, Kim et al., 2016). This does 
not completely refute our findings, as the difference in gene expression of other 
cell types in health versus disease may have been greater, therefore the difference 
in Btg3 expression may have been evident but not significant. Furthermore, 
Davanian et al. claimed that the gene expression patterns of PD gingival tissue were 
distinct from those of healthy gingival tissue, yet the healthy and diseased gingival 
sites of three of their ten participants clustered together. This was potentially 
explained by underlying subclinical disease, but like our study it also highlights that 
a PD phenotype may be difficult to define. Similarly, distinct gene expression 
profiles could not be assigned to chronic and aggressive PD (Papapanou et al., 
2004). The gene expression findings in numerous PD studies starkly contrast 
identification of specific gene expression patterns in other diseases; for example, a 
gene expression signature can distinguish between metastatic and localized breast 
cancer. This has been of huge beneficiary as it enables patient survival predictions 
and patient-tailored treatment (van 't Veer et al., 2002).  
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Moreover, numerous studies investigated the transcriptome present in PD, both by 
RNA-sequencing and microarrays; however, no similar expression pattern was found 
in any of these studies. Particularly, differential gene expression by the same 
research group but in separate studies described 453 PD-associated genes (Davanian 
et al., 2012) and 1268 PD-associated genes (Lundmark et al., 2015), respectively. 
Whilst the latter study employed substantially more patients, the gene with the 
greatest differential expression – Muc4 – wasn’t included in the 50 most 
differentially expressed genes in their earlier study. The only upregulated gene 
found to be in both data sets (as presented in the paper) was MMP7. Furthermore, 
others  found 12,744 probe sets to be expressed differently in PD by human genome 
array, yet Muc4 did not reach the 50 most up-regulated genes (Demmer et al., 
2008). Additionally, four genes with greatest difference in expression in PD were 
shared between Lundmark’s and Kim’s RNA-sequencing studies, once again 
highlighting very little overlap (Lundmark et al., 2015, Kim et al., 2016). Therefore, 
a defined transcriptome of PD has not been described. Perhaps discrimination of 
ethnicity, sex, age and environment would allow identification of a PD 
transcriptome for groups of similar patients. Likewise, IL-1 (Papapanou et al., 2001, 
Archana et al., 2012) and Fcγ (Wolf et al., 2006) polymorphisms can indicate the 
severity of PD in only some ethnic or racial populations. What has been defined by 
transcriptome analysis however, is that there is an upregulation of inflammatory 
mediators and cytokines in PD. Gene expression of such markers were not found to 
be differentially expressed in our murine RNA-sequencing data from CD4+ T cells, 
implying that inflammation at the local site of infection is not mediated by T cells – 
at least in the mouse model.  
 
Th subsets can be delineated by RNA-sequencing. Although not significant, the 
transcriptome identified in this chapter revealed that IFN-γ was upregulated by 
CD4+ T cells in disease – as was found by flow cytometry. However, RNA-sequencing 
in humans found no correlation between IFN-γ and PD, rather Th17 cytokine genes 
were upregulated significantly (Kim et al., 2016). There was no difference in Tfh 
cell genes in CD4+ T cells from dLNs of P. gingivalis infected mice. RNA-sequencing 
was conducted at 28 days post infection, whilst flow cytometry of Tfh cells was 
conducted at 14 days post infection, highlighting that an extensive time course of 
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gene expression studies would be required to identify the kinetics of the T cell 
response.  
 
There have been no other RNA-sequencing studies conducted in mouse cervical LNs 
in experimental PD, therefore no comparison can be made between dLN data from 
this RNA-seq experiment and others. The only gene found to be significantly 
differentially expressed by CD4+ T cells from the dLNs in P. gingivalis-infection was 
Gm5451. As this is a predicted mouse gene, there have been no studies 
investigating its role in any disease. To explore it’s function, and the function of 
predicted genes found to be differentially expressed by gingival CD4+ T cells, the 
genes could be silenced. RNA interference (RNAi) can silence genes by inhibiting 
transcription or most commonly by acting post-transcriptionally by sequence-
specific RNA degradation. For research purposes, long double-stranded (ds) RNAs 
can be delivered to a cell. The dsRNA is then cleaved by dicer, resulting in small 
interfering RNAs (siRNAs) that bind to target mRNA. The mRNA that is bound by 
siRNA is cleaved and cleaved mRNAs are degraded, therefore preventing protein 
synthesis (Agrawal et al., 2003). 
 
The use of qRT-PCR to determine the expression of Btg3, Prdm2, Bc147527 and 
Tcf20 by CD4+ T cells isolated from the gingivae of sham and P. gingivalis-infected 
mice only partially supported the RNA-sequencing data. With regard to the latter 
three genes, expression was not detected in at least one replicate gingival CD4+ T 
cell sample replicate. Therefore, repitition of the experiment with increased cell 
numbers – hence increased mice per group – would enable extraction of greater 
quantities of RNA and likely better quality of cDNA that would provide a true 
representation of expression. Whilst the expression of Btg3 did mimic that found by 
RNA-sequencing, the primers were known to amplify both cDNA and gDNA. The 
presence of gDNA was highlighted by the no reverse transcriptase control and 
prevented conclusive verification of increased Btg3 expression by CD4+ T cells from 
infected animals. New primers for Btg3 could be designed to span an exon-exon 
junction, preventing gDNA contamination. Furthermore, even with the 
identification and confirmation of statistically significant gene expression, 
functional significance is not necessarily reflected. Owing to translational 
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regulation not all mRNA will be translated to protein. MicroRNAs are non-coding 
RNAs that post-transcriptionally regulate gene expression and prevent protein 
synthesis upon base-pairing to 3’ untranslated regions of mRNA (Fabian et al., 
2010). Translation of mRNA to protein in samples could be confirmed by flow 
cytometry and IHC. 
 
Whilst the data from the RNA-seq experiment described in this chapter did not 
highlight a particularly exciting role for CD4+ T cells in experimental PD, it did 
provide an oral mucosal CD4+ T cell transciptome signature. There are a plethora of 
studies describing the immune cell basis of the gut mucosa, hence the gut mucosa is 
better understood than the oral mucosa (Wu et al., 2014). Therefore, the 
transcriptome profile of CD4+ T cells will help to build a basic understanding of oral 
mucosa’s immune system, an understanding that at present remains somewhat 
elusive (Cutler and Jotwani, 2006). This study has described for the first time the 
direct comparsion of CD4+ T cells from gingivae and dLNs at the level of 
transcription. This is important as the immune response is highly 
compartmentalised based on anatomical locations (Horav 2014, Crabbe et al., 
1965). It may be possible to identify publically available T cell transcriptomes from 
other mucosal barrier sites and mine these data to investgiate the differences 
between T cell in the oral mucosal compared with other sites.  
 
In conclusion, very few genes were identified as being differentially expressed by 
CD4+ T cells of gingvae or dLN in experimental PD. Unlike human RNA-sequencing 
studies of whole tissue that idenfited numerous inflammatory pathway-associated 
genes to be increased in gingival biopsies, no inflammatory genes were increased or 
decreased in the mouse model of PD, which highlighted that CD4+ T cells may not 
play a predominant role in this disease. However, the RNA-sequencing data 
demonstrated that the gene expression profile of gingival CD4+ T cells differs from 
that of cervical CD4+ T cells.  
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Key findings from this chapter: 
• Btg3, Gm20634 and Gm20633 expression was increased by CD4+ T cells from 
gingivae of P. gingivalis-infected mice. 
• Gm5451 expression was decreased by CD4+ T cells from dLNs of P. gingivalis-
infected mice. 
• CD4+ T cells did not play a key role in the orchestration of inflammation in 
experimental PD at 28 days post infection. 
• CD4+ T cells from gingivae upregulated cytokine-cytokine receptor 
interaction, osteoclast differentiation, MAPK signaling, TNF signaling and 
apoptosis pathways compared to CD4+ T cells from dLN. 
•  CD4+ T cells from dLN upregulated ribosome and oxidative phosphorylation 
pathways compared to CD4+ T cells from gingivae.  
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6 Tracking the antigen specific T cell response in PD 
 
6.1 Introduction 
 
Thus far, the phenotype of T cells in oral mucosal tissues, in the presence and 
absence of P. gingivalis infection, has been described. What is lacking, however, is 
the nature and function of T cells specific for P. gingivalis antigens. It is likely that 
the P. gingivalis-specific cells orchestrate inflammation within the oral cavity in at 
least the early stages of P. gingivalis infection.    
 
T cells specific for a particular antigen lack antigen-specific identifying markers and 
are present in low frequencies, making the study of specific T cell responses 
challenging. T cells specific for the relevant antigen can be investigated in vivo by 
adoptive transfer of antigen specific cells. T cells can be specific for epitopes on 
the antigen of interest, or heterologous antigens that are not typically expressed by 
the pathogen of interest. This system increases the number of antigen-specific T 
cells within the circulation of a recipient mouse (Jenkins et al., 2001). Initial 
studies exploiting this immunological tool determined the host-pathogen interaction 
in Salmonella typhimurium (S. typhimurium) infection. OVA-specific DO11.10 CD4+ 
T cells were assessed upon subcutaneous infection with S. typhimurium that was 
genetically manipulated to express heterologous OVA – thereby the antigen-specific 
T cell response. Antigen-specific CD4+ T cells were found to proliferate and 
increase IFN-γ secretion, validating the adoptive transfer model (Chen and Jenkins, 
1999). 
 
This technique is not exclusive to Salmonella species. OVA-expressing E. coli have 
been developed to aid in the study of antigen-specific CD4+ T cells in the induction 
of colitis in vivo (Yoshida et al., 2001, Feng et al., 2010) and to determine whether 
the presentation of gram-negative and gram-positive antigens differentially 
influence immunogenicity in vitro (Martner et al., 2013). Furthermore, E. coli 
expressing listeriolysin O and OVA have been shown to promote the presentation of 
a specific OVA epitope in MHC-I that enables OVA-specific CD8+ T cells to lyse OVA-
expressing melanoma cell-lines both in vitro and in vivo, through genetic 
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modifications of bacteria and tumour cell lines and the use of OVA specific T cells 
(Radford et al., 2002).  
 
Whilst OVA expressing bacteria are useful approaches to the study of specific 
immune responses, a major caveat is that the antigen is not naturally expressed. 
Therefore, such studies may not accurately represent T cell responses to bacterial 
antigen. To determine the immune response to natural antigens expressed by 
Salmonella, a system to adoptively transfer TCR transgenic CD4+ T cells specific for 
Salmonella flagellin was established. TCR transgenic mice with specificity to 
flagellin peptide (427-441)-I-Ab were generated by amplification of rearranged 
specific receptor sequences and insertion into TCR vectors. The vectors were then 
injected into fertilized eggs (McSorley et al., 2002). This novel technique mimicked 
the findings of oral infection with OVA-expressing Salmonella in which specific T 
cell activation occurred in Peyer’s patches. However, it also provided evidence that 
antigen processing and presentation can be conducted in 3 hours in response to 
natural Salmonella antigen.  
 
To evaluate the specific immune response generated in P. gingivalis infection, one 
study identified thiol peroxidase as a P. gingivalis antigen that potentially 
exacerbated PD. Identification of the antigen was through repeated co-culture of 
CD4+ T cells isolated from spleens of mice infected with P. gingivalis, to initially 
generate P. gingivalis-specific CD4+ T cells. APCs pulsed with transformed E. coli 
expressing P. gingivalis DNA libraries were then cultured with P. gingivalis-specific 
CD4+ T cells to identify antigens that stimulated proliferation. However, the 
specific CD4+ T cells were not exploited to assess the in vitro or in vivo responses 
to P. gingivalis. Rather, following oral infection with P. gingivalis, the Th immune 
response generated specifically to thiol peroxidase was determined by IgG2a and 
IgG1 antibodies in serum. Whilst the greater abundance of IgG2a specific for thiol 
peroxidase implied a Th1 response, the phenotype of specific cells was not 
investigated (Gonçalves et al., 2006).  
 
Furthermore, human P. gingivalis specific-CD4+ T cells were generated by a similar 
manner to that described above for murine cells, whereby P. gingivalis-pulsed DCs 
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were co-cultured repeatedly with CD4+ T cells obtained from peripheral blood. The 
supernatants from specific CD4+ T cell and P. gingivalis-pulsed DC co-cultures were 
found to contain elevated levels of IFN-γ compared to specific CD4+ T cells co-
cultured with unpulsed DCs. The phenotype of P. gingivalis-specific CD4+ T cells 
was not explored (Aroonrerk et al., 2003).  
 
Although CD4+ T cells specific to natural P. gingivalis antigens are likely to better 
address the immune response in infection, a limitation is that generation of specific 
cells requires repeated stimulation of T cells with P. gingivalis-pulsed APCS. 
Repeated stimulation has been found to cause inefficient effector CD4+ T cell 
expansion, impaired cytokine production and altered migration (Jelley-Gibbs et al., 
2005) and could therefore interfere with the natural functioning of the T cell. To 
date, the genetic manipulation of P. gingivalis to express a heterologous antigen as 
a means to assess T cell specificity has not been described in the literature. 
 
Due to the lack of studies tracking P. gingivalis-specific T responses in the context 
of PD, P. gingivalis W83 was genetically manipulated to express OVA peptide to 
gauge an idea of the specific bacterial antigen response using OVA-specific T cells.  
 
The aims of this chapter were: 
• To investigate whether OVA-expressing P. gingivalis could stimulate an 
immune response in vitro. 
• To investigate whether OVA-expressing P. gingivalis could stimulate an 
immune response in vivo. 
• Pending the outcome of the above, to investigate the antigen specific T cell 
response in a murine model of PD.  
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6.2 Results 
 
Bacteria can be genetically manipulated to enable tracking within in vitro or in vivo 
model systems. A technique previously described to track the induction and 
maintenance of specific T cell responses to bacteria uses the expression of OVA 
peptide by bacteria. OVA-specific T cells from an OTII or DO11.10 mouse can be 
adoptively transferred to a recipient mouse of non-transgenic background to allow 
tracking of the immune response to OVA-expressing bacteria. P. gingivalis W83 was 
modified to express OVA by Jan Potempa and integration of the OVA expressing 
construct confirmed by PCR. This strain – known as RgpbOVA-A – was modified to 
introduce OVA peptide (323-339) into arginine-specific gingipain B (RgpB). The 
insertion of OVA peptide into RgpB did not interfere with its activity; therefore 
RgpbOVA-A mimicked WT P. gingivalis W83.  
 
To determine the position of OVA peptide 323-339 within RgpB, a 3D model 
structure of RgpbOVA-A was generated. The amino acid sequence of conventional 
RgpB was inserted into SWISS-MODEL ExPASy online tool to model RgpB pro- and 
mature domains (figure 6.1). The insertion site LNE/SIA was found within an 
apparently highly exposed region of the mature domain of RgpB. A model structure 
of RgpbOVA-A was next generated (figure 6.2A-B) and illustrated that OVA peptide 
forms a protruding loop at the side of the mature domain. Therefore, it doesn’t 
appear likely that APCs would have difficulty accessing OVA peptide within the 
gingipain. Furthermore, APCs readily present OVA peptide 323-339 despite this 
peptide being found in the middle of OVA protein and having no amino acids 
extending out-with the structure of OVA (figure 6.2C). 
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Figure 6.1. Model structure of RgpB pro- and mature domains. 
The representative structure of P. gingivalis W83 RgpB pro- and mature domains 
was generated by inserting the amino acid sequence into SWISS-MODEL, ExPASy 
online tool. (A) Structure of pro- and mature domains of the gingipain RgpB. The 
blue structures represent the gingipain R2 mature domain and purple structures 
represent the gingipain R2 pro-domain. (B) Enlarged image of boxed area in (A). 
The red arrow indicates the region where the OVA peptide sequence has been 
inserted, between LNE and SIA sequence sites. 
 
 
 
 
 
 
 
A B 
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Figure 6.2. Model structure of RgpB pro- and mature domains with ovalbumin 
peptide insertion and ovalbumin peptide within ovalbumin protein. 
Representative structures of P. gingivalis W83 RgpB pro- and mature domains with 
insertion of OVA peptide and OVA protein were generated by inserting the amino 
acid sequences into SWISS-MODEL, ExPASy online tool. (A) Structure of pro- and 
mature domains of RgpBOVA. The blue structures represent the gingipain R2 mature 
domain and yellow structures represent the gingipain R2 pro-domain. (B) Enlarged 
image of boxed area in (A). The red arrow indicates the start of the OVA peptide 
sequence at LNE sequence site and the yellow arrow indicates the end of the OVA 
peptide sequence at SIA sequence site. (C) Structure of OVA protein. Rainbow 
colour scheme has been used for clearer identification of OVA peptide. The red 
arrow indicates the start of OVA peptide sequence and the yellow arrow indicates 
the end of the OVA peptide sequence. 
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As the OVA peptide was inserted into the middle of RgpB, studies by Jan Potempa’s 
group confirmed expression of RgpB by western blot and it was therefore plausible 
that OVA peptide was co-expressed (data not shown). Further western blots were 
conducted to determine whether the OVA peptide was expressed, using anti-OVA 
peptide 323-339 antibody. Figure 6.3A suggests that OVA peptide was expressed by 
RgpbOVA-A but not by WT P. gingivalis. The mass of OVA peptide is approximately 
1.77 kDa therefore only the 2kDa protein standard was marked on the blot as a 
reference for the expected distance migrated by OVA peptide from RgpbOVA-A. The 
peptide did not migrate as far down the gel as expected, perhaps due to its position 
within RgpB that may have prevented complete isolation of OVA peptide. OVA 
peptide alone, at concentrations of 0.5 µg and 0.1 µg could not be visualized. 
Ponceau S staining of the blot demonstrated protein bands in all of the lanes except 
those containing OVA peptide, which suggests that the peptide may have run off the 
gel during electrophoresis (ponceau S data not shown). OVA protein was used as a 
positive control for the next blot. OVA protein could clearly be identified at 10 µg, 
5 µg and 1 µg, whilst faint bands of OVA peptide could be visualized from lanes 
containing RgpbOVA-A, by the anti-OVA peptide antibody. There was no staining of 
the WT P. gingivalis using this antibody. The actual size of whole OVA protein is 45 
kDa, suggesting that the blot was successful (figure 6.3B). Finally, to determine 
that WT P. gingivalis was loaded correctly into the well of the gel, the expression 
of GroEL by both strains of P. gingivalis was evaluated. GroEL is a chaperonin found 
in many bacteria and aids in the folding of proteins (Frieden and Clark, 1997) and 
was expressed by both WT and transgenic P. gingivalis (figure 6.3C). Although each 
of the OVA peptide western blots had caveats, taken together with the PCR data, it 
appeared likely that RgpbOVA-A expressed OVA.  
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Figure 6.3. Western blot analysis of expression of ovalbumin peptide by P. 
gingivalis and RgpbOVA-A. 
Expression of ovalbumin (OVA) peptide by RgpbOVA-A was determined by western 
blot using an OVA peptide-specific antibody. (A) OVA peptide expression. Lane 1, 2 
and 3 – ladder; lane 4 – OVA peptide, 0.5 µg; lane 5 - OVA peptide 0.1 µg; lanes 6 
and 7 – WT P. gingivalis; lanes 8 and 9 RgpbOVA-A (B) OVA peptide expression. Lane 
1 – ladder; lane 2 – OVA protein 10 µg; lane 3 – OVA protein 5 µg; in lane 4 – OVA 
protein 1 µ; lanes 5 and 7 -  WT P. gingivalis; lanes 6, 8 and 9 – RgpbOVA-A. (C) 
GroEL expression. Lane 1 – ladder; lane 2 – OVA peptide 0.5 µg; lane 3 – OVA 
peptide 0.1 µg; lanes 4 and 5 - WT P. gingivalis; lanes 6 and 7 – RgpbOVA-A. Various 
kDAs have been marked at the appropriate fraction of the ladders. 
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The data described above suggest that the RgpbOVA-A seemed likely to express OVA 
peptide. The capacity for RgpbOVA-A to stimulate OVA-specific T cells in vitro was 
then investigated. Splenocytes from a DO11.10 mouse were incubated with OVA 
protein, WT P. gingivalis, OVA protein + WT P. gingivalis, RgpbOVA-A, anti-CD3 or 
media only for 2 hours at 37oC. Unbound antigen and non-adherent cells were then 
washed off, leaving the adherent APCs. Lymphocytes from DO11.10 mice were then 
incubated with the APCs described above and assessed for markers of proliferation 
(Ki67) and activation (CD69) (figure 6.4). As expected, in the media control, only a 
small percentage of OVA-specific (KJ1.26) CD4+ T cells proliferated (mean 2.47 +/- 
0.06% Ki67+) or became activated (mean 11.21 +/- 1.36% CD69+). This was also true 
of cells stimulated with WT P. gingivalis (mean 1.40 +/- 0.60% Ki67+; mean 12.34 
+/- 2.28% CD69+). On the other hand, KJ1.26+ T cells stimulated with anti-CD3 
(mean 12.93 +/- 1.00% Ki67+; mean 74.67 +/- 0.88% CD69+), OVA protein (mean 
14.31 +/- 1.05% Ki67+; mean 47.73 +/- 0.45 CD69+) and OVA protein + WT P. 
gingivalis (mean 21.36 +/- 1.01% Ki67+; mean 60.02 +/- 0.42% CD69+) both 
proliferated and became activated. Interestingly, despite the expression of OVA 
peptide by RgpbOVA-A, the cells stimulated with this transgenic strain of P. 
gingivalis expressed Ki67 and CD69 at levels similar to the media control (mean 1.52 
+/- 0.94% Ki67+; mean 9.00 +/- 4.19% CD69+). To determine whether the in vitro 
culture conditions were unfavorable for presentation of OVA peptide from 
RgpbOVA-A, the ability of RgpbOVA-A to induce activation of KJ1.26+ cells in an in 
vivo mouse model was next assessed.  
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Figure 6.4. Stimulation of ovalbumin-specific T cells by RgpbOVA-A, in vitro. 
Splenocytes and cervical lymph nodes were removed from a DO11.10 mouse and 
cells isolated. As a source of antigen presenting cells, 2 x 105 splenocytes were 
incubated with OVA protein (1 mg/ml); anti-CD3 (1 µg/ml); 1 x 107 WT P. gingivalis 
W83 (Pg W83); 1 x 107 WT P. gingivalis W83 along with OVA protein (1 mg/ml) (OVA 
+ PgW83); 1 x 107 RgpbOVA-A or media only for 2 hours. Unbound antigen and non-
adherent cells were washed off, leaving adherent APCs. Pulsed APCs were then 
incubated with 2 x 105 cervical LN cells for 72 hours. The OVA-specific T cells (CD4+ 
KJ1.26+) were analysed by flow cytometry for proliferation and activation. (A) 
Percentage of proliferating Ki67+ KJ1.26+ cells. (B) Percentage of activated CD69+ 
KJ1.26+. Data are mean + SEM, from 2 replicates (the cells from one mouse were 
used for all stimulations and each stimulation was conducted in duplicate). 
Statistical significance was determined by a multiple comparison one way ANOVA, 
comparing each stimulus with the media control, as indicated on the graph (***P < 
0.001 and ****P < 0.0001). 
 
 
For the in vivo test of RgpbOVA-A, CD4+ KJ1.26+ T cells were adoptively transferred 
from a DO11.10 mouse to BALB/c mice to increase the frequency of specific cells in 
the recipients. The mice were split into four groups as described in table 6.1 and 
received scruff injections of WT P. gingivalis, RgpbOVA-A, WT P. gingivalis + OVA 
protein all in combination with CFA or CFA only. Ten days later, the mice received 
footpad injections of the same antigen, without CFA. Seventy-two hours post 
injection, the cells of popliteal LNs were isolated and the proportion of OVA-
specific, KJ1.26+ T cells in the dLN analysed by flow cytometry (figure 6.5A-B). 
The rationale behind the experimental design was that antigen emulsified in CFA 
induced antigen processing and presenting to T cells. After re-exposure to antigen 
in the footpad and therefore the secondary antigen response, OVA-specific T cells 
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would further expand and the response would be amplified (Allen, 2013). The 
footpad is an ideal site for antigen re-exposure as it provides a dLN to focus on – 
popliteal LN. 
 
Table 6.1. Experimental setup for stimulating ovalbumin-specific T cells by 
RgpbOVA-A, in vivo. 	
Group 
(n=3) 
DO11.10 
transfer Scruff injection Footpad injections 
1 ✔ P. gingivalis W83 + CFA P. gingivalis W83 
2 ✔ RgpbOVA-A + CFA RgpbOVA-A 
3 ✔ P. gingivalis W83 + OVA + CFA P. gingivalis W83 + OVA 
4 ✔ CFA PBS 
Abbreviations: CFA, complete freud’s adjuvant; OVA, ovalbumin protein. 
 
The in vivo model demonstrated that compared to the PBS control group, RgpbOVA-
A footpad injection recruited a similar percentage of KJ1.26+ T cells to the dLN, as 
did footpad injections of WT P. gingivalis (mean 0.127 +/- 0.024% PBS vs. mean 
0.046 +/- 0.020% RgpbOVA-A vs. mean 0.019 +/- 0.004% WT P. gingivalis, NS). 
Although not statistically significant, WT P. gingivalis + OVA protein appeared to 
recruit more KJ1.26+ T cells (mean 0.402 +/- 0.220% WT P. gingivalis + OVA). With 
regard to proliferation, only WT P. gingivalis + OVA protein caused a significant 
increase in Ki67 expression of OVA specific T cells in the dLN (mean 3.760 +/- 
2.168% PBS vs. mean 8.167 +/- 1.878% RgpbOVA-A vs. mean 5.047 +/- 2.536%, NS; 
mean 3.760 +/- 2.168% PBS vs. mean 93.300 +/- 3.099% WT P. gingivalis, P < 
0.0001). Therefore only administration of exogenous OVA protein alongside P. 
gingivalis induced the proliferation of OVA-specific T cells in this model. As a 
further measure of the OVA specific immune response, serum antibody titres were 
determined (figure 6.5C). Once again, the only mice that mounted anti-OVA IgG 
titres were those of group 3, which received WT P. gingivalis + OVA protein (mean 
52.2 +/- 13.9 PBS vs. mean 2773.0 +/- 254.8 WT P. gingivalis + OVA, P < 0.0001). 
The other groups mirrored the anti-OVA response of PBS (mean 52.2 +/- 13.9 PBS 
vs. mean 43.3 +/- 9.4 RgpbOVA-A vs. mean 34.9 +/- 11.9 WT P. gingivalis, NS). To 
determine whether RgpbOVA-A itself induced an immune response, serum anti-P. 
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gingivalis IgG titres were measured (figure 6.5D). All groups which received P. 
gingivalis, either transgenic or WT, produced antibody titres significantly greater 
than PBS control mice (mean 13.8 +/- 8.0 EU PBS vs. mean 728.6 +/- 47.8 EU 
RgpbOVA-A vs. mean 816.0 +/- 129.8 EU WT P. gingivalis vs. 938.8 +/- 324.3 EU WT 
P. gingivalis + OVA, P < 0.05). The ELISA data highlighted that RgpbOVA-A acted 
similarly to WT P. gingivalis and was able to stimulate the immune response to 
generate antibodies specific for P. gingivalis. It can therefore be concluded that 
whilst RgpbOVA-A seems to express OVA peptide, it failed to induce an OVA-specific 
immune response in vitro or in vivo. 
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Figure 6.5. Stimulation of ovalbumin-specific T cells by RgpbOVA-A, in vivo. 
Three million CD4+ KJ1.26+ T cells, from DO11.10 mice, were transferred 
intravenously to BALB/c mice. Twenty-four hours post adoptive transfer, mice 
received scruff injections and 10 days later received footpad injections as described 
in table 6.1. Mice were culled 72 hours post footpad injection, and popliteal lymph 
nodes and serum collected. Cells from popliteal lymph nodes were analysed by flow 
cytometry and serum antibodies were analysed by ELISA. (A) Percentage of CD4+ 
KJ1.26+ cells of the total viable cell population from popliteal lymph nodes. (B) 
Percentage of proliferating Ki67+ CD4+ KJ1.26+ cells from popliteal lymph nodes. 
Data are shown as mean + SEM, from 1 experiment, n = 3 mice/group. (C) Anti-OVA 
IgG titres in serum. (D) Anti-P. gingivalis IgG titres in serum. Data are ELISA Units 
(EU) shown as individual mice (symbols) with mean +/- SEM for each group (lines), 
from 1 experiment, n = 3 mice/group. Statistical significance was determined by a 
Dunnett’s multiple comparison one way ANOVA, comparing each stimulus with the 
PBS control group, as indicated on the graph (*P < 0.05, ****P < 0.0001). 
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6.3 Discussion 
Previous chapters demonstrated very subtle changes in CD4+ T cell phenotype in 
experimental PD. However, these studies investigated the entire CD4+ population 
and the phenotype of antigen-specific T cells was not addressed. In an attempt to 
understand antigen-specific T cell responses to P. gingivalis, RgpbOVA-A was 
obtained. Despite seemingly expressing OVA peptide, RgpbOVA-A was unable to 
activate DO11.10 cells in vitro and in vivo.  
 
As a means to determine the antigen specific CD4+ and CD8+ T cell responses to E. 
coli and P. gingivalis LPS in vivo, LPS was co-injected with soluble OVA 
intraperitoneally or into the footpad of mice previously receiving OTII or OTI cells. 
Cytokine profiles of OVA-specific T cells were assessed and highlighted that LPS 
from different bacterial strains elicited unique immune responses. E.coli LPS was 
found to induce Th1 responses demonstrated by CD4+ T cell IFN-γ and CD8+ T cell 
IL-12 production. P. gingivalis LPS stimulated Th2 responses characterized by 
increased production of IL-5, IL-13 and IL-10 (Pulendran et al., 2001). In this model, 
it assumed that LPS was taken up and presented by APCs along with OVA, meaning 
that OVA-specific T cells are representative of LPS-specific T cells. However, OVA 
may drain independently of co-injected LPS. To overcome this caveat, P. gingivalis 
was genetically manipulated to express OVA peptide to identify the immune 
response mounted by OVA-specific T cells, in this chapter.  
 
Whilst RgpbOVA-A seemingly expressed OVA peptide and its location within RgpB 
seemed hypothetically optimal for identification by APCs, RgpbOVA-A lacked the 
capacity to activate OVA-specific T cells both in vitro and in vivo. As illustrated by 
the OVA protein 3D model, the position of the OVA peptide does not seem crucial 
for appropriate presentation by APCs to T cells. Therefore, the position of OVA 
peptide in RgpbOVA-A may not have been an important factor for activating APCs to 
prime T cells. To improve the efficiency of APCs to present OVA from RgpbOVA-A, 
the incubation time of the APC: RgpbOVA-A co-culture could have been increased. 
In other OVA-specific T cell in vitro investigations, APCs were pulsed with antigen 
for 18 hours (Martner et al., 2013) and were activated through administration of IL-
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2 (Gonçalves et al., 2006). As DCs are the most efficient APCs, a pure population of 
these cells could have been pulsed with P. gingivalis for in vitro cultures.  
 
For the in vivo studies, a control group receiving OVA protein emulsified in CFA in 
the scruff, followed by footpad injection of OVA protein only was missing. A 
shortage of donors for the adoptive transfer at the time of this experiment forced 
reduction in recipient numbers. It was decided that a minimum group size of three 
was preferable to a greater number of smaller groups. This control would have 
indicated the response of transgenic CD4+ T cells to their cognate antigen without 
the influence of P. gingivalis. Still, OVA-specific T cells from group 3 mice (WT P. 
gingivalis + OVA) increased proliferation and activation markers, demonstrating that 
the cells could efficiently respond to specific antigen, thereby essentially 
confirming a positive control.  
 
Both WT and transgenic P. gingivalis used for the experiments in this chapter were 
heat-killed, therefore the host immunoregulatory properties of P. gingivalis would 
have been impaired (Stathopoulou et al., 2009b). Heat-killing of P. gingivalis 
reduces gingipain activity – the site of the bacterium in which OVA peptide had 
been inserted. However, RgpB is anchored into the cell surface of P. gingivalis, and 
whilst it can also be secreted, the heat-killed bacteria would have expressed 
surface gingipains. Despite the unlikeliness of heat-killing P. gingivalis to affect the 
surface expression of modified RgpB, it would have been appropriate to determine 
the capacity of live bacteria to induce specific CD4+ T cell responses. Due to time 
restrictions this was not possible.  
 
Arginine gingipains (RgpA and RgpB) are arginine-specific cysteine proteinases that 
function to cleave arginine-Xaa peptide bonds (Guo et al., 2010). It is unlikely that 
the arginase activity of RgpB would have cleaved the arginine residue from OVA 
peptide, leaving it fragile to damage, as the pro-domains of RgpB prevent 
proteolytic activity prior to extracellular secretion (de Diego et al., 2013). To test 
this, RgpbOVA-A could be grown as it was for previous western blots. The 
supernatant containing secreted and potentially enzyme active RgpB could be 
collected and RgpbOVA-A bacteria containing membrane bound, non-active RgpB 
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could be collected separately. The bacteria could be lysed as before and then both 
bacterial lysates and gingipains could be assessed for OVA peptide expression by 
western blot. It would be assumed that OVA peptide would be expressed by 
RgpbOVA-A lysates and that secreted RgpB may have cleaved OVA peptide and 
therefore no or lower expression would be found.  
 
Gingipains are key virulence factors of P. gingivalis and have been found at high 
concentrations at severe PD sites in gingival tissue. Therefore, inserting OVA 
peptide into a gingipain seems optimal for inducing specific immune responses. Kgp 
has been found to be fundamental for bone resorption in a P. gingivalis-induced 
model of murine PD. Furthermore, a chimera therapeutic vaccine comprising the 
active site sequence and A1 adhesion domain of Kgp used in a murine model of PD 
was found to protect against alveolar bone loss (O’Brien-Simpson et al., 2016). 
Owing to the findings that Kgp has a strong influence over immunity and bone 
resorption, perhaps Kgp would be a better site to insert OVA peptide into.  
 
RgpbOVA-A is not the first genetically modified P. gingivalis strain to lack OVA-
specific T cell stimulatory capacity (unpublished observations, personal 
communication with Dr John Butcher, University of the West of Scotland), which 
perhaps explains the absence of OVA-expressing transgenic P. gingivalis studies. 
Furthermore, transgenic Leishmania mexicana modified to express Eα-GFP is also 
incapable of inducing activation of specific T cells (TEa) (unpublished observations, 
personal communication with with Dr Owain Millington, University of Strathclyde); 
thereby P. gingivalis is not the only pathogen that when genetically modified does 
not stimulate appropriate cells. 
 
This technique was unable to broaden the understanding of P. gingivalis-specific T 
cells and their role in PD. However, there are other methods with the potential to 
do so. As mentioned previously, Salmonella flagellin-specific CD4+ T cells were 
generated to address the activation and migration of Salmonella-specific T cells in 
response to oral infection (McSorley et al., 2002). A similar approach was taken 
with regard to P. gingivalis-specific CD4+ T cells; however the phenotype of specific 
T cells was not assessed (Gonçalves et al., 2006). With the development and 
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improvement of flow cytometers, the P. gingivalis-specific T cells generated by 
Gonçalves could be labeled (i.e. with CFSE) and adoptively transferred to recipient 
mice to assess the in vivo responses mounted by these cells in experimental PD. 
Cells from gingivae and dLNs could be isolated and phenotypic markers of interest 
stained for flow cytomtery. The specific CD4+ T cells would be identified by their 
pre-transfer labeling by flow cytometry and could be further analyzed. A limitation 
that can present with TCR transgenic mice is cell phenotypical abnormalities due to 
the initial non-physiologically high frequency of transgenic T cells (Marzo et al., 
2005). Furthermore, typical functions of cells can be impaired due to the repeated 
stimulations required for generation of specific T cells (Jelley-Gibbs et al., 2005). 
 
Antigen-specific T cells can also be tracked and quantified using MHC-I and MHC-II 
tetramers. Tetramers are recombinant peptide antigen-bound-to-MHC molecules 
that can interact and bind to specific T cells. The tetramers are usually biotinylated 
to enable coupling of fluorophore-labeled streptavidin, that makes identification of 
tetramer bound T cells possible by flow cytometry. This technique is thought to 
avoid the limitations regarding quantification and precision that other T cell 
tracking methodologies present (Kurtulus and Hildeman, 2013). Tetramers (I-Ab) 
displaying RgpA and/or Kgp peptides were used to investigate P. gingivalis-specific 
CD4+ T cell responses. RgpA and Kgp peptides were selected based on their ability 
to prime effector CD4+ T cells. Mice were orally infected with P. gingivalis and 
dLNs harvested at 21 days post infection. The cell suspensions from dLNs were 
pooled and 4 x 106 cells stained with PE-conjugated tetramers along with anti-B220, 
anti-CD3ε, anti-CD4, anti-CD8α and anti-CD44. Flow cytometry analysis illustrated 
that antigen experienced CD4+ T cells (CD3+ CD4+ CD44+) were found at elevated 
levels compared to CD4+ T cells from sham-infected mice, demonstrating clonal 
expansion had occurred in vivo. By contrast, there were few antigen inexperienced 
CD4+ T cells (CD3+ CD4+ CD44-) in dLNs (Bittner-Eddy et al., 2013). Still, R/Kgp 
peptide tetramers could be further exploited to determine the complete phenotype 
and function of P. gingivalis-specific T cells in experimental PD. 
 
In conclusion, whilst RgpbOVA-A expressed OVA peptide that could be identified by 
western blot, the transgenic strain was unable to activate OVA-specific T cells. 
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Future studies could investigate alternative expression systems, alternative model 
antigens and perhaps other T cell tracking systems, such as MHC tetramers, in the 
context of experimental PD.  
 
Key findings of this chapter were: 
• Western blotting illustrated that RgpbOVA-A expressed OVA. 
• RgpbOVA-A did not stimulate an OVA-specific T cell response in vitro or in 
vivo. 
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7 General Discussion 
 
The studies described in this thesis were conducted with an overall aim of better 
understanding the adaptive immune response associated with PD. T cells are 
undoubtedly evident in PD and years of scrutiny have identified varied and dynamic 
roles of T cells in both human and experimental PD. Whilst CD4+ T cells have and 
continue to be a focus of PD studies, there is ambiguity regarding their specific 
functions and whether they contribute to the protection or immunopathogenesis of 
this disease. For this reason, the predominant aim of these studies was to 
characterize the phenotype of CD4+ T cells in a murine model of PD at various early 
stages post infection. 
 
A key finding from the data presented in Chapter 4 was the suggested association 
of IFN-γ with PD. Whilst the production of this cytokine by CD4+ T cells isolated 
from dLNs was not statistically significantly increased by comparison to their sham-
infected counterparts, there was a clear trend by later stages of the PD model. 
Likewise, there was a trend in elevated IFN-γ expression by CD8+ T cells of dLNs 
and a significant increase in production by CD8+ T cells isolated from gingival 
tissues. Further suggestive of a link with IFN-γ and PD was the cytokine analysis of 
the supernatants from P. gingivalis re-stimulated splenocytes. Cells from P. 
gingivalis-infected mice were found to increase production of IFN-γ, at 
concentrations greater than that produced by splenocytes from sham-infected 
mice.  IFN-γ is a cytokine characteristic of a Th1 immune response, and therefore 
the systemic production of the cytokine was hinted at through a predominance of P. 
gingivalis-specific IgG2a antibodies in serum of infected mice. Altogether, it could 
be speculated that IFN-γ is involved in early orchestration of the immune response 
upon microbial dysbiosis. 
 
As aforementioned, previous studies have regarded IFN-γ as a PD-associated 
cytokine (Seymour et al., 1993, Gamonal et al., 2001, Taubman and Kawai, 2001, 
Baker et al., 1999a). Longitudinal studies found that IFN-γ concentrations and T-bet 
(Th1 transcription factor) were upregulated in GCF of active lesions from chronic PD 
patients and therefore the presence of this cytokine in GCF was deemed a risk 
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factor for PD progression (Dutzan et al., 2008, Alpagot et al., 2003). It has also 
been postulated that a decrease in levels of IFN-γ in GCF from PD patients can 
verify improvement of disease following treatment (Tsai et al., 2007). Therefore, 
IFN-γ in GCF is a significant risk for progression of established PD. However, to 
date, there are no longitudinal studies evaluating GCF cytokine composition in 
gingivitis patients that would inform whether cytokine expression in gingivitis is 
predictive of progression to periodontitis.  Perhaps GCF IFN-γ in gingivitis could be 
a risk biomarker for the development of PD. It would be advantageous to identify a 
gingivitis patient at risk of developing PD, as gingivitis is reversible through 
implementation of sufficient cleaning of teeth and is more easily treatable than 
chronic PD. The ‘at risk’ patient may be more motivated to comply with OHI and 
the dentist could employ extra prevention plans. Therefore, a longitudinal study 
evaluating GCF cytokines in patients with gingivitis at regular intervals could 
potentially identify risk biomarkers and through implementation of appropriate 
treatments, prevent the incidence of PD. There are ethical barriers with such a 
study – as it would essentially involve supervising a patient’s progression to 
periodontitis. Moreover, sampling of GCF can prove quite difficult. The washing 
method is useful for identification of cytokines, microbes and also gingipains, the 
latter of which is not possible by other methods (Guentsch et al., 2011). The 
technique is difficult to perform and can often result in blood contamination due to 
gingival irritation; therefore it is not typically used. Microcapillary pipetting is also 
used to sample GCF but again requires greater technical skills (Alpagot et al., 
2003). The absorption method, and in particular paper strips, are most commonly 
employed for sampling GCF for cytokines (Alpagot et al., 2003) and would be 
sufficient for the purposes of a longitudinal gingivitis study. 
 
For patients displaying established and progressing PD, perhaps local, topical anti-
IFN-γ therapies could be employed as adjuncts to mechanical debridement of 
dental plaque. Anti-cytokine therapy is used to restore the balance between pro- 
and anti-inflammatory mediators and is currently used to treat numerous chronic 
inflammatory diseases including RA, ulcerative colitis, Crohn’s disease, ankylosing 
spondyloarthritis, juvenile idiopathic arthritis, psoriatic arthritis and psoriasis 
(Astrakhantseva et al., 2014). Anti-cytokine therapy is currently used as an adjunct 
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to disease-modifying anti-rheumatic drugs (DMARDs) in treatment of RA patients 
whom fail to respond to conventional DMARDs. The anti-cytokine therapies offered 
by NHS target TNF-α and IL-6 and are described in table 7.1. In clinical trials, anti-
IFN-γ therapy has proven to be well tolerated and reduce disease activity in severe 
RA patients whom fail to respond to conventional DMARD treatment (Sigidin et al., 
2001). In a more recent clinical study, anti-IFN-γ was found to mimic the results 
achieved by existing anti-TNF-α therapy, and in some patients the outcome of 
therapy was actually superior (Skurkovich et al., 2015). Furthermore, patients with 
pediatric primary Hemophagocytic Lymphohistiocytosis refractory to conventional 
therapies were treated with anti-IFN-γ, which resulted in promising outcomes in a 
clinical trial (Prof et al., 2015).  
 
Table 7.1. Anti-cytokine drugs currently used to treat rheumatoid arthritis - 
available on NHS. 	
Drug Drug type Target 
Etanercept Soluble TNFR2 TNF-α 
Infliximab Chimeric monoclonal antibody TNF-α 
Adalimumab Fully humanized monoclonal antibody TNF-α 
Certolizumab PEGylated Fab fragment TNF-α 
Golimumab Fully humanized monoclonal antibody TNF-α 
Tocilizumab Humanized anti-IL-6R monoclonal antibody IL-6 
Abbreviations: Fab, antibody binding fragment; IL, interleukin; IL-6Rα, interleukin-6 
receptor alpha; PEG, polyethylene glycol;TNF-α, tumour necrosis factor alpha; 
TNFR, tumour necrosis factor receptor. (Culshaw et al., 2011). 
(http://www.nhs.uk/Conditions/Rheumatoid-arthritis/Pages/Treatment.aspx accessed on 
14/03/17) 
 
 
Whilst the potential use of anti-cytokine therapy for treatment of PD has been 
discussed for several years (Waykole et al., 2009), there have been no studies 
conducted to evaluate the efficacy of inhibitors of any inflammatory cytokine in the 
context of human PD. As mentioned above, IFN-γ could potentially be used as a 
biomarker of progression towards PD, yet for patients with established chronic PD; 
anti-IFN-γ could be the immune-targeted treatment that is required for 
amelioration of disease (figure 7.1). Both of these hypotheses require substantial 
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future research. A major disadvantage of cytokine therapies is the gateway for 
opportunistic infection that occurs as a result of the down-regulated immune 
response. However, screening of patients for latent disease prior to prescribing of 
the drug should limit the number of opportunistic infections (Keane et al., 2001). 
Furthermore, the nature of PD would likely require much lower doses than 
administered for systemic autoimmune disease, and therapy could be administered 
topically.  
 
	
 
Figure 7.1. Working hypothesis of the role of IFN-γ in the development and 
treatment of PD. 
Patients attending the dental clinic will present with gingivitis and whilst some will 
revert back to health, some will develop periodontitis. IFN-γ in gingival crevicular 
fluid (GCF) could indicate whether the gingivitis patient will develop periodontitis 
and other as yet undefined cytokines could indicate a gingivitis patient that will 
remain stable with gingivitis or revert back to health. Periodontitis patients could 
be treated with anti-IFN-γ therapy to ameliorate disease and revert patient back to 
health, alternatively anti-IFN-γ treatment could be used to supplement routine 
treatment for patients whose disease persists.  
G
CF Cytokine? 
G
CF Cytokine? 
G
CF IFN
-γ? 
G
CF IFN
-γ? 
G
CF IFN
-γ? 
G
CF Cytokine? 
G
CF Cytokine? 
G
CF Cytokine? 
Gingivitis 
Patient 
Healthy 
Periodontitis 
Patient 
Adjunctive  
anti-IFN
-γ  
therapy? 
Adjunctive  
anti-IFN
-γ  
therapy? 
Adjunctive  
anti-IFN
-γ  
therapy? 
 222	
The studies conducted in this thesis did not portray an incredibly exciting role for 
CD4+ T cells in PD. The RNA-sequencing data, in particular, revealed differences 
between CD4+ T cells of different tissues rather than differences between infection 
statuses, with the down-regulation of only a single gene in dLN CD4+ T cells and 
upregulation of only three genes in gingival CD4+ T cells following P. gingivalis 
infection (chapter 5). Notably, the greatest trend in IFN-γ production was observed 
in CD8+ T cells isolated from dLNs of infected mice. The only statistically significant 
T cell-attributed change to occur in gingival cells was elevated IFN-γ production by 
CD8+ T cells. Previously, activated CD8+ T cells were found in greater abundances 
in PD compared to healthy controls, both systemically and locally (Cifcibasi et al., 
2015a). To date, a comparison of the detailed phenotype of CD8+ T cells in health 
and PD remains elusive. Therefore, comprehensive characterization of CD8+ T is 
required and the data from our studies implies that future investigations may point 
to a role for CD8+ T cells in PD. The apparent lack of differences in the 
transcriptome of the T cells from infected compared with healthy mice suggests 
that either the T cell response is not in action at the time of sampling, or that the T 
cells are activated elsewhere. Investigation of peripheral blood from patients with 
PD had identified an increase in myeloid DCs (mDCs) and it was demonstrated that 
mDCs carried P. gingivalis (Miles et al., 2014). Therefore, it is possible that 
circulating T cells may alter their phenotype and function upon P. gingivalis-
infection. T cells could be investigated through blood collection and harvesting of 
spleens from mice.  
 
Throughout these studies, it has been assumed that the class switched antibody 
responses to P. gingivalis indicated a preceding CD4+ T cell response. However, B 
cells are capable of T cell-independent class switching. Numerous antigens can 
cause B cell activation independently of T cells and are described as T-independent 
type 1 (TI-1) or type 2 (TI-2) antigens. Whilst TI-2 antigens require non-specific T 
cell help, TI-1 antigens stimulate B cells in the absence of a second signal and 
require no T cell help. TI-1 antigens include LPS and several viruses. Introduction of 
TI-1 antigens into T cell deficient mice was shown to induce IgG class switching 
(Fehr et al., 1998). To investigate whether P. gingivalis can stimulate T cell-
independent IgG production, the PD model could be conducted using αβ T cell 
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deficient mice (Tcratm1Mom). To further investigate whether P. gingivalis antigens 
act as TI-1 or TI-2 antigens, CBA/Nxid mice could be employed. CBA/Nxid mice 
have a mutation in Bruton’s tyrosine kinase gene and subsequently lack the capacity 
to generate antibody responses to TI-2 antigens 
(https://www.jax.org/strain/001011 - accessed 02/04/17).  
 
By comparison to other barrier sites, including the gut and skin, little is known 
about the mechanisms that orchestrate oral mucosal T cell responses. However, it 
has very recently been demonstrated that instructions for oral effector CD4+ T cell 
differentiation are unique from that at other barrier tissues. For example, 
commensal bacteria mediate Th17 cell expansion in the gut but Th17 cells are 
found within gingival tissues of germ-free mice. Further still, within different sites 
of the oral cavity the requirements for CD4+ T cell differentiation differ (Dutzan et 
al., 2017). Th17 cells within the tongue are dependent upon the presence of 
commensal bacteria (Conti et al., 2014); therefore the oral cavity is not a single 
immune entity. The oral mucosal studies in this thesis have focused on gingival and 
palatal tissue. It would be of interest to identify markers that promote tissue 
tropism and residence within distinct mucosal compartments to understand the 
basic immunology within the oral cavity and to identify site-specific targets as novel 
therapies for oral disease. For example, lichen planus is a chronic mucocutaneous 
disorder that typically manifests in the oral cavity prior to development 
systemically. CD8+ T cells mediate this autoimmune disorder through inducing 
apoptosis of basal cells of the oral epithelium. Lichen planus does not affect a 
specific location within the oral cavity but presents anywhere; most commonly the 
lips, tongue, floor of the mouth, buccal mucosa, gingiva and palate are affected 
(Gupta and Jawanda, 2015). Therefore, topical oral cavity site-specific drugs 
directed at CD8+ T cells may be useful for treatment of different manifestations of 
lichen planus.  
 
The RNA-sequencing data highlighted an oral mucosal CD4+ T cell transcriptome 
profile. To validate these findings, the protein expression of the molecules of 
interest (figure 7.2) should be investigated – ideally by IHC to localize the CD4+ T 
cells within the mucosa, or by flow cytometry to determine whether the changes in 
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gene expression are reflected by changes in protein expression. Ideally, if protein 
expression is confirmed, then function would be investigated by inhibition of the 
protein of interest for example using blocking antibodies or using siRNA. 
Unfortunately time constraints limited these studies in the current work. Whilst the 
gene expression of CD4+ T cells from dLNs differed from that of CD4+ T cells from 
gingivae, the data does not provide an insight as to which CD4+ T cells were 
resident in the gingivae or which had migrated from other sites. To understand the 
migratory capacity of cells between dLN and oral mucosa, the Kaede mouse model 
could be employed. Kaede is a photoconvertible GFP that changes from green to 
red fluorescence upon exposure to UV light. Transgenic mice expressing Kaede can 
permit monitoring of the movement of cells in vivo from and to any site of interest. 
With regard to the migratory dLN and gingival cells in the PD model, the cells of the 
dLNs could be photoconverted to assess the types of cells that migrate to the oral 
cavity and the time after infection in which this happens. Likewise the migration of 
gingival cells to dLNs to induce an adaptive immune response after P. gingivalis-
infection could be evaluated through photoconversion of cells of the gingivae 
(Tomura et al., 2008).  
 
It was hypothesized that CD4+ T cells in the oral cavity had a unique phenotype and 
that that would alter with functional consequence in response to oral P. gingivalis-
infection and inflammation. Confirming the initial part of the hypothesis, the CD4+ 
T cells isolated from gingival tissue differentially expressed thousands of genes, and 
therefore a variety of pathways comparing to CD4+ T cells from dLNs. However, 
there was minimal change in phenotype of gingival CD4+ T cells upon P. gingivalis-
infection. 
 
In conclusion, the studies in this thesis have provided an insight into the possible 
nature of oral mucosal CD4+ T cells in gingival tissue (figure 7.2) and the PD-
associated phenotype of T cells in a murine model of PD. Subtle differences in CD4+ 
T cells occur upon P. gingivalis infection, most notably a suggested increase in IFN-
γ. This inflammatory cytokine was upregulated by P. gingivalis infected gingival and 
dLN CD8+ T cells, and splenocytes, and therefore was the result of both local and 
systemic immune responses. This advocates a possible role of CD8+ T cells in 
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experimental PD but also implicates a potential biological target for adjunctive PD 
treatment.  
 
 
	
Figure 7.2. Schematic of the speculative potential roles of CD4+ T cells in 
gingival tissue. 
CD4+ T cells within the gingiva upregulated the expression of a variety of genes by 
comparison to CD4+ T cells of the cervical (draining) lymph nodes (dLN). CD4+ T 
cells from gingival tissue upregulated osteoclast differentiation, MAPK and TNF 
signaling pathways, and showed elevated expression of CX3CL1 and CXCL10 
compared to that of dLN CD4+ T cells. Therefore, it could by hypothesized that  
CD4+ T cells of the gingiva may influence local osteoclast activity and induce 
immune cell migration including dendritic cells (DC), natural killer (NK) cells, 
monocytes and B cells.  
  
Health 
MUCOSAL BARRIER 
Fibroblast 
Mast Cell 
NK cell 
DC 
ALVEOLAR BONE 
Osteoclast 
Immune cell 
migration 
CD4+  
T cell 
Osteoclast 
differentiation 
IEL 
CX3CL1 
CXCL10 
B cell 
DC 
Monocyte 
CD4+  
T cell 
GINGIVA 
TOOTH 
 226	
List of Publications 
 
Campbell L, Millhouse E, Malcolm J, Culshaw S. 2016. T cells, teeth and tissue 
destruction - what do t cells do in periodontal disease? Molecular oral 
microbiology. 31(6):445-456. 
Malcolm J, Millington O, Millhouse E, Campbell L, Adrados Planell A, Butcher JP, 
Lawrence C, Ross K, Ramage G, McInnes IB et al. 2016. Mast cells contribute 
to porphyromonas gingivalis-induced bone loss. Journal of dental research. 
95(6):704-710. 
Malcolm J, Awang RA, Oliver-Bell J, Butcher JP, Campbell L, Adrados Planell A, 
Lappin DF, Fukada SY, Nile CJ, Liew FY et al. 2015. Il-33 exacerbates 
periodontal disease through induction of rankl. Journal of dental research. 
94(7):968-975. 
Oliver-Bell J, Butcher JP, Malcolm J, MacLeod MK, Adrados Planell A, Campbell L, 
Nibbs RJ, Garside P, McInnes IB, Culshaw S. 2015. Periodontitis in the 
absence of b cells and specific anti-bacterial antibody. Molecular oral 
microbiology. 30(2):160-169. 																			
 227	
References 
ABBEY, J. L. & O'NEILL, H. C. 2007. Expression of T-cell receptor genes during early 
T-cell development. Immunol Cell Biol, 86, 166-174. 
ABE, T. & HAJISHENGALLIS, G. 2013. Optimization of the ligature-induced 
periodontitis model in mice. Journal of immunological methods, 394, 49-54. 
ADIBRAD, M., DEYHIMI, P., GANJALIKHANI HAKEMI, M., BEHFARNIA, P., SHAHABUEI, 
M. & RAFIEE, L. 2012. Signs of the presence of Th17 cells in chronic 
periodontal disease. Journal of periodontal research, 47, 525-531. 
AGRAWAL, N., DASARADHI, P. V. N., MOHMMED, A., MALHOTRA, P., BHATNAGAR, R. 
K. & MUKHERJEE, S. K. 2003. RNA Interference: Biology, Mechanism, and 
Applications. Microbiology and Molecular Biology Reviews, 67, 657-685. 
ALBANDAR, J. M. 2014. Aggressive periodontitis: case definition and diagnostic 
criteria. Periodontology 2000, 65, 13-26. 
ALBANDAR, J. M. & KINGMAN, A. 1994. Gingival recession, gingival bleeding, and 
dental calculus in adults 30 years of age and older in the United States, 1988-
1994. Journal of Periodontology, 70, 30-43. 
ALJEHANI, Y. A. 2014. Risk Factors of Periodontal Disease: Review of the Literature. 
International Journal of Dentistry, 2014, 182513. 
ALLAM, J.-P. P., DUAN, Y., HEINEMANN, F., WINTER, J., GÖTZ, W., DESCHNER, J., 
WENGHOEFER, M., BIEBER, T., JEPSEN, S. & NOVAK, N. 2011. IL-23-producing 
CD68(+) macrophage-like cells predominate within an IL-17-polarized 
infiltrate in chronic periodontitis lesions. Journal of clinical periodontology, 
38, 879-886. 
ALLAM, J. P., STOJANOVSKI, G., FRIEDRICHS, N., PENG, W., BIEBER, T., WENZEL, J. 
& NOVAK, N. 2008. Distribution of Langerhans cells and mast cells within the 
human oral mucosa: new application sites of allergens in sublingual 
immunotherapy? Allergy, 63, 720-727. 
ALLEN, I. C. 2013. Delayed-Type Hypersensitivity Models in Mice. In: ALLEN, I. C. 
(ed.) Mouse Models of Innate Immunity: Methods and Protocols. Totowa, NJ: 
Humana Press. 
ALPAGOT, T., FONT, K. & LEE, A. 2003. Longitudinal evaluation of GCF IFN-γ levels 
and periodontal status in HIV+ patients. Journal of Clinical Periodontology, 
30, 944-948. 
 228	
AMUNULLA, A., VENKATESAN, R., RAMAKRISHNAN, H., ARUN, K. V., SUDARSHAN, S. 
& TALWAR, A. 2008. Lymphocyte subpopulation in healthy and diseased 
gingival tissue. Journal of Indian Society of Periodontology, 12, 45-50. 
ANDERSEN, M. H., SCHRAMA, D., THOR STRATEN, P. & BECKER, J. C. 2006. 
Cytotoxic T Cells. Journal of Investigative Dermatology, 126, 32-41. 
ANDRIOPOULOS, B., CORRADINI, E., XIA, Y., FAASSE, S. A., CHEN, S., GRGUREVIC, 
L., KNUTSON, M. D., PIETRANGELO, A., VUKICEVIC, S., LIN, H. Y. & BABITT, 
J. L. 2009. BMP-6 is a key endogenous regulator of hepcidin expression and 
iron metabolism. Nature genetics, 41, 482-487. 
ARCHANA, P. M., SALMAN, A. A., KUMAR, T. S. S., SARASWATHI, P. K., 
PANISHANKAR, K. H. & KUMARASAMY, P. 2012. Association between 
interleukin-1 gene polymorphism and severity of chronic periodontitis in a 
south Indian population group. Journal of Indian Society of Periodontology, 
16, 174-178. 
ARIZON, M., NUDEL, I., SEGEV, H., MIZRAJI, G., ELNEKAVE, M., FURMANOV, K., ELI-
BERCHOER, L., CLAUSEN, B. E., SHAPIRA, L., WILENSKY, A. & HOVAV, A.-H. 
2012. Langerhans cells down-regulate inflammation-driven alveolar bone 
loss. Proceedings of the National Academy of Sciences, 109, 7043-7048. 
ARMITAGE, G. C. 2004. Periodontal diagnoses and classification of periodontal 
diseases. Periodontology 2000, 34, 9-21. 
ARMITAGE, G. C. & CULLINAN, M. P. 2010. Comparison of the clinical features of 
chronic and aggressive periodontitis. Periodontology 2000, 53, 12-27. 
AROONRERK, N., PICHYANGKUL, S., YONGVANITCHIT, K., WISETCHANG, M., SA-ARD-
IAM, N., SIRISINHA, S. & MAHANONDA, R. 2003. Generation of gingival T cell 
lines/clones specific with Porphyromonas gingivalis pulsed dendritic cells 
from periodontitis patients. Journal of Periodontal Research, 38, 262-268. 
ARORA, P. & PORCELLI, S. A. 2016. An Efficient and High Yield Method for Isolation 
of Mouse Dendritic Cell Subsets. J Vis Exp, 18, doi: 10.3791/53824. 
ASHCROFT, G. S., MILLS, S. J. & ASHWORTH, J. J. 2002. Ageing and wound healing. 
Biogerontology, 3, 337-345. 
ASTRAKHANTSEVA, I. V., EFIMOV, G. A., DRUTSKAYA, M. S., KRUGLOV, A. A. & 
NEDOSPASOV, S. A. 2014. Modern anti-cytokine therapy of autoimmune 
diseases. Biochemistry (Mosc), 79, 1308-1321. 
AUTENGRUBER, A., GEREKE, M., HANSEN, G., HENNIG, C. & BRUDER, D. 2012. 
Impact of enzymatic tissue disintegration on the level of surface molecule 
 229	
expression and immune cell function. European Journal of Microbiology & 
Immunology, 2, 112-120. 
AWANG, R. A., LAPPIN, D. F., MACPHERSON, A., RIGGIO, M., ROBERTSON, D., 
HODGE, P., RAMAGE, G., CULSHAW, S., PRESHAW, P. M., TAYLOR, J. & NILE, 
C. 2014. Clinical associations between IL-17 family cytokines and 
periodontitis and potential differential roles for IL-17A and IL-17E in 
periodontal immunity. Inflamm Res, 63, 1001-12. 
BACHMANN, M. F., BARNER, M., VIOLA, A. & KOPF, M. 1999. Distinct kinetics of 
cytokine production and cytolysis in effector and memory T cells after viral 
infection. European Journal of Immunology, 29, 291-299. 
BAINBRIDGE, B., VERMA, R., EASTMAN, C., YEHIA, B., RIVERA, M., MOFFATT, C., 
BHATTACHARYYA, I., LAMONT, R. & KESAVALU, L. 2010. Role of 
Porphyromonas gingivalis phosphoserine phosphatase enzyme SerB in 
inflammation, immune response, and induction of alveolar bone resorption in 
rats. Infection and immunity, 78, 4560-4569. 
BAKER, P., DIXON, M., EVANS, R., DUFOUR, L., JOHNSON, E. & ROOPENIAN, D. 
1999a. CD4(+) T cells and the proinflammatory cytokines gamma interferon 
and interleukin-6 contribute to alveolar bone loss in mice. Infection and 
immunity, 67, 2804-2809. 
BAKER, P., EVANS, R. & ROOPENIAN, D. 1994a. Oral infection with Porphyromonas 
gingivalis and induced alveolar bone loss in immunocompetent and severe 
combined immunodeficient mice. Archives of oral biology, 39, 1035-1040. 
BAKER, P. J., CARTER S FAU - DIXON, M., DIXON M FAU - EVANS, R. T., EVANS RT 
FAU - ROOPENIAN, D. C. & ROOPENIAN, D. C. 1999b. Serum antibody 
response to oral infection precedes but does not prevent Porphyromonas 
gingivalis-induced alveolar bone loss in mice. Oral Microbiol Immunol, 14, 
194-196. 
BAKER, P. J., EVANS, R. T. & ROOPENIAN, D. C. 1994b. Oral infection with 
Porphyromonas gingivalis and induced alveolar bone loss in 
immunocompetent and severe combined immunodeficient mice. Arch Oral 
Biol, 39, 1035-1040. 
BAKER, P. J., HOWE, L., GARNEAU, J. & ROOPENIAN, D. C. 2002. T cell knockout 
mice have diminished alveolar bone loss after oral infection with 
Porphyromonas gingivalis. FEMS Immunology & Medical Microbiology, 34, 45-
50. 
 230	
BANCHEREAU, J., BRIERE, F., CAUX, C., DAVOUST, J., LEBECQUE, S., LIU, Y.-J., 
PULENDRAN, B. & PALUCKA, K. 2000. Immunobiology of Dendritic Cells. 
Annual Review of Immunology, 18, 767-811. 
BANCHEREAU, J. & STEINMAN, R. M. 1998. Dendritic cells and the control of 
immunity. Nature, 392, 245-252. 
BASU, S., CAMPBELL, H. M., DITTEL, B. N. & RAY, A. 2010. Purification of Specific 
Cell Population by Fluorescence Activated Cell Sorting (FACS). Journal of 
Visualized Experiments : JoVE, 1546. 
BAUMJOHANN, D. & ANSEL, K. M. 2013. Identification of T follicular helper (Tfh) 
cells by flow cytometry. Protocol exchange, doi:10.1038/protex.2013.060. 
BEKLEN, A., AINOLA, M., HUKKANEN, M., GÜRGAN, C., SORSA, T. & KONTTINEN, Y. 
T. 2007. MMPs, IL-1, and TNF are regulated by IL-17 in periodontitis. Journal 
of dental research, 86, 347-351. 
BELIBASAKIS, G. N. & BOSTANCI, N. 2012. The RANKL-OPG system in clinical 
periodontology. J Clin Periodontol, 39, 239-48. 
BELTON, C. M., IZUTSU KT FAU - GOODWIN, P. C., GOODWIN PC FAU - PARK, Y., 
PARK Y FAU - LAMONT, R. J. & LAMONT, R. J. 1999. Fluorescence image 
analysis of the association between Porphyromonas gingivalis and gingival 
epithelial cells. Cell Microbiol, 1, 215-223. 
BENSON, R. A., MACLEOD, M. K. L., HALE, B. G., PATAKAS, A., GARSIDE, P. & 
BREWER, J. M. 2015. Antigen presentation kinetics control T cell/dendritic 
cell interactions and follicular helper T cell generation in vivo. eLife, 4, 
e06994. 
BERGLUNDH, T. & DONATI, M. 2005. Aspects of adaptive host response in 
periodontitis. Journal of Clinical Periodontology, 32, 87-107. 
BERGLUNDH, T., LILJENBERG B FAU - LINDHE, J. & LINDHE, J. 2002. Some cytokine 
profiles of T-helper cells in lesions of advanced periodontitis. 
BEZERRA, M. M., LIMA, V. D., ALENCAR, V. B. M., VIEIRA, I. B., BRITO, G. A. C., 
RIBEIRO, R. A. & ROCHA, F. A. C. 2000. Selective Cyclooxygenase-2 Inhibition 
Prevents Alveolar Bone Loss in Experimental Periodontitis in Rats. Journal of 
Periodontology, 71, 1009-1014. 
BITTNER-EDDY, P. D., FISCHER, L. A. & COSTALONGA, M. 2013. Identification of 
gingipain-specific I-Ab-restricted CD4+T cells following mucosal colonization 
with Porphyromonas gingivalis in C57BL/6 mice. Molecular Oral Microbiology, 
28, 452-466. 
 231	
BOYCE, B. F., AUFDEMORTE, T. B., GARRETT, I. R., YATES, A. J. P. & MUNDY, G. R. 
1989. Effects of Interleukin-1 on Bone Turnover in Normal Mice*. 
Endocrinology, 125, 1142-1150. 
BRANCO, P., WEIDLICH, P., OPPERMANN, R. V. & ROSING, C. K. 2015. Early supra- 
and subgingival plaque formation in experimental gingivitis in smokers and 
never-smokers. Oral Health Prev Dent, 13, 13-20. 
BRISTOW, M. R. & LONG, C. S. 2002. Cardiotrophin-1 in Heart Failure. Circulation, 
106, 1430. 
BRUNNER, J., SCHERES, N., EL IDRISSI, N., DENG, D., LAINE, M., VAN WINKELHOFF, 
A. & CRIELAARD, W. 2010. The capsule of Porphyromonas gingivalis reduces 
the immune response of human gingival fibroblasts. BMC microbiology, 10, 5. 
CALANDRA, T. & ROGER, T. 2003. Macrophage migration inhibitory factor: a 
regulator of innate immunity. Nat Rev Immunol, 3, 791-800. 
CARCUAC, O., ABRAHAMSSON, I., ALBOUY, J.-P., LINDER, E., LARSSON, L. & 
BERGLUNDH, T. 2013. Experimental periodontitis and peri-implantitis in 
dogs. Clinical Oral Implants Research, 24, 363-371. 
CARDOSO, C., GARLET, G., MOREIRA, A., JÚNIOR, W., ROSSI, M. & SILVA, J. 2008a. 
Characterization of CD4+CD25+ natural regulatory T cells in the inflammatory 
infiltrate of human chronic periodontitis. Journal of leukocyte biology, 84, 
311-318. 
CARDOSO, C., GARLET, G., MOREIRA, A., JÚNIOR, W., ROSSI, M. & SILVA, J. 2008b. 
Characterization of CD4+CD25+ natural regulatory T cells in the inflammatory 
infiltrate of human chronic periodontitis. J Leukoc Biol, 84, 311-318. 
CARDOSO, C. R., GARLET, G. P., CRIPPA, G. E., ROSA, A. L., JÚNIOR, W. M., ROSSI, 
M. A. & SILVA, J. S. 2009. Evidence of the presence of T helper type 17 cells 
in chronic lesions of human periodontal disease. Oral microbiology and 
immunology, 24, 1-6. 
CARLSEN, H. S., BAEKKEVOLD, E. S., JOHANSEN, F. E., HARALDSEN, G. & 
BRANDTZAEG, P. 2002. B cell attracting chemokine 1 (CXCL13) and its 
receptor CXCR5 are expressed in normal and aberrant gut associated 
lymphoid tissue. Gut, 51, 364-371. 
CATO, M. H., YAU, I. W. & RICKERT, R. C. 2011. Magnetic-based purification of 
untouched mouse germinal center B cells for ex vivo manipulation and 
biochemical analysis. Nature Protocols, 6, 953-960. 
 232	
CHANDRAMOULI, K. & QIAN, P.-Y. 2009. Proteomics: Challenges, Techniques and 
Possibilities to Overcome Biological Sample Complexity. Human Genomics 
and Proteomics : HGP, 2009, 239204. 
CHAPPLE, I. L. 2014. Time to take periodontitis seriously. BMJ (Clinical research 
ed.), 348. 
CHAPPLE, I. L. & GENCO, R. 2013. Diabetes and periodontal diseases: consensus 
report of the Joint EFP/AAP Workshop on Periodontitis and Systemic 
Diseases. J Periodontol, 84, S106-S112. 
CHARBONNIER, L. M., JANSSEN, E., CHOU, J., OHSUMI, T. K., KELES, S., HSU, J. T., 
MASSAAD, M. J., GARCIA-LLORET, M., HANNA-WAKIM, R., DBAIBO, G., 
ALANGARI, A. A., ALSULTAN, A., AL-ZAHRANI, D., GEHA, R. S. & CHATILA, T. 
A. 2015. Regulatory T-cell deficiency and immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-
function mutations in LRBA. J Allergy Clin Immunol, 135, 217-227. 
CHEN, T., NAKAYAMA, K., BELLIVEAU, L. & DUNCAN, M. 2001. Porphyromonas 
gingivalis gingipains and adhesion to epithelial cells. Infection and immunity, 
69, 3048-3056. 
CHEN, Z.-M. & JENKINS, M. K. 1999. Clonal Expansion of Antigen-Specific CD4 T 
Cells following Infection with Salmonella typhimurium Is Similar in 
Susceptible (Ity(s)) and Resistant (Ity(r)) BALB/c Mice. Infection and 
Immunity, 67, 2025-2029. 
CHU, Y. & COREY, D. R. 2012. RNA Sequencing: Platform Selection, Experimental 
Design, and Data Interpretation. Nucleic Acid Therapeutics, 22, 271-274. 
CIFCIBASI, E., CIBLAK, M., KIRAN, B., BADUR, S., FIRATLI, E., ISSEVER, H. & CINTAN, 
S. 2015a. The Role of Activated Cytotoxic T Cells in Etiopathogenesis of 
Periodontal Disease: Does It Harm or Does It Heal? Scientific Reports, 5, 
9262. 
CIFCIBASI, E., CIBLAK, M., KIRAN, B., BADUR, S., FIRATLI, E., ISSEVER, H. & CINTAN, 
S. 2015b. The role of activated cytotoxic T cells in etiopathogenesis of 
periodontal disease: does it harm or does it heal? Sci Rep, 5, 9262. 
COATS, S., JONES, J., DO, C., BRAHAM, P., BAINBRIDGE, B., TO, T., GOODLETT, D., 
ERNST, R. & DARVEAU, R. 2009. Human Toll-like receptor 4 responses to P. 
gingivalis are regulated by lipid A 1- and 4'-phosphatase activities. Cellular 
microbiology, 11, 1587-1599. 
CONNOLLY, E., MILLHOUSE, E., DOYLE, R., CULSHAW, S., RAMAGE, G. & MORAN, G. 
P. 2017. The Porphyromonas gingivalis hemagglutinins HagB and HagC are 
 233	
major mediators of adhesion and biofilm formation. Molecular Oral 
Microbiology, 32, 35-47. 
CONTI, H. R., PETERSON, A. C., BRANE, L., HUPPLER, A. R., HERNÁNDEZ-SANTOS, 
N., WHIBLEY, N., GARG, A. V., SIMPSON-ABELSON, M. R., GIBSON, G. A., 
MAMO, A. J., OSBORNE, L. C., BISHU, S., GHILARDI, N., SIEBENLIST, U., 
WATKINS, S. C., ARTIS, D., MCGEACHY, M. J. & GAFFEN, S. L. 2014. Oral-
resident natural Th17 cells and γδ T cells control opportunistic Candida 
albicans infections. The Journal of Experimental Medicine, 211, 2075-2084. 
COPE, A. P. 2008. T cells in rheumatoid arthritis. Arthritis Research & Therapy, 10, 
S1-S1. 
COSTALONGA, M. & HERZBERG, M. C. 2014. The oral microbiome and the 
immunobiology of periodontal disease and caries. Immunology Letters, 162, 
22-38. 
CRABBE, P. A., CARBONARA, A. O. & HEREMANS, J. F. 1965. THE NORMAL HUMAN 
INTESTINAL MUCOSA AS A MAJOR SOURCE OF PLASMA CELLS CONTAINING 
GAMMA-A-IMMUNOGLOBULIN. Lab Invest, 14, 235-248. 
CRAWFORD, J. M., KRISKO, J. M., MORRIS, G. A. & CHAMBERS, D. A. 1989. The 
distribution of Langerhans cells and CD1a antigen in healthy and diseased 
human gingiva. Reg Immnol, 2, 91-97. 
CROTTY, S. 2011. Follicular helper CD4 T cells (TFH). Annual review of 
immunology, 29, 621-663. 
CROTTY, S. 2014. T Follicular Helper Cell Differentiation, Function, and Roles in 
Disease. Immunity, 41, 529-542. 
CUI, D., ZHANG, L., CHEN, J., ZHU, M., HOU, L., CHEN, B. & SHEN, B. 2015. 
Changes in regulatory B cells and their relationship with rheumatoid arthritis 
disease activity. Clinical and Experimental Medicine, 15, 285-292. 
CULSHAW, S., MCINNES, I. B. & LIEW, F. Y. 2011. What can the periodontal 
community learn from the pathophysiology of rheumatoid arthritis? Journal 
of Clinical Periodontology, 38, 106-113. 
CURTSINGER, J. M., LINS, D. C. & MESCHER, M. F. 2003. Signal 3 Determines 
Tolerance versus Full Activation of Naive CD8 T Cells: Dissociating 
Proliferation and Development of Effector Function. The Journal of 
Experimental Medicine, 197, 1141-1151. 
CURTSINGER, J. M., SCHMIDT CS FAU - MONDINO, A., MONDINO A FAU - LINS, D. C., 
LINS DC FAU - KEDL, R. M., KEDL RM FAU - JENKINS, M. K., JENKINS MK FAU - 
 234	
MESCHER, M. F. & MESCHER, M. F. 1999. Inflammatory cytokines provide a 
third signal for activation of naive CD4+ and CD8+ T cells. J Immunol, 162, 
3256-3262. 
CURY, P. R., FURUSE, C., RODRIGUES, A. E. A., BARBUTO, J. A., ARAÚJO, C. D. & 
ARAÚJO, N. S. D. 2008. Interstitial and Langerhans' dendritic cells in chronic 
periodontitis and gingivitis. Brazilian Oral Research, 22, 258-263. 
CUTLER, C. W. & JOTWANI, R. 2006. Dendritic Cells at the Oral Mucosal Interface. 
Journal of dental research, 85, 678-689. 
DAHLÉN, G., CHARALAMPAKIS, G., ABRAHAMSSON, I., BENGTSSON, L. & FALSEN, E. 
2012. Predominant bacterial species in subgingival plaque in dogs. Journal of 
Periodontal Research, 47, 354-364. 
DARVEAU, R., BELTON, C., REIFE, R. & LAMONT, R. 1998. Local chemokine 
paralysis, a novel pathogenic mechanism for Porphyromonas gingivalis. 
Infection and immunity, 66, 1660-1665. 
DARVEAU, R. P., HAJISHENGALLIS, G. & CURTIS, M. A. 2012. Porphyromonas 
gingivalis as a Potential Community Activist for Disease. Journal of Dental 
Research, 91, 816-820. 
DAVANIAN, H., STRANNEHEIM, H., BÅGE, T., LAGERVALL, M., JANSSON, L., 
LUNDEBERG, J. & YUCEL-LINDBERG, T. 2012. Gene Expression Profiles in 
Paired Gingival Biopsies from Periodontitis-Affected and Healthy Tissues 
Revealed by Massively Parallel Sequencing. PLoS ONE, 7, e46440. 
DAVIES, E. G. 2013. Immunodeficiency in DiGeorge Syndrome and Options for 
Treating Cases with Complete Athymia. Frontiers in Immunology, 4, 322. 
DE DIEGO, I., VEILLARD, F. T., GUEVARA, T., POTEMPA, B., SZTUKOWSKA, M., 
POTEMPA, J. & GOMIS-RÜTH, F. X. 2013. Porphyromonas gingivalis Virulence 
Factor Gingipain RgpB Shows a Unique Zymogenic Mechanism for Cysteine 
Peptidases. The Journal of Biological Chemistry, 288, 14287-14296. 
DE MOLON, R. S., MASCARENHAS, V. I., DE AVILA, E. D., FINOTI, L. S., TOFFOLI, G. 
B., SPOLIDORIO, D. M. P., SCAREL-CAMINAGA, R. M., TETRADIS, S. & CIRELLI, 
J. A. 2016. Long-term evaluation of oral gavage with periodontopathogens or 
ligature induction of experimental periodontal disease in mice. Clinical Oral 
Investigations, 20, 1203-1216. 
DE PABLO, P., CHAPPLE, I. L. C., BUCKLEY, C. D. & DIETRICH, T. 2009. Periodontitis 
in systemic rheumatic diseases. Nat Rev Rheumatol, 5, 218-224. 
 235	
DE SILVA, N. S. & KLEIN, U. 2015. Dynamics of B cells in germinal centres. Nat Rev 
Immunol, 15, 137-148. 
DEMMER, R., BEHLE, J. H., WOLF, D. L., HANDFIELD, M., KEBSCHULL, M., CELENTI, 
R., PAVLIDIS, P. & PAPAPANOU, P. N. 2008. Transcriptomes in Healthy and 
Diseased Gingival Tissues. Journal of periodontology, 79, 2112-2124. 
DEREKA, X. E., TOSIOS, K. I., CHRYSOMALI, E. & ANGELOPOULOU, E. 2004. Factor 
XIIIa+ dendritic cells and S-100 protein+ Langerhans' cells in adult 
periodontitis. Journal of Periodontal Research, 39, 447-452. 
DEWHIRST, F. E., CHEN, T., IZARD, J., PASTER, B. J., TANNER, A. C. R., YU, W.-H., 
LAKSHMANAN, A. & WADE, W. G. 2010. The Human Oral Microbiome. Journal 
of Bacteriology, 192, 5002-5017. 
DI PAOLO, N. C. & SHAYAKHMETOV, D. M. 2016. Interleukin 1[alpha] and the 
inflammatory process. Nat Immunol, 17, 906-913. 
DI SABATINO, A., CALAROTA, S. A., VIDALI, F., MACDONALD, T. T. & CORAZZA, G. R. 
2011. Role of IL-15 in immune-mediated and infectious diseases. Cytokine & 
Growth Factor Reviews, 22, 19-33. 
DIETRICH, T., SHARMA, P., WALTER, C., WESTON, P. & BECK, J. 2013. The 
epidemiological evidence behind the association between periodontitis and 
incident atherosclerotic cardiovascular disease. Journal of Clinical 
Periodontology, 40, S70-S84. 
DIVARIS, K., MONDA, K. L., NORTH, K. E., OLSHAN, A. F., REYNOLDS, L. M., HSUEH, 
W. C., LANGE, E. M., MOSS, K., BARROS, S. P., WEYANT, R. J., LIU, Y., 
NEWMAN, A. B., BECK, J. D. & OFFENBACHER, S. 2013. Exploring the genetic 
basis of chronic periodontitis: a genome-wide association study. Human 
Molecular Genetics, 22, 2312-2324. 
DOMMISCH, H., STAUFENBIEL, I., SCHULZE, K., STIESCH, M., WINKEL, A., FIMMERS, 
R., DOMMISCH, J., JEPSEN, S., MIOSGE, N., ADAM, K. & EBERHARD, J. 2015. 
Expression of antimicrobial peptides and interleukin-8 during early stages of 
inflammation: An experimental gingivitis study. Journal of Periodontal 
Research, 50, 836-845. 
DU, Y., HASHIZUME, T., KURITA-OCHIAI, T., YUZAWA, S., ABIKO, Y. & YAMAMOTO, 
M. 2011. Nasal immunization with a fusion protein consisting of the 
hemagglutinin A antigenic region and the maltose-binding protein elicits 
CD11c(+) CD8(+) dendritic cells for induced long-term protective immunity. 
Infection and immunity, 79, 895-904. 
 236	
DU, Y., LIU P FAU - ZANG, W., ZANG W FAU - WANG, Y., WANG Y FAU - CHEN, X., 
CHEN X FAU - LI, M., LI M FAU - ZHAO, G. & ZHAO, G. 2015. BTG3 
upregulation induces cell apoptosis and suppresses invasion in esophageal 
adenocarcinoma. Mol Cell Biochem, 404, 31-38. 
DUAN, X., GLEASON, R. C., LI, F., HOSUR, K. B., DUAN, X., HUANG, D., WANG, H., 
HAJISHENGALLIS, G. & LIANG, S. 2016. Sex dimorphism in periodontitis in 
animal models. Journal of Periodontal Research, 51, 196-202. 
DUDLEY, E. C., PETRIE, H. T., SHAH, L. M., OWEN, M. J. & HAYDAY, A. C. 1994. T 
cell receptor beta chain gene rearrangement and selection during thymocyte 
development in adult mice. Immunity, 1, 83-93. 
DUNCAN, L., YOSHIOKA, M., CHANDAD, F. & GRENIER, D. 2004. Loss of 
lipopolysaccharide receptor CD14 from the surface of human macrophage-
like cells mediated by Porphyromonas gingivalis outer membrane vesicles. 
Microbial pathogenesis, 36, 319-325. 
DUTZAN, N., ABUSLEME, L., BRIDGEMAN, H., GREENWELL-WILD, T., ZANGERLE-
MURRAY, T., FIFE, M. E., BOULADOUX, N., LINLEY, H., BRENCHLEY, L., 
WEMYSS, K., CALDERON, G., HONG, B.-Y., BREAK, T. J., BOWDISH, D. M. E., 
LIONAKIS, M. S., JONES, S. A., TRINCHIERI, G., DIAZ, P. I., BELKAID, Y., 
KONKEL, J. E. & MOUTSOPOULOS, N. M. 2017. On-going Mechanical Damage 
from Mastication Drives Homeostatic Th17 Cell Responses at the Oral Barrier. 
Immunity, 46, 133-147. 
DUTZAN, N., GAMONAL, J., SILVA, A., SANZ, M. & VERNAL, R. 2009. Over-expression 
of forkhead box P3 and its association with receptor activator of nuclear 
factor-κ B ligand, interleukin (IL) -17, IL-10 and transforming growth factor-β 
during the progression of chronic periodontitis. J Clin Periodontol, 36, 396-
403. 
DUTZAN, N., KONKEL, J. E., GREENWELL-WILD, T. & MOUTSOPOULOS, N. M. 2016. 
Characterization of the human immune cell network at the gingival barrier. 
Mucosal immunology, 9, 1163-1172. 
DUTZAN, N., VERNAL R FAU - VAQUE, J. P., VAQUE JP FAU - GARCIA-SESNICH, J., 
GARCIA-SESNICH J FAU - HERNANDEZ, M., HERNANDEZ M FAU - ABUSLEME, L., 
ABUSLEME L FAU - DEZEREGA, A., DEZEREGA A FAU - GUTKIND, J. S., 
GUTKIND JS FAU - GAMONAL, J. & GAMONAL, J. 2012a. Interleukin-21 
expression and its association with proinflammatory cytokines in untreated 
chronic periodontitis patients. J Periodontol, 83, 948-954. 
DUTZAN, N., VERNAL, R., HERNANDEZ, M., DEZEREGA, A., RIVERA, O., SILVA, N., 
AGUILLON, J. C., PUENTE, J., POZO, P. & GAMONAL, J. 2008. Levels of 
Interferon-Gamma and Transcription Factor T-Bet in Progressive Periodontal 
 237	
Lesions in Patients With Chronic Periodontitis. Journal of Periodontology, 80, 
290-296. 
DUTZAN, N., VERNAL, R., VAQUE, J. P., GARCÍA-SESNICH, J., HERNANDEZ, M., 
ABUSLEME, L., DEZEREGA, A., GUTKIND, J. S. & GAMONAL, J. 2012b. 
Interleukin-21 expression and its association with proinflammatory cytokines 
in untreated chronic periodontitis patients. Journal of periodontology, 83, 
948-954. 
EASTCOTT, J., YAMASHITA, K., TAUBMAN, M., HARADA, Y. & SMITH, D. 1994. 
Adoptive transfer of cloned T helper cells ameliorates periodontal disease in 
nude rats. Oral microbiology and immunology, 9, 284-289. 
EBERHARD, J., GROTE, K., LUCHTEFELD, M., HEUER, W., SCHUETT, H., DIVCHEV, 
D., SCHERER, R., SCHMITZ-STREIT, R., LANGFELDT, D., STUMPP, N., 
STAUFENBIEL, I., SCHIEFFER, B. & STIESCH, M. 2013. Experimental Gingivitis 
Induces Systemic Inflammatory Markers in Young Healthy Individuals: A 
Single-Subject Interventional Study. PLoS ONE, 8, e55265. 
EDWARDS, J. C. W., SEDGWICK, A. D. & WILLOUGHBY, D. A. 1981. The formation of 
a structure with the features of synovial lining by subcutaneous injection of 
air: An in vivo tissue culture system. The Journal of Pathology, 134, 147-156. 
ESKAN, M., JOTWANI, R., ABE, T., CHMELAR, J., LIM, J.-H., LIANG, S., CIERO, P., 
KRAUSS, J., LI, F., RAUNER, M., HOFBAUER, L., CHOI, E., CHUNG, K.-J., 
HASHIM, A., CURTIS, M., CHAVAKIS, T. & HAJISHENGALLIS, G. 2012. The 
leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory 
bone loss. Nature immunology, 13, 465-473. 
FABIAN, M. R., SONENBERG, N. & FILIPOWICZ, W. 2010. Regulation of mRNA 
Translation and Stability by microRNAs. Annual Review of Biochemistry, 79, 
351-379. 
FEHR, T., SKRASTINA, D., PUMPENS, P. & ZINKERNAGEL, R. M. 1998. T cell-
independent type I antibody response against B cell epitopes expressed 
repetitively on recombinant virus particles. Proceedings of the National 
Academy of Sciences of the United States of America, 95, 9477-9481. 
FENG, T., WANG, L., SCHOEB, T. R., ELSON, C. O. & CONG, Y. 2010. Microbiota 
innate stimulation is a prerequisite for T cell spontaneous proliferation and 
induction of experimental colitis. The Journal of Experimental Medicine, 
207, 1321. 
FERRETTI, E., PISTOIA, V. & CORCIONE, A. 2014. Role of Fractalkine/CX3CL1 and Its 
Receptor in the Pathogenesis of Inflammatory and Malignant Diseases with 
Emphasis on B Cell Malignancies. Mediators of Inflammation, 2014, 480941. 
 238	
FORD, A. L., FOULCHER, E., GOODSALL, A. L. & SEDGWICK, J. D. 1996. Tissue 
digestion with dispase substantially reduces lymphocyte and macrophage 
cell-surface antigen expression. Journal of Immunological Methods, 194, 71-
75. 
FOX, S. W. & CHAMBERS, T. J. 2000. Interferon-γ Directly Inhibits TRANCE-Induced 
Osteoclastogenesis. Biochemical and Biophysical Research Communications, 
276, 868-872. 
FRIEDEN, C. & CLARK, A. C. 1997. Protein folding: how the mechanism of GroEL 
action is defined by kinetics. Proceedings of the National Academy of 
Sciences of the United States of America, 94, 5535-5538. 
GADDIS, D. E., MAYNARD, C. L., WEAVER, C. T., MICHALEK, S. M. & KATZ, J. 2013. 
Role of TLR2-dependent IL-10 production in the inhibition of the initial IFN-γ 
T cell response to Porphyromonas gingivalis. Journal of Leukocyte Biology, 
93, 21-31. 
GAFFEN, S. & HAJISHENGALLIS, G. 2008. A new inflammatory cytokine on the block: 
re-thinking periodontal disease and the Th1/Th2 paradigm in the context of 
Th17 cells and IL-17. Journal of dental research, 87, 817-828. 
GALINDO, R., LEVI, P., LAROCCA, A. P. & NART, J. 2015. Periodontal Re-treatment 
in Patients on Maintenance Following Pocket Reduction Surgery. Journal of 
oral Health and Dental Management, 14, 58-63. 
GAMONAL, J., ACEVEDO, A., BASCONES, A., JORGE, O. & SILVA, A. 2001. 
Characterization of cellular infiltrate, detection of chemokine receptor CCR5 
and interleukin-8 and RANTES chemokines in adult periodontitis. J 
Periodontal Res, 36, 194-203. 
GAO, Y., GRASSI, F., RYAN, M. R., TERAUCHI, M., PAGE, K., YANG, X., WEITZMANN, 
M. N. & PACIFICI, R. 2007. IFN-γ stimulates osteoclast formation and bone 
loss in vivo via antigen-driven T cell activation. Journal of Clinical 
Investigation, 117, 122-132. 
GARLET, G., CARDOSO, C., CAMPANELLI, A., GARLET, T., AVILA-CAMPOS, M., 
CUNHA, F. & SILVA, J. 2008. The essential role of IFN-gamma in the control 
of lethal Aggregatibacter actinomycetemcomitans infection in mice. 
Microbes and infection / Institut Pasteur, 10, 489-496. 
GARLET, G. P., CARDOSO, C. R., MARIANO, F. S., CLAUDINO, M., DE ASSIS, G. F., 
CAMPANELLI, A. P., AVILA-CAMPOS, M. J. & SILVA, J. S. S. 2010a. Regulatory 
T cells attenuate experimental periodontitis progression in mice. Journal of 
clinical periodontology, 37, 591-600. 
 239	
GARLET, G. P., CARDOSO, C. R., MARIANO, F. S., CLAUDINO, M., DE ASSIS, G. F., 
CAMPANELLI, A. P., AVILA-CAMPOS, M. J. & SILVA, J. S. S. 2010b. Regulatory 
T cells attenuate experimental periodontitis progression in mice. J Clin 
Periodontol, 37, 591-600. 
GEMMELL, E., CARTER, C. L., HART, D. N. J., DRYSDALE, K. E. & SEYMOUR, G. J. 
2002. Antigen-presenting cells in human periodontal disease tissues. Oral 
Microbiology and Immunology, 17, 388-393. 
GEMMELL, E., FELDNER, B. & SEYMOUR, G. J. 1992. CD45RA and CD45RO positive 
CD4 cells in human peripheral blood and periodontal disease tissue before 
and after stimulation with periodontopathic bacteria. Oral Microbiol 
Immunol, 7, 84-8. 
GENCO, C. A., CUTLER, C. W., KAPCZYNSKI, D., MALONEY, K. & ARNOLD, R. R. 
1991. A novel mouse model to study the virulence of and host response to 
Porphyromonas (Bacteroides) gingivalis. Infection and Immunity, 59, 1255-
1263. 
GERMAIN, R. N. 2002. T-cell development and the CD4-CD8 lineage decision. Nat 
Rev Immunol, 2, 309-322. 
GHORESCHI, K., LAURENCE, A., YANG, X. P., TATO, C. M., MCGEACHY, M. J., 
KONKEL, J. E., RAMOS, H. L., WEI, L., DAVIDSON, T. S., BOULADOUX, N., 
GRAINGER, J. R., CHEN, Q., KANNO, Y., WATFORD, W. T., SUN, H. W., 
EBERL, G., SHEVACH, E. M., BELKAID, Y., CUA, D. J., CHEN, W. & O'SHEA, J. 
J. 2010. Generation of pathogenic T(H)17 cells in the absence of TGF-beta 
signalling. Nature, 467, 967-71. 
GLENN, T. C. 2011. Field Guide to Next Generation DNA Sequencers. Molecular 
Ecology Resources, doi: 10.1111/j.1755-0998.2011.03024. 
GMÜR, R., HRODEK, K., SAXER, U. P. & GUGGENHEIM, B. 1986. Double-blind analysis 
of the relation between adult periodontitis and systemic host response to 
suspected periodontal pathogens. Infection and immunity, 52, 768-776. 
GODFREY, D. I., KENNEDY J FAU - SUDA, T., SUDA T FAU - ZLOTNIK, A. & ZLOTNIK, 
A. 1993. A developmental pathway involving four phenotypically and 
functionally distinct subsets of CD3-CD4-CD8- triple-negative adult mouse 
thymocytes defined by CD44 and CD25 expression. J Immunol, 150, 4244-
4252. 
GONÇALVES, R. B., LESHEM, O., BERNARDS, K., WEBB, J. R., STASHENKO, P. P. & 
CAMPOS-NETO, A. 2006. T-Cell Expression Cloning of Porphyromonas 
gingivalis Genes Coding for T Helper-Biased Immune Responses during 
Infection. Infection and Immunity, 74, 3958-3966. 
 240	
GOOD-JACOBSON, K. L., SZUMILAS, C. G., CHEN, L., SHARPE, A. H., TOMAYKO, M. 
M. & SHLOMCHIK, M. J. 2010. PD-1 regulates germinal center B cell survival 
and the formation and affinity of long-lived plasma cells. Nat Immunol, 11, 
535-542. 
GOODYEAR, A. W., KUMAR, A., DOW, S. & RYAN, E. P. 2014. Optimization of murine 
small intestine leukocyte isolation for global immune phenotype analysis. 
Journal of Immunological Methods, 405, 97-108. 
GRASWINCKEL, J. E. M., VAN DER VELDEN, U., VAN WINKELHOFF, A. J., HOEK, F. J. 
& LOOS, B. G. 2004. Plasma antibody levels in periodontitis patients and 
controls. Journal of Clinical Periodontology, 31, 562-568. 
GRAVES, D. T., FINE, D., TENG, Y.-T. A., VAN DYKE, T. E. & HAJISHENGALLIS, G. 
2008. The Use of Rodent Models to Investigate Host-Bacteria Interactions 
Related to Periodontal Diseases. Journal of clinical periodontology, 35, 89-
105. 
GRAVES, D. T., OSKOUI, M., VOLEINIKOVA, S., NAGUIB, G., CAI, S., DESTA, T., 
KAKOURAS, A. & JIANG, Y. 2001. Tumor Necrosis Factor Modulates Fibroblast 
Apoptosis, PMN Recruitment, and Osteoclast Formation in Response to P. 
gingivalis Infection. Journal of Dental Research, 80, 1875-1879. 
GRENIER, D. & MAYRAND, D. 1987. Selected characteristics of pathogenic and 
nonpathogenic strains of Bacteroides gingivalis. Journal of clinical 
microbiology, 25, 738-740. 
GRIFFEN, A. L., BEALL, C. J., CAMPBELL, J. H., FIRESTONE, N. D., KUMAR, P. S., 
YANG, Z. K., PODAR, M. & LEYS, E. J. 2012. Distinct and complex bacterial 
profiles in human periodontitis and health revealed by 16S pyrosequencing. 
The ISME Journal, 6, 1176-1185. 
GRIFFEN, A. L., BECKER, M. R., LYONS, S. R., MOESCHBERGER, M. L. & LEYS, E. J. 
1998. Prevalence of Porphyromonas gingivalis and Periodontal Health Status. 
Journal of Clinical Microbiology, 36, 3239-3242. 
GUENTSCH, A., KRAMESBERGER, M., SROKA, A., PFISTER, W., POTEMPA, J. & EICK, 
S. 2011. Comparison of Gingival Crevicular Fluid Sampling Methods in 
Patients with Severe Chronic Periodontitis. Journal of periodontology, 82, 
1051-1060. 
GUO, Y., NGUYEN, K.-A. & POTEMPA, J. 2010. Dichotomy of gingipains action as 
virulence factors: from cleaving substrates with the precision of a surgeon's 
knife to a meat chopper-like brutal degradation of proteins. Periodontology 
2000, 54, 15-44. 
 241	
GUPTA, A. K. & GUPTA, U. D. 2014. Chapter 19 - Next Generation Sequencing and 
Its Applications A2 - Verma, Ashish S. In: SINGH, A. (ed.) Animal 
Biotechnology. San Diego: Academic Press. 
GUPTA, S. & JAWANDA, M. K. 2015. Oral Lichen Planus: An Update on Etiology, 
Pathogenesis, Clinical Presentation, Diagnosis and Management. Indian 
Journal of Dermatology, 60, 222-229. 
HAFFAJEE, A. D., SOCRANSKY SS FAU - GUNSOLLEY, J. C. & GUNSOLLEY, J. C. 2003. 
Systemic anti-infective periodontal therapy. A systematic review. Ann 
Periodontol, 8, 115-181. 
HAJISHENGALLIS, G., LIANG, S., PAYNE, M., HASHIM, A., JOTWANI, R., ESKAN, M., 
MCINTOSH, M., ALSAM, A., KIRKWOOD, K., LAMBRIS, J., DARVEAU, R. & 
CURTIS, M. 2011a. Low-abundance biofilm species orchestrates inflammatory 
periodontal disease through the commensal microbiota and complement. Cell 
host & microbe, 10, 497-506. 
HAJISHENGALLIS, G., LIANG, S., PAYNE, MARK A., HASHIM, A., JOTWANI, R., ESKAN, 
MEHMET A., MCINTOSH, MEGAN L., ALSAM, A., KIRKWOOD, KEITH L., 
LAMBRIS, JOHN D., DARVEAU, RICHARD P. & CURTIS, MICHAEL A. 2011b. Low-
Abundance Biofilm Species Orchestrates Inflammatory Periodontal Disease 
through the Commensal Microbiota and Complement. Cell Host & Microbe, 
10, 497-506. 
HAJISHENGALLIS, G., LIANG, S., PAYNE, M. A., HASHIM, A., JOTWANI, R., ESKAN, M. 
A., MCINTOSH, M. L., ALSAM, A., KIRKWOOD, K. L., LAMBRIS, J. D., DARVEAU, 
R. P. & CURTIS, M. A. 2011c. A Low-Abundance Biofilm Species Orchestrates 
Inflammatory Periodontal Disease through the Commensal Microbiota and the 
Complement Pathway. Cell host & microbe, 10, 497-506. 
HAMEL, K. M., CAO, Y., WANG, Y., RODEGHERO, R., KOBEZDA, T., CHEN, L. & 
FINNEGAN, A. 2010. B7-H1 expression on non-B and non-T cells promotes 
distinct effects on T- and B-cell responses in autoimmune arthritis. European 
Journal of Immunology, 40, 3117-3127. 
HAN, X., KAWAI, T., EASTCOTT, J. W. & TAUBMAN, M. A. 2006. Bacterial-Responsive 
B Lymphocytes Induce Periodontal Bone Resorption. The Journal of 
Immunology, 176, 625-631. 
HAN, X., LIN, X., SELIGER, A. R., EASTCOTT, J., KAWAI, T. & TAUBMAN, M. A. 2009. 
Expression of receptor activator of nuclear factor-kappaB ligand by B cells in 
response to oral bacteria. Oral Microbiol Immunol, 24, 190-6. 
HASEGAWA, Y., TRIBBLE, G., BAKER, H., MANS, J., HANDFIELD, M. & LAMONT, R. 
2008. Role of Porphyromonas gingivalis SerB in gingival epithelial cell 
 242	
cytoskeletal remodeling and cytokine production. Infection and immunity, 
76, 2420-2427. 
HASENBERG, M., KÖHLER, A., BONIFATIUS, S., BORUCKI, K., RIEK-BURCHARDT, M., 
ACHILLES, J., MÄNN, L., BAUMGART, K., SCHRAVEN, B. & GUNZER, M. 2011. 
Rapid Immunomagnetic Negative Enrichment of Neutrophil Granulocytes from 
Murine Bone Marrow for Functional Studies In Vitro and In Vivo. PLoS ONE, 6, 
e17314. 
HAWLISCH, H., BELKAID, Y., BAELDER, R., HILDEMAN, D., GERARD, C. & KÖHL, J. 
2005. C5a negatively regulates toll-like receptor 4-induced immune 
responses. Immunity, 22, 415-426. 
HAYES, S. M., LI, L. & LOVE, P. E. 2005. TCR Signal Strength Influences αβ/γδ 
Lineage Fate. Immunity, 22, 583-593. 
HAYNES, N. M., ALLEN CD FAU - LESLEY, R., LESLEY R FAU - ANSEL, K. M., ANSEL KM 
FAU - KILLEEN, N., KILLEEN N FAU - CYSTER, J. G. & CYSTER, J. G. 2007. Role 
of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a 
programmed cell death gene-1high germinal center-associated 
subpopulation. J Immunol, 179, 5099-5108. 
HEASMAN, P. A., COLLINS, J. G. & OFFENBACHER, S. 1993. Changes in crevicular 
fluid levels of interleukin-1 beta, leukotriene B4, prostaglandin E2, 
thromboxane B2 and tumour necrosis factor alpha in experimental gingivitis 
in humans. J Periodontal Res, 28, 241-247. 
HENDERSON, L. A., KING, S. L., AMERI, S., MARTIN, S. D., SIMMONS, B. P., 
NIGROVIC, P. A. & FUHLBRIGGE, R. C. 2014. A161: Novel 3-Dimensional 
Explant Method Facilitates the Study of Lymphocyte Populations in the 
Synovium and Reveals a Large Population of Resident Memory T cells in 
Rheumatoid Arthritis. Arthritis & Rheumatology, 66, S209-S209. 
HERRERA, D., SANZ, M., JEPSEN, S., NEEDLEMAN, I. & ROLDÁN, S. 2002. A 
systematic review on the effect of systemic antimicrobials as an adjunct to 
scaling and root planing in periodontitis patients. Journal of Clinical 
Periodontology, 29, 136-159. 
HO, S., CLIPSTONE, N., TIMMERMANN, L., NORTHROP, J., GRAEF, I., FIORENTINO, 
D., NOURSE, J. & CRABTREE, G. R. 1996. The mechanism of action of 
cyclosporin A and FK506. Clinical immunology and immunopathology, 80, 5. 
HOENNSCHEIDT, C., MAX D FAU - RICHTER, N., RICHTER N FAU - STAEGE, M. S. & 
STAEGE, M. S. 2009. Expression of CD4 on Epstein-Barr virus-immortalized B 
cells. Scandinavian journal of immunology, 70, 216-225. 
 243	
HOFFMAN, E. S., PASSONI, L., CROMPTON, T., LEU, T. M., SCHATZ, D. G., KOFF, A., 
OWEN, M. J. & HAYDAY, A. C. 1996. Productive T-cell receptor beta-chain 
gene rearrangement: coincident regulation of cell cycle and clonality during 
development in vivo. Genes & Development, 10, 948-962. 
HOLT, S. & EBERSOLE, J. 2005. Porphyromonas gingivalis, Treponema denticola, 
and Tannerella forsythia: the "red complex", a prototype polybacterial 
pathogenic consortium in periodontitis. Periodontology 2000, 38, 72-122. 
HOLT, S., KESAVALU, L., WALKER, S. & GENCO, C. 1999. Virulence factors of 
Porphyromonas gingivalis. Periodontology 2000, 20, 168-238. 
HONDA, T., AOKI, Y., TAKAHASHI, N., MAEKAWA, T., NAKAJIMA, T., ITO, H., 
TABETA, K., OKUI, T., KAJITA, K., DOMON, H. & YAMAZAKI, K. 2008. Elevated 
expression of IL-17 and IL-12 genes in chronic inflammatory periodontal 
disease. Clinica chimica acta; international journal of clinical chemistry, 
395, 137-141. 
HORAV , A. H. 2014. Dendritic cells of the oral mucosa. Mucosal immunology, 7, 27-
37. 
HOVAV, A. H. 2014. Dendritic cells of the oral mucosa. Mucosal Immunol, 7, 27-37. 
HUANG, J., WU, C., TIAN, B., ZHOU, X., MA, N. & QIAN, Y. 2016. Myricetin Prevents 
Alveolar Bone Loss in an Experimental Ovariectomized Mouse Model of 
Periodontitis. International Journal of Molecular Sciences, 17. 
IWASAKI, A. & MEDZHITOV, R. 2015. Control of adaptive immunity by the innate 
immune system. Nat Immunol, 16, 343-353. 
JAIN, R., WALDVOGEL-THURLOW, S., DARVEAU, R. & DOUGLAS, R. 2016. Differences 
in the paranasal sinuses between germ-free and pathogen-free mice. 
International Forum of Allergy & Rhinology, 6, 631-637. 
JAMUR, M. C., GRODZKI, A. C. G., MORENO, A. N., DE MELLO, L. D. F. C., PASTOR, 
M. V. D., BERENSTEIN, E. H., SIRAGANIAN, R. P. & OLIVER, C. 2001. 
Identification and Isolation of Rat Bone Marrow-derived Mast Cells Using the 
Mast Cell-specific Monoclonal Antibody AA4. Journal of Histochemistry & 
Cytochemistry, 49, 219-228. 
JELLEY-GIBBS, D. M., DIBBLE, J. P., FILIPSON, S., HAYNES, L., KEMP, R. A. & SWAIN, 
S. L. 2005. Repeated stimulation of CD4 effector T cells can limit their 
protective function. The Journal of Experimental Medicine, 201, 1101-1112. 
JENKINS, M. K., KHORUTS A FAU - INGULLI, E., INGULLI E FAU - MUELLER, D. L., 
MUELLER DL FAU - MCSORLEY, S. J., MCSORLEY SJ FAU - REINHARDT, R. L., 
 244	
REINHARDT RL FAU - ITANO, A., ITANO A FAU - PAPE, K. A. & PAPE, K. A. 
2001. In vivo activation of antigen-specific CD4 T cells. Annual review of 
immunology, 19, 23-45. 
JEPSEN, K. & JEPSEN, S. 2016. Antibiotics/antimicrobials: systemic and local 
administration in the therapy of mild to moderately advanced periodontitis. 
Periodontology 2000, 71, 82-112. 
JOHNSON, L. A. & JACKSON, D. G. 2013. The chemokine CX3CL1 promotes 
trafficking of dendritic cells through inflamed lymphatics. Journal of Cell 
Science, 126, 5259-5270. 
JÖNSSON, D., RAMBERG, P., DEMMER, R. T., KEBSCHULL, M., DAHLÉN, G. & 
PAPAPANOU, P. N. 2011. Gingival tissue transcriptomes in experimental 
gingivitis. Journal of clinical periodontology, 38, 599-611. 
JOTWANI, R., PALUCKA, A. K., AL-QUOTUB, M., NOURI-SHIRAZI, M., KIM, J., BELL, 
D., BANCHEREAU, J. & CUTLER, C. W. 2001. Mature Dendritic Cells Infiltrate 
the T Cell-Rich Region of Oral Mucosa in Chronic Periodontitis: In Situ, In 
Vivo, and In Vitro Studies(). Journal of immunology (Baltimore, Md. : 1950), 
167, 4693-4700. 
JUNGBLUT, M., OELTZE, K., ZEHNTER, I., HASSELMANN, D. & BOSIO, A. 2009. 
Standardized Preparation of Single-Cell Suspensions from Mouse Lung Tissue 
using the gentleMACS Dissociator. Journal of Visualized Experiments : JoVE, 
1266. 
KAECH, S. M., TAN JT FAU - WHERRY, E. J., WHERRY EJ FAU - KONIECZNY, B. T., 
KONIECZNY BT FAU - SURH, C. D., SURH CD FAU - AHMED, R. & AHMED, R. 
2003. Selective expression of the interleukin 7 receptor identifies effector 
CD8 T cells that give rise to long-lived memory cells. Nat Immunol, 4, 1191-
1198. 
KAECH, S. M., WHERRY, E. J. & AHMED, R. 2002. Effector and memory T-cell 
differentiation: implications for vaccine development. Nat Rev Immunol, 2, 
251-262. 
KAWAI, T., MATSUYAMA, T., HOSOKAWA, Y., MAKIHIRA, S., SEKI, M., KARIMBUX, N., 
GONCALVES, R., VALVERDE, P., DIBART, S., LI, Y.-P., MIRANDA, L., ERNST, 
C., IZUMI, Y. & TAUBMAN, M. 2006. B and T lymphocytes are the primary 
sources of RANKL in the bone resorptive lesion of periodontal disease. The 
American journal of pathology, 169, 987-998. 
KE, Y., LI, Y. & KAPP, J. A. 1995. Ovalbumin injected with complete Freund's 
adjuvant stimulates cytolytic responses. European Journal of Immunology, 
25, 549-553. 
 245	
KEANE, J., GERSHON S FAU - WISE, R. P., WISE RP FAU - MIRABILE-LEVENS, E., 
MIRABILE-LEVENS E FAU - KASZNICA, J., KASZNICA J FAU - SCHWIETERMAN, 
W. D., SCHWIETERMAN WD FAU - SIEGEL, J. N., SIEGEL JN FAU - BRAUN, M. 
M. & BRAUN, M. M. 2001. Tuberculosis associated with infliximab, a tumor 
necrosis factor alpha-neutralizing agent. N Engl J Med, 345, 1098-1104. 
KEESTRA, J. A. J., GROSJEAN, I., COUCKE, W., QUIRYNEN, M. & TEUGHELS, W. 
2015a. Non-surgical periodontal therapy with systemic antibiotics in patients 
with untreated aggressive periodontitis: a systematic review and meta-
analysis. Journal of Periodontal Research, 50, 689-706. 
KEESTRA, J. A. J., GROSJEAN, I., COUCKE, W., QUIRYNEN, M. & TEUGHELS, W. 
2015b. Non-surgical periodontal therapy with systemic antibiotics in patients 
with untreated chronic periodontitis: a systematic review and meta-analysis. 
Journal of Periodontal Research, 50, 294-314. 
KHALAF, H. & BENGTSSON, T. 2012. Altered T-Cell Responses by the Periodontal 
Pathogen Porphyromonas gingivalis. PLoS ONE, 7, e45192. 
KILIAN, M., CHAPPLE, I. L. C., HANNIG, M., MARSH, P. D., MEURIC, V., PEDERSEN, A. 
M. L., TONETTI, M. S., WADE, W. G. & ZAURA, E. 2016. The oral microbiome 
- an update for oral healthcare professionals. Br Dent J, 221, 657-666. 
KIM, P. D., XIA-JUAN, X., CRUMP, K. E., ABE, T., HAJISHENGALLIS, G. & SAHINGUR, 
S. E. 2015. Toll-Like Receptor 9-Mediated Inflammation Triggers Alveolar 
Bone Loss in Experimental Murine Periodontitis. Infection and Immunity, 83, 
2992-3002. 
KIM, Y.-G., KIM, M., KANG, J. H., KIM, H. J., PARK, J.-W., LEE, J.-M., SUH, J.-Y., 
KIM, J.-Y., LEE, J.-H. & LEE, Y. 2016. Transcriptome sequencing of gingival 
biopsies from chronic periodontitis patients reveals novel gene expression 
and splicing patterns. Human Genomics, 10, 28. 
KISTLER, J. O., BOOTH, V., BRADSHAW, D. J. & WADE, W. G. 2013. Bacterial 
Community Development in Experimental Gingivitis. PLOS ONE, 8, e71227. 
KITTIPATARIN, C. & KHALED, A. R. 2007. INTERLINKING INTERLEUKIN-7. Cytokine, 
39, 75-83. 
KLEINSCHEK, M. A., BONIFACE, K., SADEKOVA, S., GREIN, J., MURPHY, E. E., 
TURNER, S. P., RASKIN, L., DESAI, B., FAUBION, W. A., DE WAAL MALEFYT, 
R., PIERCE, R. H., MCCLANAHAN, T. & KASTELEIN, R. A. 2009. Circulating and 
gut-resident human Th17 cells express CD161 and promote intestinal 
inflammation. The Journal of Experimental Medicine, 206, 525-534. 
 246	
KOLENBRANDER, P. 2000. Oral microbial communities: biofilms, interactions, and 
genetic systems. Annual review of microbiology, 54, 413-437. 
KONDRACK, R. M., HARBERTSON J FAU - TAN, J. T., TAN JT FAU - MCBREEN, M. E., 
MCBREEN ME FAU - SURH, C. D., SURH CD FAU - BRADLEY, L. M. & BRADLEY, 
L. M. 2003. Interleukin 7 regulates the survival and generation of memory 
CD4 cells. J Exp Med, 198. 
KROEMER, G., CUENDE E FAU - MARTINEZ, C. & MARTINEZ, C. 1993. 
Compartmentalization of the peripheral immune system. Adv Immunol, 53, 
157-216. 
KUPER, C. F., HAMELEERS, D. M., BRUIJNTJES, J. P., VAN DER VEN, I., BIEWENGA, J. 
& SMINIA, T. 1990. Lymphoid and non-lymphoid cells in nasal-associated 
lymphoid tissue (NALT) in the rat. An immuno- and enzyme-histochemical 
study. Cell Tissue Res, 259, 371-377. 
KURTULUS, S. & HILDEMAN, D. 2013. Assessment of CD4(+) and CD8(+) T Cell 
Responses Using MHC Class I and II Tetramers. Methods in molecular biology 
(Clifton, N.J.), 979, 71-79. 
LAPPIN, D. F., KOULOURI, O., RADVAR, M., HODGE, P. & KINANE, D. F. 1999. 
Relative proportions of mononuclear cell types in periodontal lesions 
analyzed by immunohistochemistry. Journal of Clinical Periodontology, 26, 
183-189. 
LAPPIN, D. F., MACLEOD, C. P., KERR, A., MITCHELL, T. & KINANE, D. F. 2001. Anti-
inflammatory cytokine IL-10 and T cell cytokine profile in periodontitis 
granulation tissue. Clinical and experimental immunology, 123, 294-300. 
LAURELL, L., RYLANDER H FAU - SUNDIN, Y. & SUNDIN, Y. 1987. Histologic 
characteristics of clinically healthy gingiva in adolescents. Scand J Dent Res, 
95, 456-462. 
LI, C. H. & AMAR, S. 2007. Morphometric, Histomorphometric, and Microcomputed 
Tomographic Analysis of Periodontal Inflammatory Lesions in a Murine Model. 
Journal of Periodontology, 78, 1120-1128. 
LIANG, S., KRAUSS, J. L., DOMON, H., MCINTOSH, M. L., HOSUR, K. B., QU, H., LI, 
F., TZEKOU, A., LAMBRIS, J. D. & HAJISHENGALLIS, G. 2011. The C5a 
receptor impairs IL-12–dependent clearance of Porphyromonas gingivalis and 
is required for induction of periodontal bone loss. Journal of immunology 
(Baltimore, Md. : 1950), 186, 869-877. 
 247	
LIOU, Y.-R., WANG, Y.-H., LEE, C.-Y. & LI, P.-C. 2015. Buoyancy-Activated Cell 
Sorting Using Targeted Biotinylated Albumin Microbubbles. PLoS ONE, 10, 
e0125036. 
LISTGARTEN, M. A., SCHIFTER, C. C. & LASTER, L. 1985. 3-year longitudinal study of 
the periodontal status of an adult population with gingivitis. Journal of 
Clinical Periodontology, 12, 225-238. 
LISTL, S., GALLOWAY, J., MOSSEY, P. A. & MARCENES, W. 2015. Global Economic 
Impact of Dental Diseases. Journal of Dental Research, 94, 1355-1361. 
LIU, M., GUO, S. & STILES, J. K. 2011. The emerging role of CXCL10 in cancer 
(Review). Oncology Letters, 2, 583-589. 
LIU, Y.-Z., MANEY, P., PURI, J., ZHOU, Y., BADDOO, M., STRONG, M., WANG, Y.-P., 
FLEMINGTON, E. & DENG, H.-W. 2016. RNA-sequencing study of peripheral 
blood monocytes in chronic periodontitis. Gene, 581, 152-160. 
LÖE, H., ANERUD, A., BOYSEN, H. & MORRISON, E. 1986. Natural history of 
periodontal disease in man. Rapid, moderate and no loss of attachment in Sri 
Lankan laborers 14 to 46 years of age. Journal of clinical periodontology, 13, 
431-445. 
LÖE, H., THEILADE, E. & JENSEN, S. B. 1965. EXPERIMENTAL GINGIVITIS IN MAN. J 
Periodontol, 36, 177-187. 
LONDON, C. A., LODGE MP FAU - ABBAS, A. K. & ABBAS, A. K. 2000. Functional 
responses and costimulator dependence of memory CD4+ T cells. J Immunol, 
64, 265-272. 
LOOS, B. G., DYER, D. W., WHITTAM, T. S. & SELANDER, R. K. 1993. Genetic 
structure of populations of Porphyromonas gingivalis associated with 
periodontitis and other oral infections. Infection and Immunity, 61, 204-212. 
LORD, M. S., CHENG, B., FARRUGIA, B. L., MCCARTHY, S. & WHITELOCK, J. M. 2017. 
Platelet factor 4 binds to vascular proteoglycans and controls both growth 
factor activities and platelet activation. Journal of Biological Chemistry. 
LU, Y.-C., YEH, W.-C. & OHASHI, P. 2008. LPS/TLR4 signal transduction pathway. 
Cytokine, 42, 145-151. 
LUNDMARK, A., DAVANIAN, H., BÅGE, T., JOHANNSEN, G., KORO, C., LUNDEBERG, 
J. & YUCEL-LINDBERG, T. 2015. Transcriptome analysis reveals mucin 4 to be 
highly associated with periodontitis and identifies pleckstrin as a link to 
systemic diseases. Scientific Reports, 5, 18475. 
 248	
MACKAY, F. & BROWNING, J. L. 2002. BAFF: A fundamental survival factor for B 
cells. Nat Rev Immunol, 2, 465-475. 
MACKAY, L. K., RAHIMPOUR, A., MA, J. Z., COLLINS, N., STOCK, A. T., HAFON, M.-
L., VEGA-RAMOS, J., LAUZURICA, P., MUELLER, S. N., STEFANOVIC, T., 
TSCHARKE, D. C., HEATH, W. R., INOUYE, M., CARBONE, F. R. & GEBHARDT, 
T. 2013. The developmental pathway for CD103+CD8+ tissue-resident 
memory T cells of skin. Nat Immunol, 14, 1294-1301. 
MACLEOD, M. K. L., KAPPLER, J. W. & MARRACK, P. 2010. Memory CD4 T cells: 
generation, reactivation and re-assignment. Immunology, 130, 10-15. 
MACLEOD, M. K. L., MCKEE, A., CRAWFORD, F., WHITE, J., KAPPLER, J. & MARRACK, 
P. 2008. CD4 memory T cells divide poorly in response to antigen because of 
their cytokine profile. Proceedings of the National Academy of Sciences of 
the United States of America, 105, 14521-14526. 
MADIANOS, P., PAPAPANOU, P. & SANDROS, J. 1997. Porphyromonas gingivalis 
infection of oral epithelium inhibits neutrophil transepithelial migration. 
Infection and immunity, 65, 3983-3990. 
MAGGI, L., CAPONE M FAU - GIUDICI, F., GIUDICI F FAU - SANTARLASCI, V., 
SANTARLASCI V FAU - QUERCI, V., QUERCI V FAU - LIOTTA, F., LIOTTA F FAU - 
FICARI, F., FICARI F FAU - MAGGI, E., MAGGI E FAU - TONELLI, F., TONELLI F 
FAU - ANNUNZIATO, F., ANNUNZIATO F FAU - COSMI, L. & COSMI, L. 2013. 
CD4+CD161+ T lymphocytes infiltrate Crohn's disease-associated perianal 
fistulas and are reduced by anti-TNF-alpha local therapy. 
MAHANONDA, R., SA-ARD-IAM, N., YONGVANITCHIT, K., WISETCHANG, M., 
ISHIKAWA, I., NAGASAWA, T., WALSH, D. S. & PICHYANGKUL, S. 2002. 
Upregulation of co-stimulatory molecule expression and dendritic cell marker 
(CD83) on B cells in periodontal disease. J Periodontal Res, 37, 177-183. 
MALCOLM, J., AWANG, R. A., OLIVER-BELL, J., BUTCHER, J. P., CAMPBELL, L., 
ADRADOS PLANELL, A., LAPPIN, D. F., FUKADA, S. Y., NILE, C. J., LIEW, F. Y. 
& CULSHAW, S. 2015a. IL-33 Exacerbates Periodontal Disease through 
Induction of RANKL. J Dent Res, 94, 968-975. 
MALCOLM, J., AWANG, R. A., OLIVER-BELL, J., BUTCHER, J. P., CAMPBELL, L., 
ADRADOS PLANELL, A., LAPPIN, D. F., FUKADA, S. Y., NILE, C. J., LIEW, F. Y. 
& CULSHAW, S. 2015b. IL-33 Exacerbates Periodontal Disease through 
Induction of RANKL. Journal of Dental Research. 
MALCOLM, J., MILLINGTON, O., MILLHOUSE, E., CAMPBELL, L., ADRADOS PLANELL, 
A., BUTCHER, J. P., LAWRENCE, C., ROSS, K., RAMAGE, G., MCINNES, I. B. & 
 249	
CULSHAW, S. 2016. Mast Cells Contribute to Porphyromonas gingivalis–
induced Bone Loss. Journal of Dental Research, 95, 704-710. 
MALEK, R., FISHER, J., CALECA, A., STINSON, M., VAN OSS, C., LEE, J., CHO, M., 
GENCO, R., EVANS, R. & DYER, D. 1994. Inactivation of the Porphyromonas 
gingivalis fimA gene blocks periodontal damage in gnotobiotic rats. Journal 
of bacteriology, 176, 1052-1059. 
MALISSEN, M., GILLET, A., ARDOUIN, L., BOUVIER, G., TRUCY, J., FERRIER, P., 
VIVIER, E. & MALISSEN, B. 1995. Altered T cell development in mice with a 
targeted mutation of the CD3-epsilon gene. The EMBO Journal, 14, 4641-
4653. 
MALOY, K. J. & POWRIE, F. 2001. Regulatory T cells in the control of immune 
pathology. Nat Immunol, 2, 816-822. 
MANHART, S. S., REINHARDT, R. A., PAYNE, J. B., SEYMOUR, G. J., GEMMELL, E., 
DYER, J. K. & PETRO, T. M. 1994. Gingival cell IL-2 and IL-4 in early-onset 
periodontitis. Journal of periodontology, 65, 807-813. 
MARCOTTE, H. & LAVOIE, M. C. 1998. Oral Microbial Ecology and the Role of 
Salivary Immunoglobulin A. Microbiology and Molecular Biology Reviews, 62, 
71-109. 
MARTNER, A., ÖSTMAN, S., LUNDIN, S., RASK, C., BJÖRNSSON, V., TELEMO, E., 
COLLINS, L. V., AXELSSON, L. & WOLD, A. E. 2013. Stronger T Cell 
Immunogenicity of Ovalbumin Expressed Intracellularly in Gram-Negative 
than in Gram-Positive Bacteria. PLoS ONE, 8, e65124. 
MARZO, A. L., KLONOWSKI, K. D., LE BON, A., BORROW, P., TOUGH, D. F. & 
LEFRANÇOIS, L. 2005. Initial T cell frequency dictates memory CD8(+) T cell 
lineage commitment. Nature immunology, 6, 793-799. 
MATSUDA, K., IWAKI, K. K., GARCIA-GOMEZ, J., HOFFMAN, J., INDERLIED, C. B., 
MASON, W. H. & IWAKI, Y. 2011. Bacterial Identification by 16S rRNA Gene 
PCR-Hybridization as a Supplement to Negative Culture Results. Journal of 
Clinical Microbiology, 49, 2031-2034. 
MAURI, C., GRAY, D., MUSHTAQ, N. & LONDEI, M. 2003. Prevention of Arthritis by 
Interleukin 10–producing B Cells. The Journal of Experimental Medicine, 197, 
489-501. 
MCINTOSH, M. L. & HAJISHENGALLIS, G. 2012. Inhibition of Porphyromonas 
gingivalis-induced periodontal bone loss by CXCR4 antagonist treatment. 
Molecular oral microbiology, 27, 449-457. 
 250	
MCMANUS, M. M. & GRILL, R. J. 2011. Longitudinal Evaluation of Mouse Hind Limb 
Bone Loss After Spinal Cord Injury using Novel, in vivo, Methodology. Journal 
of Visualized Experiments : JoVE, 3246. 
MCSORLEY, S. J., ASCH, S., COSTALONGA, M., REINHARDT, R. L. & JENKINS, M. K. 
2002. Tracking Salmonella-Specific CD4 T Cells In Vivo Reveals a Local 
Mucosal Response to a Disseminated Infection. Immunity, 16, 365-377. 
MDALA, I., OLSEN, I., HAFFAJEE, A. D., SOCRANSKY, S. S., DE BLASIO, B. F. & 
THORESEN, M. 2013. Multilevel analysis of bacterial counts from chronic 
periodontitis after root planing/scaling, surgery, and systemic and local 
antibiotics: 2-year results. Journal of Oral Microbiology, 5, 
10.3402/jom.v5i0.20939. 
MICHALOWICZ, B. S., DIEHL, S. R., GUNSOLLEY, J. C., SPARKS, B. S., BROOKS, C. N., 
KOERTGE, T. E., CALIFANO, J. V., BURMEISTER, J. A. & SCHENKEIN, H. A. 
2000. Evidence of a Substantial Genetic Basis for Risk of Adult Periodontitis. 
Journal of Periodontology, 71, 1699-1707. 
MILES, A. A., MISRA, S. S. & IRWIN, J. O. 1938. The estimation of the bactericidal 
power of the blood. The Journal of Hygiene, 38, 732-749. 
MILES, B., ABDEL-GHAFFAR, K. A., GAMAL, A. Y., BABAN, B. & CUTLER, C. W. 2014. 
Blood dendritic cells: “canary in the coal mine” to predict chronic 
inflammatory disease? Frontiers in Microbiology, 5, 6. 
MILLER, J. 1961. Immunological function of the thymus. Lancet, ii, 748-749. 
MILLER, J. 1962. Effect of neonatal thymectomy on the immunological 
responsiveness of the mouse. Proc Roy Soc London, 156B, 410-428. 
MITANI, A., NIEDBALA, W., FUJIMURA, T., MOGI, M., MIYAMAE, S., HIGUCHI, N., 
ABE, A., HISHIKAWA, T., MIZUTANI, M., ISHIHARA, Y., NAKAMURA, H., 
KURITA, K., OHNO, N., TANAKA, Y., HATTORI, M. & NOGUCHI, T. 2015. 
Increased expression of interleukin (IL)-35 and IL-17, but not IL-27, in 
gingival tissues with chronic periodontitis. Journal of periodontology, 86, 
301-309. 
MIZRAJI, G., SEGEV, H., WILENSKY, A. & HOVAV, A.-H. 2013. Isolation, processing 
and analysis of murine gingival cells. Journal of visualized experiments : 
JoVE. 
MKONYI, L. E., BLETSA, A., BOLSTAD, A. I., BAKKEN, V., WIIG, H. & BERGGREEN, E. 
2012. Gingival Lymphatic Drainage Protects Against Porphyromonas 
gingivalis–Induced Bone Loss in Mice. The American Journal of Pathology, 
181, 907-916. 
 251	
MOSER, B., CLARK-LEWIS, I., ZWAHLEN, R. & BAGGIOLINI, M. 1990. Neutrophil-
activating properties of the melanoma growth-stimulatory activity. The 
Journal of Experimental Medicine, 171, 1797-1802. 
MOUGHAL, N. A., ADONOGIANAKI E FAU - KINANE, D. F. & KINANE, D. F. 1992. 
Langerhans cell dynamics in human gingiva during experimentally induced 
inflammation. J Biol Buccale, 20, 163-167. 
MOUTSOPOULOS, N. M., KLING, H. M., ANGELOV, N., JIN, W., PALMER, R. J., 
NARES, S., OSORIO, M. & WAHL, S. M. 2012. Porphyromonas gingivalis 
promotes Th17 inducing pathways in chronic periodontitis. Journal of 
autoimmunity, 39, 294-303. 
MYERS, L. A., PATEL, D. D., PUCK, J. M. & BUCKLEY, R. H. 2002. Hematopoietic 
stem cell transplantation for severe combined immunodeficiency in the 
neonatal period leads to superior thymic output and improved survival. 
Blood, 99, 872-878. 
MYNENI, S., SETTEM, R., CONNELL, T., KEEGAN, A., GAFFEN, S. & SHARMA, A. 2011. 
TLR2 signaling and Th2 responses drive Tannerella forsythia-induced 
periodontal bone loss. Journal of immunology (Baltimore, Md. : 1950), 187, 
501-509. 
NACER, A., CARAPAU, D., MITCHELL, R., MELTZER, A., SHAW, A., FREVERT, U. & 
NARDIN, E. H. 2014. Imaging murine NALT following intranasal immunization 
with flagellin-modified circumsporozoite protein malaria vaccines. Mucosal 
immunology, 7, 304-314. 
NAKAJIMA, T., UEKI-MARUYAMA K FAU - ODA, T., ODA T FAU - OHSAWA, Y., OHSAWA 
Y FAU - ITO, H., ITO H FAU - SEYMOUR, G. J., SEYMOUR GJ FAU - YAMAZAKI, 
K. & YAMAZAKI, K. 2005. Regulatory T-cells infiltrate periodontal disease 
tissues. J Dent Res, 84, 639-643. 
NEEDLEMAN, I., SUVAN, J., MOLES, D. R. & PIMLOTT, J. 2005. A systematic review 
of professional mechanical plaque removal for prevention of periodontal 
diseases. Journal of Clinical Periodontology, 32, 229-282. 
NEGISHI, I., MOTOYAMA, N., NAKAYAMA, K.-I., NAKAYAMA, K., SENJU, S., 
HATAKEYAMA, S., ZHANG, Q., CHAN, A. C. & LOH, D. Y. 1995. Essential role 
for ZAP-70 in both positive and negative selection of thymocytes. Nature, 
376, 435-438. 
NISTALA, K., ADAMS, S., CAMBROOK, H., URSU, S., OLIVITO, B., DE JAGER, W., 
EVANS, J. G., CIMAZ, R., BAJAJ-ELLIOTT, M. & WEDDERBURN, L. R. 2010. 
Th17 plasticity in human autoimmune arthritis is driven by the inflammatory 
 252	
environment. Proceedings of the National Academy of Sciences of the United 
States of America, 107, 14751-14756. 
NORDERYD, O. & HUGOSON, A. 1998. Risk of severe periodontal disease in a 
Swedish adult population. Journal of Clinical Periodontology, 25, 1022-1028. 
NORDERYD, O., HUGOSON, A. & GRUSOVIN, G. 1999. Risk of severe periodontal 
disease in a Swedish adult population. Journal of Clinical Periodontology, 26, 
608-615. 
NORDLAND, P., GARRETT, S., KIGER, R., VANOOTEGHEM, R., HUTCHENS, L. H. & 
EGELBERG, J. 1987. The effect of plaque control and root debridement in 
molar teeth. Journal of Clinical Periodontology, 14, 231-236. 
NOVAK, N., HABERSTOK, J., BIEBER, T. & ALLAM, J.-P. 2008. The immune privilege 
of the oral mucosa. Trends in Molecular Medicine, 14, 191-198. 
O'GRADY, N. P., TROPEA, M., PREAS, I. I. H. L., REDA, D., VANDIVIER, R. W., BANKS, 
S. M. & SUFFREDINI, A. F. 1999. Detection of Macrophage Inflammatory 
Protein (MIP)-1α and MIP-β during Experimental Endotoxemia and Human 
Sepsis. The Journal of Infectious Diseases, 179, 136-141. 
O’BRIEN-SIMPSON, N. M., HOLDEN, J. A., LENZO, J. C., TAN, Y., BRAMMAR, G. C., 
WALSH, K. A., SINGLETON, W., ORTH, R. K. H., SLAKESKI, N., CROSS, K. J., 
DARBY, I. B., BECHER, D., ROWE, T., MORELLI, A. B., HAMMET, A., NASH, A., 
BROWN, A., MA, B., VINGADASSALOM, D., MCCLUSKEY, J., KLEANTHOUS, H. & 
REYNOLDS, E. C. 2016. A therapeutic Porphyromonas gingivalis gingipain 
vaccine induces neutralising IgG1 antibodies that protect against 
experimental periodontitis. Npj Vaccines, 1, 16022. 
OFFENBACHER, S., BARROS, S. P., PAQUETTE, D. W., WINSTON, J. L., BIESBROCK, 
A. R., THOMASON, R. G., GIBB, R. D., FULMER, A. W., TIESMAN, J. P., 
JUHLIN, K. D., WANG, S. L., REICHLING, T. D., CHEN, K.-S. & HO, B. 2009. 
Gingival Transcriptome Patterns During Induction and Resolution of 
Experimental Gingivitis in Humans. Journal of Periodontology, 80, 1963-
1982. 
OFFENBACHER, S., DIVARIS, K., BARROS, S. P., MOSS, K. L., MARCHESAN, J. T., 
MORELLI, T., ZHANG, S., KIM, S., SUN, L., BECK, J. D., LAUDES, M., MUNZ, 
M., SCHAEFER, A. S. & NORTH, K. E. 2016. Genome-wide association study of 
biologically informed periodontal complex traits offers novel insights into the 
genetic basis of periodontal disease. Human Molecular Genetics, 25, 2113-
2129. 
OGAWA, T., TARKOWSKI, A., MCGHEE, M. L., MOLDOVEANU, Z., MESTECKY, J., 
HIRSCH, H. Z., KOOPMAN, W. J., HAMADA, S., MCGHEE, J. R. & KIYONO, H. 
 253	
1989. Analysis of human IgG and IgA subclass antibody-secreting cells from 
localized chronic inflammatory tissue. The Journal of Immunology, 142, 
1150. 
OKADA, H., KIDA, T. & YAMAGAMI, H. 1983. Identification and distribution of 
immunocompetent cells in inflamed gingiva of human chronic periodontitis. 
Infection and Immunity, 41, 365-374. 
OLDENHOVE, G., DE HEUSCH M FAU - URBAIN-VANSANTEN, G., URBAIN-VANSANTEN 
G FAU - URBAIN, J., URBAIN J FAU - MALISZEWSKI, C., MALISZEWSKI C FAU - 
LEO, O., LEO O FAU - MOSER, M. & MOSER, M. 2003. CD4+ CD25+ regulatory T 
cells control T helper cell type 1 responses to foreign antigens induced by 
mature dendritic cells in vivo. J Exp Med, 198, 259-266. 
OLIVEIRA, M., TAVARES, M., GOMES, D., TOURET, T., SÃO BRAZ, B., TAVARES, L. & 
SEMEDO-LEMSADDEK, T. 2016. Virulence traits and antibiotic resistance 
among enterococci isolated from dogs with periodontal disease. Comparative 
Immunology, Microbiology and Infectious Diseases, 46, 27-31. 
OLIVER-BELL, J., BUTCHER, J. P., MALCOLM, J., MACLEOD, M. K. L., ADRADOS 
PLANELL, A., CAMPBELL, L., NIBBS, R. J. B., GARSIDE, P., MCINNES, I. B. & 
CULSHAW, S. 2015. Periodontitis in the absence of B cells and specific anti-
bacterial antibody. Molecular Oral Microbiology, 30, 160-169. 
OZ, H. S. & PULEO, D. A. 2011. Animal Models for Periodontal Disease. Journal of 
Biomedicine and Biotechnology, 2011, 754857. 
PAPAPANOU, P. N., ABRON, A., VERBITSKY, M., PICOLOS, D., YANG, J., QIN, J., 
FINE, J. B. & PAVLIDIS, P. 2004. Gene expression signatures in chronic and 
aggressive periodontitis: a pilot study. European Journal of Oral Sciences, 
112, 216-223. 
PAPAPANOU, P. N., NEIDERUD, A.-M., SANDROS, J. & DAHLÉN, G. 2001. Interleukin-
1 gene polymorphism and periodontal status 
Interleukin-1 Gen Polymorphismus und parodontaler Status: Eine Fall-kontrollierte 
Studie 
Polymorphisme du gène Interleukine-1 et état parodontal: une étude d’un cas. 
Journal of Clinical Periodontology, 28, 389-396. 
PAPE, K. A., KHORUTS A FAU - MONDINO, A., MONDINO A FAU - JENKINS, M. K. & 
JENKINS, M. K. 1997. Inflammatory cytokines enhance the in vivo clonal 
expansion and differentiation of antigen-activated CD4+ T cells. J Immunol, 
159, 591-598. 
 254	
PARK, C. & KUPPER, T. S. 2015. The emerging role of resident memory T cells in 
protective immunity and inflammatory disease Nature medicine, 21, 688-
697. 
PARK, C. H., ABRAMSON, Z. R., TABA, M., JIN, Q., CHANG, J., KREIDER, J. M., 
GOLDSTEIN, S. A. & GIANNOBILE, W. V. 2007. Three-Dimensional Micro-
Computed Tomographic Imaging of Alveolar Bone in Experimental Bone Loss 
or Repair. Journal of periodontology, 78, 273-281. 
PARK, S.-N., PARK, J.-Y. & KOOK, J.-K. 2011. Development of Porphyromonas 
gingivalis-specific quantitative real-time PCR primers based on the 
nucleotide sequence of rpoB. The Journal of Microbiology, 49, 315. 
PARRY, G. & MACKMAN, N. 1997. Role of cyclic AMP response element-binding 
protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. Journal 
of immunology (Baltimore, Md. : 1950), 159, 5450-5456. 
PASTER, B. J., OLSEN, I., AAS, J. A. & DEWHIRST, F. E. 2006. The breadth of 
bacterial diversity in the human periodontal pocket and other oral sites. 
Periodontology 2000, 42, 80-87. 
PAVLICA, Z., PETELIN, M., NEMEC, A., ERZEN, D. & SKALERIC, U. 2004. Measurement 
of total antioxidant capacity in gingival crevicular fluid and serum in dogs 
with periodontal disease. Am J Vet Res, 65, 1584-1588. 
PEJCIC, A., DJORDJEVIC V FAU - KOJOVIC, D., KOJOVIC D FAU - ZIVKOVIC, V., 
ZIVKOVIC V FAU - MINIC, I., MINIC I FAU - MIRKOVIC, D., MIRKOVIC D FAU - 
STOJANOVIC, M. & STOJANOVIC, M. 2014. Effect of periodontal treatment in 
renal transplant recipients. 
PELLEGRINO, M., SCIAMBI, A., YATES, J. L., MAST, J. D., SILVER, C. & EASTBURN, D. 
J. 2016. RNA-Seq following PCR-based sorting reveals rare cell transcriptional 
signatures. BMC Genomics, 17, 361. 
PERRIER, S., DARAKHSHAN, F. & HAJDUCH, E. 2006. IL-1 receptor antagonist in 
metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett, 580, 6289-6294. 
PERUZZO, D. C., GIMENES, J. H., TAIETE, T., CASARIN, R. C. V., FERES, M., SALLUM, 
E. A., CASATI, M. Z., KANTOVITZ, K. R. & NOCITI, F. H. 2016. Impact of 
smoking on experimental gingivitis. A clinical, microbiological and 
immunological prospective study. Journal of Periodontal Research, 51, 800-
811. 
PETIT, M. D., HOVENKAMP E FAU - HAMANN, D., HAMANN D FAU - ROOS, M. T., 
ROOS MT FAU - VAN DER VELDEN, U., VAN DER VELDEN U FAU - MIEDEMA, F., 
 255	
MIEDEMA F FAU - LOOS, B. G. & LOOS, B. G. 2001. Phenotypical and 
functional analysis of T cells in periodontitis. J Periodontal Res, 36, 214-220. 
POPADIAK, K., POTEMPA, J., RIESBECK, K. & BLOM, A. 2007. Biphasic effect of 
gingipains from Porphyromonas gingivalis on the human complement system. 
Journal of immunology (Baltimore, Md. : 1950), 178, 7242-7250. 
POULIOT, M., CLISH, C. B., PETASIS, N. A., VAN DYKE, T. E. & SERHAN, C. N. 2000. 
Lipoxin A4 Analogues Inhibit Leukocyte Recruitment to Porphyromonas 
gingivalis:  A Role for Cyclooxygenase-2 and Lipoxins in Periodontal Disease. 
Biochemistry, 39, 4761-4768. 
PROF, F. L., ALLEN, C., DE BENEDETTI, F., GROM, A. A., BALLABIO, M., FERLIN, W. 
G. & DE MIN, C. 2015. A Novel Targeted Approach to the Treatment of 
Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma 
(IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 
Study in Children with Primary HLH. Blood, 126, LBA-3. 
PULENDRAN, B., KUMAR, P., CUTLER, C. W., MOHAMADZADEH, M., VAN DYKE, T. & 
BANCHEREAU, J. 2001. Lipopolysaccharides from Distinct Pathogens Induce 
Different Classes of Immune Responses In Vivo. Journal of immunology 
(Baltimore, Md. : 1950), 167, 5067-5076. 
PUNKOSDY, G. A., BLAIN, M., GLASS, D. D., LOZANO, M. M., O'MARA, L., DUDLEY, J. 
P., AHMED, R. & SHEVACH, E. M. 2011. Regulatory T-cell expansion during 
chronic viral infection is dependent on endogenous retroviral superantigens. 
Proceedings of the National Academy of Sciences of the United States of 
America, 108, 3677-3682. 
RADFORD, K. J., HIGGINS DE FAU - PASQUINI, S., PASQUINI S FAU - CHEADLE, E. J., 
CHEADLE EJ FAU - CARTA, L., CARTA L FAU - JACKSON, A. M., JACKSON AM 
FAU - LEMOINE, N. R., LEMOINE NR FAU - VASSAUX, G. & VASSAUX, G. 2002. A 
recombinant E. coli vaccine to promote MHC class I-dependent antigen 
presentation: application to cancer immunotherapy. Gene Therapy, 9, 1455-
1463. 
RAJESH, N., ARUN, K. V., KUMAR, T. S. S., REDDY, K. K. M., ALAMELU, S. & REDDY, 
B. R. 2015. Evaluation of mRNA expression of the transcription factors of Th1 
and Th2 subsets (T-bet and GATA-3) in periodontal health and disease - A 
pilot study in south Indian population. Journal of Indian Society of 
Periodontology, 19, 624-627. 
RENVERT, S., PERSSON, R. E. & PERSSON, G. R. 2013. Tooth Loss and Periodontitis 
in Older Individuals: Results From the Swedish National Study on Aging and 
Care. Journal of Periodontology, 84, 1134-1144. 
 256	
RETTENMIER, C. W., ROUSSEL, M. F. & SHERR, C. J. 1988. The colony-stimulating 
factor 1 (CSF-1) receptor (c-fms proto-oncogene product) and its ligand. J 
Cell Sci Suppl, 9, 27-44. 
ROBEY, E. & FOWLKES, B. J. 1994. Selective Events in T Cell Development. Annual 
Review of Immunology, 12, 675-705. 
RODRIGUE, L. & LAVOIE, M. C. 1996. Comparison of the proportions of oral bacterial 
species in BALB/c mice from different suppliers. Lab Anim, 30, 108-113. 
ROSSER, ELIZABETH C. & MAURI, C. 2015. Regulatory B Cells: Origin, Phenotype, 
and Function. Immunity, 42, 607-612. 
RYDER, M. I., NITTAYANANTA, W., COOGAN, M., GREENSPAN, D. & GREENSPAN, J. 
S. 2012. Periodontal disease in HIV/AIDS. Periodontology 2000, 60, 78-97. 
SÁNCHEZ-MARTÍN, L., ESTECHA, A., SAMANIEGO, R., SÁNCHEZ-RAMÓN, S., VEGA, M. 
Á. & SÁNCHEZ-MATEOS, P. 2011. The chemokine CXCL12 regulates monocyte-
macrophage differentiation and RUNX3 expression. Blood, 117, 88. 
SANZ, M., TEUGHELS, W. & ON BEHALF OF GROUP, A. O. T. E. W. O. P. 2008. 
Innovations in non-surgical periodontal therapy: Consensus Report of the 
Sixth European Workshop on Periodontology. Journal of Clinical 
Periodontology, 35, 3-7. 
SATTLER, S., LING, G.-S., XU, D., HUSSAARTS, L., ROMAINE, A., ZHAO, H., FOSSATI-
JIMACK, L., MALIK, T., COOK, H. T., BOTTO, M., LAU, Y.-L., SMITS, H. H., 
LIEW, F. Y. & HUANG, F.-P. 2014. IL-10-producing regulatory B cells induced 
by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses 
in the gut(). Journal of Autoimmunity, 50, 107-122. 
SCHIFFERLE, R., WILSON, M., LEVINE, M. & GENCO, R. 1993a. Activation of serum 
complement by polysaccharide-containing antigens of Porphyromonas 
gingivalis. Journal of Periodontal Research, 28. 
SCHIFFERLE, R. E., CHEN, P. B., DAVERN, L. B., AGUIRRE, A., GENCO, R. J. & 
LEVINE, M. J. 1993b. Modification of experimental Porphyromonas gingivalis 
murine infection by immunization with a polysaccharide-protein conjugate. 
Oral Microbiology and Immunology, 8. 
SCHLAPBACH, C., GEHAD, A., YANG, C., WATANABE, R., GUENOVA, E., TEAGUE, J. 
E., CAMPBELL, L., YAWALKAR, N., KUPPER, T. S. & CLARK, R. A. 2014. Human 
T(H)9 cells are skin-tropic and have autocrine and paracrine pro-
inflammatory capacity. Science translational medicine, 6, 219ra8-219ra8. 
 257	
SÉGUIER, S., GODEAU, G., LEBORGNE, M., PIVERT, G. & BROUSSE, N. 2000. 
Quantitative morphological analysis of Langerhans cells in healthy and 
diseased human gingiva. Archives of Oral Biology, 45, 1073-1081. 
SEYMOUR, G. J., GEMMELL E FAU - REINHARDT, R. A., REINHARDT RA FAU - 
EASTCOTT, J., EASTCOTT J FAU - TAUBMAN, M. A. & TAUBMAN, M. A. 1993. 
Immunopathogenesis of chronic inflammatory periodontal disease: cellular 
and molecular mechanisms. 
SHARMA, A., INAGAKI, S., HONMA, K., SFINTESCU, C., BAKER, P. J. & EVANS, R. T. 
2005. Tannerella forsythia-induced Alveolar Bone Loss in Mice Involves 
Leucine-rich-repeat BspA Protein. Journal of Dental Research, 84, 462-467. 
SHEETS, S., POTEMPA, J., TRAVIS, J., FLETCHER, H. & CASIANO, C. 2006. Gingipains 
from Porphyromonas gingivalis W83 synergistically disrupt endothelial cell 
adhesion and can induce caspase-independent apoptosis. Infection and 
immunity, 74, 5667-5678. 
SIGIDIN, Y. A., LOUKINA GV FAU - SKURKOVICH, B., SKURKOVICH B FAU - 
SKURKOVICH, S. & SKURKOVICH, S. 2001. Randomized, double-blind trial of 
anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J 
Rheumatol, 30, 203-207. 
SIMON, V., HO, D. D. & KARIM, Q. A. 2006. HIV/AIDS epidemiology, pathogenesis, 
prevention, and treatment. Lancet, 368, 489-504. 
SINGH, A., WYANT, T., ANAYA-BERGMAN, C., ADUSE-OPOKU, J., BRUNNER, J., 
LAINE, M., CURTIS, M. & LEWIS, J. 2011. The capsule of Porphyromonas 
gingivalis leads to a reduction in the host inflammatory response, evasion of 
phagocytosis, and increase in virulence. Infection and immunity, 79, 4533-
4542. 
SKURKOVICH, S., LUKINA, G., SIGIDIN, Y. A., PUSHKOVA, O., MACH, E. & 
SKURKOVICH, B. 2015. Comparative Clinical Trial of Antibodies to Interferon-
Gamma (IFN-γ) and Tumor Necrosis Factor-Alpha (TNF-α) in the Treatment of 
Rheumatoid Arthritis. Journal of Immune Based Therapies, Vaccines and 
Antimicrobials, 4, 1-8. 
SLADE, G. D. & SPENCER, A. J. 1995. Periodontal attachment loss among adults 
aged 60+ in South Australia. Community Dentistry and Oral Epidemiology, 
23, 237-242. 
SOCRANSKY, S. S., HAFFAJEE, A. D., CUGINI, M. A., SMITH, C. & KENT, R. L. 1998. 
Microbial complexes in subgingival plaque. Journal of Clinical 
Periodontology, 25, 134-144. 
 258	
SONG, W.-C. 2012. Crosstalk between complement and toll-like receptors. 
Toxicologic pathology, 40, 174-182. 
STARR, T. K., JAMESON, S. C. & HOGQUIST, K. A. 2003. Positive and Negative 
Selection of T cells. Annual Review of Immunology, 21, 139-176. 
STATHOPOULOU, P., BENAKANAKERE, M., GALICIA, J. & KINANE, D. 2009a. The host 
cytokine response to Porphyromonas gingivalis is modified by gingipains. Oral 
microbiology and immunology, 24, 11-17. 
STATHOPOULOU, P. G., BENAKANAKERE, M. R., GALICIA, J. C. & KINANE, D. F. 
2009b. The host cytokine response to Porphyromonas gingivalis is modified by 
gingipains. Oral microbiology and immunology, 24, 11-17. 
STELIN, S., RAMAKRISHAN, H., TALWAR, A., ARUN, K. & KUMAR, T. S. S. 2009. 
Immunohistological analysis of CD1a+ langerhans cells and CD57+ natural 
killer cells in healthy and diseased human gingival tissue: A comparative 
study. Journal of Indian Society of Periodontology, 13, 150-154. 
STRUILLOU, X., BOUTIGNY, H., SOUEIDAN, A. & LAYROLLE, P. 2010. Experimental 
Animal Models in Periodontology: A Review. The Open Dentistry Journal, 4, 
37-47. 
SUÁREZ-FARIÑAS, M., FUENTES-DUCULAN, J., LOWES, M. A. & KRUEGER, J. G. 2011. 
Resolved psoriasis lesions retain expression of a subset of disease-related 
genes. The Journal of investigative dermatology, 131, 391-400. 
SZAFRAŃSKI, S. P., DENG, Z.-L., TOMASCH, J., JAREK, M., BHUJU, S., MEISINGER, 
C., KÜHNISCH, J., SZTAJER, H. & WAGNER-DÖBLER, I. 2015. Functional 
biomarkers for chronic periodontitis and insights into the roles of Prevotella 
nigrescens and Fusobacterium nucleatum; a metatranscriptome analysis. Npj 
Biofilms And Microbiomes, 1, 15017. 
TAKEICHI, O., HABER, J., KAWAI, T., SMITH, D., MORO, I. & TAUBMAN, M. 2000. 
Cytokine profiles of T-lymphocytes from gingival tissues with pathological 
pocketing. Journal of dental research, 79, 1548-1555. 
TAUBMAN, M. A. & KAWAI, T. 2001. Involvement of T-lymphocytes in periodontal 
disease and in direct and indirect induction of bone resorption. Crit Rev Oral 
Biol Med, 12, 125-35. 
THORBERT-MROS, S., LARSSON, L. & BERGLUNDH, T. 2015. Cellular composition of 
long-standing gingivitis and periodontitis lesions. Journal of Periodontal 
Research, 50, 535-543. 
 259	
TOHYAMA, M., SAYAMA, K., KOMATSUZAWA, H., HANAKAWA, Y., SHIRAKATA, Y., 
DAI, X., YANG, L., TOKUMARU, S., NAGAI, H., HIRAKAWA, S., SUGAI, M. & 
HASHIMOTO, K. 2007. CXCL16 is a novel mediator of the innate immunity of 
epidermal keratinocytes. International Immunology, 19, 1095-1102. 
TOMASI, C., KOUTOUZIS T FAU - WENNSTROM, J. L. & WENNSTROM, J. L. 2008. 
Locally delivered doxycycline as an adjunct to mechanical debridement at 
retreatment of periodontal pockets. J Periodontol, 79, 431-439. 
TOMURA, M., YOSHIDA, N., TANAKA, J., KARASAWA, S., MIWA, Y., MIYAWAKI, A. & 
KANAGAWA, O. 2008. Monitoring cellular movement in vivo with 
photoconvertible fluorescence protein “Kaede” transgenic mice. Proceedings 
of the National Academy of Sciences of the United States of America, 105, 
10871-10876. 
TORRES DE HEENS, G. L., LOOS, B. G. & VAN DER VELDEN, U. 2010. Monozygotic 
twins are discordant for chronic periodontitis: clinical and bacteriological 
findings. Journal of Clinical Periodontology, 37, 120-128. 
TRIBBLE, G. & LAMONT, R. 2010. Bacterial invasion of epithelial cells and spreading 
in periodontal tissue. Periodontology 2000, 52, 68-83. 
TSAI, C.-C., KU, C.-H., HO, Y.-P., HO, K.-Y., WU, Y.-M. & HUNG, C.-C. 2007. 
Changes in Gingival Crevicular Fluid Interleukin-4 and Interferon-gamma in 
Patients with Chronic Periodontitis Before and After Periodontal Initial 
Therapy. The Kaohsiung Journal of Medical Sciences, 23, 1-7. 
TZANKOV, A., BOURGAU C FAU - KAISER, A., KAISER A FAU - ZIMPFER, A., ZIMPFER A 
FAU - MAURER, R., MAURER R FAU - PILERI, S. A., PILERI SA FAU - WENT, P., 
WENT P FAU - DIRNHOFER, S. & DIRNHOFER, S. 2005. Rare expression of T-
cell markers in classical Hodgkin's lymphoma. Mod Pathol, 18, 1542-1549. 
UNSOELD, H. & PIRCHER, H. 2005. Complex Memory T-Cell Phenotypes Revealed by 
Coexpression of CD62L and CCR7. Journal of Virology, 79, 4510-4513. 
VAN 'T VEER, L. J., DAI, H., VAN DE VIJVER, M. J., HE, Y. D., HART, A. A. M., MAO, 
M., PETERSE, H. L., VAN DER KOOY, K., MARTON, M. J., WITTEVEEN, A. T., 
SCHREIBER, G. J., KERKHOVEN, R. M., ROBERTS, C., LINSLEY, P. S., 
BERNARDS, R. & FRIEND, S. H. 2002. Gene expression profiling predicts 
clinical outcome of breast cancer. Nature, 415, 530-536. 
VAN HOUTE, J. 1982. Bacterial adherence and dental plaque formation. Infection, 
10, 252-260. 
 260	
VAN OERS, N. S., VON BOEHMER, H. & WEISS, A. 1995. The pre-T cell receptor (TCR) 
complex is functionally coupled to the TCR-zeta subunit. The Journal of 
Experimental Medicine, 182, 1585. 
VAN OERS, N. S. C., LOWIN-KROPF, B., FINLAY, D., CONNOLLY, K. & WEISS, A. 1996. 
T Cell Development Is Abolished in Mice Lacking Both Lck and Fyn Protein 
Tyrosine Kinases. Immunity, 5, 429-436. 
VERNAL, R., DIAZ-GUERRA, E., SILVA, A., SANZ, M. & GARCIA-SANZ, J. 2014. Distinct 
human T-lymphocyte responses triggered by Porphyromonas gingivalis 
capsular serotypes. Journal of clinical periodontology, 41, 19-30. 
VERNAL, R., DUTZAN, N., HERNANDEZ, M., CHANDIA, S., PUENTE, J., LEON, R., 
GARCIA, L., DEL VALLE, I., SILVA, A. & GAMONAL, J. 2006. High expression 
levels of receptor activator of nuclear factor-kappa B ligand associated with 
human chronic periodontitis are mainly secreted by CD4+ T lymphocytes. J 
Periodontol, 77, 1772-80. 
VERNAL, R., LEÓN, R., SILVA, A., VAN WINKELHOFF, A., GARCIA-SANZ, J. & SANZ, 
M. 2009. Differential cytokine expression by human dendritic cells in 
response to different Porphyromonas gingivalis capsular serotypes. Journal of 
clinical periodontology, 36, 823-829. 
VOGEL, C. & MARCOTTE, E. M. 2012. Insights into the regulation of protein 
abundance from proteomic and transcriptomic analyses. Nature reviews. 
Genetics, 13, 227-232. 
VON BOEHMER, H. & FEHLING, H. J. 1997. Structure and function of the pre-T cell 
receptor. Annual Review of Immunology, 15, 433-452. 
VON BOEHMER, H., TEH, H. S. & KISIELOW, P. 1989. The thymus selects the useful, 
neglects the useless and destroys the harmful. Immunology Today, 10, 57-61. 
WALK, E. L., MCLAUGHLIN, S. L. & WEED, S. A. 2015. High-frequency Ultrasound 
Imaging of Mouse Cervical Lymph Nodes. Journal of Visualized Experiments : 
JoVE, 52718. 
WANG, H.-L. & GREENWELL, H. 2001. Surgical periodontal therapy. Periodontology 
2000, 25, 89-99. 
WANG, M., KRAUSS, J., DOMON, H., HOSUR, K., LIANG, S., MAGOTTI, P., 
TRIANTAFILOU, M., TRIANTAFILOU, K., LAMBRIS, J. & HAJISHENGALLIS, G. 
2010a. Microbial hijacking of complement-toll-like receptor crosstalk. 
Science signaling, 3. 
 261	
WANG, R. N., GREEN, J., WANG, Z., DENG, Y., QIAO, M., PEABODY, M., ZHANG, Q., 
YE, J., YAN, Z., DENDULURI, S., IDOWU, O., LI, M., SHEN, C., HU, A., 
HAYDON, R. C., KANG, R., MOK, J., LEE, M. J., LUU, H. L. & SHI, L. L. 2014. 
Bone Morphogenetic Protein (BMP) signaling in development and human 
diseases. Genes & Diseases, 1, 87-105. 
WANG, Y.-H. H., VOO, K. S., LIU, B., CHEN, C.-Y. Y., UYGUNGIL, B., SPOEDE, W., 
BERNSTEIN, J. A., HUSTON, D. P. & LIU, Y.-J. J. 2010b. A novel subset of 
CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 
cytokine and promote the exacerbation of chronic allergic asthma. The 
Journal of experimental medicine, 207, 2479-2491. 
WANG, Z., GERSTEIN, M. & SNYDER, M. 2009. RNA-Seq: a revolutionary tool for 
transcriptomics. Nature reviews. Genetics, 10, 57-63. 
WARRINGTON, R., WATSON, W., KIM, H. L. & ANTONETTI, F. R. 2011. An 
introduction to immunology and immunopathology. Allergy Asthma Clin 
Immunol, 7, doi: 10.1186/1710-1492-7S1-S1. 
WAYKOLE, Y. P., DOIPHODE, S. S., RAKHEWAR, P. S. & MHASKE, M. 2009. 
Anticytokine therapy for periodontal diseases: Where are we now? Journal of 
Indian Society of Periodontology, 13, 64-68. 
WESTHOVENS, R. & VERSCHUEREN, P. 2010. The Efficacy and Safety of Abatacept in 
Rheumatoid Arthritis. Therapeutic Advances in Musculoskeletal Disease, 2, 
89-94. 
WHITE, D. A., TSAKOS, G., PITTS, N. B., FULLER, E., DOUGLAS, G. V. A., MURRAY, 
J. J. & STEELE, J. G. 2012. Adult Dental Health Survey 2009: common oral 
health conditions and their impact on the population. Br Dent J, 213, 567-
572. 
WILENSKY, A., POLAK, D., HOURI-HADDAD, Y. & SHAPIRA, L. 2013. The role of RgpA 
in the pathogenicity of Porphyromonas gingivalis in the murine periodontitis 
model. Journal of clinical periodontology, 40, 924-932. 
WILENSKY, A., SEGEV, H., MIZRAJI, G., SHAUL, Y., CAPUCHA, T., SHACHAM, M. & 
HOVAV, A. H. 2014. Dendritic cells and their role in periodontal disease. Oral 
Diseases, 20, 119-126. 
WILENSKY, A., TZACH-NAHMAN, R., POTEMPA, J., SHAPIRA, L. & NUSSBAUM, G. 
2015. Porphyromonas gingivalis gingipains selectively reduce CD14 
expression, leading to macrophage hypo-responsiveness to bacterial 
infection. Journal of innate immunity, 7, 127-135. 
 262	
WISHART, D. S. 2016. Emerging applications of metabolomics in drug discovery and 
precision medicine. Nat Rev Drug Discov, 15, 473-484. 
WOLF, D. L., NEIDERUD, A. M., HINCKLEY, K., DAHLÉN, G., VAN DE WINKEL, J. G. J. 
& PAPAPANOU, P. N. 2006. Fcγ receptor polymorphisms and periodontal 
status: a prospective follow-up study. Journal of Clinical Periodontology, 33, 
691-698. 
WU, H. Y., NGUYEN, H. H. & RUSSELL, M. W. 1997. Nasal lymphoid tissue (NALT) as 
a mucosal immune inductive site. Scandinavian journal of immunology, 46, 
506-513. 
WU, R.-Q., ZHANG, D.-F., TU, E., CHEN, Q.-M. & CHEN, W. 2014. The mucosal 
immune system in the oral cavity—an orchestra of T cell diversity. 
International Journal of Oral Science, 6, 125-132. 
WYATT, A. W., OSBORNE, R. J., STEWART, H. & RAGGE, N. K. 2010. Bone 
morphogenetic protein 7 (BMP7) mutations are associated with variable 
ocular, brain, ear, palate, and skeletal anomalies. Human Mutation, 31, 781-
787. 
XU, X., HE, J., XUE, J., WANG, Y., LI, K., ZHANG, K., GUO, Q., LIU, X., ZHOU, Y., 
CHENG, L., LI, M., LI, Y., LI, Y., SHI, W. & ZHOU, X. 2015. Oral cavity 
contains distinct niches with dynamic microbial communities. Environmental 
Microbiology, 17, 699-710. 
XU, X.-C., CHEN, H., ZHANG, X., ZHAI, Z.-J., LIU, X.-Q., QIN, A. & LU, E.-Y. 2014. 
Simvastatin prevents alveolar bone loss in an experimental rat model of 
periodontitis after ovariectomy. Journal of Translational Medicine, 12, 284. 
YAMAZAKI, S., MARUYAMA A FAU - OKADA, K., OKADA K FAU - MATSUMOTO, M., 
MATSUMOTO M FAU - MORITA, A., MORITA A FAU - SEYA, T. & SEYA, T. 2012. 
Dendritic cells from oral cavity induce Foxp3(+) regulatory T cells upon 
antigen stimulation. PLoS ONE, 7, e51665. 
YAO, Y., LIU, R., SHIN, M. S., TRENTALANGE, M., ALLORE, H., NASSAR, A., KANG, I., 
POBER, J. & MONTGOMERY, R. R. 2014. CyTOF supports efficient detection of 
immune cell subsets from small samples. Journal of immunological methods, 
415, 1-5. 
YOSHIDA, M., WATANABE, T., USUI, T., MATSUNAGA, Y., SHIRAI, Y., YAMORI, M., 
ITOH, T., HABU, S., CHIBA, T., KITA, T. & WAKATSUKI, Y. 2001. CD4 T cells 
monospecific to ovalbumin produced by Escherichia coli can induce colitis 
upon transfer to BALB/c and SCID mice. International Immunology, 13, 1561-
1570. 
 263	
YU, J., RUDDY, M., WONG, G., SFINTESCU, C., BAKER, P., SMITH, J., EVANS, R. & 
GAFFEN, S. 2007. An essential role for IL-17 in preventing pathogen-initiated 
bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 
receptor-dependent signals. Blood, 109, 3794-3802. 
YU, P., HU, Y., LIU, Z., KAWAI, T., TAUBMAN, M. A., LI, W. & HAN, X. 2016. Local 
Induction of B Cell Interleukin-10 Competency Alleviates Inflammation and 
Bone Loss in Ligature-Induced Experimental Periodontitis in Mice. . Infect 
Immun, 85, doi:10.1128/IAI.00645-16. 
YUN, P., DECARLO, A., CHAPPLE, C., COLLYER, C. & HUNTER, N. 2005. Binding of 
Porphyromonas gingivalis gingipains to human CD4(+) T cells preferentially 
down-regulates surface CD2 and CD4 with little affect on co-stimulatory 
molecule expression. Microbial pathogenesis, 38, 85-96. 
ZHANG, W., JU, J., RIGNEY, T. & TRIBBLE, G. 2014. Porphyromonas gingivalis 
infection increases osteoclastic bone resorption and osteoblastic bone 
formation in a periodontitis mouse model. BMC Oral Health, 14, 89. 
ZHANG, X., KIMURA, Y., FANG, C., ZHOU, L., SFYROERA, G., LAMBRIS, J., WETSEL, 
R., MIWA, T. & SONG, W.-C. 2007. Regulation of Toll-like receptor-mediated 
inflammatory response by complement in vivo. Blood, 110, 228-236. 
ZHANG, Y., WANG, T., CHEN, W., YILMAZ, O., PARK, Y., JUNG, I.-Y., HACKETT, M. 
& LAMONT, R. 2005. Differential protein expression by Porphyromonas 
gingivalis in response to secreted epithelial cell components. Proteomics, 5, 
198-211. 
ZINKERNAGEL, R. M. 1997. The Nobel Lectures in Immunology. The Nobel Prize for 
Physiology or Medicine, 1996. Cellular immune recognition and the biological 
role of major transplantation antigens. Scandinavian journal of immunology, 
46, 421-436. 
 
